Compositions and methods for targeting, editing, or modifying genes

ABSTRACT

Provided herein are nucleic acids useful as guide nucleic acids (gNAs), e.g., guide ribonucleic acids (gRNAs), in a CRISPR system wherein the guide nucleic acids contain one or more modifications to one or more nucleotides, use of such guide nucleic acids in modifying cells, and other uses wherein CRISPR Cas proteins are utilized.

CROSS-REFERENCE

This application is a continuation of U.S. patent application Ser. No. 17/958,973 filed Oct. 3, 2022, which is a continuation of PCT/US22/17582 filed Feb. 23, 2022, which claims the benefit of U.S. Provisional Application No. 63/153,847, filed Feb. 25, 2021, and U.S. Provisional Application No. 63/285,851 filed Dec. 3, 2021, which applications are incorporated herein by reference.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in .XML format and is hereby incorporated by reference in its entirety. Said .XML copy, created on Jan. 17, 2023, is named ARTN-003CON-T1_ST26.xml and is 2,471,492 bytes in size. The sequence listing contained in this .XML file is part of the specification and is hereby incorporated by reference herein in its entirety.

BACKGROUND OF THE INVENTION

Recent advances have been made in precise genome targeting technologies. For example, specific loci in genomic DNA can be targeted, edited, or otherwise modified by designer meganucleases, zinc finger nucleases, or transcription activator-like effectors (TALEs). Furthermore, the CRISPR-Cas systems of bacterial and archaeal adaptive immunity have been adapted for precise targeting of genomic DNA in eukaryotic cells. Compared to the earlier generations of genome editing tools, the CRISPR-Cas systems are easy to set up, scalable, and amenable to targeting multiple positions within the eukaryotic genome, thereby providing a major resource for new applications in genome engineering. Two distinct classes of CRISPR-Cas systems have been identified. Class 1 CRISPR-Cas systems utilize multi-protein effector complexes, whereas class 2 CRISPR-Cas systems utilize single-protein effectors. Among the three types of class 2 CRISPR-Cas systems, type II and type V systems typically target DNA and type VI systems typically target RNA. Naturally occurring type II effector complexes consist of Cas9, CRISPR RNA (crRNA), and trans-activating CRISPR RNA (tracrRNA), but the crRNA and tracrRNA can be fused as a single guide RNA in an engineered system for simplicity. Certain naturally occurring type V systems, such as type V-A, type V-C, and type V-D systems, do not require tracrRNA and use crRNA alone as the guide for cleavage of target DNA.

The CRISPR-Cas systems have been engineered for various purposes, such as genomic DNA cleavage, base editing, epigenome editing, and genomic imaging. Although significant developments have been made, there still remains a need for new and useful CRISPR-Cas systems as powerful precise genome targeting tools.

SUMMARY OF THE INVENTION

In one aspect, provided herein are compositions.

In certain embodiments, provided herein is a composition comprising a synthetic guide RNA (gRNA) comprising (i) a targeter nucleic acid with a 3′ end and a 5′ end, comprising: (a) a spacer sequence comprising the 3′ end, configured to hybridize with a target nucleotide sequence, and (b) a targeter stem sequence comprising the 5′ end; and (ii) a modulator nucleic acid with a 3′ end and a 5′ end, comprising (a) a modulator stem sequence comprising the 3′ end, complementary to the targeter stem sequence, and (b) a 5′ sequence, e.g., tail sequence, comprising the 5′ end; wherein the targeter nucleic acid and the modulator nucleic acid are separate nucleic acids; and either the targeter nucleic acid or the modulator nucleic acid, or both, is modified at one or more nucleotides or internucleotide linkages at or near its 3′ end, at or near its 5′ end, or at or near both, and a complex comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating a CRISPR Associated (Cas) nuclease that, in a naturally occurring system, is activated by a single crRNA in the absence of a tracrRNA. In certain embodiments, the modification is a chemical modification. In certain embodiments, the Cas nuclease is a Type V Cas nuclease, such as a type V-A, type V-C, or type V-D Cas nuclease, for example a type V-A Cas nuclease. In certain embodiments the Type V-A Cas nuclease is a Cpf1, MAD, Csm1, ART, or ABW nuclease, or derivative or variant thereof. In certain embodiments the composition further comprises the Cas nuclease that, in a naturally occurring system, is activated by a single crRNA in the absence of a tracrRNA. In certain embodiments the composition further comprises the Cas nuclease. In certain embodiments the targeter nucleic acid, the modulator nucleic acid, and the Cas nuclease are present in a ribonucleoprotein (RNP) complex. In certain embodiments some or all of the nucleic acid is RNA. In certain embodiments the modification, e.g., the chemical modification comprises a chemical modification at or near the 3′ end of the targeter nucleic acid. In certain embodiments the chemical modification comprises a chemical modification at a nucleotide or internucleotide linkage within 10 nucleotides of the 3′ end. In certain embodiments the chemical modification comprises a chemical modification to the 3′ terminal nucleotide or internucleotide linkage. In certain embodiments comprising a modification at or near the 3′ end of the targeter nucleic acid the composition further comprises a chemical modification at or near the 5′ end of the targeter nucleic acid. In certain embodiments the chemical modifications at or near the 3′ and 5′ ends are the same. In certain embodiments the chemical modifications at or near the 3′ and 5′ ends are different. In certain embodiments comprising a modification at or near the 3′ and, optionally, at or near the 5′ end of the targeter nucleic acid the composition further comprises a chemical modification at or near the 3′ end of the modulator nucleic acid. In certain embodiments the chemical modification at or near the 3′ end of the modulator nucleic acid is the same as the chemical modification at or near the 3′ end of the targeter nucleic acid; different from the chemical modification at or near the 3′ end of the targeter nucleic acid; the same as the chemical modification at or near the 5′ end of the targeter nucleic acid, if present; different from the chemical modification at or near the 5′ end of the targeter nucleic acid, if present; or a combination thereof. In certain embodiments comprising a modification at or near the 3′ and, optionally, at or near the 5′ end of the targeter nucleic acid and a chemical modification at or near the 3′ end of the modulator nucleic acid the composition further comprises a chemical modification at or near the 5′ end of the modulator nucleic acid. In certain embodiments the chemical modification at or near the 5′ end of the modulator nucleic acid is the same as the chemical modification at or near the 3′ end of the targeter nucleic acid; different from the chemical modification at or near the 3′ end of the targeter nucleic acid; the same as the chemical modification at or near the 5′ end of the targeter nucleic acid, if present; different from the chemical modification at or near the 5′ end of the targeter nucleic acid, if present; the same as the chemical modification at or near the 3′ end of the modulator nucleic acid, if present; different from the chemical modification at or near the 3′ end of the modulator nucleic acid, if present; or a combination thereof. In certain embodiments the chemical modification comprises a chemical modification at or near the 5′ end of the targeter nucleic acid. In certain embodiments comprising a modification at or near the 5′ end of the targeter nucleic acid the composition further comprises a chemical modification at or near the 3′ end of the targeter nucleic acid. In certain embodiments the chemical modifications at or near the 3′ and at or near the 5′ ends are the same. In certain embodiments the chemical modifications at or near the 3′ and at or near the 5′ ends are different. In certain embodiments comprising a modification at or near the 5′ end of the targeter nucleic acid and, optionally, a chemical modification at or near the 3′ end of the targeter nucleic acid, the composition further comprises a chemical modification at or near the 3′ end of the modulator nucleic acid. In certain embodiments the chemical modification at or near the 3′ end of the modulator nucleic acid is the same as the chemical modification at or near the 5′ end of the targeter nucleic acid; different from the chemical modification at or near the 5′ end of the targeter nucleic acid; the same as the chemical modification at or near the 3′ end of the targeter nucleic acid, if present; different from the chemical modification at or near the 3′ end of the targeter nucleic acid, if present; or a combination thereof. In certain embodiments comprising a modification at or near the 5′ end of the targeter nucleic acid and, optionally, a chemical modification at or near the 3′ end of the targeter nucleic acid and/or a chemical modification at or near the 3′ end of the modulator nucleic acid the composition further comprises a chemical modification at or near the 5′ end of the modulator nucleic acid. In certain embodiments the chemical modification at or near the 5′ end of the modulator nucleic acid is the same as the chemical modification at or near the 5′ end of the targeter nucleic acid; different from the chemical modification at or near the 5′ end of the targeter nucleic acid; the same as the chemical modification at or near the 3′ end of the targeter nucleic acid, if present; different from the chemical modification at or near the 3′ end of the targeter nucleic acid, if present; the same as the chemical modification at or near the 3′ end of the modulator nucleic acid, if present; different from the chemical modification at or near the 3′ end of the modulator nucleic acid, if present; or a combination thereof. In certain embodiments the chemical modification comprises a chemical modification at or near the 3′ end of the modulator nucleic acid. In certain embodiments the composition further comprises a chemical modification at or near the 5′ end of the modulator nucleic acid. In certain embodiments the chemical modifications at or near the 3′ and at or near the 5′ ends are the same. In certain embodiments the chemical modifications at or near the 3′ and at or near the 5′ ends are different. In certain embodiments comprising a modification at or near the 3′ end of the modulator nucleic acid and, optionally, a modification at or near the 5′ end of the modulator nucleic acid, the composition further comprises a chemical modification at or near the 3′ end of the targeter nucleic acid. In certain embodiments the chemical modification at or near the 3′ end of the targeter nucleic acid is the same as the chemical modification at or near the 3′ end of the modulator nucleic acid; different from the chemical modification at or near the 3′ end of the modulator nucleic acid; the same as the chemical modification at or near the 5′ end of the modulator nucleic acid, if present; different from the chemical modification at or near the 5′ end of the modulator nucleic acid, if present; or a combination thereof. In certain embodiments comprising a modification at or near the 3′ end of the modulator nucleic acid and, optionally, a modification at or near the 5′ end of the modulator nucleic acid and/or a chemical modification at or near the 3′ end of the targeter nucleic acid the composition further comprises a chemical modification at or near the 5′ end of the targeter nucleic acid. In certain embodiments the chemical modification at or near the 5′ end of the targeter nucleic acid is the same as the chemical modification at or near the 3′ end of the modulator nucleic acid; different from the chemical modification at or near the 3′ end of the modulator nucleic acid; the same as the chemical modification at or near the 5′ end of the modulator nucleic acid, if present; different from the chemical modification at or near the 5′ end of the modulator nucleic acid, if present; the same as the chemical modification at or near the 3′ end of the targeter nucleic acid, if present; different from the chemical modification at or near the 3′ end of the targeter nucleic acid, if present; or a combination thereof. In certain embodiments the chemical modification comprises a chemical modification at or near the 5′ end of the modulator nucleic acid. In certain embodiments comprising a chemical modification at or near the 5′ end of the modulator nucleic acid the composition further comprises a chemical modification at or near the 3′ end of the modulator nucleic acid. In certain embodiments the chemical modifications at or near the 3′ and at or near the 5′ ends are the same. In certain embodiments the chemical modifications at or near the 3′ and at or near the 5′ ends are different. In certain embodiments comprising a chemical modification at or near the 5′ end of the modulator nucleic acid and, optionally, a chemical modification at or near the 3′ end of the modulator nucleic acid, the composition further comprises a chemical modification at or near the 3′ end of the targeter nucleic acid. In certain embodiments the chemical modification at or near the 3′ end of the targeter nucleic acid is the same as the chemical modification at or near the 5′ end of the modulator nucleic acid; different from the chemical modification at or near the 5′ end of the modulator nucleic acid; the same as the chemical modification at or near the 3′ end of the modulator nucleic acid, if present; different from the chemical modification at or near the 3′ end of the modulator nucleic acid, if present; or a combination thereof. In certain embodiments comprising a chemical modification at or near the 5′ end of the modulator nucleic acid and, optionally, a chemical modification at or near the 3′ end of the modulator nucleic acid and/or a chemical modification at or near the 3′ end of the targeter nucleic acid the composition further comprises a chemical modification at or near the 5′ end of the targeter nucleic acid. In certain embodiments the chemical modification at or near the 5′ end of the targeter nucleic acid is the same as the chemical modification at or near the 5′ end of the modulator nucleic acid; different from the chemical modification at or near the 5′ end of the modulator nucleic acid; the same as the chemical modification at or near the 3′ end of the modulator nucleic acid, if present; different from the chemical modification at or near the 3′ end of the modulator nucleic acid, if present; the same as the chemical modification at or near the 3′ end of the targeter nucleic acid, if present; different from the chemical modification at or near the 3′ end of the targeter nucleic acid, if present; or a combination thereof. In any of the previous embodiments, the chemical modification can be selected from the group consisting of 2′-O-methyl (M), a phosphorothioate (S), a phosphonoacetate (P), a thiophosphonoacetate (SP), a 2′-O-methyl-3′-phosphorothioate (MS), a 2′-O-methyl-3′-phosphonoacetate (MP), a 2′-O-methyl-3′-thiophosphonoacetate (MSP), a 2′-deoxy-3′-phosphonoacetate (DP), a 2′-deoxy-3′-thiophosphonoacetate (DSP), and a combination thereof. In any of the previous embodiments, the spacer sequence can comprise a sequence capable of hybridizing with a human ADORA2A, B2M, CD3E, CD38, CD40LG, CD52, CIITA, CSF2, CTLA4, DCK, FAS, HAVCR2 (also called TIM3), LAG3, PDCD1 (also called PD-1), PTPN6, TIGIT, TRAC, TRBC1, TRBC2, CARD11, CD247, IL7R, LCK, PLCG1, ALPNR, BBS1, CALR, CD3G, CD58, COL17A1, DEFB134, ERAP1, ERAP2, IFNGR1, IFNGR2, JAK1, JAK2, mir-101-2, MLANA, PSMB5, PSMB8, PSMB9, PTCD2, RFX5, RFXANK, RFXAP, RPL23, SOX10, SRP54, STAT1, Tap1, TAP2, TAPBP, TWF1, CD3D, or NLRC5 gene. Any of the previous embodiments may further comprise a Cas protein, for example a Cas nuclease. In certain embodiments, provided is eukaryotic cell comprising the gRNA of any of the previous embodiments, in some cases further comprising a Cas nuclease to which the gRNA binds. In certain embodiments the cell is an immune cell such as a human immune cell. In certain embodiments the immune cell is a T cell. In certain embodiments, the immune cell is a CAR-T cell. In certain embodiments, the gNA-Cas complex is introduced into host cell, e.g., an immune cell, e.g., a T cell, along with an exogenous donor template, e.g., a CAR cassette, where the the exogenous donor template is introduced into the genome of the host cell through the activity of the gNA-Cas complex resulting in a modified cell, e.g., a CAR-T cell. In certain embodiments provided herein is a composition comprising any of the preceding composition and further comprising a Cas protein. In certain embodiments the Cas protein comprises a Cas nuclease. In certain embodiments the Cas nuclease is a Type I, II, III, IV, V, or VI Cas nuclease. In certain embodiments the Cas nuclease is a Type V Cas nuclease. In certain embodiments the Cas nuclease is a Type V-A, V-C, or V-D nuclease. In certain embodiments the Cas nuclease is a Type V-A Cas nuclease. In certain embodiments the Type V-A Cas nuclease is a Cpf1, MAD, Csm1, ART, or ABW Cas nuclease, or a derivative or variant thereof. In certain embodiments provided herein is a pharmaceutical composition comprising any of the preceding compositions and a pharmaceutically acceptable carrier.

In one aspect, provided herein are methods.

In certain embodiments, provided herein is method of cleaving a target DNA having a target nucleotide sequence, the method comprising contacting the target DNA with a composition of the preceding paragraph, thereby resulting in cleavage of the target DNA. In certain embodiments the contacting occurs in vitro. In certain embodiments the contacting occurs in a cell ex vivo. In certain embodiments the target DNA is genomic DNA of the cell. In certain embodiments the system is delivered into the cell as a pre-formed RNP complex. In certain embodiments the pre-formed RNP complex is delivered into the cell by electroporation, lipofection, or a viral method. In certain embodiments the pre-formed RNP complex is delivered into the cell by electroporation.

In certain embodiments provided herein is a method of editing the genome of a eukaryotic cell, the method comprising delivering the engineered, non-naturally occurring system of any of the embodiments of the first paragraph of this section, thereby resulting in editing of the genome of the eukaryotic cell. In certain embodiments the system is delivered into the cell as a pre-formed RNP complex. In certain embodiments the system is delivered into the cell by electroporation, lipofection, or a viral method. In certain embodiments the system is delivered into the cell by electroporation. In certain embodiments the cell is an immune cell. In certain embodiments the immune cell is a T lymphocyte. In certain embodiments the engineered, non-naturally occurring system is delivered to a plurality of eukaryotic cells, and wherein the system comprises a guide nucleic acid comprising one or modifications as described herein, wherein the editing efficiency of the genomes of the plurality of cells is increased by at least 5% compared to the editing efficiency when the same system but without the modification or modifications is used.

In certain embodiments, provided herein is a method of treating a disease or a disorder comprising administering to a subject in need thereof an effective amount of a composition of the first paragraph of this section. In certain embodiments the method comprises administering to a subject in need thereof of cells modified by treatment with a composition of the first paragraph of this section. In certain embodiments the cells are cells that are removed from an individual and treated ex vivo. In certain embodiments the subject in need of treatment and the individual whose cells are treated ex vivo are the same.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

FIG. 1A shows a schematic representation showing the structure of an exemplary dual single guide CRISPR-Cas system.

FIG. 1B shows a schematic representation showing the structure of an exemplary dual guide CRISPR-Cas system.

FIG. 2A-2C show a series of schematic representations of exemplary modifications to dual guide gRNA. 2A: protecting group at 5′ end of modulator nucleic acid; 2B: donor template recruiting sequence at 5′ end of modulator nucleic acid; 2C: editing enhancer at 5′ end of modulator nucleic acid.

FIG. 3 shows data for editing efficiency (as measured by # of reads modified/total # of reads) in primary T cells in an exon of an exemplary gene 1. Shown are editing results relative to the single gRNA design (left bar) vs. the negative control (far right bar).

FIG. 4A shows a series of data for editing efficiency in primary T cells in an exon of an exemplary gene 1. Shown are editing results of multiple modified gRNA designs over the single gRNA design (2 right bars).

FIG. 4B shows a series of data for editing efficiency in primary T cells in an exon of an exemplary gene 1. Shown are editing results of multiple modified gRNA designs over the single gRNA design (2 right bars).

FIG. 5A shows a series of data for editing efficiency in primary T cells in an exon of an exemplary gene 2. Shown are editing results of multiple modified gRNA designs over the single gRNA design (2 right bars).

FIG. 5B shows a series of data for editing efficiency in primary T cells in an exon of an exemplary gene 2. Shown are editing results of multiple modified gRNA designs over the single gRNA design (2 right bars).

FIG. 6A shows a series of data for editing efficiency in primary T cells in an exon of an exemplary gene 3. Shown are editing results of multiple modified gRNA designs over the single gRNA design (2 right bars).

FIG. 6B shows a series of data for editing efficiency in primary T cells in an exon of an exemplary gene 3. Shown are editing results of multiple modified gRNA designs over the single gRNA design (2 right bars).

FIG. 7 shows chemical structures for a 5′ (panel A), 3′ (panel B), and internal (panel C) propanediol modification.

FIG. 8 shows editing efficiency in primary T cells in a B2M gene. Shown are the editing results of multiple modified gRNA designs over the single gRNA design.

FIG. 9 shows HLA-1 surface expression knock down after treatment with RNP comprising multiple modified gRNA design compared to the single gRNA design targeting the B2M gene as measured by flow cytometry.

DETAILED DESCRIPTION OF THE INVENTION

-   -   I. Engineered, non-naturally occurring modified guide, e.g.,         dual guide CRISPR-Cas Systems         -   A. Nucleic Acid Modifications to Guide Nucleic Acids             -   1. Specific Modifications to Targeter and/or Modulator                 Nucleic Acids         -   B. Targeter and Modulator Nucleic Acids         -   C. Cas Proteins     -   II. Methods of Targeting, Editing, and/or Modifying Genomic DNA         -   A. Ribonucleoprotein (RNP) Delivery and “Cas RNA” Delivery         -   B. CRISPR Expression Systems         -   C. Donor Templates         -   D. Efficiency and Specificity         -   E. Multiplex Methods     -   III. Pharmaceutical Compositions     -   IV. Therapeutic Uses         -   A. Gene Therapies         -   B. Immune Cell Engineering     -   V. Kits     -   VI. Embodiments     -   VII. Examples

The invention is based, in part, upon the design of a modified guide CRISPR-Cas system, such as a modified dual guide CRISPR-Cas system in which a targeter nucleic acid and a modulator nucleic acid, when hybridized to form a complex, can, e.g., activate a Cas nuclease that, in a naturally occurring system, is activated by a single crRNA in the absence of a tracrRNA. The engineered modified dual guide CRISPR-Cas systems described herein can be used to target, edit, or modify a target nucleic acid such as genomic DNA. Modifications include a chemical modification to one or more nucleotides or internucleotide linkages at or near the 3′ end of the targeter nucleic acid, at or near the 5′ end of the targeter nucleic acid (if a dual guide system), at or near the 3′ end of the modulator nucleic acid (if a dual guide system), at or near the 5′ end of the modulator nucleic acid, or combinations thereof. In cases where more than one locus is modified, the chemical modification at each locus can be the same or different. In certain embodiments the modified guide nucleic acid (gNA) can be a single guide nucleic acid such as a single guide RNA, wherein the targeter and modulator nucleic acid are joined by a plurality of nucleotides; while embodiments are described in terms of dual guide nucleic acids it is understood that the same can be applied to single guide nucleic acids, where appropriate.

A CRISPR-Cas system generally comprises a Cas protein and one or more guide nucleic acids, e.g., gRNAs. The Cas protein can be directed to a specific location in a double-stranded DNA target by recognizing a protospacer adjacent motif (PAM) in the non-target strand of the DNA, and the one or more guide nucleic acids can be directed to a specific location by hybridizing with a target nucleotide sequence in the target strand of the DNA. Both PAM recognition and target nucleotide sequence hybridization are required for stable binding of a CRISPR-Cas complex to the DNA target and, if the Cas protein has an effector function, e.g., nuclease activity, activation of the effector function. As a result, when creating a CRISPR-Cas system, a guide nucleic acid can be designed to comprise a nucleotide sequence called spacer sequence that hybridizes with a target nucleotide sequence, where target nucleotide sequence is located adjacent to a PAM in an orientation operable with the Cas protein. It has been observed that not all CRISPR-Cas systems designed by these criteria are equally effective.

Type V-A, type V-C, and type V-D CRISPR-Cas systems naturally include a Cas nuclease and a single guide RNA (i.e., crRNA) while lacking a tracrRNA. By splitting the single guide RNA into two different nucleic acids, where at least one end of one of the nucleic acids is chemically modified, the engineered system describe herein provides better flexibility and tunability. For example, the efficiency of nucleic acid cleavage can be increased or decreased by adjusting the hybridization length and/or affinity of the targeter nucleic acid and the modulator nucleic acid. Furthermore, given the length limitation of nucleic acids that can be synthesized with high yield and accuracy, the use of modified dual guide nucleic acids allows incorporation of more polynucleotide elements that can improve editing efficacy and/or specificity.

In particular, the modified dual guide system can be engineered as a tunable system to decrease off-target editing, and thus can be used to edit a nucleic acid with high specificity. The system can be employed in a number of applications, for example, editing cells such as mammalian cells for use in therapy. A decrease in off-target editing is particularly desirable when creating genetically engineered proliferating cells, such as stem cells, progenitor cells, and immune memory cells, to be administered to a subject in need of the therapy. High specificity can be accomplished using the modified dual guide systems described herein, which optionally further include, for example, one or more chemical modifications to the targeter nucleic acid and/or modulator nucleic acid, an editing enhancer sequence, and/or a donor template-recruiting sequence. The nature and/or location of the chemical modifications can modulate editing efficiency in the CRISPR system. For example, in certain embodiments a modification at or near the 5′ end, at or near the 3′ end, and/or at or near both of a targeter and/or modulator nucleic acid, e.g., one or more modifications to one or more nucleotides, as described elsewhere herein, can result in at least a 1, 2, 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, or 90% increase in editing efficiency; in some cases a similar decrease in editing efficiency may be achieved, compared to non-modulated nucleic acids.

Thus, provided herein are guide nucleic acids, such as RNAs, comprising a targeter nucleic acid and a modulator nucleic acid; see, e.g., FIG. 1A, showing a single guide nucleic acid, and FIG. 1B, showing a dual guide nucleic acid. One or more nucleotides or internucleotide linkages at or near the 5′ end (of the modulator nucleic acid in a sgNA, of either or both of modulator nucleic acid and/or targeter nucleic acid in dual gNA), at or near the 3′ end (of the targeter nucleic acid in a sgNA, of either or both of modulator nucleic acid and/or targeter nucleic acid in dual gNA), or both of the targeter and/or modulator nucleic acids comprise one or more modified nucleotides or internucleotide linkages, e.g., chemically modified nucleotides. Specific embodiments are as described herein, and include embodiments in which a specific gene is targeted by the modified guide nucleic acid, e.g., modified single guide nucleic acid such as modified single guide RNA, or modified dual guide nucleic acid such as a modified dual guide RNA. In certain embodiments, provided are compositions comprising a modified guide nucleic acid as described herein and a Cas protein, such as a Cas nuclease. The protein, e.g., nuclease can be any suitable protein, e.g., nuclease; in certain embodiments, the nuclease is a Type I, II, III, IV, V, or VI Cas nuclease; in certain embodiments the nuclease is Type V Cas nuclease, such as a Type V-A, V-C, or V-D nuclease, for example, a Type V-A nuclease. Specific nucleases are as described herein. In certain embodiments, the composition can also comprise a donor template. In certain embodiments, provided are CRISPR expression systems for expressing one or more of the nuclease, the targeter nucleic acid, the modulator nucleic acid, and/or, optionally, a donor template; it will be appreciated that, in general, the modified nucleic acids cannot be expressed by such a system. Also provided are cells, such as an immune cell, e.g., a T cell, comprising one or more of the modified guide nucleic acids described herein, Cas nucleases as described herein, and/or donor template. In certain embodiments, provided are pharmaceutical compositions comprising compositions comprising modified guide nucleic acids, as described herein. In certain embodiments, provided are methods for targeting, editing, and/or modifying genomic DNA using the modified guide nucleic acid compositions described herein. In certain embodiments, provided herein are methods of gene therapy utilizing the modified guide nucleic acid compositions described herein. In certain embodiments, provided herein are methods of immune cell engineering utilizing the modified guide nucleic acid compositions described herein. In certain embodiments, provided are kits comprising the modified guide nucleic acids described herein.

The features and uses of the modified single and dual guide CRISPR-Cas system are discussed in detail in the following sections.

I. ENGINEERED, NON-NATURALLY OCCURRING MODIFIED GUIDE NUCLEIC ACID-CRISPR-CAS Systems

In certain embodiments, the engineered, non-naturally occurring system of the present invention comprises a targeter nucleic acid comprising a spacer sequence designed to hybridize with a target nucleotide sequence and a targeter stem sequence; and a modulator nucleic acid comprising a modulator stem sequence complementary to the targeter stem sequence and, optionally, a 5′ sequence, e.g., a tail sequence, wherein, in the case of a single guide nucleic acid the guide nucleic acid is a single polynucleotide, and in the case of a dual guide nucleic acid, the targeter nucleic acid and the modulator nucleic acid are separate nucleic acids, and wherein a guide nucleic acid comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating a Cas nuclease; in certain cases of dual gNAs, the nuclease is one that, in a naturally occurring system, is activated by a single crRNA in the absence of a tracrRNA. See FIGS. 1A and 1B. One or both of the targeter nucleic acid and/or the modulator nucleic acid includes one or more modified nucleotides or internucleotide linkages at or near the 3′ end, at or near the 5′ end, or at or near both.

The terms “targeter stem sequence” and “modulator stem sequence,” as used herein, can include a pair of nucleotide sequences in one or more guide nucleic acids that hybridize with each other. When a targeter stem sequence and a modulator stem sequence are contained in a single guide nucleic acid, the targeter stem sequence is proximal to a spacer sequence designed to hybridize with a target nucleotide sequence, and the modulator stem sequence is proximal to the targeter stem sequence. When a targeter stem sequence and a modulator stem sequence are in separate nucleic acids, i.e. in a dual guide nucleic acid, the targeter stem sequence is in the same nucleic acid as a spacer sequence designed to hybridize with a target nucleotide sequence. In a CRISPR-Cas system that naturally includes separate crRNA and tracrRNA (e.g., a type II system), the duplex formed between the targeter stem sequence and the modulator stem sequence corresponds to the duplex formed between the crRNA and the tracrRNA. In a CRISPR-Cas system that naturally includes a single crRNA but no tracrRNA (e.g., a type V-A system), the duplex formed between the targeter stem sequence and the modulator stem sequence corresponds to the stem portion of a stem-loop structure in the scaffold sequence (also called direct repeat sequence) of the crRNA. It is understood that 100% complementarity is not required between the targeter stem sequence and the modulator stem sequence. In a type V-A CRISPR-Cas system, however, the targeter stem sequence is typically 100% complementary to the modulator stem sequence.

In certain embodiments wherein the target nucleic acid and the modulator nucleic acid comprise a single polynucleotide, a loop motif may exist between the 3′ stem sequence of the targeter nucleic acid and the 5′ stem sequence of the modulator nucleic acid, e.g., a stem loop. In certain embodiments, the loop motif is between 1-11, 2-11, 3-11, 4-11, 5-11, 3-10, 3-9, 3-8, 3-7, 3-6, 1-11, 2-10, 3-9, 4-8, 5-7, 4-6, 1-7, 2-6, 3-5 nucleotides in length. In a preferred embodiment, the loop motif is between 3-5 nucleotides in length. In a separate preferred embodiment, the loop motif is four nucleotides in length. In certain embodiments, the loop motif is 5′-TCTT-3′ or 5′-TATT-3′.

The term “targeter nucleic acid,” as used herein in the context of a dual guide nucleic acid CRISPR-Cas system, can include a nucleic acid comprising (i) a spacer sequence designed to hybridize with a target nucleotide sequence; and (ii) a targeter stem sequence capable of hybridizing with an additional nucleic acid to form a complex, wherein the complex is capable of activating a Cas nuclease (e.g., a type II or type V-A Cas nuclease) under suitable conditions, and wherein the targeter nucleic acid alone, in the absence of the additional nucleic acid, is not capable of activating the Cas nuclease under the same conditions. The term “targeter nucleic acid,” as used herein in the context of a single guide nucleic acid CRISPR-Cas system, can include a nucleic acid comprising (i) a spacer sequence designed to hybridize with a target nucleotide sequence; and (ii) a targeter stem sequence capable of hybridizing with a complementary stem sequence in a modulator nucleic acid that is 5′ to the targeter nucleic acid in the single polynucleotide of the sgNA, wherein the sgNA is capable of activating a Cas nuclease (e.g., a type II or type V-A Cas nuclease).

The term “modulator nucleic acid,” as used herein in connection with a given targeter nucleic acid and its corresponding Cas nuclease, can include a nucleic acid capable of hybridizing with the targeter nucleic acid, to form an intra-polynucleotide hybridized portion in the case of a sgNA, and to form a complex in the case of a dual gNA, wherein the sgNA or complex, but not the modulator nucleic acid alone, is capable of activating the type Cas nuclease under suitable conditions.

The term “suitable conditions,” as used in connection with the definitions of “targeter nucleic acid” and “modulator nucleic acid,” can include the conditions under which a naturally occurring CRISPR-Cas system is operative, such as in a prokaryotic cell, in a eukaryotic (e.g., mammalian or human) cell, or in an in vitro assay.

Type V-A, type V-C, and type V-D CRISPR-Cas systems are distinctive subtypes of CRISPR-Cas systems under the classification described in Makarova et al. (2017) CELL, 168: 328. Naturally occurring CRISPR-Cas systems of these subtypes lack a tracrRNA and rely on a single crRNA to guide the CRISPR-Cas complex to the target DNA. Naturally occurring type V-A Cas proteins comprise a RuvC-like nuclease domain but lack an HNH endonuclease domain, and recognize a 5′ T-rich protospacer adjacent motif (PAM), the 5′ orientation determined using the non-target strand (i.e. the strand not hybridized with the spacer sequence) as the coordinate.

Naturally occurring type V-A CRISPR-Cas systems cleave a double-stranded DNA to generate a staggered double-stranded break rather than a blunt end. The cleavage site is distant from the PAM site (e.g., separated by at least 10, 11, 12, 13, 14, or 15 nucleotides from the PAM on the non-target strand and/or separated by at least 15, 16, 17, 18, or 19 nucleotides from the sequence complementary to PAM on the target strand).

The instant disclosure provides an engineered, non-naturally occurring system comprising a targeter nucleic acid comprising: a spacer sequence designed to hybridize with a target nucleotide sequence; and a targeter stem sequence; and a modulator nucleic acid comprising a modulator stem sequence complementary to the targeter stem sequence, and, optionally, a 5′ sequence, e.g., a tail sequence, wherein, in the case of a single guide nucleic acid the targeter nucleic acid and the modulator nucleic acid are part of a single polynucleotide, and in the case of a dual guide nucleic acid, the targeter nucleic acid and the modulator nucleic acid are separate nucleic acids; modifications can include one or more chemical modifications to one or more nucleotides at or near the 3′ end of the targeter nucleic acid (dual and single gNA), at or near the 5′ end of the targeter nucleic acid (dual gNA), at or near the 3′ end of the modulator nucleic acid (dual gNA), at or near the 5′ end of the modulator nucleic acid (single and dual gNA), or combinations thereof, and wherein the gNA comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating a Cas nuclease, such as a Type I, II, III, IV, V, or VI Cas nuclease, such as a Type V Cas nuclease, for example, a type V-A, type V-C, or type V-D Cas nuclease. In certain embodiments, the Cas nuclease is a type V-A Cas nuclease. In certain embodiments the targeter sequence comprises, from 5′ to 3′, a targeter stem sequence and a spacer sequence and the modulator sequence comprises, from 5′ to 3′, a 5′ sequence, e.g., a tail sequence, and a modulator stem sequence. In certain embodiments, the system also comprises a Cas nuclease, such as type V-A, type V-C, or type V-D Cas nuclease, for example, a Type V-A Cas nuclease.

A. Nucleic Acid Modifications in Guide Nucleic Acids

Provided herein are engineered, non-naturally occurring systems comprising a targeter nucleic acid comprising: a spacer sequence designed to hybridize with a target nucleotide sequence and a targeter stem sequence; and a modulator nucleic acid comprising a modulator stem sequence complementary to the targeter stem sequence, and, optionally, a 5′ sequence, e.g., a tail sequence, wherein, in a single guide nucleic acid the targeeter nucleic acid and the modulator nucleic acid are part of a single polynucleotide, and in a dual guide nucleic acid, the targeter nucleic acid and the modulator nucleic acid are separate nucleic acids; modifications can include one or more chemical modifications to one or more nucleotides or internucleotide linkages at or near the 3′ end of the targeter nucleic acid (dual and single gNA), at or near the 5′ end of the targeter nucleic acid (dual gNA), at or near the 3′ end of the modulator nucleic acid (dual gNA), at or near the 5′ end of the modulator nucleic acid (single and dual gNA), or combinations thereof as appropriate for single or dual gNA. In certain embodiments, the Cas nuclease is a type V-A Cas nuclease. Modulator and/or targeter nucleic sequences can include further sequences, as detailed in Section IB, and modifications can be in these further sequences, as appropriate and apparent to one of skill in the art. In embodiments described in this section, below, in certain embodiments, guide nucleic acid is oriented from 5′ at the modulator nucleic acid to 3′ at the modulator stem sequence, and 5′ at the targeter stem sequence to 3′ at the targeter sequence (see, e.g., FIGS. 1A and 1B); in certain embodiments, as appropriate, guide nucleic acid is oriented from 3′ at the modulator nucleic acid to 5′ at the modulator stem sequence, and 3′ at the targeter stem sequence to 5′ at the targeter sequence.

The targeter nucleic acid may comprise a DNA (e.g., modified DNA), an RNA (e.g., modified RNA), or a combination thereof. The modulator nucleic acid may comprise a DNA (e.g., modified DNA), an RNA (e.g., modified RNA), or a combination thereof. In certain embodiments, the targeter nucleic acid is an RNA and the modulator nucleic acid is an RNA. A targeter nucleic acid in the form of an RNA is also called targeter RNA, and a modulator nucleic acid in the form of an RNA is also called modulator RNA. The nucleotide sequences disclosed herein are presented as DNA sequences by including thymidines (T) and/or RNA sequences including uridines (U). It is understood that corresponding DNA sequences, RNA sequences, and DNA/RNA chimeric sequences are also contemplated. For example, where a spacer sequence is presented as a DNA sequence, a nucleic acid comprising this spacer sequence as an RNA can be derived from the DNA sequence disclosed herein by replacing each T with U. As a result, for the purpose of describing a nucleotide sequence, T and U are used interchangeably herein.

In certain embodiments some or all of the gNA is RNA, e.g., a gRNA. In certain embodiments, 5-100%, 10-100%, 20-100%, 30-100%, 40-100%, 50-100%, 60-100%, 70-100%, 80-100%, 90-100%, 95-100%, 99-100%, 99.5-100% of the gNA is gRNA. In certain embodiments, 20%-80%, 20%-70%, 20%-60%, 20%-50%, 20%-40%, 20%-30%, 30%-80%, 30%-70%, 30%-60%, 30%-50%, 30%-40%, 40%-80%, 40%-70%, 40%-60%, 40%-50%, 50%-80%, 50%-70%, 50%-60%, 60%-80%, 60%-70%, or 70%-80% of gNA is RNA. In certain embodiments, 50% of the gNA is RNA. In certain embodiments, 70% of the gNA is RNA. In certain embodiments, 90% of the gNA is RNA. In certain embodiments, 100% of the gNA is RNA, e.g., a gRNA.

In certain embodiments the stem sequences are 1-20, 2-19, 3-18, 4-17, 5-16, 6,-15, 7-14, 8-13, 9-12, 10-11, 1-9, 2-8, 3-7, 4-6, or 2-9 nucleotides in length. In a preferred embodiment, the stem sequences are 4-6 nucleotides in length. In certain embodiments, the stem sequence of the modulator and targeter nucleic acids share 5%-100%, 10%-100%, 20%-100%, 30%-100%, 40%-100%, 50%-100%, 60%-100%, 70%-100%, 80%-100%, 90%-100%, 95%-100%, 99%-100%, 99.5%-100% of the gNA is gRNA. In certain embodiments, 20%-80%, 20%-70%, 20%-60%, 20%-50%, 20%-40%, 20%-30%, 30%-80%, 30%-70%, 30%-60%, 30%-50%, 30%-40%, 40%-80%, 40%-70%, 40%-60%, 40%-50%, 50%-80%, 50%-70%, 50%-60%, 60%-80%, 60%-70%, or 70%-80% sequence complementarity. In certain embodiments, the stem sequence of the modulator and targeter nucleic acids share 80%, 90%, 95%, or 100% sequence complementarity. In a preferred embodiment, the stem sequence of the modulator and targeter nucleic acids share 80%-100% sequence complementarity.

In certain embodiments, the targeter nucleic acid and/or the modulator nucleic acid are RNAs with one or more modifications in a ribose group, one or more modifications in a phosphate group, one or more modifications in a nucleobase, one or more terminal modifications, or a combination thereof. Exemplary modifications are disclosed in U.S. Pat. Nos. 10,900,034 and 10,767,175, U.S. Patent Application Publication No. 2018/0119140, Watts et al. (2008) Drug Discov. Today 13: 842-55, and Hendel et al. (2015) NAT. BIOTECHNOL. 33: 985.

Modifications in a ribose group include but are not limited to modifications at the 2′ position or modifications at the 4′ position. For example, in certain embodiments, the ribose comprises 2′-O—C1-4alkyl, such as 2′-O-methyl (2′-OMe, or M). In certain embodiments, the ribose comprises 2′-O—C1-3alkyl-O—C1-3alkyl, such as 2′-methoxyethoxy (2′-O—CH₂CH₂OCH₃) also known as 2′-O-(2-methoxyethyl) or 2′-MOE. In certain embodiments, the ribose comprises 2′-O-allyl. In certain embodiments, the ribose comprises 2′-O-2,4-Dinitrophenol (DNP). In certain embodiments, the ribose comprises 2′-halo, such as 2′-F, 2′-Br, 2′-Cl, or 2′-I. In certain embodiments, the ribose comprises 2′-NH₂. In certain embodiments, the ribose comprises 2′-H (e.g., a deoxynucleotide). In certain embodiments, the ribose comprises 2′-arabino or 2′-F-arabino. In certain embodiments, the ribose comprises 2′-LNA or 2′-ULNA. In certain embodiments, the ribose comprises a 4′-thioribosyl.

Modifications can also include a deoxy group, for example a 2′-deoxy-3′-phosphonoacetate (DP), a 2′-deoxy-3′-thiophosphonoacetate (DSP).

Internucleotide linkage modifications in a phosphate group include but are not limited to a phosphorothioate (S), a chiral phosphorothioate, a phosphorodithioate, a boranophosphonate, a C1-4alkyl phosphonate such as a methylphosphonate, a boranophosphonate, a phosphonocarboxylate such as a phosphonoacetate (P), a phosphonocarboxylate ester such as a phosphonoacetate ester, an amide, a thiophosphonocarboxylate such as a thiophosphonoacetate (SP), a thiophosphonocarboxylate ester such as a thiophosphonoacetate ester, and a 2′,5′-linkage having a phosphodiester or any of the modified phosphates above. Various salts, mixed salts and free acid forms are also included.

Modifications in a nucleobase include but are not limited to 2-thiouracil, 2-thiocytosine, 4-thiouracil, 6-thioguanine, 2-aminoadenine, 2-aminopurine, pseudouracil, hypoxanthine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deazaadenine, 7-deaza-8-azaadenine, 5-methylcytosine, 5-methyluracil, 5-hydroxymethylcytosine, 5-hydroxymethyluracil, 5,6-dehydrouracil, 5-propynylcytosine, 5-propynyluracil, 5-ethynylcytosine, 5-ethynyluracil, 5-allyluracil, 5-allylcytosine, 5-aminoallyluracil, 5-aminoallyl-cytosine, 5-bromouracil, 5-iodouracil, diaminopurine, difluorotoluene, dihydrouracil, an abasic nucleotide, Z base, P base, Unstructured Nucleic Acid, isoguanine, isocytosine (see, Piccirilli et al. (1990) NATURE, 343: 33), 5-methyl-2-pyrimidine (see, Rappaport (1993) BIOCHEMISTRY, 32: 3047), x(A,G,C,T), and y(A,G,C,T).

Terminal modifications include but are not limited to polyethyleneglycol (PEG), hydrocarbon linkers (such as heteroatom (O,S,N)-substituted hydrocarbon spacers; halo-substituted hydrocarbon spacers; keto-, carboxyl-, amido-, thionyl-, carbamoyl-, thionocarbamaoyl-containing hydrocarbon spacers, propanediol), spermine linkers, dyes such as fluorescent dyes (for example, fluoresceins, rhodamines, cyanines), quenchers (for example, dabcyl, BHQ), and other labels (for example biotin, digoxigenin, acridine, streptavidin, avidin, peptides and/or proteins). In certain embodiments, a terminal modification comprises a conjugation (or ligation) of the RNA to another molecule comprising an oligonucleotide (such as deoxyribonucleotides and/or ribonucleotides), a peptide, a protein, a sugar, an oligosaccharide, a steroid, a lipid, a folic acid, a vitamin and/or other molecule. In certain embodiments, a terminal modification incorporated into the RNA is located internally in the RNA sequence via a linker such as 2-(4-butylamidofluorescein)propane-1,3-diol bis(phosphodiester) linker, which is incorporated as a phosphodiester linkage and can be incorporated anywhere between two nucleotides in the RNA.

The modifications disclosed above can be combined in the targeter nucleic acid and/or the modulator nucleic acid that are in the form of RNA. In certain embodiments, the modification in the RNA is selected from the group consisting of incorporation of 2′-O-methyl-3′phosphorothioate (MS), 2′-O-methyl-3′-phosphonoacetate (MP), 2′-O-methyl-3′-thiophosphonoacetate (MSP), 2′-halo-3′-phosphorothioate (e.g., 2′-fluoro-3′-phosphorothioate), 2′-halo-3′-phosphonoacetate (e.g., 2′-fluoro-3′-phosphonoacetate), and 2′-halo-3′-thiophosphonoacetate (e.g., 2 ‘-fluoro-3’-thiophosphonoacetate).

In certain embodiments, modifications can include 2′-O-methyl (M), a phosphorothioate (S), a phosphonoacetate (P), a thiophosphonoacetate (SP), a 2′-O-methyl-3′-phosphorothioate (MS), a 2′-O-methyl-3′-phosphonoacetate (MP), a 2′-O-methyl-3′-thiophosphonoacetate (MSP), a 2′-deoxy-3′-phosphonoacetate (DP), a 2′-deoxy-3′-thiophosphonoacetate (DSP), or a combination thereof, at or near either the 3′ or 5′ end of either the targeter or modulator nucleic acid, as appropriate for single or dual gNA.

In certain embodiments, modifications can include either a 5′ or a 3′ propanediol or C3 linker modification as depicted in FIG. 7A or B respectively.

In certain embodiments, the modification alters the stability of the RNA. In certain embodiments, the modification enhances the stability of the RNA, e.g., by increasing nuclease resistance of the RNA relative to a corresponding RNA without the modification. Stability-enhancing modifications include but are not limited to incorporation of 2′-O-methyl, a 2′-O—C1-4alkyl, 2′-halo (e.g., 2′-F, 2′-Br, 2′-Cl, or 2′-I), 2′MOE, a 2′-O—C1-3alkyl-O—C1-3alkyl, 2′-NH₂, 2′-H (or 2′-deoxy), 2′-arabino, 2′-F-arabino, 4′-thioribosyl sugar moiety, 3′-phosphorothioate, 3′-phosphonoacetate, 3′-thiophosphonoacetate, 3′-methylphosphonate, 3′-boranophosphate, 3′-phosphorodithioate, locked nucleic acid (“LNA”) nucleotide which comprises a methylene bridge between the 2′ and 4′ carbons of the ribose ring, and unlocked nucleic acid (“ULNA”) nucleotide. Such modifications are suitable for use as a protecting group to prevent or reduce degradation of the 5′ sequence, e.g., a tail sequence, modulator stem sequence (dual guide nucleic acids), targeter stem sequence (dual guide nucleic acids), and/or spacer sequence (see, the “Targeter and Modulator nucleic acids” subsection).

1. Specific Modifications to Targeter and/or Modulator Nucleic Acids

In certain embodiments, a targeter nucleic acid, e.g., RNA, comprises at least one nucleotide at or near the 3′ end comprising a modification to a ribose, phosphate group, nucleobase, or terminal modification. In certain embodiments, the 3′ end of the targeter nucleic acid comprises the spacer sequence. In certain embodiments, the 3′ end of the targeter nucleic acid comprises the targeter stem sequence. Exemplary modifications are disclosed in Dang et al. (2015) Genome Biol. 16: 280, Kocaz et al. (2019) Nature Biotech. 37: 657-66, Liu et al. (2019) Nucleic Acids Res. 47(8): 4169-4180, Schubert et al. (2018) J. Cytokine Biol. 3(1): 121, Teng et al. (2019) Genome Biol. 20(1): 15, Watts et al. (2008) Drug Discov. Today 13(19-20): 842-55, and Wu et al. (2018) Cell Mol. Life. Sci. 75(19): 3593-607.

In certain embodiments, one or more nucleotides or internucleotide linkages within 15, 10, 5, 4, 3, 2, or 1 nucleotides of the 3′ end of the targeter nucleic acid is modified. In certain embodiments, the nucleotide or internucleotide linkage at or near the 3′ end of the targeter nucleic acid is modified. In certain embodiments, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or internucleotide linkages within 15, 10, 5, 4, 3, or 2, or nucleotides of the 3′ end of the targeter nucleic acid (as appropriate for total number of nucleotides or internucleotide linkages modified) of the targeter nucleic acid are modified, wherein the modified nucleotides or internucleotide linkages can have the same modification, different modification, or any combination thereof. In certain embodiments, modifications can include 2′-O-methyl (M), a phosphorothioate (S), a phosphonoacetate (P), a thiophosphonoacetate (SP), a 2′-O-methyl-3′-phosphorothioate (MS), a 2′-O-methyl-3′-phosphonoacetate (MP), a 2′-O-methyl-3′-thiophosphonoacetate (MSP), a 2′-deoxy-3′-phosphonoacetate (DP), a 2′-deoxy-3′-thiophosphonoacetate (DSP), or a combination thereof, at or near the 3′ end of the targeter nucleic acid. In certain embodiments, a nucleotide at or near the 3′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotides of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-O-methyl (M). In certain embodiments, an internucleotide linkage at or near the 3′ end of the targeter sequence, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 3′ end, for example the 3′ end internucleotide linkage, comprises a phosphorothioate (S). In certain embodiments, an internucleotide linkage at or near the 3′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 3′ end, for example the 3′ end internucleotide linkage, comprises a phosphonoacetate (P). In certain embodiments, an internucleotide linkage at or near the 3′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 3′ end, for example the 3′ end internucleotide linkage, comprises a thiophosphonoacetate (SP). In certain embodiments, a nucleotide at or near the 3′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-O-methyl-3′-phosphorothioate (MS). In certain embodiments, a nucleotide at or near the 3′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-O-methyl-3′-phosphonoacetate (MP). In certain embodiments, a nucleotide at or near the 3′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-O-methyl-3′-thiophosphonoacetate (MSP). In certain embodiments, a nucleotide at or near the 3′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-deoxy-3′-phosphonoacetate (DP). In certain embodiments, a nucleotide at or near the 3′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-deoxy-3′-thiophosphonoacetate (DSP). In embodiments in which a nucleotide at or near the 3′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotides of the 3′ end, for example the 3′ end nucleotide, is modified, one or more other nucleotides at or near the 3′ end are also modified, for example, an additional 1, 2, 3, 4, 5, 6, 7, 8, or 9 nucleotides are also modified, for example with one or more of the modifications just described.

In certain embodiments, a targeter nucleic acid in a dual gNA, e.g., dual gRNA, comprises at least one nucleotide at or near the 5′ end comprising a modification to a ribose, phosphate internucleotide linkage, nucleobase, or terminal modification. In certain embodiments, the 5′ end of the targeter nucleic acid comprises the spacer sequence. In certain embodiments, the 5′ end of the targeter nucleic acid comprises the targeter stem sequence.

In certain embodiments, a nucleotide or internucleotide linkage within 15, 10, 5, 4, 3, 2, or 1 nucleotides of the 5′ end of the targeter nucleic acid is modified. In certain embodiments, the nucleotide or internucleotide linkage at or near the 5′ end of the targeter nucleic acid is modified. In certain embodiments, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or internucleotide linkages within 15, 10, 5, 4, 3, or 2, or nucleotides of the 5′ end of the targeter nucleic acid (as appropriate for total number of nucleotides or internucleotide linkages modified) of the targeter nucleic acid are modified, wherein the modified nucleotides or internucleotide linkages can have the same modification, different modification, or any combination thereof. In certain embodiments, modifications can include 2′-O-methyl (M), a phosphorothioate (S), a phosphonoacetate (P), a thiophosphonoacetate (SP), a 2′-O-methyl-3′-phosphorothioate (MS), a 2′-O-methyl-3′-phosphonoacetate (MP), a 2′-O-methyl-3′-thiophosphonoacetate (MSP), a 2′-deoxy-3′-phosphonoacetate (DP), a 2′-deoxy-3′-thiophosphonoacetate (DSP), or a combination thereof, at or near the 5′ end of the targeter nucleic acid. In certain embodiments, a nucleotide at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl (M). In certain embodiments, an internucleotide linkage at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 5′ end, for example the 5′ end internucleotide linkage, comprises a phosphorothioate (S). In certain embodiments, an internucleotide linkage at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 5′ end, for example the 5′ end internucleotide linkage, comprises a phosphonoacetate (P). In certain embodiments, an internucleotide linkage at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 5′ end, for example the 5′ end nucleotide, comprises a thiophosphonoacetate (SP). In certain embodiments, a nucleotide at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl-3′-phosphorothioate (MS). In certain embodiments, a nucleotide at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl-3′-phosphonoacetate (MP). In certain embodiments, a nucleotide at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl-3′-thiophosphonoacetate (MSP). In certain embodiments, a nucleotide at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a a 2′-deoxy-3′-phosphonoacetate (DP). In certain embodiments, a nucleotide at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-deoxy-3′-thiophosphonoacetate (DSP). In embodiments in which a nucleotide or internucleotide linkage at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide or internucleotide linkage, is modified, one or more other nucleotides or internucleotide linkages at or near the 5′ end are also modified, for example, an additional 1, 2, 3, 4, 5, 6, 7, 8, or 9 nucleotides or internucleotide linkages are modified, for example with one or more of the modifications just described.

In certain embodiments, a modulator nucleic acid in a dual gNA, e.g., dual gRNA, comprises at least one nucleotide or internucleotide linkage at or near the 3′ end comprising a modification to a ribose, phosphate internucleotide linkage, nucleobase, or terminal modification. In certain embodiments, the 3′ end of the modulator nucleic acid comprises a modulator stem sequence. In certain embodiments, the 5′ end of the modulator nucleic acid includes a 5′ sequence, e.g., a tail sequence. In certain embodiments, one or more nucleotides or internucleotide linkage within 15, 10, 5, 4, 3, 2, or 1 nucleotides of the 3′ end of the modulator nucleic acid is modified. In certain embodiments, the nucleotide or internucleotide linkage at or near the 3′ end of the modulator nucleic acid is modified. In certain embodiments, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or internucleotide linkage within 15, 10, 5, 4, 3, or 2, or nucleotides of the 3′ end of the modulator nucleic acid (as appropriate for total number of nucleotides modified) of the modulator nucleic acid are modified, wherein the modified nucleotides or internucleotide linkages can have the same modification, different modification, or any combination thereof. In certain embodiments, modifications can include 2′-O-methyl (M), a phosphorothioate (S), a phosphonoacetate (P), a thiophosphonoacetate (SP), a 2′-O-methyl-3′-phosphorothioate (MS), a 2′-O-methyl-3′-phosphonoacetate (MP), a 2′-O-methyl-3′-thiophosphonoacetate (MSP), a 2′-deoxy-3′-phosphonoacetate (DP), a 2′-deoxy-3′-thiophosphonoacetate (DSP), or a combination thereof, at or near the 3′ end of the modulator nucleic acid. In certain embodiments, a nucleotide at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-O-methyl (M). In certain embodiments, an internucleotide linkage at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkages of the 3′ end, for example the 3′ end internucleotide linkage, comprises a phosphorothioate (S). In certain embodiments, an internucleotide linkage at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 3′ end, for example the 3′ end internucleotide linkage, comprises a phosphonoacetate (P). In certain embodiments, an internucleotide linkage at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 3′ end, for example the 3′ end internucleotide linkage, comprises a thiophosphonoacetate (SP). In certain embodiments, a nucleotide at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-O-methyl-3′-phosphorothioate (MS). In certain embodiments, a nucleotide at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-O-methyl-3′-phosphonoacetate (MP). In certain embodiments, a nucleotide at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-O-methyl-3′-thiophosphonoacetate (MSP). In certain embodiments, a nucleotide at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a a 2′-deoxy-3′-phosphonoacetate (DP). In certain embodiments, a nucleotide at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-deoxy-3′-thiophosphonoacetate (DSP). In embodiments in which a nucleotide or internucleotide linkage at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide or internucleotide linkage, is modified, one or more other nucleotides or internucleotide linkages at or near the 3′ end are also modified, for example, an additional 1, 2, 3, 4, 5, 6, 7, 8, or 9 nucleotides or internucleotide linkages are modified, for example with one or more of the modifications just described.

In certain embodiments, a modulator nucleic acid, e.g., RNA, such as a single or dual gNA, e.g., single or dual gRNA, comprises at least one nucleotide at or near the 5′ end comprising a modification to a ribose, phosphate group, nucleobase, or terminal modification. In certain embodiments, the 3′ end of the modulator nucleic acid of a dual gNA comprises the modulator stem sequence. In certain embodiments, the 5′ end of the modulator nucleic acid comprises a 5′ sequence, e.g., a tail sequence. In certain embodiments, a nucleotide or internucleotide linkage within 15, 10, 5, 4, 3, 2, or 1 nucleotides of the 5′ end of the modulator nucleic acid is modified. In certain embodiments, the nucleotide or internucleotide linkage at or near the 5′ end of the modulator nucleic acid is modified. In certain embodiments, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or internucleotide linkages within 15, 10, 5, 4, 3, or 2, or nucleotides of the 5′ end of the modulator nucleic acid (as appropriate for total number of nucleotides modified) of the modulator nucleic acid are modified, wherein the modified nucleotides or internucleotide linkages can have the same modification, different modification, or any combination thereof. In certain embodiments, modifications can include 2′-O-methyl (M), a phosphorothioate (S), a phosphonoacetate (P), a thiophosphonoacetate (SP), a 2′-O-methyl-3′-phosphorothioate (MS), a 2′-O-methyl-3′-phosphonoacetate (MP), a 2′-O-methyl-3′-thiophosphonoacetate (MSP), a 2′-deoxy-3′-phosphonoacetate (DP), a 2′-deoxy-3′-thiophosphonoacetate (DSP), or a combination thereof, at or near the 5′ end of the modulator nucleic acid. In certain embodiments, a nucleotide at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl (M). In certain embodiments, an internucleotide linkage at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 5′ end, for example the 5′ end internucleotide linkage, comprises a phosphorothioate (S). In certain embodiments, an internucleotide linkage at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 5′ end, for example the 5′ end internucleotide linkage, comprises a phosphonoacetate (P). In certain embodiments, an internucleotide linkage at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 5′ end, for example the 5′ end internucleotide linkage, comprises a thiophosphonoacetate (SP). In certain embodiments, a nucleotide at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl-3′-phosphorothioate (MS). In certain embodiments, a nucleotide at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl-3′-phosphonoacetate (MP). In certain embodiments, a nucleotide at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl-3′-thiophosphonoacetate (MSP). In certain embodiments, a nucleotide at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a a 2′-deoxy-3′-phosphonoacetate (DP). In certain embodiments, a nucleotide at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-deoxy-3′-thiophosphonoacetate (DSP). In embodiments in which a nucleotide or internucleotide linkage at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide or internucleotide linkage, is modified, one or more other nucleotides or internucleotide linkages at or near the 5′ end are also modified, for example, an additional 1, 2, 3, 4, 5, 6, 7, 8, or 9 nucleotides or internucleotide linkages are modified, for example with one or more of the modifications just described.

In embodiments in which one or more nucleotides or internucleotide linkages at or near the 3′ end of the targeter nucleic acid in a dual gNA, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide or internucleotide linkage, is modified, one or more nucleotides or internucleotide linkages at or near the 5′ end of the targeter nucleic acid, for example, within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide or internucleotide linkage, is also modified. In certain embodiments, a nucleotide at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl (M). In certain embodiments, an internucleotide linkage at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 5′ end, for example the 5′ end internucleotide linkage, comprises a phosphorothioate (S). In certain embodiments, an internucleotide linkage at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 5′ end, for example the 5′ end internucleotide linkage, comprises a phosphonoacetate (P). In certain embodiments, an internucleotide linkage at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 5′ end, for example the 5′ end internucleotide linkage, comprises a thiophosphonoacetate (SP). In certain embodiments, a nucleotide at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl-3′-phosphorothioate (MS). In certain embodiments, a nucleotide at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl-3′-phosphonoacetate (MP). In certain embodiments, a nucleotide at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl-3′-thiophosphonoacetate (MSP). In certain embodiments, a nucleotide at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-deoxy-3′-phosphonoacetate (DP). In certain embodiments, a nucleotide at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-deoxy-3′-thiophosphonoacetate (DSP). In embodiments in which a nucleotide or internucleotide linkage at or near the 3′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide or internucleotide linkage, is modified, and a nucleotide or internucleotide linkage at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide or internucleotide linkage, is modified, one or more other nucleotides or internucleotide linkage at or near the 5′ end are also modified, for example, an additional 1, 2, 3, 4, 5, 6, 7, 8, or 9 nucleotides or internucleotide linkages are modified, for example with one or more of the modifications just described.

In embodiments in which one or more nucleotides or internucleotide linkages at or near the 3′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotides of the 3′ end, for example the 3′ end nucleotide or internucleotide linkage, is modified, and/or one or more nucleotides or internucleotide linkages at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotides of the 5′ end, for example the 5′ end nucleotide or internucleotide linkage, is modified, a nucleotide or internucleotide linkage at or near the 3′ end of a modulator nucleic acid, for example, within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide or internucleotide linkage, is also modified. In certain embodiments, a nucleotide at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-O-methyl (M). In certain embodiments, an internucleotide linkage at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 3′ end, for example the 3′ end internucleotide linkage, comprises a phosphorothioate (S). In certain embodiments, an internucleotide linkage at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 3′ end, for example the 3′ end internucleotide linkage, comprises a phosphonoacetate (P). In certain embodiments, an internucleotide linkage at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 3′ end, for example the 3′ end internucleotide linkage, comprises a thiophosphonoacetate (SP). In certain embodiments, a nucleotide at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-O-methyl-3′-phosphorothioate (MS). In certain embodiments, a nucleotide at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-O-methyl-3′-phosphonoacetate (MP). In certain embodiments, a nucleotide at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-O-methyl-3′-thiophosphonoacetate (MSP). In certain embodiments, a nucleotide at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a a 2′-deoxy-3′-phosphonoacetate (DP). In certain embodiments, a nucleotide at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, comprises a 2′-deoxy-3′-thiophosphonoacetate (DSP). In embodiments in which a nucleotide or internucleotide linkage at or near the 3′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide or internucleotide linkage, is modified, one or more other nucleotides or internucleotide linkages at or near the 3′ end are also modified, for example, an additional 1, 2, 3, 4, 5, 6, 7, 8, or 9 nucleotides or internucleotide linkages are modified, for example with one or more of the modifications just described.

In embodiments in which one or more nucleotides or internucleotide linkages at or near the 3′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotides of the 3′ end, for example the 3′ end nucleotide or internucleotide linkage, is modified, and/or one or more nucleotides or internucleotide linkages at or near the 5′ end of the targeter nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotides of the 5′ end, for example the 5′ end nucleotide or internucleotide linkage, is modified, and/or one or more nucleotides or internucleotide linkages at or near the 3′ end of a modulator nucleic acid, for example, within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide or internucleotide linkage, is modified, one or more nucleotides or internucleotide linkages at or near the 5′ end of a modulator nucleic acid, for example, within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide or internucleotide linkage, is modified. In certain embodiments, a nucleotide at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl (M). In certain embodiments, an internucleotide linkage at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 5′ end, for example the 5′ end internucleotide linkage, comprises a phosphorothioate (S). In certain embodiments, an internucleotide linkage at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 5′ end, for example the 5′ end internucleotide linkage, comprises a phosphonoacetate (P). In certain embodiments, an internucleotide linkage at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 internucleotide linkage of the 5′ end, for example the 5′ end internucleotide linkage, comprises a thiophosphonoacetate (SP). In certain embodiments, a nucleotide at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl-3′-phosphorothioate (MS). In certain embodiments, a nucleotide at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl-3′-phosphonoacetate (MP). In certain embodiments, a nucleotide at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-O-methyl-3′-thiophosphonoacetate (MSP). In certain embodiments, a nucleotide at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-deoxy-3′-phosphonoacetate (DP). In certain embodiments, a nucleotide at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 5′ end nucleotide, comprises a 2′-deoxy-3′-thiophosphonoacetate (DSP). In embodiments in which a nucleotide or internucleotide linkage at or near the 5′ end of the modulator nucleic acid, for example within 10, 5, 4, 3, 2, or 1 nucleotide of the 5′ end, for example the 3′ end nucleotide or internucleotide linkage, is modified, one or more other nucleotides or internucleotide linkages at or near the 5′ end are also modified, for example, an additional 1, 2, 3, 4, 5, 6, 7, 8, or 9 nucleotides or internucleotide linkages are modified, for example with one or more of the modifications just described.

In certain embodiments in which the 3′ end of the targeter nucleic acid is unmodified, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator may be modified. In certain embodiments, the modifications comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or internucleotide linkages within 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 nucleotides or internucleotide linkages of the 5′ end of the modulator (as appropriate for total number of nucleotides modified), wherein the modified nucleotides or internucleotide linkages can have the same modification, different modification, or any combination thereof. In certain embodiments, the modifications comprise 1-5, 1-4, 1-3, 1-2, 2-4, 2-3, for example 1, 2, 3, 4, or 5, 2′-O-methoxy-3′-phosphorothioate modifications within 5, 4, 3, 2 or 1 (as appropriate for total number of nucleotides modified) nucleotides of the 5′ end of the modulator nucleic acid. In certain embodiments, the modifications comprise 1-3, for example 1, 2, or 3, 2′-O-methoxy-3′-phorophothioate modifications within the first 3 nucleotides of the 5′ end of the modulator nucleic acid. In a preferred embodiment, the first 2 nucleotides of the 5′ end of the modulator nucleic acid are 2′-O-methoxy-3′-phosphorothioate modified. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in which the 3′ end of the targeter nucleic acid is unmodified, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator may be modified. In certain embodiments, the modifications comprise 1-17, 2-16, 3-15, 4-14, 5-13, 6-12, 7-11, or 8-10, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17, phosphorothioate modification within the first 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 (as appropriate for total number of nucleotides modified) internucleotide linkages of the 5′ end of the modulator nucleic acid. In certain embodiments, the modifications comprise 8-10, for example 8, 9 or 10, phosphorothioate modifications within the first 10, 9 or 8 internucleotide linkages (as appropriate for total number of internucleotide linkages modified) of the 5′ end of the modulator nucleic acid. In a preferred embodiment, the first 9 internucleotide linkages of the 5′ end of the modulator nucleic acid are phosphorothioate modified. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in which the 3′ end of the targeter nucleic acid is unmodified, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator may be modified. In certain embodiments, modifications comprise 1-3, for example, 1, 2, or 3, 2′-O-methoxy and/or 1-3, for example, 1, 2, or 3, 3′-phosphorothioate modifications within the first 3 nucleotides (as appropriate for the total number of nucleotides modified) of the 5′ end of the modulator nucleic acid. In this embodiment, any combination of 2′-O-methoxy nucleotide modifications and phosphorothioate internucleotide modifications may be used. In a preferred embodiment, the first nucleotide from the 5′ end of the modulator nucleic acid is 2′-O-methoxy-3′-phosphorothioate modified and the second internucleotide linkage is phosphorothioate modified. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in which the 3′ end of the targeter nucleic acid is unmodified, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, the 5′ end of the modulator nucleic acid is modified with a terminal propanediol. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in which the 3′ end of the targeter nucleic acid comprises a terminal propanediol modification, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, the modifications comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or internucleotide linkages within 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 nucleotides or internucleotide linkages of the 5′ end of the modulator (as appropriate for total number of nucleotides modified), wherein the modified nucleotides or internucleotide linkages can have the same modification, different modification, or any combination thereof. In certain embodiments, the modifications comprise 1-5, 1-4, 1-3, 1-2, 2-4, 2-3, for example 1, 2, 3, 4, or 5, 2′-O-methoxy-3′-phosphorothioate modifications within 5, 4, 3, 2 or 1 (as appropriate for total number of nucleotides modified) nucleotides of the 5′ end of the modulator nucleic acid. In certain embodiments, the modifications comprise 1-3, for example 1, 2, or 3, 2′-O-methoxy-3′-phorophothioate modifications within the first 3 nucleotides of the 5′ end of the modulator nucleic acid. In a preferred embodiment, the first 2 nucleotides of the 5′ end of the modulator nucleic acid are 2′-O-methoxy-3′-phosphorothioate modified. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in which the 3′ end of the targeter nucleic acid comprises a terminal propanediol modification, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, the modifications comprise 1-17, 2-16, 3-15, 4-14, 5-13, 6-12, 7-11, or 8-10, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17, phosphorothioate modification within the first 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 (as appropriate for total number of nucleotides modified) internucleotide linkages of the 5′ end of the modulator nucleic acid. In certain embodiments, the modifications comprise 8-10, for example 8, 9 or 10, 3 phosphorothioate modifications within the first 10, 9 or 8 internucleotide linkages (as appropriate for total number of internucleotide linkages modified) of the 5′ end of the modulator nucleic acid. In a preferred embodiment, the first 9 internucleotide linkages of the 5′ end of the modulator nucleic acid are phosphorothioate modified. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in which the 3′ end of the targeter nucleic acid comprises a terminal propanediol modification, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, modifications comprise 1-3, for example, 1, 2, or 3, 2′-O-methoxy and/or 1-3, for example, 1, 2, or 3, 3′-phosphorothioate modifications within the first 3 nucleotide (as appropriate for the total number of nucleotides modified) of the 5′ end of the modulator nucleic acid. In this embodiment, any combination of 2′-O-methoxy and 3′-phosphorothioate modifications may be used. In a preferred embodiment, the first nucleotide from the 5′ end of the modulator nucleic acid is 2′-O-methoxy-3′-phosphorothioate modified and the second nucleotide is 3′-phosphorothioate modified. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in which the 3′ end of the targeter nucleic acid comprises a terminal propanediol modification, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, the 5′ end of the modulator nucleic acid is modified with a terminal propanediol. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in which the 3′ end of the targeter nucleic acid comprises two 2′-O-methoxy-3′-phosphorothioate modifications, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, the modifications comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or internucleotide linkages within 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 nucleotides or internucleotide linkages of the 5′ end of the modulator (as appropriate for total number of nucleotides modified), wherein the modified nucleotides or internucleotide linkages can have the same modification, different modification, or any combination thereof. In certain embodiments, the modifications comprise 1-5, 1-4, 1-3, 1-2, 2-4, 2-3, for example 1, 2, 3, 4, or 5, 2′-O-methoxy-3′-phosphorothioate modifications within 5, 4, 3, 2 or 1 (as appropriate for total number of nucleotides modified) nucleotides of the 5′ end of the modulator nucleic acid. In certain embodiments, the the modifications comprise 1-3, for example 1, 2, or 3, 2′-O-methoxy-3′-phorophothioate modifications within the first 3 nucleotides of the 5′ end of the modulator nucleic acid. In a preferred embodiment, the first 2 nucleotides of the 5′ end of the modulator nucleic acid are 2′-O-methoxy-3′-phosphorothioate modified. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in which the 3′ end of the targeter nucleic acid comprises two 2′-O-methoxy-3′-phosphorothioate modifications, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, the modifications comprise 1-17, 2-16, 3-15, 4-14, 5-13, 6-12, 7-11, or 8-10, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17, phosphorothioate modifications within the first 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 (as appropriate for total number of nucleotides modified) internucleotide linkages of the 5′ end of the modulator nucleic acid. In certain embodiments, the modifications comprise 8-10, for example 8, 9 or 10, phosphorothioate modifications within the first 10, 9 or 8 internucleotide linkages (as appropriate for total number of nucleotides modified) of the 5′ end of the modulator nucleic acid. In a preferred embodiment, the first 9 nucleotides of the 5′ end of the modulator nucleic acid are 3′-phosphorothioate modified. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in which the 3′ end of the targeter nucleic acid comprises two 2′-O-methoxy-3′-phosphorothioate modifications, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, modifications comprise 1-3, for example, 1, 2, or 3, 2′-O-methoxy and/or 1-3, for example, 1, 2, or 3, 3′-phosphorothioate modifications within the first 3 nucleotide (as appropriate for the total number of nucleotides modified) of the 5′ end of the modulator nucleic acid. In this embodiment, any combination of 2′-O-methoxy and 3′-phosphorothioate modifications may be used. In a preferred embodiment, the first nucleotide from the 5′ end of the modulator nucleic acid is 2′-O-methoxy-3′-phosphorothioate modified and the second nucleotide is 3′-phosphorothioate modified. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in which the 3′ end of the targeter nucleic acid comprises two 2′-O-methoxy-3′-phosphorothioate modifications, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, the 5′ end of the modulator nucleic acid is modified with a terminal propanediol. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in 3′ end of the targeter nucleic acid comprises five 2′-fluoro modifications, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, the modifications comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides or internucleotide linkages within 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 nucleotides or internucleotide linkages of the 5′ end of the modulator (as appropriate for total number of nucleotides modified), wherein the modified nucleotides or internucleotide linkages can have the same modification, different modification, or any combination thereof. In certain embodiments, the modifications comprise 1-5, 1-4, 1-3, 1-2, 2-4, 2-3, for example 1, 2, 3, 4, or 5, 2′-O-methoxy-3′-phosphorothioate modifications within 5, 4, 3, 2 or 1 (as appropriate for total number of nucleotides modified) nucleotides of the 5′ end of the modulator nucleic acid. In certain embodiments, the the modifications comprise 1-3, for example 1, 2, or 3, 2′-O-methoxy-3′-phorophothioate modifications within the first 3 nucleotides of the 5′ end of the modulator nucleic acid. In a preferred embodiment, the first 2 nucleotides of the 5′ end of the modulator nucleic acid are 2′-O-methoxy-3′-phosphorothioate modified. For each of the described embodiments, the 3′ nucleotide of the moculator nucleic acid nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in 3′ end of the targeter nucleic acid comprises five 2′-fluoro modifications, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, the modifications comprise 1-17, 2-16, 3-15, 4-14, 5-13, 6-12, 7-11, or 8-10, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17, phosphorothioate modification within the first 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 (as appropriate for total number of nucleotides modified) internucleotide linkages of the 5′ end of the modulator nucleic acid. In certain embodiments, the modifications comprise 8-10, for example 8, 9 or 10, phosphorothioate modifications within the first 10, 9 or 8 internucleotide linkages (as appropriate for total number of nucleotides modified) of the 5′ end of the modulator nucleic acid. In a preferred embodiment, the first 9 internucleotide linkages of the 5′ end of the modulator nucleic acid are phosphorothioate modified. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in 3′ end of the targeter nucleic acid comprises five 2′-fluoro modifications, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, modifications comprise 1-3, for example, 1, 2, or 3, 2′-O-methoxy and/or 1-3, for example, 1, 2, or 3, 3′-phosphorothioate modifications within the first 3 nucleotides or internucleotide linkages (as appropriate for the total number of nucleotides or internucleotide linkages modified) of the 5′ end of the modulator nucleic acid. In this embodiment, any combination of 2′-O-methoxy and phosphorothioate modifications may be used. In a preferred embodiment, the first nucleotide from the 5′ end of the modulator nucleic acid is 2′-O-methoxy-3′-phosphorothioate modified and the second internucleotide linkage is phosphorothioate modified. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments in 3′ end of the targeter nucleic acid comprises five 2′-fluoro modifications, one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid may be modified. In certain embodiments, the 5′ end of the modulator nucleic acid is modified with a terminal propanediol. For each of the described embodiments, the 3′ nucleotide of the modulator nucleic acid is may be either an A, T, G, C with a preferred terminal nucleotide of either A or C.

In certain embodiments the modulator nucleic acid comprises any one of SEQ ID NOs: 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, or 1037. In certain embodiments, the targeter nucleic acid comprises a stem sequence complementary to a modulator stem sequence of any one of SEQ ID NOs: 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, or 1037 and a spacer sequence that may hybridize with a target nucleotide sequence in a target DNA of interest to a skilled artisan. Such a targeter nucleic acid may comprise any composition of modifications as described herein.

In certain embodiments, modulator and targeter nucleic acids comprise a single polynucleotide wherein the stem sequence of the modulator is in physically connection to the stem sequence of the targeter nucleic acid through a linker, e.g., a loop sequence or a chemical spacer sequence, e.g., a propanediol linker and the like. In certain embodiments, modulator and target nucleic acids are separate polynucleotides. In either of these embodiments, the gNA may comprise any combination of chemical modification as desired by one skilled in the art.

In certain embodiments, the modification alters the specificity of the engineered, non-naturally occurring system. In certain embodiments, the modification enhances the specificity of the engineered, non-naturally occurring system, e.g., by enhancing on-target binding and/or cleavage, or reducing off-target binding and/or cleavage, or a combination thereof. Specificity-enhancing modifications include but are not limited to 2-thiouracil, 2-thiocytosine, 4-thiouracil, 6-thioguanine, 2-aminoadenine, and pseudouracil. Within 10, 5, 4, 3, 2, or 1 nucleotide of the 3′ end, for example the 3′ end nucleotide, is modified

In certain embodiments, the modification alters the immunostimulatory effect of the RNA relative to a corresponding RNA without the modification. For example, in certain embodiments, the modification reduces the ability of the RNA to activate TLR7, TLR8, TLR9, TLR3, RIG-I, and/or MDAS.

In certain embodiments, the targeter nucleic acid and/or the modulator nucleic acid comprise at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 modified nucleotides or internucleotide linkages. The modification can be made at one or more positions in the targeter nucleic acid and/or the modulator nucleic acid such that these nucleic acids retain functionality. For example, the modified nucleic acids can still direct the Cas protein to the target nucleotide sequence and allow the Cas protein to exert its effector function. It is understood that the particular modification(s) at a position may be selected based on the functionality of the nucleotide or internucleotide linkage at the position. For example, a specificity-enhancing modification may be suitable for a nucleotide or internucleotide linkage in the spacer sequence, the targeter stem sequence, or the modulator stem sequence. A stability-enhancing modification may be suitable for one or more terminal nucleotides or internucleotide linkages in the targeter nucleic acid and/or the modulator nucleic acid. In certain embodiments, at least 1 (e.g., at least 2, at least 3, at least 4, or at least 5) terminal nucleotides or internucleotide linkages at or near the 5′ end and/or at least 1 (e.g., at least 2, at least 3, at least 4, or at least 5) terminal nucleotides or internucleotide linkages at or near the 3′ end of the targeter nucleic acid are modified. In certain embodiments, 5 or fewer (e.g., 1 or fewer, 2 or fewer, 3 or fewer, or 4 or fewer) terminal nucleotides or internucleotide linkages at or near the 5′ end and/or 5 or fewer (e.g., 1 or fewer, 2 or fewer, 3 or fewer, or 4 or fewer) terminal nucleotides or internucleotide linkages at or near the 3′ end of the targeter nucleic acid are modified. In certain embodiments, at least 1 (e.g., at least 2, at least 3, at least 4, or at least 5) terminal nucleotides or internucleotide linkages at or near the 5′ end and/or at least 1 (e.g., at least 2, at least 3, at least 4, or at least 5) terminal nucleotides or internucleotide linkages at or near the 3′ end of the modulator nucleic acid are modified. In certain embodiments, 5 or fewer (e.g., 1 or fewer, 2 or fewer, 3 or fewer, or 4 or fewer) terminal nucleotides or internucleotide linkages at or near the 5′ end and/or 5 or fewer (e.g., 1 or fewer, 2 or fewer, 3 or fewer, or 4 or fewer) terminal nucleotides or internucleotide linkages at or near the 3′ end of the modulator nucleic acid are modified. Selection of positions for modifications is described in U.S. Pat. Nos. 10,900,034 and 10,767,175. As used in this paragraph, where the targeter or modulator nucleic acid is a combination of DNA and RNA, the nucleic acid as a whole is considered as an RNA, and the DNA nucleotide(s) are considered as modification(s) of the RNA, including a 2′-H modification of the ribose and optionally a modification of the nucleobase.

It is understood that, in dual guide nucleic acid systems the targeter nucleic acid and the modulator nucleic acid, while not in the same nucleic acids, i.e., not linked end-to-end through a traditional internucleotide bond, can be covalently conjugated to each other through one or more chemical modifications introduced into these nucleic acids, thereby increasing the stability of the double-stranded complex and/or improving other characteristics of the system.

B. Targeter and Modulator Nucleic Acids

The engineered, non-naturally occurring systems provided herein comprise a targeter nucleic acid and a modulator nucleic acid, one or both of which contains a modification of one or more nucleotides or internucleotide linkages at or near 3′ end, at or near the 5′, or at or near both ends, that, when hybridized to form a complex, are capable of activating a Cas nuclease disclosed herein. In certain embodiments, the Cas nuclease is activated by a single crRNA in the absence of a tracrRNA in a naturally occurring system. In certain embodiments, the Cas nuclease is a Type I, II, III, IV, V, or VI nuclease. In certain embodiments, the Cas nuclease is a Type V nuclease. In certain embodiments, the Cas nuclease is a type V-A, type V-C, or type V-D nuclease. In certain embodiments, the Cas nuclease is a Type V-A nuclease.

The term “targeter nucleic acid,” as used herein, includes a nucleic acid comprising (i) a spacer sequence designed to hybridize with a target nucleotide sequence; and (ii) a targeter stem sequence capable of hybridizing with an additional nucleic acid to form a complex, wherein the complex is capable of activating a Cas nuclease (e.g., a type V-A Cas nuclease) under suitable conditions, and wherein the targeter nucleic acid alone, in the absence of the additional nucleic acid, is not capable of activating the Cas nuclease under the same conditions.

The term “modulator nucleic acid,” as used herein in connection with a given targeter nucleic acid and its corresponding Cas nuclease, includes a nucleic acid capable of hybridizing with the targeter nucleic acid to form a complex, wherein the complex, but not the modulator nucleic acid alone, is capable of activating the type Cas nuclease under suitable conditions.

The term “suitable conditions,” as used in the definitions of “targeter nucleic acid” and “modulator nucleic acid,” includes the conditions under which a naturally occurring CRISPR-Cas system is operative, such as in a prokaryotic cell, in a eukaryotic (e.g., mammalian or human) cell, or in an in vitro assay.

The targeter nucleic acid and/or the modulator nucleic acid can be synthesized chemically or produced in a biological process (e.g., catalyzed by an RNA polymerase in an in vitro reaction). Such reaction or process may limit the lengths of the targeter and modulator nucleic acids. In certain embodiments, the targeter nucleic acid is no more than 100, 90, 80, 70, 60, 50, 40, 30, or 25 nucleotides in length. In certain embodiments, the targeter nucleic acid is at least 20, 25, 30, 40, 50, 60, 70, 80, or 90 nucleotides in length. In certain embodiments, the targeter nucleic acid is 20-100, 20-90, 20-80, 20-70, 20-60, 20-50, 20-40, 20-30, 20-25, 25-100, 25-90, 25-80, 25-70, 25-60, 25-50, 25-40, 25-30, 30-100, 30-90, 30-80, 30-70, 30-60, 30-50, 30-40, 40-100, 40-90, 40-80, 40-70, 40-60, 40-50, 50-100, 50-90, 50-80, 50-70, 50-60, 60-100, 60-90, 60-80, 60-70, 70-100, 70-90, 70-80, 80-100, 80-90, or 90-100 nucleotides in length. In certain embodiments, the modulator nucleic acid is no more than 100, 90, 80, 70, 60, 50, 40, 30, or 20 nucleotides in length. In certain embodiments, the modulator nucleic acid is at least 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, or 90 nucleotides in length. In certain embodiments, the modulator nucleic acid is 10-100, 10-90, 10-80, 10-70, 10-60, 10-50, 10-40, 10-30, 10-20, 15-100, 15-90, 15-80, 15-70, 15-60, 15-50, 15-40, 15-30, 15-20, 20-100, 20-90, 20-80, 20-70, 20-60, 20-50, 20-40, 20-30, 25-100, 25-90, 25-80, 25-70, 25-60, 25-50, 25-40, 25-30, 30-100, 30-90, 30-80, 30-70, 30-60, 30-50, 30-40, 40-100, 40-90, 40-80, 40-70, 40-60, 40-50, 50-100, 50-90, 50-80, 50-70, 50-60, 60-100, 60-90, 60-80, 60-70, 70-100, 70-90, 70-80, 80-100, 80-90, or 90-100 nucleotides in length.

In naturally occurring type V-A CRISPR-Cas systems, the crRNA comprises a scaffold sequence (also called direct repeat sequence) and a spacer sequence that hybridizes with the target nucleotide sequence. In certain naturally occurring type V-A CRISPR-Cas systems, the scaffold sequence forms a stem-loop structure in which the stem consists of five consecutive base pairs. A dual guide type V-A CRISPR-Cas system may be derived from a naturally occurring type V-A CRISPR-Cas system, or a variant thereof in which the Cas protein is guided to the target nucleotide sequence by a crRNA alone, such system referred to herein as a “single guide type V-A CRISPR-Cas system.” In certain modified dual guide type V-A CRISPR-Cas systems disclosed herein, the targeter nucleic acid comprises the chain of the stem sequence between the spacer and the loop (the “targeter stem sequence”) and the spacer sequence, and the modulator nucleic acid comprises the other chain of the stem sequence (the “modulator stem sequence”) and the 5′ sequence, e.g., a tail sequence, positioned 5′ to the modulator stem sequence. The targeter stem sequence is 100% complementary to the modulator stem sequence. As such, the double-stranded complex of the targeter nucleic acid and the modulator nucleic acid retains the orientation of the 5′ sequence, e.g., a tail sequence, the modulator stem sequence, the targeter stem sequence, and the spacer sequence of a single guide type V-A CRISPR-Cas system but lacks the loop structure between the modulator stem sequence and the targeter stem sequence. A schematic representation of an exemplary double-stranded complex is shown in FIG. 1 .

Notwithstanding the general structural similarity, it has been discovered that the stem-loop structure of the crRNA in a naturally occurring type V-A CRISPR complex is dispensable for the functionality of the CRISPR system. This discovery is surprising because the prior art has suggested that the stem-loop structure is critical (see, Zetsche et al. (2015) CELL, 163: 759) and that removal of the loop structure by “splitting” the crRNA abrogated the activity of a AsCpfl CRISPR system (see, Li et al. (2017) NAT. BIOMED. ENG., 1: 0066).

It is contemplated that the length of the duplex may be a factor in providing an operative modified dual guide CRISPR system. In certain embodiments, the targeter stem sequence and the modulator stem sequence each consist of 4-10 nucleotides that base pair with each other. In certain embodiments, the targeter stem sequence and the modulator stem sequence each consist of 4-9, 4-8, 4-7, 4-6, 4-5, 5-10, 5-9, 5-8, 5-7, or 5-6 nucleotides that base pair with each other. In certain embodiments, the targeter stem sequence and the modulator stem sequence each consist of 4, 5, 6, 7, 8, 9, or 10 nucleotides. It is understood that the composition of the nucleotides in each sequence affects the stability of the duplex, and a C-G base pair confers greater stability than an A-U base pair. In certain embodiments, 20%-80%, 20%-70%, 20%-60%, 20%-50%, 20%-40%, 20%-30%, 30%-80%, 30%-70%, 30%-60%, 30%-50%, 30%-40%, 40%-80%, 40%-70%, 40%-60%, 40%-50%, 50%-80%, 50%-70%, 50%-60%, 60%-80%, 60%-70%, or 70%-80% of the base pairs are C-G base pairs. In certain embodiments, the targeter stem sequence and the modulator stem share at least 80%, 85%, 90%, 95%, 99%, 99.5%, or 100% sequence complementarity. In a preferred embodiment, the target stem sequence and the modulator stem sequence share at 80-100% sequence complementarity.

In certain embodiments, the targeter stem sequence and the modulator stem sequence each consist of 5 nucleotides. As such, the targeter stem sequence and the modulator stem sequence form a duplex of 5 base pairs. In certain embodiments, 0-4, 0-3, 0-2, 0-1, 1-5, 1-4, 1-3, 1-2, 2-5, 2-4, 2-3, 3-5, 3-4, or 4-5 out of the 5 base pairs are C-G base pairs. In certain embodiments, 0, 1, 2, 3, 4, or 5 out of the 5 base pairs are C-G base pairs. In certain embodiments, the targeter stem sequence consists of 5′-GUAGA-3′ (SEQ ID NO: 21) and the modulator stem sequence consists of 5′-UCUAC-3′. In certain embodiments, the targeter stem sequence consists of 5′-GUGGG-3′ (SEQ ID NO: 22) and the modulator stem sequence consists of 5′-CCCAC-3′.

It is also contemplated that the compatibility of the duplex for a given Cas nuclease may be a factor in providing an operative modified dual guide CRISPR system. For example, the targeter stem sequence and the modulator stem sequence can be derived from a naturally occurring crRNA capable of activating a Cas nuclease in the absence of a tracrRNA. In certain embodiments, the nucleotide sequences of the targeter stem sequence and the modulator stem sequence are identical to the corresponding stem sequences of a stem-loop structure in such naturally occurring crRNA.

In certain embodiments, the targeter nucleic acid comprises, from 5′ to 3′, a targeter stem sequence and a spacer sequence. The spacer sequence is designed to hybridize with the target nucleotide sequence. To provide sufficient targeting to the target nucleotide sequence, the spacer sequence is generally 16 or more nucleotides in length. In certain embodiments, the spacer sequence is at least 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides in length. In certain embodiments, the spacer sequence is shorter than or equal to 75, 50, 45, 40, 35, 30, 25, or 20 nucleotides in length. Shorter spacer sequence may be desirable for reducing off-target events. Accordingly, in certain embodiments, the spacer sequence is shorter than or equal to 19, 18, or 17 nucleotides. In certain embodiments, the spacer sequence is 17-30 nucleotides in length, e.g., 20-30 nucleotides, 20-25 nucleotides, 20-24 nucleotides, 20-23 nucleotides, 23-25 nucleotides, 20-22 nucleotides, such as 20 or 21 nucleotides in length. In certain embodiments, the spacer sequence is 21 nucleotides in length. In certain embodiments, the spacer sequence is 20 nucleotides in length. In certain embodiments, the spacer sequence is at least 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% complementary to the target nucleotide sequence. In certain embodiments, the spacer sequence is 100% complementary to the target nucleotide sequence in the seed region (5-10 base pairs proximal to the PAM). In certain embodiments, the spacer sequence is 100% complementary to the target nucleotide sequence. It has been reported that compared to DNA binding, DNA cleavage is less tolerant to mismatches between the spacer sequence and the target nucleotide sequence (see, Klein et al. (2018) CELL REPORTS, 22: 1413). Accordingly, in specific embodiments, when the engineered, non-naturally occurring system comprises a Cas nuclease, the spacer sequence is 100% complementary to the target nucleotide sequence.

Proper design of the spacer sequence is dependent upon the selection of target nucleotide sequence. For example, to select a target nucleotide sequence in a specific gene in a given genome, sequence analysis can be conducted to minimize potential hybridization of the spacer sequence with any other loci in the genome. The association of the target nucleotide sequence with a PAM recognized by the Cas protein is also considered by many design methods. In a type V-A CRISPR-Cas system, the PAM is immediately upstream from the target nucleotide sequence when using the non-target strand (i.e., the strand not hybridized with the spacer sequence) as the coordinate. Computational models have been developed to assess the targetability of the target nucleotide sequence as well as any potential off-target effect, for example, as disclosed in Doench et al. (2016) NAT. BIOTECHNOL., 34: 184; Chuai et al. (2018) GENOME BIOLOGY, 19: 80; and Klein et al. (2018) CELL REPORTS, 22: 1413. Although computational methods are useful for selection of spacer sequences, it is generally advisable to design multiple spacer sequences and select one or more with high efficiency and specificity based upon the results of in vitro and/or in vivo experiments.

In certain embodiments, the engineered CRISPR-Cas systems (e.g., type V-A CRISPR-Cas systems) provided can be used to target, edit, or otherwise modify specific target nucleotide sequences in human ADORA2A, B2M, CD3E, CD38, CD40LG, CD52, CIITA, CSF2, CTLA4, DCK, FAS, HAVCR2 (also called TIM3), LAG3, PDCD1 (also called PD-1), PTPN6, TIGIT, TRAC, TRBC1, TRBC2, TRBC1_2 (or TRBC1+2), CARD11, CD247, IL7R, LCK, PLCG1, ALPNR, BBS1, CALR, CD3G, CD58, COL17A1, DEFB134, ERAP1, ERAP2, IFNGR1, IFNGR2, JAKE JAK2, mir-101-2, MLANA, PSMB5, PSMB8, PSMB9, PTCD2, RFX5, RFXANK, RFXAP, RPL23, SOX10, SRP54, STAT1, Tap1, TAP2, TAPBP, TWF1, CD3D, or NLRC5 gene. In particular, the modified guide nucleic acids, such as single guide nucleic acids and dual guide nucleic acids, can be designed to hybridize with the selected target nucleotide sequence and, e.g., activate a Cas nuclease to edit the human genes. CRISPR-Cas systems comprising such guide nucleic acids are also useful for targeting or modifying the human genes.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 51 and 131-137, wherein the spacer sequence is capable of hybridizing with the human ADORA2A gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the ADORA2A gene locus is edited in at least 1.5% of the cells.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 52, 64-66, 138-145, 622, 625-626, and 634-635, wherein the spacer sequence is capable of hybridizing with the human B2M gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the B2M gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human ADORA2A gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 724, 726-727, 730-732, 735-738, 741-742, and 744-745, wherein the spacer sequence is capable of hybridizing with the human CD247 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CD247 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CD247 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 53 and 146, wherein the spacer sequence is capable of hybridizing with the human CD52 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CD52 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CD52 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 54, 147-148, 636-640, 642, 644-648, 650-652, 655-656, 660-663, 666, 668, 670-671, 673-676, 678-679, and 682-685, wherein the spacer sequence is capable of hybridizing with the human CIITA gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CIITA gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CIITA gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 795, 67, 797, 798, 70, and 149-155, wherein the spacer sequence is capable of hybridizing with the human CTLA4 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CTLA4 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CTLA4 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 796, 71-74, and 156-159, wherein the spacer sequence is capable of hybridizing with the human DCK gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the DCK gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human DCK gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 57, 75-79, and 160-173, wherein the spacer sequence is capable of hybridizing with the human FAS gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the FAS gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human FAS gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 58, 80, 799, 800, 83-86, and 174-187, wherein the spacer sequence is capable of hybridizing with the human HAVCR2 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the HAVCR2 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human HAVCR2 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 748-749 and 753-754, wherein the spacer sequence is capable of hybridizing with the human IL7R gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the IL7R gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human IL7R gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 59, 87, 88, and 188-198, wherein the spacer sequence is capable of hybridizing with the human LAG3 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the LAG3 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human LAG3 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises the nucleotide sequence of SEQ ID NO: 757, wherein the spacer sequence is capable of hybridizing with the human LCK gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the LCK gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human LCK gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 60, 89-92, and 199-201, wherein the spacer sequence is capable of hybridizing with the human PDCD1 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the PDCD1 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human PDCD1 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 759 and 761-762, wherein the spacer sequence is capable of hybridizing with the human PLCG1 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the PLCG1 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human PLCG1 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 61, 93, 801, 802, 96-101, 803, 103, 104, and 202-213, wherein the spacer sequence is capable of hybridizing with the human PTPN6 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the PTPN6 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human PTPN6 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 62, 105, and 214-217, wherein the spacer sequence is capable of hybridizing with the human TIGIT gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the TIGIT gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human TIGIT gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 63, 106, 804, 805, 109-130, and 218-241, wherein the spacer sequence is capable of hybridizing with the human TRAC gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the TRAC gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human TRAC gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 705-706, 711-712, 714-715, 717, and 719-720, wherein the spacer sequence is capable of hybridizing with the human TRBC2 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the TRBC2 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human TRBC2 gene, for example one of the spacer sequences above.

In certain embodiments, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 705-706, wherein the spacer sequence is capable of hybridizing with both the human TRBC1 gene and the human TRBC2 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the TRBC1 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human TRBC1 gene and the human TRBC2 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 721-723, wherein the spacer sequence is capable of hybridizing with the human CARD11 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CARD11 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CARD11 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1255-1291, wherein the spacer sequence is capable of hybridizing with the human CD38 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CD38 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CD38 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1213-1254, wherein the spacer sequence is capable of hybridizing with the human CD3E gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CD3E gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CD3E gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1153-1212, wherein the spacer sequence is capable of hybridizing with the human CD40LG gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CD40LG gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CD40LG gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1100-1152, wherein the spacer sequence is capable of hybridizing with the human CSF2 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CSF2 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CSF2 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1292-1301, wherein the spacer sequence is capable of hybridizing with the human APLNR gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the APLNR gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human APLNR gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1302-1311, wherein the spacer sequence is capable of hybridizing with the human BBS1 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the BBS1 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human BBS1 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1312-1321, wherein the spacer sequence is capable of hybridizing with the human CALR gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CALR gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CALR gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1322-1331, wherein the spacer sequence is capable of hybridizing with the human CD3G gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CD3G gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CD3G gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1332-1341, wherein the spacer sequence is capable of hybridizing with the human CD58 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CD58 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CD58 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1342-1351, wherein the spacer sequence is capable of hybridizing with the human COL17A1 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the COL17A1 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human COL17A1 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1352-1361, wherein the spacer sequence is capable of hybridizing with the human DEFB134 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the DEFB134 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human DEFB134 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1362-1371, wherein the spacer sequence is capable of hybridizing with the human ERAP1 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the ERAP1 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human ERAP1 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1372-1381, wherein the spacer sequence is capable of hybridizing with the human ERAP2 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the ERAP2 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human ERAP2 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1382-1391, wherein the spacer sequence is capable of hybridizing with the human IFNGR1 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the IFNGR1 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human IFNGR1 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1392-1401, wherein the spacer sequence is capable of hybridizing with the human IFNGR2 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the IFNGR2 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human IFNGR2 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1402-1411, wherein the spacer sequence is capable of hybridizing with the human JAK1 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the JAK1 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human JAK1 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1412-1421, wherein the spacer sequence is capable of hybridizing with the human JAK2 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the JAK2 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human JAK2 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1422-1424, wherein the spacer sequence is capable of hybridizing with the human mir-101-2 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the mir-101-2 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human mir-101-2 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1425-1434, wherein the spacer sequence is capable of hybridizing with the human MLANA gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the MLANA gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human MLANA gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1435-1444, wherein the spacer sequence is capable of hybridizing with the human PSMB5 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the PSMB5 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human PSMB5 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1445-1454, wherein the spacer sequence is capable of hybridizing with the human PSMB8 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the PSMB8 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human PSMB8 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1455-1464, wherein the spacer sequence is capable of hybridizing with the human PSMB9 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the PSMB9 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human PSMB9 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1465-1474, wherein the spacer sequence is capable of hybridizing with the human PTCD2 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the PTCD2 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human PTCD2 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1475-1484, wherein the spacer sequence is capable of hybridizing with the human RFX5 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the RFX5 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human RFX5 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1485-1494, wherein the spacer sequence is capable of hybridizing with the human RFXANK gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the RFXANK gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human RFXANK gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1495-1504, wherein the spacer sequence is capable of hybridizing with the human RFXAP gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the RFXAP gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human RFXAP gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1505-1514, wherein the spacer sequence is capable of hybridizing with the human RPL23 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the RPL23 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human RPL23 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1515-1520, wherein the spacer sequence is capable of hybridizing with the human SOX10 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the SOX10 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human SOX10 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1521-1531, wherein the spacer sequence is capable of hybridizing with the human SRP54 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the SRP54 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human SRP54 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1532-1541, wherein the spacer sequence is capable of hybridizing with the human STAT1 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the STAT1 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human STAT1 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1542-1551, wherein the spacer sequence is capable of hybridizing with the human Tap1 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the Tap1 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human Tap1 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1552-1561, wherein the spacer sequence is capable of hybridizing with the human TAP2 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the TAP2 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human TAP2 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1562-1571, wherein the spacer sequence is capable of hybridizing with the human TAPBP gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the TAPBP gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human TAPBP gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1572-1581, wherein the spacer sequence is capable of hybridizing with the human TWF1 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the TWF1 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human TWF1 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1582-1591, wherein the spacer sequence is capable of hybridizing with the human CD3D gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the CD3D gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human CD3D gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the spacer sequence comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1592-1610, wherein the spacer sequence is capable of hybridizing with the human NLRC5 gene. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the NLRC5 gene locus is edited in at least 1.5% of the cells. In certain embodiments, a modified guide nucleic acid, e.g., modified guide RNA, comprises one or more modifications as described in section IA, for example, one or more modifications as described in section IA1., and a spacer sequence capable of hybridizing with the human NLRC5 gene, for example one of the spacer sequences above.

In certain embodiments of the engineered, non-naturally occurring system, the modulator-targeter complex comprises any one of SEQ ID NOs: 1004 and 1012, 1004 and 1013, 1004 and 1014, 1004 and 1015, 1004 and 1016, 1004 and 1017, 1004 and 1018, 1004 and 1019, 1004 and 1020, 1004 and 1021, 1004 and 1022, 1004 and 1023, 1004 and 1024, 1004 and 1025, 1004 and 1026, 1004 and 1027, 1004 and 1028, 1004 and 1029, 1004 and 1030, 1004 and 1031, 1004 and 1032, 1004 and 1033, 1004 and 1034, 1004 and 1035, 1004 and 1036, 1004 and 1037, 1005 and 1012, 1005 and 1013, 1005 and 1014, 1005 and 1015, 1005 and 1016, 1005 and 1017, 1005 and 1018, 1005 and 1019, 1005 and 1020, 1005 and 1021, 1005 and 1022, 1005 and 1023, 1005 and 1024, 1005 and 1025, 1005 and 1026, 1005 and 1027, 1005 and 1028, 1005 and 1029, 1005 and 1030, 1005 and 1031, 1005 and 1032, 1005 and 1033, 1005 and 1034, 1005 and 1035, 1005 and 1036, 1005 and 1037, 1006 and 1012, 1006 and 1013, 1006 and 1014, 1006 and 1015, 1006 and 1016, 1006 and 1017, 1006 and 1018, 1006 and 1019, 1006 and 1020, 1006 and 1021, 1006 and 1022, 1006 and 1023, 1006 and 1024, 1006 and 1025, 1006 and 1026, 1006 and 1027, 1006 and 1028, 1006 and 1029, 1006 and 1030, 1006 and 1031, 1006 and 1032, 1006 and 1033, 1006 and 1034, 1006 and 1035, 1006 and 1036, 1006 and 1037, 1007 and 1012, 1007 and 1013, 1007 and 1014, 1007 and 1015, 1007 and 1016, 1007 and 1017, 1007 and 1018, 1007 and 1019, 1007 and 1020, 1007 and 1021, 1007 and 1022, 1007 and 1023, 1007 and 1024, 1007 and 1025, 1007 and 1026, 1007 and 1027, 1007 and 1028, 1007 and 1029, 1007 and 1030, 1007 and 1031, 1007 and 1032, 1007 and 1033, 1007 and 1034, 1007 and 1035, 1007 and 1036, or 1007 and 1037 wherein the spacer sequence of the complex is capable of hybridizing with a target nucleotide sequence within a first human gene as referred to herein as “gene 1”. Exemplary data for these complexes may be found in Example 2, FIG. 4 . In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the gene 1 locus is edited at least 70% as efficiently as a single crRNA such as with modulator-targeter complexes comprising any one of SEQ ID NOs: 1005 and 1014, 1005 and 1027, 1006 and 1014, or 1006 and 1027. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the gene 1 locus is edited at least as efficiently as a single crRNA. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the gene 1 locus is edited more efficiently than a single crRNA.

In certain embodiments of the engineered, non-naturally occurring system, the modulator-targeter complex comprises any one of SEQ ID NOs: 1000 and 1012, 1000 and 1013, 1000 and 1014, 1000 and 1015, 1000 and 1016, 1000 and 1017, 1000 and 1018, 1000 and 1019, 1000 and 1020, 1000 and 1021, 1000 and 1022, 1000 and 1023, 1000 and 1024, 1000 and 1025, 1000 and 1026, 1000 and 1027, 1000 and 1028, 1000 and 1029, 1000 and 1030, 1000 and 1031, 1000 and 1032, 1000 and 1033, 1000 and 1034, 1000 and 1035, 1000 and 1036, 1000 and 1037, 1001 and 1012, 1001 and 1013, 1001 and 1014, 1001 and 1015, 1001 and 1016, 1001 and 1017, 1001 and 1018, 1001 and 1019, 1001 and 1020, 1001 and 1021, 1001 and 1022, 1001 and 1023, 1001 and 1024, 1001 and 1025, 1001 and 1026, 1001 and 1027, 1001 and 1028, 1001 and 1029, 1001 and 1030, 1001 and 1031, 1001 and 1032, 1001 and 1033, 1001 and 1034, 1001 and 1035, 1001 and 1036, 1001 and 1037, 1002 and 1012, 1002 and 1013, 1002 and 1014, 1002 and 1015, 1002 and 1016, 1002 and 1017, 1002 and 1018, 1002 and 1019, 1002 and 1020, 1002 and 1021, 1002 and 1022, 1002 and 1023, 1002 and 1024, 1002 and 1025, 1002 and 1026, 1002 and 1027, 1002 and 1028, 1002 and 1029, 1002 and 1030, 1002 and 1031, 1002 and 1032, 1002 and 1033, 1002 and 1034, 1002 and 1035, 1002 and 1036, 1002 and 1037, 1003 and 1012, 1003 and 1013, 1003 and 1014, 1003 and 1015, 1003 and 1016, 1003 and 1017, 1003 and 1018, 1003 and 1019, 1003 and 1020, 1003 and 1021, 1003 and 1022, 1003 and 1023, 1003 and 1024, 1003 and 1025, 1003 and 1026, 1003 and 1027, 1003 and 1028, 1003 and 1029, 1003 and 1030, 1003 and 1031, 1003 and 1032, 1003 and 1033, 1003 and 1034, 1003 and 1035, 1003 and 1036, or 1003 and 1037 wherein the spacer sequence of the complex is capable of hybridizing with a target nucleotide sequence within a second human gene as referred to herein as “gene 2”. Exemplary data for these complexes may be found in Example 2, FIG. 5 . In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the gene 2 locus is edited at least 70% as efficiently as a single crRNA such as with modulator-targeter complexes comprising any one of SEQ ID NOs: 1000 and 1012, 1000 and 1012, 1000 and 1013, 1000 and 1016, 1000 and 1017, 1000 and 1018, 1000 and 1019, 1000 and 1020, 1000 and 1025, 1000 and 1025, 1000 and 1025, 1000 and 1025, 1000 and 1026, 1000 and 1031, 1000 and 1032, 1000 and 1033, 1001 and 1012, 1001 and 1012, 1001 and 1018, 1001 and 1019, 1001 and 1025, 1001 and 1025, 1001 and 1026, 1001 and 1032, 1001 and 1033, 1003 and 1013, 1003 and 1014, 1003 and 1025, 1003 and 1025, 1003 and 1025, 1003 and 1027, 1003 and 1032, 1000 and 1014, 1000 and 1027, 1001 and 1014, or 1001 and 1027. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the gene 2 locus is edited at least as efficiently as a single crRNA such as with modulator-targeter complexes comprising any one of SEQ ID NOs: 1000 and 1014, 1000 and 1027, 1001 and 1014, or 1001 and 1027. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the gene 2 locus is edited more efficiently than a single crRNA such as with modulator-targeter complexes comprising SEQ ID NOs: 1000 and 1014, 1000 and 1027, 1001 and 1014, or 1001 and 1027.

In certain embodiments of the engineered, non-naturally occurring system, the modulator-targeter complex comprises any one of SEQ ID NOs: 1008 and 1012, 1008 and 1013, 1008 and 1014, 1008 and 1015, 1008 and 1016, 1008 and 1017, 1008 and 1018, 1008 and 1019, 1008 and 1020, 1008 and 1021, 1008 and 1022, 1008 and 1023, 1008 and 1024, 1008 and 1025, 1008 and 1026, 1008 and 1027, 1008 and 1028, 1008 and 1029, 1008 and 1030, 1008 and 1031, 1008 and 1032, 1008 and 1033, 1008 and 1034, 1008 and 1035, 1008 and 1036, 1008 and 1037, 1009 and 1012, 1009 and 1013, 1009 and 1014, 1009 and 1015, 1009 and 1016, 1009 and 1017, 1009 and 1018, 1009 and 1019, 1009 and 1020, 1009 and 1021, 1009 and 1022, 1009 and 1023, 1009 and 1024, 1009 and 1025, 1009 and 1026, 1009 and 1027, 1009 and 1028, 1009 and 1029, 1009 and 1030, 1009 and 1031, 1009 and 1032, 1009 and 1033, 1009 and 1034, 1009 and 1035, 1009 and 1036, 1009 and 1037, 1010 and 1012, 1010 and 1013, 1010 and 1014, 1010 and 1015, 1010 and 1016, 1010 and 1017, 1010 and 1018, 1010 and 1019, 1010 and 1020, 1010 and 1021, 1010 and 1022, 1010 and 1023, 1010 and 1024, 1010 and 1025, 1010 and 1026, 1010 and 1027, 1010 and 1028, 1010 and 1029, 1010 and 1030, 1010 and 1031, 1010 and 1032, 1010 and 1033, 1010 and 1034, 1010 and 1035, 1010 and 1036, 1010 and 1037, 1011 and 1012, 1011 and 1013, 1011 and 1014, 1011 and 1015, 1011 and 1016, 1011 and 1017, 1011 and 1018, 1011 and 1019, 1011 and 1020, 1011 and 1021, 1011 and 1022, 1011 and 1023, 1011 and 1024, 1011 and 1025, 1011 and 1026, 1011 and 1027, 1011 and 1028, 1011 and 1029, 1011 and 1030, 1011 and 1031, 1011 and 1032, 1011 and 1033, 1011 and 1034, 1011 and 1035, 1011 and 1036, or 1011 and 1037 wherein the spacer sequence of the complex is capable of hybridizing with a target nucleotide sequence within a third human gene as referred to herein as “gene 3”. Exemplary data for these complexes may be found in Example 2, FIG. 6 . In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the gene 3 locus is edited at least 70% as efficiently as a single crRNA such as with modulator-targeter complexes comprising any one of SEQ ID NOs: 1008 and 1012, 1008 and 1013, 1008 and 1014, 1008 and 1016, 1008 and 1017, 1008 and 1023, 1008 and 1024, 1008 and 1026, 1008 and 1027, 1008 and 1029, 1008 and 1030, 1008 and 1032, 1008 and 1033, 1008 and 1034, 1008 and 1035, 1008 and 1037, 1009 and 1012, 1009 and 1013, 1009 and 1014, 1009 and 1016, 1009 and 1017, 1009 and 1018, 1009 and 1019, 1009 and 1020, 1009 and 1021, 1009 and 1022, 1009 and 1023, 1009 and 1024, 1010 and 1012, 1010 and 1013, 1010 and 1014, 1010 and 1016, 1010 and 1017, 1010 and 1018, 1010 and 1020, 1010 and 1021, 1010 and 1022, 1010 and 1023, 1010 and 1024, 1010 and 1027, 1010 and 1030, 1008 and 1021, 1008 and 1031, 1008 and 1018, 1008 and 1019, 1008 and 1020, 1008 and 1022, or 1010 and 1019. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the gene 3 locus is edited at least as efficiently as a single crRNA such as with modulator-targeter complexes comprising any one of SEQ ID NOs: 1008 and 1021, 1008 and 1031, 1008 and 1018, 1008 and 1019, 1008 and 1020, 1008 and 1022, or 1010 and 1019. In certain embodiments, when the system is delivered into a population of human cells ex vivo, the genomic sequence at the gene 3 locus is edited more efficiently than a single crRNA such as with modulator-targeter complexes comprising any one of SEQ ID NOs: 1008 and 1018, 1008 and 1019, 1008 and 1020, 1008 and 1022, or 1010 and 1019.

In certain embodiments of the engineered, non-naturally occurring system, genomic mutations are detected in no more than 2% of the cells at any off-target loci by CIRCLE-Seq. In certain embodiments, genomic mutations are detected in no more than 1% of the cells at any off-target loci by CIRCLE-Seq.

In certain embodiments, provided is a guide nucleic acid a modified guide nucleic acid, e.g., modified guide RNA, comprising one or more modifications as described in section IA, for example, one or more modifications as described in section IA1, and comprising a targeter stem sequence and a spacer sequence, wherein the spacer sequence comprises a nucleotide sequence listed Table 1, 2, or 3, or a portion thereof sufficient to hybridize with the corresponding target gene listed in the table. In particular, Table 1 lists the guide nucleic acid that showed the best editing efficiency for each target gene. Table 2 lists the guide nucleic acids that showed at least 10% editing efficiency. Table 3 lists the guide nucleic acids that showed at least 1.5% and lower than 10% editing efficiency.

In certain embodiments, a guide nucleic acid of the present invention is capable of binding the genomic locus of the corresponding target gene in the human genome. In certain embodiments, a guide nucleic acid of the present invention, alone or in combination with a modulator nucleic acid, is capable of directing a Cas protein to the genomic locus of the corresponding target gene in the human genome. In certain embodiments, a guide nucleic acid of the present invention, alone or in combination with a modulator nucleic acid, is capable of directing a Cas nuclease to the genomic locus of the corresponding target gene in the human genome, thereby resulting in cleavage of the genomic DNA at the genomic locus.

TABLE 1 Selected Spacer Sequences Targeting Human Genes Target SEQ ID Gene crRNA Spacer Sequence NO ADORA2A gADORA2A_12 AGGATGTGGTCCCCATGAACT 51 B2M gB2M_41 ATAGATCGAGACATGTAAGCA 635 CARD11 gCARD11_1 TAGTACCGCTCCTGGAAGGTT 721 CD247 gCD247_12 CTAGCAGAGAAGGAAGAACCC 735 CD52 gCD52_1 CTCTTCCTCCTACTCACCATC 53 CIITA gCIITA_32 CCTTGGGGCTCTGACAGGTAG 636 CTLA4 gCTLA4_4 AGCGGCACAAGGCTCAGCTGA 795 DCK gDCK_6 CGGAGGCTCCTTACCGATGTT 796 FAS gFAS_36 GTGTTGCTGGTGAGTGTGCAT 57 HAVCR2 gTIM3_6 CTTGTAAGTAGTAGCAGCAGC 58 IL7R gIL7R_3 CAGGGGAGATGGATCCTATCT 749 LAG3 gLAG3_6 GGGTGCATACCTGTCTGGCTG 59 LCK gLCK1_3 ACCCATCAACCCGTAGGGATG 757 PDCD1 gPD_23 TCTGCAGGGACAATAGGAGCC 60 PLCG1 gPLCG1_2 CCTTTCTGCGCTTCGTGGTGT 759 PTPN6 gPTPN6_6 TATGACCTGTATGGAGGGGAG 61 TIGIT gTIGIT_2 AGGCCTTACCTGAGGCGAGGG 62 TRAC gTRAC006 TGAGGGTGAAGGATAGACGCT 63 TRBC1+2 gTRBC1+2_3 CGCTGTCAAGTCCAGTTCTAC 706 TRBC2 gTRBC2_12 CCGGAGGTGAAGCCACAGTCT 712

TABLE 2 Selected Spacer Sequences Targeting Human Genes Target SEQ ID Gene crRNA Spacer sequence NO ADORA2A gADORA2A_12 AGGATGTGGTCCCCATGAACT 51 B2M gB2M_4 CTCACGTCATCCAGCAGAGAA 52 B2M gB2M_7 ACTTTCCATTCTCTGCTGGAT 64 B2M gB2M_2 TGGCCTGGAGGCTATCCAGCG 65 B2M gB2M_17 TATCTCTTGTACTACACTGAA 66 B2M gB2M_30 AGTGGGGGTGAATTCAGTGTA 625 B2M gB2M_41 ATAGATCGAGACATGTAAGCA 635 CIITA gCIITA_32 CCTTGGGGCTCTGACAGGTAG 636 CIITA gCIITA_33 ACCTTGGGGCTCTGACAGGTA 637 CIITA gCIITA_35 CTCCCAGAACCCGACACAGAC 639 CIITA gCIITA_36 TGGGCTCAGGTGCTTCCTCAC 640 CIITA gCIITA_38 CTTGTCTGGGCAGCGGAACTG 642 CIITA gCIITA_40 TCAAAGTAGAGCACATAGGAC 644 CIITA gCIITA_41 TGCCCAACTTCTGCTGGCATC 645 CIITA gCIITA_43 TCTGCAGCCTTCCCAGAGGAG 647 CIITA gCIITA_44 TCCAGGCGCATCTGGCCGGAG 648 CIITA gCIITA_48 CTCGGGAGGTCAGGGCAGGTT 652 CIITA gCIITA_57 CAGAAGAAGCTGCTCCGAGGT 660 CIITA gCIITA_59 AGAGCTCAGGGATGACAGAGC 662 CIITA gCIITA_60 TGCCGGGCAGTGTGCCAGCTC 663 CIITA gCIITA_63 GCCACTCAGAGCCAGCCACAG 666 CIITA gCIITA_65 GCAGCACGTGGTACAGGAGCT 668 CIITA gCIITA_67 TGGGCACCCGCCTCACGCCTC 670 CIITA gCIITA_70 CCAGGTCTTCCACATCCTTCA 673 CIITA gCIITA_71 AAAGCCAAGTCCCTGAAGGAT 674 CIITA gCIITA_72 GGTCCCGAACAGCAGGGAGCT 675 CIITA gCIITA_73 TTTAGGTCCCGAACAGCAGGG 676 CIITA gCIITA_76 GGGAAAGCCTGGGGGCCTGAG 679 CIITA gCIITA_80 CAAGGACTTCAGCTGGGGGAA 682 CIITA gCIITA_81 TAGGCACCCAGGTCAGTGATG 683 CIITA gCIITA_82 CGACAGCTTGTACAATAACTG 684 CD247 gCD247_1 TGTGTTGCAGTTCAGCAGGAG 724 CD247 gCD247_3 CGGAGGGTCTACGGCGAGGCT 726 CD247 gCD247_4 TTATCTGTTATAGGAGCTCAA 727 CD247 gCD247_8 GACAAGAGACGTGGCCGGGAC 731 CD247 gCD247_12 CTAGCAGAGAAGGAAGAACCC 735 CD247 gCD247_15 ATCCCAATCTCACTGTAGGCC 738 CD247 gCD247_18 TCATTTCACTCCCAAACAACC 741 CD247 gCD247_19 ACTCCCAAACAACCAGCGCCG 742 CD52 gCD52_1 CTCTTCCTCCTACTCACCATC 53 CIITA gCIITA_4 TAGGGGCCCCAACTCCATGGT 54 CTLA4 gCTLA4_4 AGCGGCACAAGGCTCAGCTGA 795 CTLA4 gCTLA4_14 CCTGGAGATGCATACTCACAC 67 CTLA4 gCTLA4_6 CAGAAGACAGGGATGAAGAGA 797 CTLA4 gCTLA4_19 CACTGGAGGTGCCCGTGCAGA 798 CTLA4 gCTLA4_13 TGTGTGAGTATGCATCTCCAG 70 DCK gDCK_6 CGGAGGCTCCTTACCGATGTT 796 DCK gDCK_2 TCAGCCAGCTCTGAGGGGACC 71 DCK gDCK_8 CTCACAACAGCTGCAGGGAAG 72 DCK gDCK_26 AGCTTGCCATTCAGAGAGGCA 73 DCK gDCK_30 TACATACCTGTCACTATACAC 74 FAS gFAS_36 GTGTTGCTGGTGAGTGTGCAT 57 FAS gFAS_34 TTTTTCTAGATGTGAACATGG 75 FAS gFAS_35 ATGATTCCATGTTCACATCTA 76 FAS gFAS_12 GTGTAACATACCTGGAGGACA 77 FAS gFAS_1 GGAGGATTGCTCAACAACCAT 78 FAS gFAS_59 TAGGAAACAGTGGCAATAAAT 79 HAVCR2 gTIM3_6 CTTGTAAGTAGTAGCAGCAGC 58 HAVCR2 gTTM3_29 CAAGGATGCTTACCACCAGGG 80 HAVCR2 gTIM3_6 TAAGTAGTAGCAGCAGCAGCA 799 HAVCR2 gTIM3_32 TATCAGGGAGGCTCCCCAGTG 800 HAVCR2 gTIM3_30 CCACCAGGGGACATGGCCCAG 83 HAVCR2 gTIM3_12 AATGTGGCAACGTGGTGCTCA 84 HAVCR2 gTIM3_25 TGACATTAGCCAAGGTCACCC 85 HAVCR2 gTIM3_18 CGCAAAGGAGATGTGTCCCTG 86 IL7R gIL7R_3 CAGGGGAGATGGATCCTATCT 749 IL7R gIL7R_8 CATAACACACAGGCCAAGATG 754 LAG3 gLAG3_6 GGGTGCATACCTGTCTGGCTG 59 LAG3 gLAG3_38 TCAGGACCTTGGCTGGAGGCA 87 LAG3 gLAG3_33 GGTCACCTGGATCCCTGGGGA 88 LCK gLCK1_3 ACCCATCAACCCGTAGGGATG 757 PDCD1 gPD_23 TCTGCAGGGACAATAGGAGCC 60 PDCD1 gPD_2 CCTTCCGCTCACCTCCGCCTG 89 PDCD1 gPD_8 GCACGAAGCTCTCCGATGTGT 90 PDCD1 gPD_29 CTAGCGGAATGGGCACCTCAT 91 PDCD1 gPD_27 CAGTGGCGAGAGAAGACCCCG 92 PTPN6 gPTPN6_6 TATGACCTGTATGGAGGGGAG 61 PTPN6 gPTPN6_46 ACTGCCCCCCACCCAGGCCTG 93 PTPN6 gPTPN6_7 CGACTCTGACAGAGCTGGTGG 801 PTPN6 gPTPN6_26 CAGAAGCAGGAGGTGAAGAAC 802 PTPN6 gPTPN6_1 ACCGAGACCTCAGTGGGCTGG 96 PTPN6 gPTPN6_37 TGGGCCCTACTCTGTGACCAA 97 PTPN6 gPTPN6_16 TGTGCTCAGTGACCAGCCCAA 98 PTPN6 gPTPN6_25 CCCACCCACATCTCAGAGTTT 99 PTPN6 gPTPN6_12 TTGTGCGTGAGAGCCTCAGCC 100 PTPN6 gPTPN6_22 AAGAAGACGGGGATTGAGGAG 101 PTPN6 gPTPN6_5 TCCCCTCCATACAGGTCATAG 803 PTPN6 gPTPN6_19 GCTCCCCCCAGGGTGGACGCT 103 PTPN6 gPTPN6_14 GGCTGGTCACTGAGCACAGAA 104 TIGIT gTIGIT_2 AGGCCTTACCTGAGGCGAGGG 62 TIGIT gTIGIT_18 GTCCTCCCTCTAGTGGCTGAG 105 TRAC gTRAC006 TGAGGGTGAAGGATAGACGCT 63 TRAC gTRAC073 GCAGACAGGGAGAAATAAGGA 106 TRAC gTRAC017 CAGGTGAAATTCCTGAGATGT 804 TRAC gTRAC059 GACATCATTGACCAGAGCTCT 805 TRAC gTRAC078 CCAGCTCACTAAGTCAGTCTC 109 TRAC gTRAC012 TATGGAGAAGCTCTCATTTCT 110 TRAC gTRAC039 TAAGATGCTATTTCCCGTATA 111 TRAC gTRAC067 CCGTGTCATTCTCTGGACTGC 112 TRAC gTRAC079 ATTCCTCCACTTCAACACCTG 113 TRAC gTRAC038 TACGGGAAATAGCATCTTAGA 114 TRAC gTRAC061 GTGGCAATGGATAAGGCCGAG 115 TRAC gTRAC058 CTTGCTTCAGGAATGGCCAGG 116 TRAC gTRAC021 TAGTTCAAAACCTCTATCAAT 117 TRAC gTRAC049 TCTGTGATATACACATCAGAA 118 TRAC gTRAC074 GGCAGACAGGGAGAAATAAGG 119 TRAC gTRAC018 CTCGATATAAGGCCTTGAGCA 120 TRAC gTRAC043 GAGTCTCTCAGCTGGTACACG 121 TRAC gTRAC075 TGGCAGACAGGGAGAAATAAG 122 TRAC gTRAC082 CCAGCTGACAGATGGGCTCCC 123 TRAC gTRAC040 CCGTATAAAGCATGAGACCGT 124 TRAC gTRAC041 CCCCAACCCAGGCTGGAGTCC 125 TRAC gTRAC076 TTGGCAGACAGGGAGAAATAA 126 TRAC gTRAC014 TCAGAAGAGCCTGGCTAGGAA 127 TRAC gTRAC029 CTCTGCCAGAGTTATATTGCT 128 TRAC gTRAC028 CCATGCCTGCCTTTACTCTGC 129 TRAC gTRAC050 GTCTGTGATATACACATCAGA 130 TRBC1+2 gTRBC1+2_1 AGCCATCAGAAGCAGAGATCT 705 TRBC1+2 gTRBC1+2_3 CGCTGTCAAGTCCAGTTCTAC 706 TRBC2 gTRBC2_11 AGACTGTGGCTTCACCTCCGG 711 TRBC2 gTRBC2_12 CCGGAGGTGAAGCCACAGTCT 712 TRBC2 gTRBC2_15 CTAGGGAAGGCCACCTTGTAT 715 TRBC2 gTRBC2_21 GAGCTAGCCTCTGGAATCCTT 720

TABLE 3 Selected Spacer Sequences Targeting Human Genes Target Gene crRNA Spacer sequence SEQ ID NO ADORA2A gADORA2A_16 CGGATCTTCCTGGCGGCGCGA 131 ADORA2A gADORA2A_28 AAGGCAGCTGGCACCAGTGCC 132 ADORA2A gADORA2A_2 TGGTGTCACTGGCGGCGGCCG 133 ADORA2A gADORA2A_23 TTCTGCCCCGACTGCAGCCAC 134 ADORA2A gADORA2A_7 GTGACCGGCACGAGGGCTAAG 135 ADORA2A gADORA2A_8 CCATCGGCCTGACTCCCATGC 136 ADORA2A gADORA2A_4 CCATCACCATCAGCACCGGGT 137 B2M gB2M_21 TCACAGCCCAAGATAGTTAAG 138 B2M gB2M_8 CTGAATTGCTATGTGTCTGGG 139 B2M gB2M_11 CTGAAGAATGGAGAGAGAATT 140 B2M gB2M_18 TCAGTGGGGGTGAATTCAGTG 141 B2M gB2M_5 CATTCTCTGCTGGATGACGTG 142 B2M gB2M_10 ATCCATCCGACATTGAAGTTG 143 B2M gB2M_22 CCCCACTTAACTATCTTGGGC 144 B2M gB2M_1 GCTGTGCTCGCGCTACTCTCT 145 B2M gB2M_27 AATTCTCTCTCCATTCTTCAG 622 B2M gB2M_31 CAGTGGGGGTGAATTCAGTGT 626 B2M gB2M_40 CATAGATCGAGACATGTAAGC 634 CD247 gCD247_7 CCCCCATCTCAGGGTCCCGGC 730 CD247 gCD247_9 TCTCCCTCTAACGTCTTCCCG 732 CD247 gCD247_13 TGCAGTTCCTGCAGAAGAGGG 736 CD247 gCD247_14 TGCAGGAACTGCAGAAAGATA 737 CD247 gCD247_21 TGATTTGCTTTCACGCCAGGG 744 CD247 gCD247_22 CTTTCACGCCAGGGTCTCAGT 745 CD52 gCD52_4 GCTGGTGTCGTTTTGTCCTGA 146 CIITA gCIITA_18 TGCTGGCATCTCCATACTCTC 147 CIITA gCIITA_29 GTCTCTTGCAGTGCCTTTCTC 148 CIITA gCIITA_34 CCGGCCTTTTTACCTTGGGGC 638 CIITA gCIITA_42 TGACTTTTCTGCCCAACTTCT 646 CIITA gCIITA_46 CCAGAGCCCATGGGGCAGAGT 650 CIITA gCIITA_47 TCCCCACCATCTCCACTCTGC 651 CIITA gCIITA_51 CAGAGCCGGTGGAGCAGTTCT 655 CIITA gCIITA_52 CCCAGCACAGCAATCACTCGT 656 CIITA gCIITA_55 AGCCACATCTTGAAGAGACCT 658 CIITA gCIITA_58 AGCTGTCCGGCTTCTCCATGG 661 CIITA gCIITA_68 CCCCTCTGGATTGGGGAGCCT 671 CIITA gCIITA_75 CCTCCTAGGCTGGGCCCTGTC 678 CIITA gCIITA_83 TCTTGCCAGCGTCCAGTACAA 685 CTLA4 gCTLA4_27 CTGTTGCAGATCCAGAACCGT 149 CTLA4 gCTLA4_36 ACAGCTAAAGAAAAGAAGCCC 150 CTLA4 gCTLA4_4 TCAATTGATGGGAATAAAATA 151 CTLA4 gCTLA4_28 CTCCTCTGGATCCTTGCAGCA 152 CTLA4 gCTLA4_37 CACATAGACCCCTGTTGTAAG 153 CTLA4 gCTLA4_18 CTAGATGATTCCATCTGCACG 154 CTLA4 gCTLA4_5 TTCTTCTCTTCATCCCTGTCT 155 DCK gDCK_9 AGGATATTCACAAATGTTGAC 156 DCK gDCK_22 GAAGGTAAAAGACCATCGTTC 157 DCK gDCK_21 TCATACATCATCTGAAGAACA 158 DCK gDCK_7 ATCTTTCCTCACAACAGCTGC 159 FAS gFAS_47 AGTGAAGAGAAAGGAAGTACA 160 FAS gFAS_45 TTTGTTCTTTCAGTGAAGAGA 161 FAS gFAS_25 CTAGGCTTAGAAGTGGAAATA 162 FAS gFAS_10 GAAGGCCTGCATCATGATGGC 163 FAS gFAS_32 GTGCAAGGGTCACAGTGTTCA 164 FAS gFAS_5 GGACGATAATCTAGCAACAGA 165 FAS gFAS_14 TTCCTTGGGCAGGTGAAAGGA 166 FAS gFAS_29 GTTTACATCTGCACTTGGTAT 167 FAS gFAS_33 CTTGGTGCAAGGGTCACAGTG 168 FAS gFAS_71 CTGTTCTGCTGTGTCTTGGAC 169 FAS gFAS_38 CTCTTTGCACTTGGTGTTGCT 170 FAS gFAS_70 TGTTCTGCTGTGTCTTGGACA 171 FAS gFAS_4 ACAGGTTCTTACGTCTGTTGC 172 FAS gFAS_15 GGCAGGTGAAAGGAAAGCTAG 173 HAVCR2 gTIM3_42 CTAGGGTATTCTCATAGCAAA 174 HAVCR2 gTIM3_10 CCCCAGCAGACGGGCACGAGG 175 HAVCR2 gTIM3_47 GCCAACCTCCCTCCCTCAGGA 176 HAVCR2 gTIM3_34 TGTTTCCATAGCAAATATCCA 177 HAVCR2 gTIM3_19 GATCCGGCAGCAGTAGATCCC 178 HAVCR2 gTIM3_48 CCAATCCTGAGGGAGGGAGGT 179 HAVCR2 gTIM3_36 CGGGACTCTGGAGCAACCATC 180 HAVCR2 gTIM3_15 GCCAGTATCTGGATGTCCAAT 181 HAVCR2 gTIM3_27 ACTGCAGCCTTTCCAAGGATG 182 HAVCR2 gTIM3_41 CCCCTTACTAGGGTATTCTCA 183 HAVCR2 gTIM3_23 ACCTGAAGTTGGTCATCAAAC 184 HAVCR2 gTIM3_28 CCAAGGATGCTTACCACCAGG 185 HAVCR2 gTIM3_40 GTTTCCCCCTTACTAGGGTAT 186 HAVCR2 gTIM3_13 ATCAGTCCTGAGCACCACGTT 187 IL7R gIL7R_2 CCAGGGGAGATGGATCCTATC 748 IL7R gIL7R_7 TCTGTCGCTCTGTTGGTCATC 753 LAG3 gLAG3_35 TGAGGTGACTCCAGTATCTGG 188 LAG3 gLAG3_41 CCAGCCTTGGCAATGCCAGCT 189 LAG3 gLAG3_37 TGTGGAGCTCTCTGGACACCC 190 LAG3 gLAG3_16 GGGCAGGAAGAGGAAGCTTTC 191 LAG3 gLAG3_46 TCCATAGGTGCCCAACGCTCT 192 LAG3 gLAG3_27 CCACCTGAGGCTGACCTGTGA 193 LAG3 gLAG3_31 CCCAGGGATCCAGGTGACCCA 194 LAG3 gLAG3_3 ACCTGGAGCCACCCAAAGCGG 195 LAG3 gLAG3_25 CCCTTCGACTAGAGGATGTGA 196 LAG3 gLAG3_13 CGCTAAGTGGTGATGGGGGGA 197 LAG3 gLAG3_22 GCAGTGAGGAAAGACCGGGTC 198 PDCD1 gPD_20 CAGAGAGAAGGGCAGAAGTGC 199 PDCD1 gPD_22 GAACTGGCCGGCTGGCCTGGG 200 PDCD1 gPD_18 GTGCCCTTCCAGAGAGAAGGG 201 PLCG1 gPLCG1_2 CCTTTCTGCGCTTCGTGGTGT 759 PLCG1 gPLCG1_4 TGCGCTTCGTGGTGTATGAGG 761 PLCG1 gPLCG1_5 GTGGTGTATGAGGAAGACATG 762 PTPN6 gPTPN6_20 GAGACCTTCGACAGCCTCACG 202 PTPN6 gPTPN6_41 CTGGACCAGATCAACCAGCGG 203 PTPN6 gPTPN6_53 CCCCCCTGCACCCGGCTGCAG 204 PTPN6 gPTPN6_28 CACCAGCGTCTGGAAGGGCAG 205 PTPN6 gPTPN6_42 CTGCCGCTGGTTGATCTGGTC 206 PTPN6 gPTPN6_32 TGGCAGATGGCGTGGCAGGAG 207 PTPN6 gPTPN6_4 CTGGCTCGGCCCAGTCGCAAG 208 PTPN6 gPTPN6_8 AGGTGGATGATGGTGCCGTCG 209 PTPN6 gPTPN6_40 GGGAGACCTGATTCGGGAGAT 210 PTPN6 gPTPN6_48 AATGAACTGGGCGATGGCCAC 211 PTPN6 gPTPN6_10 TCTAGGTGGTACCATGGCCAC 212 PTPN6 gPTPN6_39 CAGGTCTCCCCGCTGGACAAT 213 TIGIT gTIGIT_11 GGGTGGCACATCTCCCCATCC 214 TIGIT gTIGIT_7 TGCAGAGAAAGGTGGCTCTAT 215 TIGIT gTIGIT_10 TAATGCTGACTTGGGGTGGCA 216 TIGIT gTIGIT_27 CTCCTGAGGTCACCTTCCACA 217 TRAC gTRAC066 CTAAGAAACAGTGAGCCTTGT 218 TRAC gTRAC042 CCTCTTTGCCCCAACCCAGGC 219 TRAC gTRAC035 AGGTTTCCTTGAGTGGCAGGC 220 TRAC gTRAC044 AGAATCAAAATCGGTGAATAG 221 TRAC gTRAC072 CCCCTTACTGCTCTTCTAGGC 222 TRAC gTRAC062 GGTGGCAATGGATAAGGCCGA 223 TRAC gTRAC020 GAACTATAAATCAGAACACCT 224 TRAC gTRAC013 TTTCTCAGAAGAGCCTGGCTA 225 TRAC gTRAC068 CCCGTGTCATTCTCTGGACTG 226 TRAC gTRAC025 CTGGGCCTTTTTCCCATGCCT 227 TRAC gTRAC019 AACTATAAATCAGAACACCTG 228 TRAC gTRAC048 ATTCTCAAACAAATGTGTCAC 229 TRAC gTRAC036 CTTGAGTGGCAGGCCAGGCCT 230 TRAC gTRAC056 CATGTGCAAACGCCTTCAACA 231 TRAC gTRAC064 TACTAAGAAACAGTGAGCCTT 232 TRAC gTRAC071 CTCAGACTGTTTGCCCCTTAC 233 TRAC gTRAC081 TAATTCCTCCACTTCAACACC 234 TRAC gTRAC030 ATAGGATCTTCTTCAAAACCC 235 TRAC gTRAC033 GAAGAAGATCCTATTAAATAA 236 TRAC gTRAC001 TGTTTTTAATGTGACTCTCAT 237 TRAC gTRAC009 GTACTTTACAGTTTATTAAAT 238 TRAC gTRAC007 ATAAACTGTAAAGTACCAAAC 239 TRAC gTRAC084 GACTTTTCCCAGCTGACAGAT 240 TRAC gTRAC083 CCCAGCTGACAGATGGGCTCC 241 TRBC2 gTRBC2_14 CCAGCAAGGGGTCCTGTCTGC 714 TRBC2 gTRBC2_17 CCATGGCCATCAGCACGAGGG 717 TRBC2 gTRBC2_19 CACAGGTCAAGAGAAAGGATT 719 CSF2 gCSF2_001 TGAGATGACTTCTACTGTTTC 1100 CSF2 gCSF2_002 CCTTTTCTACAGAATGAAACA 1101 CSF2 gCSF2_003 CTTTTCTACAGAATGAAACAG 1102 CSF2 gCSF2_004 CTACAGAATGAAACAGTAGAA 1103 CSF2 gCSF2_005 TACAGAATGAAACAGTAGAAG 1104 CSF2 gCSF2_006 CCACAGGAGCCGACCTGCCTA 1105 CSF2 gCSF2_007 CACAGGAGCCGACCTGCCTAC 1106 CSF2 gCSF2_008 ttatttttctttttttAAAGG 1107 CSF2 gCSF2_009 tatttttctttttttAAAGGA 1108 CSF2 gCSF2_010 atttttctttttttAAAGGAA 1109 CSF2 gCSF2_011 tttttctttttttAAAGGAAA 1110 CSF2 gCSF2_012 tctttttttAAAGGAAACTTC 1111 CSF2 gCSF2_013 ctttttttAAAGGAAACTTCC 1112 CSF2 gCSF2_014 tttttttAAAGGAAACTTCCT 1113 CSF2 gCSF2_015 tttAAAGGAAACTTCCTGTGC 1114 CSF2 gCSF2_016 ttAAAGGAAACTTCCTGTGCA 1115 CSF2 gCSF2_017 tAAAGGAAACTTCCTGTGCAA 1116 CSF2 gCSF2_018 AAAGGTGATAATCTGGGTTGC 1117 CSF2 gCSF2_019 AAAGGAAACTTCCTGTGCAAC 1118 CSF2 gCSF2_020 AAGGAAACTTCCTGTGCAACC 1119 CSF2 gCSF2_021 AAACTTTCAAAGGTGATAATC 1120 CSF2 gCSF2_022 AAAGTTTCAAAGAGAACCTGA 1121 CSF2 gCSF2_023 AAAGAGAACCTGAAGGACTTT 1122 CSF2 gCSF2_024 TGCTTGTCATCCCCTTTGACT 1123 CSF2 gCSF2_025 ACTGCTGGGAGCCAGTCCAGG 1124 CSF2 gCSF2_026 CCTAGGTGGTCAGGCTTGGGG 1125 CSF2 gCSF2_027 TGGTCACCATTAATCATTTCC 1126 CSF2 gCSF2_028 CTCTGTGTATTTAAGAGCTCT 1127 CSF2 gCSF2_029 AGAGCTCTTTTGCCAGTGAGC 1128 CSF2 gCSF2_030 ATTCTGTAGAAAAGGAAAATG 1129 CSF2 gCSF2_031 ACCTCCAGGTAAGATGCTTCT 1130 CSF2 gCSF2_032 CAGAAGCCCCTGCCCTGGGGT 1131 CSF2 gCSF2_033 GATGGCACCACACAGGGTTGT 1132 CSF2 gCSF2_034 TCTCCAGTCAGCTGGCTGCAG 1133 CSF2 gCSF2_035 TCAGCTGAGCGGCCATGGGCA 1134 CSF2 gCSF2_036 CCACCTGTCCCCTGGTGACTC 1135 CSF2 gCSF2_037 GGGCGCTCACTGTGCCCCGAG 1136 CSF2 gCSF2_038 AGGAACAACCCTTGCCCACCC 1137 CSF2 gCSF2_039 CTGCTGCCCCCAGCCCCCAGG 1138 CSF2 gCSF2_040 TGTGCCAACAGTTATGTAATG 1139 CSF2 gCSF2_041 ATCCCAAGGAGTCAGAGCCAC 1140 CSF2 gCSF2_042 CCCTCACCTCTGACCTCATTA 1141 CSF2 gCSF2_043 CTTGGGTTTGCCCTCACCTCT 1142 CSF2 gCSF2_044 CTCTGGCCCCACATGGGGTGC 1143 CSF2 gCSF2_045 CTCCCTTCCCGCAGGAAGGAG 1144 CSF2 gCSF2_046 TGGCCTTGACTCCACTCCTTC 1145 CSF2 gCSF2_047 GTCCCAGGGCAGAGCAGGGCA 1146 CSF2 gCSF2_048 ACTGCCCAGAAGGCCAACCTC 1147 CSF2 gCSF2_049 TCTACTGCCTCTTAGAACTCA 1148 CSF2 gCSF2_050 AAAGGAAACTTCCTGTGCAAt 1149 CSF2 gCSF2_051 AAGGAAACTTCCTGTGCAAtC 1150 CSF2 gCSF2_052 AAAGGTGATAgTCTGGaTTGC 1151 CSF2 gCSF2_053 AAACTTTCAAAGGTGATAgTC 1152 CD40LG gCD40LG_001 GTTGTATGTTTCGATCATGCT 1153 CD40LG gCD40LG_002 AACTTTAACACAGCATGATCG 1154 CD40LG gCD40LG_003 ACACAGCATGATCGAAACATA 1155 CD40LG gCD40LG_004 ATGCTGATGGGCAGTCCAGTG 1156 CD40LG gCD40LG_005 CATGCTGATGGGCAGTCCAGT 1157 CD40LG gCD40LG_006 TATGTATTTACTTACTGTTTT 1158 CD40LG gCD40LG_007 ATGTATTTACTTACTGTTTTT 1159 CD40LG gCD40LG_008 TGTATTTACTTACTGTTTTTC 1160 CD40LG gCD40LG_009 CTTACTGTTTTTCTTATCACC 1161 CD40LG gCD40LG_010 TCTTATCACCCAGATGATTGG 1162 CD40LG gCD40LG_011 CTTATCACCCAGATGATTGGG 1163 CD40LG gCD40LG_012 TTATCACCCAGATGATTGGGT 1164 CD40LG gCD40LG_013 TGCTGTGTATCTTCATAGAAG 1165 CD40LG gCD40LG_014 GCTGTGTATCTTCATAGAAGG 1166 CD40LG gCD40LG_015 CTGTGTATCTTCATAGAAGGT 1167 CD40LG gCD40LG_016 ATGAATACAAAATCTTCATGA 1168 CD40LG gCD40LG_017 CATGAATACAAAATCTTCATG 1169 CD40LG gCD40LG_018 TCCTGTGTTGCATCTCTGTAT 1170 CD40LG gCD40LG_019 GTATTCATGAAAACGATACAG 1171 CD40LG gCD40LG_020 TATTCATGAAAACGATACAGA 1172 CD40LG gCD40LG_021 ATCTCCTCACAGTTCAGTAAG 1173 CD40LG gCD40LG_022 AATCTCCTCACAGTTCAGTAA 1174 CD40LG gCD40LG_023 CCAGTAATTAAGCTGCTTACC 1175 CD40LG gCD40LG_024 ACCAGTAATTAAGCTGCTTAC 1176 CD40LG gCD40LG_025 AAGGCTTTGTGAAGGTAAGCA 1177 CD40LG gCD40LG_026 TTCGTCTCCTCTTTGTTTAAC 1178 CD40LG gCD40LG_027 TTTCTTCGTCTCCTCTTTGTT 1179 CD40LG gCD40LG_028 CTTTCTTCGTCTCCTCTTTGT 1180 CD40LG gCD40LG_029 AGGATATAATGTTAAACAAAG 1181 CD40LG gCD40LG_030 GGATATAATGTTAAACAAAGA 1182 CD40LG gCD40LG_031 AAAGCTGTTTTCTTTCTTCGT 1183 CD40LG gCD40LG_032 CATTTCAAAGCTGTTTTCTTT 1184 CD40LG gCD40LG_033 GCATTTCAAAGCTGTTTTCTT 1185 CD40LG gCD40LG_034 TGCATTTCAAAGCTGTTTTCT 1186 CD40LG gCD40LG_035 AGGATTCTGATCACCTGAAAT 1187 CD40LG gCD40LG_036 TGGTTCCATTTCAGGTGATCA 1188 CD40LG gCD40LG_037 GGTTCCATTTCAGGTGATCAG 1189 CD40LG gCD40LG_038 GTTCCATTTCAGGTGATCAGA 1190 CD40LG gCD40LG_039 AGGTGATCAGAATCCTCAAAT 1191 CD40LG gCD40LG_040 CTGCTGGCCTCACTTATGACA 1192 CD40LG gCD40LG_041 AGCCCACTGTAACACTGTTAC 1193 CD40LG gCD40LG_042 CAGCCCACTGTAACACTGTTA 1194 CD40LG gCD40LG_043 TCAGCCCACTGTAACACTGTT 1195 CD40LG gCD40LG_044 CCTTTCTTTGTAACAGTGTTA 1196 CD40LG gCD40LG_045 TTTGTAACAGTGTTACAGTGG 1197 CD40LG gCD40LG_046 TAACAGTGTTACAGTGGGCTG 1198 CD40LG gCD40LG_047 CAGGGTTACCAAGTIGTTGCT 1199 CD40LG gCD40LG_048 CCAGGGTTACCAAGTTGTTGC 1200 CD40LG gCD40LG_049 CCATTTTCCAGGGTTACCAAG 1201 CD40LG gCD40LG_050 ACGGTCAGCTGTTTCCCATTT 1202 CD40LG gCD40LG_051 AACGGTCAGCTGTTTCCCATT 1203 CD40LG gCD40LG_052 GGCAGAGGCTGGCTATAAATG 1204 CD40LG gCD40LG_053 TAGCCAGCCTCTGCCTAAAGT 1205 CD40LG gCD40LG_054 CAGCTCTGAGTAAGATTCTCT 1206 CD40LG gCD40LG_055 GCGGAACTGTGGGTATTTGCA 1207 CD40LG gCD40LG_056 AATTGCAACCAGGTGCTTCGG 1208 CD40LG gCD40LG_057 TCAATGTGACTGATCCAAGCC 1209 CD40LG gCD40LG_058 AGTAAGCCAAAGGACGTGAAG 1210 CD40LG gCD40LG_059 GCTTACTCAAACTCTGAACAG 1211 CD40LG gCD40LG_060 ACTGCTGGCCTCACTTATGAC 1212 CD3E gCD3E_1 CACTCCATCCTACTCACCTGA 1213 CD3E gCD3E_2 tttttCTTATTTATTTTCTAG 1214 CD3E gCD3E_3 ttttCTTATTTATTTTCTAGT 1215 CD3E gCD3E_4 tttCTTATTTATTTTCTAGTT 1216 CD3E gCD3E_5 ttCTTATTTATTTTCTAGTTG 1217 CD3E gCD3E_6 tCTTATTTATTTTCTAGTTGG 1218 CD3E gCD3E_7 CTTATTTATTTTCTAGTTGGC 1219 CD3E gCD3E_8 TTATTTATTTTCTAGTTGGCG 1220 CD3E gCD3E_9 TTTTCTAGTTGGCGTTTGGGG 1221 CD3E gCD3E_10 CTAGTTGGCGTTTGGGGGCAA 1222 CD3E gCD3E_11 TAGTTGGCGTTTGGGGGCAAG 1223 CD3E gCD3E_12 CTTTTCAGGTAATGAAGAAAT 1224 CD3E gCD3E_13 CAGGTAATGAAGAAATGGGTA 1225 CD3E gCD3E_14 AGGTAATGAAGAAATGGGTAA 1226 CD3E gCD3E_15 CTTTTTTCATTTTCAGGTGGT 1227 CD3E 9CD3E_16 TTCATTTTCAGGTGGTATTAC 1228 CD3E gCD3E_17 TCATTTTCAGGTGGTATTACA 1229 CD3E 9CD3E 18 CATTTTCAGGTGGTATTACAC 1230 CD3E gCD3E_19 ATTTTCAGGTGGTATTACACA 1231 CD3E gCD3E_20 CAGGTGGTATTACACAGACAC 1232 CD3E gCD3E_21 AGGTGGTATTACACAGACACG 1233 CD3E gCD3E_22 CCTTCTTTCTCCCCAGCATAT 1234 CD3E gCD3E_23 TCCCCAGCATATAAAGTCTCC 1235 CD3E gCD3E_24 AGATCCAGGATACTGAGGGCA 1236 CD3E gCD3E_25 tcatTGTGTTGCCATAGTATT 1237 CD3E gCD3E_26 atcatTGTGTTGCCATAGTAT 1238 CD3E gCD3E_27 tatcatTGTGTTGCCATAGTA 1239 CD3E gCD3E_28 tcatcctcatcaccgcctatg 1240 CD3E gCD3E_29 atcatcctcatcaccgcctat 1241 CD3E gCD3E_30 tatcatcctcatcaccgccta 1242 CD3E gCD3E_31 CTCCAATTCTGAAAATTCCTT 1243 CD3E gCD3E_32 CAGAATTGGAGCAAAGTGGTT 1244 CD3E gCD3E_33 AGAATTGGAGCAAAGTGGTTA 1245 CD3E gCD3E_34 CTTCCTCTGGGGTAGCAGACA 1246 CD3E gCD3E_35 ATCTCTACCTGAGGGCAAGAG 1247 CD3E gCD3E_36 TCTCTACCTGAGGGCAAGAGG 1248 CD3E gCD3E_37 TATTCTTGCTCCAGTAGTAAA 1249 CD3E gCD3E_38 CTACTGGAGCAAGAATAGAAA 1250 CD3E gCD3E_39 CCTGCCGCCAGCACCCGCTCC 1251 CD3E gCD3E_40 CCCTCCTTCCTCCGCAGGACA 1252 CD3E gCD3E_41 TATCCCACGTTACCTCATAGT 1253 CD3E gCD3E_42 ACCCCCAGCCCATCCGGAAAG 1254 CD38 gCD38_001 TCCCCGGACACCGGGCTGAAC 1255 CD38 gCD38_002 AGTGTACTTGACGCATCGCGC 1256 CD38 gCD38_003 CCGAGACCGTCCTGGCGCGAT 1257 CD38 gCD38_004 GCAGTCTACATGTCTGAGATA 1258 CD38 gCD38_005 TGTGTTTTATCTCAGACATGT 1259 CD38 gCD38_006 TCTCAGACATGTAGACTGCCA 1260 CD38 gCD38_007 AAATAAATGCACCCTTGAAAG 1261 CD38 gCD38_008 AAGGGTGCATTTATTTCAAAA 1262 CD38 gCD38_009 TTTCAAAACATCCTTGCAACA 1263 CD38 gCD38_010 AAAACATCCTTGCAACATTAC 1264 CD38 gCD38_011 TTCTGCTCCAAAGAAGAATCT 1265 CD38 gCD38_012 TTCTTCCTTAGATTCTTCTTT 1266 CD38 gCD38_013 GAGCAGAATAAAAGATCTGGC 1267 CD38 gCD38_014 TACAAACTATGTCTTTTAGAA 1268 CD38 gCD38_015 TCCAGTCTGGGCAAGATTGAT 1269 CD38 gCD38_016 GAAATAAACTATCAATCTTGC 1270 CD38 gCD38_017 CAGAATACTGAAACAGGGTTG 1271 CD38 gCD38_018 AGTATTCTGGAAAACGGTTTC 1272 CD38 gCD38_019 ACTACTTGGTACTTACCCTGC 1273 CD38 gCD38_020 AGTTTGCAGAAGCTGCCTGTG 1274 CD38 gCD38_021 CAGAAGCTGCCTGTGATGTGG 1275 CD38 gCD38_022 CTGCGGGATCCATTGAGCATC 1276 CD38 gCD38_023 TCAAAGATTTTACTGCGGGAT 1277 CD38 gCD38_024 GGGTTCTTTGTTTCTTCTATT 1278 CD38 gCD38_025 TTTCTTCTATTTTAGCACTTT 1279 CD38 gCD38_026 TTCTATTTTAGCACTTTTGGG 1280 CD38 gCD38_027 GCACTTTTGGGAGTGTGGAAG 1281 CD38 gCD38_028 GGAGTGTGGAAGTCCATAATT 1282 CD38 gCD38_029 CAACCAGAGAAGGTTCAGACA 1283 CD38 gCD38_030 TGGTGGGATCCTGGCATAAGT 1284 CD38 gCD38_031 TTCCCCAGAGACTTATGCCAG 1285 CD38 gCD38_032 CTTATAATCGATTCCAGCTCT 1286 CD38 gCD38_033 CTTTTTTGCTTTCTTGTCATA 1287 CD38 gCD38_034 CTTTCTTGTCATAGACCTGAC 1288 CD38 gCD38_035 ACACACTGAAGAAACTTGTCA 1289 CD38 gCD38_036 TTGTCATAGACCTGACAAGTT 1290 CD38 gCD38_037 TTCAGTGTGTGAAAAATCCTG 1291 ALPNR gAPLNR_001 ACAACTACTATGGGGCAGACA 1292 ALPNR gAPLNR_002 CAGTCTGTGTACTCACACTCA 1293 ALPNR gAPLNR_003 GGAGCAGCCGGGAGAAGAGGC 1294 ALPNR gAPLNR_004 GGACCTTCTTCTGCAAGCTCA 1295 ALPNR gAPLNR_006 TGGTGCCCTTCACCATCATGC 1296 ALPNR gAPLNR_007 GGCGATGAAGAAGTAACAGGT 1297 ALPNR gAPLNR_008 CCCTGTGCTGGATGCCCTACC 1298 ALPNR gAPLNR_009 ACCTCTTCCTCATGAACATCT 1299 ALPNR gAPLNR_010 GACCCCCGCTTCCGCCAGGCC 1300 ALPNR gAPLNR_011 TCGTGCATCTGTTCTCCACCC 1301 BBS1 gBBS1_005 CATGGGGATGGGGAATACAAG 1302 BBS1 gBBS1_007 GGTCATCACCAGTGGTCCTTT 1303 BBS1 gBBS1_009 GCCTGGTTCCAAAGGTCTTGT 1304 BBS1 gBBS1_015 ACTTAGCTCCAGCTGCAGAAA 1305 BBS1 gBBS1_016 CAAATGCCTCCATTTCACTTA 1306 BBS1 gBBS1_017 TGCAGCTGGAGCTAAGTGAAA 1307 BBS1 gBBS1_018 TAAACCAACACAAGTCCAACT 1308 BBS1 gBBS1_028 CACTGTCCACTTCCCTAGGTG 1309 BBS1 gBBS1_032 CGTGGATCAGACACTGCGAGA 1310 BBS1 gBBS1_033 TCCACCCACCCTCTCCATAGG 1311 CALR gCALR_001 GATTCGATCCAGCGGGAAGTC 1312 CALR gCALR_006 CAGACAAGCCAGGATGCACGC 1313 CALR gCALR_011 ACCGTGAACTGCACCACCAGC 1314 CALR gCALR_012 CTAATAGTTTGGACCAGACAG 1315 CALR gCALR_013 GACCAGACAGACATGCACGGA 1316 CALR gCALR_014 CCACCACCCCCAGGCACACCT 1317 CALR gCALR_015 CACACCTGTACACACTGATTG 1318 CALR gCALR_017 AAGCATCAGGATCCTTTATCT 1319 CALR gCALR_019 TGGGTGGATCCAAGTGCCCTT 1320 CALR gCALR_021 CTCCAAGTCTCACCTGCCAGA 1321 CD3G gCD3G_001 CCGGAGGACAGAGACTGACAT 1322 CD3G gCD3G_004 GCTTCTGCATCACAAGTCAGA 1323 CD3G gCD3G_006 TCTTCAGTTAGGAAGCCGATC 1324 CD3G gCD3G_007 AAGATGGGAAGATGATCGGCT 1325 CD3G gCD3G_008 CACTGATACATCCCTCGAGGG 1326 CD3G gCD3G_011 GTTCAATGCAGTTCTGACACA 1327 CD3G gCD3G_012 CCTACAGTGTGTCAGAACTGC 1328 CD3G gCD3G_017 CCTCTCGACTGGCGAACTCCA 1329 CD3G gCD3G_022 CTTGAAGGTGGCTGTACTGGT 1330 CD3G gCD3G_023 CAGGTACTTTGGCCCAGTCAA 1331 CD58 gCD58_004 CCAACAAATATATGGTGTTGT 1332 CD58 gCD58_005 AAGGCACATTGCTTGGTACAT 1333 CD58 gCD58_010 AAAGAGGTCCTATGGAAAAAA 1334 CD58 gCD58_012 AAAGATGAGAAAGCTCTGAAT 1335 CD58 gCD58_018 GCGATTCCATTTCATACTCAT 1336 CD58 gCD58_019 CAGAGTCTCTTCCATCTCCCA 1337 CD58 gCD58_020 CATTGCTCCATAGGACAATCC 1338 CD58 gCD58_023 AGATGGAAAATGATCTTCCAC 1339 CD58 gCD58_028 TAGGTCATTCAAGACACAGAT 1340 CD58 gCD58_033 GGTATTCTGAAATGTGACAGA 1341 COL17A1 gCOL17A1_005 TAGTTGTCACTGAAACAGTAA 1342 COL17A1 gCOL17A1_006 GCATAGCCATTGCTGGTCCCG 1343 COL17A1 gCOL17A1_017 ACTCCGTCCTCTGGTTGAAGA 1344 COL17A1 gCOL17A1_024 CAGTGTCAGGCACCTACGATG 1345 COL17A1 gCOL17A1_047 CTGTTCCATCATTAGCTTCTT 1346 COL17A1 gCOL17A1_054 AGGTGACATGGGAAGTCCAGG 1347 COL17A1 gCOL17A1_065 CAAGAAGCAGCAAACTGACCT 1348 COL17A1 gCOL17A1_070 GGTGACAAAGGACCAATGGGA 1349 COL17A1 gCOL17A1_084 AGAGGGGTCATCGATGCTCAC 1350 COL17A1 gCOL17A1_094 ATGCCGGCTCTACTGTACCTT 1351 DEFB134 gDEFB134_001 CCTGCCAGCACTGGATCCCAA 1352 DEFB134 gDEFB134_004 CTTTGGGATCCAGTGCTGGCA 1353 DEFB134 gDEFB134_007 CTTCCAGGTATAAATTCATTA 1354 DEFB134 gDEFB134_008 TTGTGCATTTCTGATGATAAT 1355 DEFB134 gDEFB134_009 TAGCATTTCTTGTGCATTTCT 1356 DEFB134 gDEFB134_010 ACTCTCATAGCATTCAAGTCT 1357 DEFB134 gDEFB134_011 ACACAGCACTCCAGCTGAAAC 1358 DEFB134 gDEFB134_012 CTTTGACACAGCACTCCAGCT 1359 DEFB134 gDEFB134_013 AGCTGGAGTGCTGTGTCAAAG 1360 DEFB134 gDEFB134_014 TTATGTCAGGGTGCAGGATTT 1361 ERAP1 gERAP1_008 CATGGATCAAGAGATCATAAT 1362 ERAP1 gERAP1_015 CAAAAGCACCTACAGAACCAA 1363 ERAP1 gERAP1_029 AGTCTGTCAGCAAGATAACCA 1364 ERAP1 gERAP1_035 GGTAGGGGATACGGTATGCTG 1365 ERAP1 gERAP1_037 AGCATACCGTATCCCCTACCC 1366 ERAP1 gERAP1_039 CATAGCACCAGACTGAAAGTC 1367 ERAP1 gERAP1_061 CCTTATCATAAGAAACATCAT 1368 ERAP1 gERAP1_065 AATGCGTCAGCACTAAGATAC 1369 ERAP1 gERAP1_077 CCCTAATAACCATCACAGTGA 1370 ERAP1 gERAP1_078 CTCTAGGAGCATTACCCAGTG 1371 ERAP2 gERAP2_001 TGTGTGAATTAACCATTGCAG 1372 ERAP2 gERAP2_014 ATGTATCTTGAATCTTCCTCT 1373 ERAP2 gERAP2_018 AGTTACCCTGCTCATGAACAA 1374 ERAP2 gERAP2_046 GAGAGTGGATAGTAGATATCA 1375 ERAP2 gERAP2_048 ATATCTACTATCCACTCTCCA 1376 ERAP2 gERAP2_099 ATGTGGACTCAAATGGTTACT 1377 ERAP2 gERAP2_108 CCTGTCAATCACTGGCTTAAA 1378 ERAP2 gERAP2_118 GAGCAATATGAACTGTCAATG 1379 ERAP2 gERAP2_134 ACTTGGGCTCATATGACATAA 1380 ERAP2 gERAP2_261 TCCTTACCATGTTACTTGTCA 1381 IFNGR1 gIFNGR1_004 TTACAGTGCCTACACCAACTA 1382 IFNGR1 gIFNGR1_006 CCGTAGAGGTAAAGAACTATG 1383 IFNGR1 gIFNGR1_008 GTGTTAAGAATTCAGAATGGA 1384 IFNGR1 gIFNGR1_010 ATGGATCACCAACATGATCAG 1385 IFNGR1 gIFNGR1_012 ACTCTGACCCAAAGAGAATTT 1386 IFNGR1 gIFNGR1_021 GGGATCATAATCGACTTCCTG 1387 IFNGR1 gIFNGR1_025 AGTTGTAACACCCCACACATG 1388 IFNGR1 gIFNGR1_042 GAGACAAAACCTGAATCAAAA 1389 IFNGR1 gIFNGR1_049 AGTAGTAACCAGTCTGAACCT 1390 IFNGR1 gIFNGR1_052 TGGAGTGATCACTCTCAGAAC 1391 IFNGR2 gIFNGR2_001 TCTGTCCCCCTCAAGACCCTC 1392 IFNGR2 gIFNGR2_003 AACTGCACTTGGTAGACAACA 1393 IFNGR2 gIFNGR2_005 CTTCCCAGCACCGACAGTAAA 1394 IFNGR2 gIFNGR2_006 AATGTCACTCTACGCCTTCGA 1395 IFNGR2 gIFNGR2_012 CCAGTAATGGACATAATAACA 1396 IFNGR2 gIFNGR2_015 AGTTATCCAATGAAATGGAGT 1397 IFNGR2 gIFNGR2_017 ATTGGATAACTTAAAACCCTC 1398 IFNGR2 gIFNGR2_021 GTAGCAAGATATGTTGCTTAA 1399 IFNGR2 gIFNGR2_026 GCCTCCACTGAGCTTCAGCAA 1400 IFNGR2 gIFNGR2_031 ACACTCCACCAAGCATCCCAT 1401 JAK1 gJAK1_002 CTTCCACAACAGTATCTAAAT 1402 JAK1 gJAK1_021 GCTACAAGCGATATATTCCAG 1403 JAK1 gJAK1_037 ATTCGAATGACGGTGGAAACG 1404 JAK1 gJAK1_059 GCATGAAGCTGATGTTATCCG 1405 JAK1 gJAK1_074 GTACACACATTTCCATGGACC 1406 JAK1 gJAK1_075 CCAGAGCGTGGTTCCAAAGCT 1407 JAK1 gJAK1_090 AGATCAGCTATGTGGTTACCT 1408 JAK1 gJAK1_100 CCTTACAAATCTGAACGGCAT 1409 JAK1 gJAK1_108 ACCAAAGCAATTGAAACCGAT 1410 JAK1 gJAK1_111 GATTGCATTAAACATTCTGGA 1411 JAK2 gJAK2_009 GAAGCAGCAATACAGATTTCT 1412 JAK2 gJAK2_101 AAGGCGTACGAAGAGAAGTAG 1413 JAK2 gJAK2_118 AGATATGTATCTAGTGATCCA 1414 JAK2 gJAK2_121 GATCACTAGATACATATCTGA 1415 JAK2 gJAK2_126 GCACATACATTCCCATGAATA 1416 JAK2 gJAK2_132 AATGCATTCAGGTGGTACCCA 1417 JAK2 gJAK2_137 CCACAAAGTGGTACCAAAACT 1418 JAK2 gJAK2_175 AAGATAGTCTCGTAAACTTCC 1419 JAK2 gJAK2_187 GGTTAACCAAAGTCTTGCCAC 1420 JAK2 gJAK2_191 CAGGTATGCTCCAGAATCACT 1421 mir-101-2 gmir-101-2_001 GGTTATCATGGTACCGATGCT 1422 mir-101-2 gmir-101-2_002 AGATATACAGCATCGGTACCA 1423 mir-101-2 gmir-101-2_003 TCAATGTGATGGCACCACCAT 1424 MLANA gMLANA_001 AACTTACTCTTCAGCCGTGGT 1425 MLANA gMLANA_002 TCTATCTCTTGGGCCAGGGCC 1426 MLANA gMLANA_003 GTCTTCTACAATACCAACAGC 1427 MLANA gMLANA_004 CCAACCATCAAGGCTCTGTAT 1428 MLANA gMLANA_008 CATTTCAGGATAAAAGTCTTC 1429 MLANA gMLANA_009 AGGATAAAAGTCTTCATGTTG 1430 MLANA gMLANA_010 CTGTCCCGATGATCAAACCCT 1431 MLANA gMLANA_011 TCTTGAAGAGACACTTTGCTG 1432 MLANA gMLANA_012 ATCATCGGGACAGCAAAGTGT 1433 MLANA gMLANA_020 TCATAAGCAGGTGGAGCATTG 1434 PSMB5 gPSMB5_001 TGCCCACACTAGACATGGCGC 1435 PSMB5 gPSMB5_002 GGACTTGGGGGTCGTGCAGAT 1436 PSMB5 gPSMB5_003 GATTCCTGGCTCTTCTGGGAC 1437 PSMB5 gPSMB5_005 CTCTGATCTTAACAGTTCCGC 1438 PSMB5 gPSMB5_006 GAAGCTCATAGATTCGACATT 1439 PSMB5 gPSMB5_007 GAGGCAGCTGCTACAGAGATG 1440 PSMB5 gPSMB5_008 TACTGATACACCATGTTGGCA 1441 PSMB5 gPSMB5_010 CAGGCCTCTACTACGTGGACA 1442 PSMB5 gPSMB5_011 AGGGGCCACCTTCTCTGTAGG 1443 PSMB5 gPSMB5_012 AGGGGGTAGAGCCACTATACT 1444 PSMB8 gPSMB8_001 TCTATGCGATCTCCAGAGCTC 1445 PSMB8 gPSMB8_004 TCTTATCAGCCCACAGAATTC 1446 PSMB8 gPSMB8_005 TCCGTCCCCACCCAGGGACTG 1447 PSMB8 gPSMB8_008 AGTGTCGGCAGCCTCCAAGCT 1448 PSMB8 gPSMB8_010 ATCTTATAGGGTCCTGGACTC 1449 PSMB8 gPSMB8_011 CTGAGAGCCGAGTCCCATGTT 1450 PSMB8 gPSMB8_012 TCATTTGTCCACAGTGTACCA 1451 PSMB8 gPSMB8_013 ACCCAACCATCTTCCTTCATG 1452 PSMB8 gPSMB8_014 TCCACAGTGTACCACATGAAG 1453 PSMB8 gPSMB8_015 TACTTTCACCCAACCATCTTC 1454 PSMB9 gPSMB9_001 ACGGGGGCGTTGTGATGGGTT 1455 PSMB9 gPSMB9_002 CTCACCCTGCAGACACTCGGG 1456 PSMB9 gPSMB9_005 CCTCAGGATAGAACTGGAGGA 1457 PSMB9 gPSMB9_007 TCACCACATTTGCAGCAGCCA 1458 PSMB9 gPSMB9_009 GCTGCTGCAAATGTGGTGAGA 1459 PSMB9 gPSMB9_010 GGAGAAACTCACCTGACCTCC 1460 PSMB9 gPSMB9_011 ACCTGAGGATCCCTTTCCCAG 1461 PSMB9 gPSMB9_012 CCAGGTATATGGAACCCTGGG 1462 PSMB9 gPSMB9_014 TCTATGGTTATGTGGATGCAG 1463 PSMB9 gPSMB9_015 GCAGTTCATTGCCCAAGATGA 1464 PTCD2 gPTCD2_005 ACCACATTATCTGTAAGTAGG 1465 PTCD2 gPTCD2_007 GCTAAAAGATACCTACTTACA 1466 PTCD2 gPTCD2_011 GTGCCAGAAAGATTACATGCA 1467 PTCD2 gPTCD2_018 ATTACCAGGTACCATGCAGAG 1468 PTCD2 gPTCD2_026 TTCTCAGACTCCACATCATTC 1469 PTCD2 gPTCD2_032 ATCTCTATCAATACTTGCAAA 1470 PTCD2 gPTCD2_033 GCAGGTGCTTTGCAAGTATTG 1471 PTCD2 gPTCD2_042 CCTGATTCAGAGCTAATGCCA 1472 PTCD2 gPTCD2_043 GCTGTGGCATTAGCTCTGAAT 1473 PTCD2 gPTCD2_064 ATAGCAACGTGTGAGATTTCC 1474 RFX5 gRFX5_008 TGTAGCTCAGAGCCAAGTACA 1475 RFX5 gRFX5_012 GCAAGATCATCAGAGAGATCT 1476 RFX5 gRFX5_013 ACTTGCATCAGATATTGCTAC 1477 RFX5 gRFX5_015 GTACTTACACTCTCAGAACCC 1478 RFX5 gRFX5_016 AGGATCCGCTCTGCCCAGTCA 1479 RFX5 gRFX5_017 GTACCTCTGCAGAAGAGGACG 1480 RFX5 gRFX5_018 GATGACCGTTCCCGAGGTGCA 1481 RFX5 gRFX5_026 GCTGGTGGAGCCTGCCCACTG 1482 RFX5 gRFX5_028 GCATCACTTGCTGTATCCTCT 1483 RFX5 gRFX5_038 GCTTCTGCTGCCCTTGATGAC 1484 RFXANK gRFXANK_001 CCCATGGAGCTTACCCAGCCT 1485 RFXANK gRFXANK_002 CCTGCACCCCTGAGCCTGTGA 1486 RFXANK gRFXANK_003 CCAGCAGGCAGCTCCCTGAAG 1487 RFXANK gRFXANK_005 GAGAGATTGAGACCGTTCGCT 1488 RFXANK gRFXANK_006 CCAGGATGTGGGGGTCGGCAC 1489 RFXANK gRFXANK_007 TCCTGCCCCTACCCACGACAG 1490 RFXANK gRFXANK_008 ACGTGGTTCCCGCGCACAGCG 1491 RFXANK gRFXANK_009 CAGCCCGAGGCGCTGACCTCA 1492 RFXANK gRFXANK_010 CGGTATCCCAGGGCCACGGCA 1493 RFXANK gRFXANK_011 CCTGCCCCATCTCAGTGCAAC 1494 RFXAP gRFXAP_001 GAGGATCTAGAGGACGAGGAG 1495 RFXAP gRFXAP_004 TACTTGTCCTTGTACATCTTG 1496 RFXAP gRFXAP_005 CCGCGCTGCCAGTCGAGGCAG 1497 RFXAP gRFXAP_009 ACAATGGAGAGTATGTTATCT 1498 RFXAP gRFXAP_012 GGGATCGTCCTGCAAGACCTA 1499 RFXAP gRFXAP_016 GAACAAGTGTTAAATCAAAAA 1500 RFXAP gRFXAP_020 TAAGTCGTTACTAAGAAGTCC 1501 RFXAP gRFXAP_021 TGTAAAAATTGCACTACTTCT 1502 RFXAP gRFXAP_023 CAGAAACAGCAACAGCTATTA 1503 RFXAP gRFXAP_025 GAGCAAAGACAACAGCAGTTT 1504 RPL23 gRPL23_003 GCACCAGAGGACCCACCACGT 1505 RPL23 gRPL23_004 TATCCACAGGACGTGGTGGGT 1506 RPL23 gRPL23_008 TAGGAGCCAAAAACCTGTATA 1507 RPL23 gRPL23_013 GTTGTCGAATGACCACTGCTG 1508 RPL23 gRPL23_014 TTCTCTCAGTACATCCAGCAG 1509 RPL23 gRPL23_019 AAGATAATGCAGGAGTCATAG 1510 RPL23 gRPL23_021 CTACCTTTCATCTCGCCTTTA 1511 RPL23 gRPL23_025 ATGCAGGTTCTGCCATTACAG 1512 RPL23 gRPL23_026 CAAATATACTGGAGAATCATG 1513 RPL23 gRPL23_027 CCTTCCCTTTATATCCACAGG 1514 SOX10 gSOX10_001 CTGGCGCCGTTGACGCGCACG 1515 SOX10 gSOX10_002 TTGTGCTGCATACGGAGCCGC 1516 SOX10 gSOX10_003 ATGTGGCTGAGTTGGACCAGT 1517 SOX10 gSOX10_004 GCATCCACACCAGGTGGTGAG 1518 SOX10 gSOX10_005 ACTACTCTGACCATCAGCCCT 1519 SOX10 gSOX10_006 GGGCCGGGACAGTGTCGTATA 1520 SRP54 gSRP54_011 TCTTAGTTGCTTCACTAGTTT 1521 SRP54 gSRP54_020 GTGGGTGTCCATGCCTTAACT 1522 SRP54 gSRP54_021 GCTTGTAGACCCTGGAGTTAA 1523 SRP54 gSRP54_024 CCACTCCCTTGCAATCCAACA 1524 SRP54 gSRP54_029 TCACCCAGCTAGCATATTATT 1525 SRP54 gSRP54_030 ATATGTGCAGACACATTCAGA 1526 SRP54 gSRP54_064 ATTGGTACAGGGGAACATATA 1527 SRP54 gSRP54_087 GCACCATCCGTACTGTCTAGT 1528 SRP54 gSRP54_090 GTAAACAACCAGGAAGAATCC 1529 SRP54 gSRP54_096 CCCTCAGGTGGCGACATGTCT 1530 SRP54 gSRP54_139 AGGATAACTAACCAAGATCTG 1531 STAT1 gSTAT1_003 CATGGGAAAACTGTCATCATA 1532 STAT1 gSTAT1_005 TAACCACTGTGCCAGGTACTG 1533 STAT1 gSTAT1_009 ATGACCTCCTGTCACAGCTGG 1534 STAT1 gSTAT1_013 TTCTAACCACTCAAATCTAGG 1535 STAT1 gSTAT1_014 AGGAAGACCCAATCCAGATGT 1536 STAT1 gSTAT1_026 TAGTGTATAGAGCATGAAATC 1537 STAT1 gSTAT1_032 TGATCACTCTTTGCCACACCA 1538 STAT1 gSTAT1_102 CCTGACATCATTCGCAATTAC 1539 STAT1 gSTAT1_103 GATACAGATACTTCAGGGGAT 1540 STAT1 gSTAT1_113 GTCACCCTTCTAGACTTCAGA 1541 Tap1 gTap1_011 GAGTGAAGGTATCGGCTGAGC 1542 Tap1 gTap1_012 AGCCCCCAGACCTGGCTATGG 1543 Tap1 gTap1_016 AGGAGAAACCTGTCTGGTTCT 1544 Tap1 gTap1_020 CTTCTGCCCAAGAAGGTGGGA 1545 Tap1 gTap1_026 GGGAAAAGCTGCAAGAAATAA 1546 Tap1 gTap1_030 AGGTATGCTGCTGAAAGTGGG 1547 Tap1 gTap1_033 TCTGAGGAGCCCACAGCCTTC 1548 Tap1 gTap1_035 GGTAGGCAAAGGAGACATCTT 1549 Tap1 gTap1_036 CCTACCCAAACCGCCCAGATG 1550 Tap1 gTap1_039 GAAGAAGTCTTCAAGAAAATA 1551 TAP2 gTAP2_004 GCAGCCCCCACAGCCCTCCCA 1552 TAP2 gTAP2_008 AGGTGAGACATTAATCCCTCA 1553 TAP2 gTAP2_014 AAGGAAGCCAGTTACTCATCA 1554 TAP2 gTAP2_027 CAGACCCTGGTATACATATAT 1555 TAP2 gTAP2_028 GCTGTCGGTCCATGTAGGAGA 1556 TAP2 gTAP2_029 TCCTACATGGACCGACAGCCA 1557 TAP2 gTAP2_030 ACAACCCCCTGCAGAGTGGTG 1558 TAP2 gTAP2_037 ATCCAGCAGCACCTGTCCCCC 1559 TAP2 gTAP2_038 AGTTGGGCAGGAGCCTGTGCT 1560 TAP2 gTAP2_040 TAGAAGATACCTGTGTATATT 1561 TAPBP gTAPBP_001 CGCTCGCATCCTCCACGAACC 1562 TAPBP gTAPBP_002 GCAGAGGCGGGGAGAGGCACG 1563 TAPBP gTAPBP_003 CCTACATGCCCCCCACCTCCG 1564 TAPBP gTAPBP_004 GGCTAGAGTGGCGACGCCAGC 1565 TAPBP gTAPBP_007 AGGAGGGCACCTATCTGGCCA 1566 TAPBP gTAPBP_010 GTCCTCTTTCCCCAGAACCCC 1567 TAPBP gTAPBP_011 CCCAGAACCCCCCAAAGTGTC 1568 TAPBP gTAPBP_012 AGGGCCCTCCCTTGAGGACAG 1569 TAPBP gTAPBP_013 CTGTCTGCCTTTCTTCTGCTT 1570 TAPBP gTAPBP_016 CCCACAGCTGTCTACCTGTCC 1571 TWF1 gTWF1_005 CACAGCAAGTGAAGATGTTAA 1572 TWF1 gTWF1_012 ATAGAGCAACTTGTGATTGGA 1573 TWF1 gTWF1_015 CCCCTGTTGGAGGACAAACAA 1574 TWF1 gTWF1_018 ATGTGGCCACCTCCAAATTCC 1575 TWF1 gTWF1_020 GAGGTGGCCACATTAAAGATG 1576 TWF1 gTWF1_022 ATCTGTCGTAGTTCTTCCTCA 1577 TWF1 gTWF1_051 CAGATCGAGATAGACAATGGG 1578 TWF1 gTWF1_053 TGAAGAAGTACATCCCAAGCA 1579 TWF1 gTWF1_060 ATGTGATGACTTTAATCAGTA 1580 TWF1 gTWF1_101 AAATAGGTGGGCTACCTTTCT 1581 CD3D gCD3D_001 TCTCTGGCCTGGTACTGGCTA 1582 CD3D gCD3D_002 CCCTTTAGTGAGCCCCTTCAA 1583 CD3D gCD3D_003 GTGAGCCCCTTCAAGATACCT 1584 CD3D gCD3D_004 TGAATTGCAATACCAGCATCA 1585 CD3D gCD3D_005 CCAGGTCCAGTCTTGTAATGT 1586 CD3D gCD3D_006 TCCTTGTATATATCTGTCCCA 1587 CD3D gCD3D_007 GGAGTCTTCTGCTTTGCTGGA 1588 CD3D gCD3D_008 CTGGACATGAGACTGGAAGGC 1589 CD3D gCD3D_009 TCTTCTCCTCTCTTAGCCCCT 1590 CD3D gCD3D_010 CTCCAAGGTGGCTGTACTGAG 1591 NLRC5 gNLRC5_001 GCTCCTGTAGCGCTGCTGGGC 1592 NLRC5 gNLRC5_002 GGGAAGGCTGGCATGGGCAAG 1593 NLRC5 gNLRC5_003 CAGGCCCTGTTCCTTTTTGAA 1594 NLRC5 gNLRC5_004 AATTCCGCCAGCTCAACTTGA 1595 NLRC5 gNLRC5_005 ATCTGTACCTGAGCCCTGAAT 1596 NLRC5 gNLRC5_006 ATGGGCTAGATGAGGCCCTCC 1597 NLRC5 gNLRC5_007 TCCCATCTCTGCAATGGGACC 1598 NLRC5 gNLRC5_008 ATGGGCCACGGGTGGAAGAAT 1599 NLRC5 gNLRC5_009 TCTGTAACTCCACCAGGGCCC 1600 NLRC5 gNLRC5_010 CATAGAAGATAACCTTCCCTG 1601 NLRC5 gNLRC5_011 GGGCCACTCACAGCCTGCTGA 1602 NLRC5 gNLRC5_012 ACCCACCTCAGCCTGCAGGAG 1603 NLRC5 gNLRC5_013 TTCACCTTGGGGCTGGCCATC 1604 NLRC5 gNLRC5_014 TTGCTGCCCTGCACCTGATGG 1605 NLRC5 gNLRC5_015 GTCCGCTGTACCCAGCGGGAA 1606 NLRC5 gNLRC5_016 GCCCTGTGAGCTTGCGGGTGG 1607 NLRC5 gNLRC5_017 TGCGGTGAGACTGGCCAGCTC 1608 NLRC5 gNLRC5_018 CCACTGACCTGCACCGACCTG 1609 NLRC5 gNLRC5_019 ATGGCTGTCCCCTGGAGCCCC 1610

The spacer sequences provided in Tables 1-3 are designed based upon identification of target nucleotide sequences associated with a PAM in a given target gene locus, and are selected based upon the editing efficiency detected in human cells.

Further exemplary spacer sequences useful in embodiments of the methods and compositions disclosed herein are shown in Tables 4-23.

TABLE_4 Tested crRNAs Targeting Human ADORA2A Gene crRNA Spacer Sequence SEQ ID NO % Indel gADORA2A_1 GTGGTGTCACTGGCGGCGGCC 242 0.3 gADORA2A_2 TGGTGTCACTGGCGGCGGCCG 133 3.9 gADORA2A_3 GCCATCACCATCAGCACCGGG 243 0.5 gADORA2A_4 CCATCACCATCAGCACCGGGT 137 2.1 gADORA2A_5 GTCCTGGTCCTCACGCAGAGC 244 0.1 gADORA2A_6 GCCCTCGTGCCGGTCACCAAG 245 0.9 gADORA2A_7 GTGACCGGCACGAGGGCTAAG 135 2.8 gADORA2A_8 CCATCGGCCTGACTCCCATGC 136 2.2 gADORA2A_9 GCTGACCGCAGTTGTTCCAAC 246 1.1 gADORA2A_10 GGCTGACCGCAGTTGTTCCAA 247 0.5 gADORA2A_11 GCCCTCCCCGCAGCCCTGGGA 248 1.3 gADORA2A_12 AGGATGTGGTCCCCATGAACT 51 18.2 gADORA2A_13 AACTTCTTTGCCTGTGTGCTG 249 0.1 gADORA2A_14 TTTGCCTGTGTGCTGGTGCCC 250 0.2 gADORA2A_15 CCTGTGTGCTGGTGCCCCTGC 251 1.1 gADORA2A_16 CGGATCTTCCTGGCGGCGCGA 131 7.8 gADORA2A_17 AGCTGTCGTCGCGCCGCCAGG 252 0.1 gADORA2A_18 TGCAGTGTGGACCGTGCCCGC 253 0.2 gADORA2A_19 GCAGCATGGACCTCCTTCTGC 254 0.4 gADORA2A_20 CCCTCTGCTGGCTGCCCCTAC 255 0.6 gADORA2A_21 ACTTTCTTCTGCCCCGACTGC 256 0.6 gADORA2A_22 CTTCTGCCCCGACTGCAGCCA 257 1.0 gADORA2A_23 TTCTGCCCCGACTGCAGCCAC 134 2.8 gADORA2A_24 ATCTACGCCTACCGTATCCGC 258 0.0 gADORA2A_25 CGCAAGATCATTCGCAGCCAC 259 0.1 gADORA2A_26 AAAGGTTCTTGCTGCCTCAGG 260 0.1 gADORA2A_27 CAAGGCAGCTGGCACCAGTGC 261 0.1 gADORA2A_28 AAGGCAGCTGGCACCAGTGCC 132 5.8 gADORA2A_29 AGCTCATGGCTAAGGAGCTCC 262 0.2 gADORA2A_30 GCCATGAGCTCAAGGGAGTGT 263 0.5

TABLE_5 Tested crRNAs Targeting Human B2M Gene crRNA Name Spacer Sequence SEQ ID NO % Indel gB2M_1 GCTGTGCTCGCGCTACTCTCT 145 1.8 gB2M_2 TGGCCTGGAGGCTATCCAGCG 65 17.4 gB2M_3 CCCGATATTCCTCAGGTACTC 264 0.1 gB2M_4 CTCACGTCATCCAGCAGAGAA 52 74.1 gB2M_5 CATTCTCTGCTGGATGACGTG 142 2.2 gB2M_6 CCATTCTCTGCTGGATGACGT 265 1.0 gB2M_7 ACTTTCCATTCTCTGCTGGAT 64 17.9 gB2M_8 CTGAATTGCTATGTGTCTGGG 139 3.5 gB2M_9 AATGTCGGATGGATGAAACCC 266 0.5 gB2M_10 ATCCATCCGACATTGAAGTTG 143 2.0 gB2M_11 CTGAAGAATGGAGAGAGAATT 140 3.4 gB2M_12 TCAATTCTCTCTCCATTCTTC 267 0.7 gB2M_13 TTCAATTCTCTCTCCATTCTT 268 0.7 gB2M_14 CTGAAAGACAAGTCTGAATGC 269 0.4 gB2M_15 TCTTTCAGCAAGGACTGGTCT 270 0.9 gB2M_16 AGCAAGGACTGGTCTTTCTAT 271 0.3 gB2M_17 TATCTCTTGTACTACACTGAA 66 15.3 gB2M_18 TCAGTGGGGGTGAATTCAGTG 141 3.0 gB2M_19 ACTATCTTGGGCTGTGACAAA 272 0.1 gB2M_20 GTCACAGCCCAAGATAGTTAA 273 0.8 gB2M_21 TCACAGCCCAAGATAGTTAAG 138 5.3 gB2M_22 CCCCACTTAACTATCTTGGGC 144 2.0 gB2M_23 CTGGCCTGGAGGCTATCCAGC 618 0.77 gB2M_24 TCCCGATATTCCTCAGGTACT 619 0.54 gB2M_25 CCGATATTCCTCAGGTACTCC 620 0.14 gB2M_26 AGTAAGTCAACTTCAATGTCG 621 0.11 gB2M_27 AATTCTCTCTCCATTCTTCAG 622 2.70 gB2M_28 CAATTCTCTCTCCATTCTTCA 623 0.26 gB2M_29 CAGCAAGGACTGGTCTTTCTA 624 0.19 gB2M_30 AGTGGGGGTGAATTCAGTGTA 625 91.96 gB2M_31 CAGTGGGGGTGAATTCAGTGT 626 8.10 gB2M_33 CTATCTCTTGTACTACACTGA 627 0.21 gB2M_34 TACTACACTGAATTCACCCCC 628 0.80 gB2M_35 GGCTGTGACAAAGTCACATGG 629 0.18 gB2M_36 CAAAAGAATGTAAGACTTACC 630 0.13 gB2M_37 CCTCCATGATGCTGCTTACAT 631 0.81 gB2M_38 TTCATAGATCGAGACATGTAA 632 0.18 gB2M_39 TCATAGATCGAGACATGTAAG 633 0.20 gB2M_40 CATAGATCGAGACATGTAAGC 634 4.25 gB2M_41 ATAGATCGAGACATGTAAGCA 635 93.92

TABLE_6 Tested crRNAs Targeting Human CD52 Gene crRNA_Name Spacer_Sequence SEQ ID NO % Indel gCD52_1 CTCTTCCTCCTACTCACCATC 53 28.4 gCD52_2 TCCTCCTACAGATACAAACTG 274 N.D. gCD52_3 GTCCTGAGAGTCCAGTTTGTA 275 N.D. gCD52_4 GCTGGTGTCGTTTTGTCCTGA 146 4.1 gCD52_5 TGTTGCTGGATGCTGAGGGGC 276 1.1 gCD52_6 CCTTTTCTTCGTGGCCAATGC 277 0.2 gCD52_7 TCTTCGTGGCCAATGCCATAA 278 0.2 gCD52_8 CTTCGTGGCCAATGCCATAAT 279 0.15

TABLE_7 Tested crRNAs Targeting Human CIITA Gene crRNA Spacer Sequence SEQ ID NO % Indel gCIITA_1 GGGCTCTGACAGGTAGGACCC 280 0.5 gCIITA_2 TACCTTGGGGCTCTGACAGGT 281 0.0 gCIITA_3 TTACCTTGGGGCTCTGACAGG 282 0.0 gCIITA_4 TAGGGGCCCCAACTCCATGGT 54 13.5 gCIITA_5 TTAACAGCGATGCTGACCCCC 284 0.1 gCIITA_6 TATGACCAGATGGACCTGGCT 285 0.2 gCIITA_7 TCCTCCCAGAACCCGACACAG 286 0.1 gCIITA_8 CCTCCCAGAACCCGACACAGA 287 0.1 gCIITA_9 CATGTCACACAACAGCCTGCT 288 0.1 gCIITA_10 CTCACCGATATTGGCATAAGC 289 0.1 gCIITA_11 TCCTTGTCTGGGCAGCGGAAC 290 0.1 gCIITA_12 CCTTGTCTGGGCAGCGGAACT 291 0.4 gCIITA_13 TCTGGGCAGCGGAACTGGACC 292 0.1 gCIITA_14 CTCAGGCCCTCCAGCTGGGAG 293 0.2 gCIITA_15 CTGAAAATGTCCTTGCTCAGG 294 0.2 gCIITA_16 TCTCAAAGTAGAGCACATAGG 295 0.1 gCIITA_17 ATCTGGTCCTATGTGCTCTAC 296 0.2 gCIITA_18 TGCTGGCATCTCCATACTCTC 147 4.8 gCIITA_19 CTGCCCAACTTCTGCTGGCAT 297 0.5 gCIITA_20 TCTGCCCAACTTCTGCTGGCA 298 0.1 gCIITA_21 CTGACTTTTCTGCCCAACTTC 299 0.1 gCIITA_22 CTCTGCAGCCTTCCCAGAGGA 300 0.6 gCIITA_23 CCAGAGGAGCTTCCGGCAGAC 301 0.9 gCIITA_24 AGGTCTGCCGGAAGCTCCTCT 302 0.1 gCIITA_25 CAGTGCTTCAGGTCTGCCGGA 303 0.2 gCIITA_26 CGGCAGACCTGAAGCACTGGA 304 0.3 gCIITA_27 CTCACAGCTGAGCCCCCCACT 305 0.4 gCIITA_28 CTCCAGGCGCATCTGGCCGGA 306 0.7 gCIITA_29 GTCTCTTGCAGTGCCTTTCTC 148 2.4 gCIITA_30 TCTCTTGCAGTGCCTTTCTCC 307 0.1 gCIITA_31 CTCCAGTTCCTCGTTGAGCTG 308 0.1 gCIITA_32 CCTTGGGGCTCTGACAGGTAG 636 93.85 gCIITA_33 ACCTTGGGGCTCTGACAGGTA 637 11.83 gCIITA_34 CCGGCCTTTTTACCTTGGGGC 638 2.26 gCIITA_35 CTCCCAGAACCCGACACAGAC 639 48.70 gCIITA_36 TGGGCTCAGGTGCTTCCTCAC 640 85.46 gCIITA_37 CTGGGCTCAGGTGCTTCCTCA 641 0.45 gCIITA_38 CTTGTCTGGGCAGCGGAACTG 642 38.38 gCIITA_39 CTCAAAGTAGAGCACATAGGA 643 0.25 gCIITA_40 TCAAAGTAGAGCACATAGGAC 644 15.68 gCIITA_41 TGCCCAACTTCTGCTGGCATC 645 46.21 gCIITA_42 TGACTTTTCTGCCCAACTTCT 646 2.72 gCIITA_43 TCTGCAGCCTTCCCAGAGGAG 647 55.09 gCIITA_44 TCCAGGCGCATCTGGCCGGAG 648 39.16 gCIITA_45 TCCAGTTCCTCGTTGAGCTGC 649 0.22 gCIITA_46 CCAGAGCCCATGGGGCAGAGT 650 1.51 gCIITA_47 TCCCCACCATCTCCACTCTGC 651 2.05 gCIITA_48 CTCGGGAGGTCAGGGCAGGTT 652 61.63 gCIITA_49 GAAGCTTGTTGGAGACCTCTC 653 0.67 gCIITA_50 GGAAGCTTGTTGGAGACCTCT 654 0.57 gCIITA_51 CAGAGCCGGTGGAGCAGTTCT 655 8.94 gCIITA_52 CCCAGCACAGCAATCACTCGT 656 2.63 gCIITA_53 TCTTCTCTGTCCCCTGCCATT 657 0.28 gCIITA_55 AGCCACATCTTGAAGAGACCT 658 5.71 gCIITA_56 CCAGAAGAAGCTGCTCCGAGG 659 0.52 gCIITA_57 CAGAAGAAGCTGCTCCGAGGT 660 12.02 gCIITA_58 AGCTGTCCGGCTTCTCCATGG 661 3.25 gCIITA_59 AGAGCTCAGGGATGACAGAGC 662 16.35 gCIITA_60 TGCCGGGCAGTGTGCCAGCTC 663 11.98 gCIITA_61 ATGTCTGCGGCCCAGCTCCCA 664 1.25 9CITTA_62 GCCATCGCCCAGGTCCTCACG 665 1.29 gCIITA_63 GCCACTCAGAGCCAGCCACAG 666 35.47 9CITTA_64 TGGCTGGGCTGATCTTCCAGC 667 0.50 gCIITA_65 GCAGCACGTGGTACAGGAGCT 668 70.73 gCIITA_66 CTGGGCACCCGCCTCACGCCT 669 0.31 gCIITA_67 TGGGCACCCGCCTCACGCCTC 670 12.57 gCIITA_68 CCCCTCTGGATTGGGGAGCCT 671 4.61 gCIITA_69 AAAGGCTCGATGGTGAACTTC 672 1.17 gCIITA_70 CCAGGTCTTCCACATCCTTCA 673 38.98 gCIITA_71 AAAGCCAAGTCCCTGAAGGAT 674 39.50 gCIITA_72 GGTCCCGAACAGCAGGGAGCT 675 89.25 gCIITA_73 TTTAGGTCCCGAACAGCAGGG 676 10.88 gCIITA_74 CTTACGCAAACTCCAGTTTCT 677 0.79 gCIITA_75 CCTCCTAGGCTGGGCCCTGTC 678 2.78 gCIITA_76 GGGAAAGCCTGGGGGCCTGAG 679 68.93 gCIITA_77 CCCAAACTGGTGCGGATCCTC 680 0.57 gCIITA_79 CTCCCTGCAGCATCTGGAGTG 681 1.12 gCIITA_80 CAAGGACTTCAGCTGGGGGAA 682 87.87 gCIITA_81 TAGGCACCCAGGTCAGTGATG 683 44.56 gCIITA_82 CGACAGCTTGTACAATAACTG 684 34.37 gCIITA_83 TCTTGCCAGCGTCCAGTACAA 685 5.62 gCIITA_84 CCCGGCCTTTTTACCTTGGGG 686 0.38 gCIITA_85 CCTCCCAGGCAGCTCACAGTG 687 0.74 gCIITA_87 TCCAGCCAGGTCCATCTGGTC 688 0.15 gCIITA_88 TTCTCCAGCCAGGTCCATCTG 689 0.21 gCIITA_89 ATCACCTTCCATGTCACACAA 690 0.31 gCIITA_90 TCTGGGCTCAGGTGCTTCCTC 691 0.25 gCIITA_91 TGCCAATATCGGTGAGGAAGC 692 0.17 gCIITA_92 CAGGACTCCCAGCTGGAGGGC 693 0.61 gCIITA_93 TCTGACTTTTCTGCCCAACTT 694 0.21 gCIITA_94 CAGTGCCTTTCTCCAGTTCCT 695 0.25 gCIITA_95 GCTGGCCTGGGGCACCTCACC 696 0.59 gCIITA_96 GCTCCATCAGCCACTGACCTG 697 0.29 gCIITA_97 CCTGTCATGTTTGCTCGGGAG 698 0.27 gCIITA_98 TCCATCTCCAGAGCACAAGAC 699 0.23 gCIITA_99 TTGGAGACCTCTCCAGCTGCC 700 0.99 gCIITA_100 GCAGAGCCGGTGGAGCAGTTC 701 0.46 gCIITA_101 CTGCTGCTCCTCTCCAGCCTG 702 0.23 gCIITA_103 GCAGCCAACAGCACCTCAGCC 703 0.22 gCIITA_104 GCCCAGCACAGCAATCACTCG 704 0.07

TABLE_8 Tested crRNAs Targeting Human CTLA4 Gene crRNA Spacer Sequence SEQ ID NO % Indel gCTLA4_1 TGCCGCTGAAATCCAAGGCAA 309 1.3 gCTLA4_2 CCTTGGATTTCAGCGGCACAA 310 0.8 gCTLA4_3 GATTTCAGCGGCACAAGGCTC 311 0.6 gCTLA4_4 AGCGGCACAAGGCTCAGCTGA 795 58.4 gCTLA4_5 TTCTTCTCTTCATCCCTGTCT 155 1.7 gCTLA4_6 CAGAAGACAGGGATGAAGAGA 797 44.6 gCTLA4_7 GCAGAAGACAGGGATGAAGAG 312 0.2 gCTLA4_8 GGCTTTTCCATGCTAGCAATG 313 0.1 gCTLA4_9 GCTTTTCCATGCTAGCAATGC 314 0.2 gCTLA4_10 TCCATGCTAGCAATGCACGTG 315 0.1 gCTLA4_11 CCATGCTAGCAATGCACGTGG 316 0.1 gCTLA4_12 GTGTGTGAGTATGCATCTCCA 317 0.8 gCTLA4_13 TGTGTGAGTATGCATCTCCAG 70 12.6 gCTLA4_14 CCTGGAGATGCATACTCACAC 67 47.4 gCTLA4_15 GCCTGGAGATGCATACTCACA 318 0.2 gCTLA4_16 GGCAGGCTGACAGCCAGGTGA 319 1.2 gCTLA4_17 AGTCACCTGGCTGTCAGCCTG 320 0.4 gCTLA4_18 CTAGATGATTCCATCTGCACG 154 2.0 gCTLA4_19 CACTGGAGGTGCCCGTGCAGA 798 42.5 9CTLA4_20 ATTTCCACTGGAGGTGCCCGT 321 0.1 gCTLA4_21 GATAGTGAGGTTCACTTGATT 322 0.6 gCTLA4_22 CAGATGTAGAGTCCCGTGTCC 323 0.6 gCTLA4_23 CTCACCAATTACATAAATCTG 324 0.8 gCTLA4_24 GCTCACCAATTACATAAATCT 325 1.0 gCTLA4_25 GTTTTCTGTTGCAGATCCAGA 326 0.1 gCTLA4_26 TTTTCTGTTGCAGATCCAGAA 327 0.1 gCTLA4_27 CTGTTGCAGATCCAGAACCGT 149 5.0 gCTLA4_28 CTCCTCTGGATCCTTGCAGCA 152 3.0 gCTLA4_29 CAGCAGTTAGTTCGGGGTTGT 328 0.7 gCTLA4_30 TTTATAGCTTTCTCCTCACAG 329 0.6 gCTLA4_31 CTCCTCACAGCTGTTTCTTTG 330 1.0 gCTLA4_32 TCCTCACAGCTGTTTCTTTGA 331 0.7 gCTLA4_33 GCTCAAAGAAACAGCTGTGAG 332 0.8 gCTLA4_34 TTTTTGTGTTTGACAGCTAAA 333 0.5 gCTLA4_35 TGTGTTTGACAGCTAAAGAAA 334 0.1 gCTLA4_36 ACAGCTAAAGAAAAGAAGCCC 150 3.9 gCTLA4_37 CACATAGACCCCTGTTGTAAG 153 2.9 gCTLA4_38 CACATTCTGGCTCTGTTGGGG 335 0.2 gCTLA4_39 TCACATTCTGGCTCTGTTGGG 336 0.3 gCTLA4_40 AGCCTTATTTTATTCCCATCA 337 0.3 gCTLA4_41 TCAATTGATGGGAATAAAATA 151 3.0

TABLE_9 Tested crRNAs Targeting Human DCK Gene crRNA Spacer Sequence SEQ ID NO % Indel gDCK_1 TCTTGGGCGGGGTGGCCATTC 338 0.1 gDCK_2 TCAGCCAGCTCTGAGGGGACC 71 50.4 gDCK_3 CTTGATGCGGGTCCCCTCAGA 339 0.3 gDCK_4 GATGGAGATTTTCTTGATGCG 340 0.3 gDCK_5 CCGATGTTCCCTTCGATGGAG 341 0.5 gDCK_6 CGGAGGCTCCTTACCGATGTT 796 85.1 gDCK_7 ATCTTTCCTCACAACAGCTGC 159 1.5 gDCK_8 CTCACAACAGCTGCAGGGAAG 72 31.7 gDCK_9 AGGATATTCACAAATGTTGAC 156 8.1 gDCK_10 TGAATATCCTTAAACAATTGT 342 1.0 gDCK_11 CCAATCTTCACACAATTGTTT 343 0.1 gDCK_12 AACAATTGTGTGAAGATTGGG 344 0.8 gDCK_13 AACATTGCACCATCTGGCAAC 345 1.2 gDCK_14 GAACATTGCACCATCTGGCAA 346 0.6 gDCK_15 CATACCTCAAATTCATCTTGA 347 0.3 gDCK_16 ATTTTCATACCTCAAATTCAT 348 0.1 gDCK_17 AATTTTATTTTCATACCTCAA 349 0.0 gDCK_18 TGCACATTCAAAATAGGAACT 350 0.4 gDCK_19 TCTGAGACATTGTAAGTTCCT 351 0.7 gDCK_20 CAATGTCTCAGAAAAATGGTG 352 0.6 gDCK_21 TCATACATCATCTGAAGAACA 158 3.6 gDCK_22 GAAGGTAAAAGACCATCGTTC 157 5.6 gDCK_23 ACCTTCCAAACATATGCCTGT 353 1.2 gDCK_24 CAAACATATGCCTGTCTCAGT 354 1.1 gDCK_25 CCATTCAGAGAGGCAAGCTGA 355 0.9 gDCK_26 AGCTTGCCATTCAGAGAGGCA 73 13.3 gDCK_27 CCTCTCTGAATGGCAAGCTCA 356 1.1 gDCK_28 TCTGCATCTTTGAGCTTGCCA 357 0.1 gDCK_29 TTGAACGATCTGTGTATAGTG 358 0.2 gDCK_30 TACATACCTGTCACTATACAC 74 12.8 gDCK_31 AGGTATATTTTTGCATCTAAT 359 0.05

TABLE 10 Tested crRNAs Targeting Human FAS Gene SEQ  crRNA Spacer Sequence ID NO % Indel gFAS_1 GGAGGATTGCTCAACAACCAT  78 22.6 gFAS_2 TATTTTACAGGTTCTTACGTC 360  0.1 gFAS_3 ATTTTACAGGTTCTTACGTCT 361  0.7 gFAS_4 ACAGGTTCTTACGTCTGTTGC 172  1.5 gFAS_5 GGACGATAATCTAGCAACAGA 165  1.9 gFAS_6 TGGACGATAATCTAGCAACAG 362  0.0 gFAS_7 GGCATTAACACTTTTGGACGA 363  0.1 gFAS_8 GAGTTGATGTCAGTCACTTGG 364  0.1 gFAS_9 CAAGTTCTGAGTCTCAACTGT 365  0.1 gFAS_10 GAAGGCCTGCATCATGATGGC 163  2.4 gFAS_11 TGGCAGAATTGGCCATCATGA 366  0.8 gFAS_12 GTGTAACATACCTGGAGGACA  77 29.9 gFAS_13 TTTCCTTGGGCAGGTGAAAGG 367  1.1 gFAS_14 TTCCTTGGGCAGGTGAAAGGA 166  1.7 gFAS_15 GGCAGGTGAAAGGAAAGCTAG 173  1.5 gFAS_16 TTGGCAGGGCACGCAGTCTGG 368  0.7 gFAS_17 CCTTCTTGGCAGGGCACGCAG 369  0.8 gFAS_18 TCTGTGTACTCCTTCCCTTCT 370  1.0 gFAS_19 GTCTGTGTACTCCTTCCCTTC 371  0.6 gFAS_20 GAAGAAAAATGGGCTTTGTCT 372  0.7 gFAS_21 TCTTCCAAATGCAGAAGATGT 373  0.7 gFAS_22 ATCACACAATCTACATCTTCT 374  0.5 gFAS_23 AAGACTCTTACCATGTCCTTC 375  0.6 gFAS_24 CAAACTGATTTTCTAGGCTTA 376  0.1 gFAS_25 CTAGGCTTAGAAGTGGAAATA 162  3.5 gFAS_26 GAAGTGGAAATAAACTGCACC 377  0.3 gFAS_27 GTATTCTGGGTCCGGGTGCAG 378  1.3 gFAS_28 CATCTGCACTTGGTATTCTGG 379  1.2 gFAS_29 GTTTACATCTGCACTTGGTAT 167  1.6 gFAS_30 TTTTGTAACTCTACTGTATGT 380  0.8 gFAS_31 TTTGTAACTCTACTGTATGTG 381  1.4 gFAS_32 GTGCAAGGGTCACAGTGTTCA 164  2.4 gFAS_33 CTTGGTGCAAGGGTCACAGTG 168  1.6 gFAS_34 TTTTTCTAGATGTGAACATGG  75 59.1 gFAS_35 ATGATTCCATGTTCACATCTA  76 58.5 gFAS_36 GTGTTGCTGGTGAGTGTGCAT  57 61.9 gFAS_37 CACTTGGTGTTGCTGGTGAGT 382  1.3 gFAS_38 CTCTTTGCACTTGGTGTTGCT 170  1.5 gFAS_39 GGGTGGCTTTGTCTTCTTCTT 383  0.1 gFAS_40 GTCTTCTTCTTTTGCCAATTC 384  0.6 gFAS_41 TCTTCTTCTTTTGCCAATTCC 385  0.1 gFAS_42 GCCAATTCCACTAATTGTTTG 386  0.4 gFAS_43 CCCCAAACAATTAGTGGAATT 387  0.4 gFAS_44 AACAAAGCAAGAACTTACCCC 388  0.3 gFAS_45 TTTGTTCTTTCAGTGAAGAGA 161  6.0 gFAS_46 TTCTTTCAGTGAAGAGAAAGG 389  0.9 gFAS_47 AGTGAAGAGAAAGGAAGTACA 160  9.8 gFAS_48 CTGTACTTCCTTTCTCTTCAC 390  0.8 gFAS_49 TGCATGTTTTCTGTACTTCCT 391  0.6 gFAS_50 CTGCATGTTTTCTGTACTTCC 392  0.4 gFAS_51 TGTGCTTTCTGCATGTTTTCT 393  0.3 gFAS_52 CTGTGCTTTCTGCATGTTTTC 394  0.3 gFAS_53 CCTTTCTGTGCTTTCTGCATG 395  0.3 gFAS_54 GTTTTCCTTTCTGTGCTTTCT 396  0.4 gFAS_55 AAGTTGGAGATTCATGAGAAC 397  0.4 gFAS_56 AATACCTACAGGATTTAAAGT 398  0.3 gFAS_57 TTGCTTTCTAGGAAACAGTGG 399  1.1 gFAS_58 CTAGGAAACAGTGGCAATAAA 400  1.3 gFAS_59 TAGGAAACAGTGGCAATAAAT  79 11.0 gFAS_60 CCAGATAAATTTATTGCCACT 401  0.7 gFAS_61 CTATTTTTCAGATGTTGACTT 402  0.1 gFAS_62 TCAGATGTTGACTTGAGTAAA 403  0.6 gFAS_63 AGTAAATATATCACCACTATT 404  0.8 gFAS_64 AACTTGACTTAGTGTCATGAC 405  0.4 gFAS_65 GAACAAAGCCTTTAACTTGAC 406  0.5 gFAS_66 GTTCGAAAGAATGGTGTCAAT 407  0.9 gFAS_67 ATTGACACCATTCTTTCGAAC 408  0.5 gFAS_68 TTCGAAAGAATGGTGTCAATG 409  0.7 gFAS_69 GGCTTCATTGACACCATTCTT 410  0.4 gFAS_70 TGTTCTGCTGTGTCTTGGACA 171  1.5 gFAS_71 CTGTTCTGCTGTGTCTTGGAC 169  1.5 gFAS_72 GTAATTGGCATCAACTTCATG 411  0.3 gFAS_73 CATGAAGTTGATGCCAATTAC 412  0.8 gFAS_74 TTTCCATGAAGTTGATGCCAA 413  0.4 gFAS_75 TTTCTTTCCATGAAGTTGATG 414  0.5 gFAS_76 ATGGAAAGAAAGAAGCGTATG 415  1.3 gFAS_77 ATCAATGTGTCATACGCTTCT 416  0.8 gFAS_78 TTGAGATCTTTAATCAATGTG 417  1.0 gFAS_79 TTTGAGATCTTTAATCAATGT 418  0.9 gFAS_80 CTCTGCAAGAGTACAAAGATT 419  0.2 gFAS_81 TACTCTTGCAGAGAAAATTCA 420  0.2 gFAS_82 AGGATGATAGTCTGAATTTTC 421  0.4 gFAS_83 CTGAGTCACTAGTAATGTCCT 422  0.7 gFAS_84 AATTTTCTGAGTCACTAGTAA 423  0.6 gFAS_85 TGAAGTTTGAATTTTCTGAGT 424  0.4 gFAS_86 ATTTCTGAAGTTTGAATTTTC 425  0.3 gFAS_87 GATTTCATTTCTGAAGTTTGA 426  0.5 gFAS_88 GGATTTCATTTCTGAAGTTTG 427  0.5 gFAS_89 AGAAATGAAATCCAAAGCTTG 428  0.5 gFAS_90 TCACTCTAGACCAAGCTTTGG 429  0.5 gFAS_91 TTGTTTTTCACTCTAGACCAA 430  0.7 gFAS_92 GTCTAGAGTGAAAAACAACAA 431  0.5

TABLE 11 Tested crRNAs Targeting Human HAVCR2 Gene SEQ  crRNA Spacer Sequence ID NO % Indel gTIM3_1 TCTTCTGCAAGCTCCATGTTT 432  0.1 gTIM3_2 TCTTCTGCAAGCTCCATGTTT 433   0.07 gTIM3_3 CTTCTGCAAGCTCCATGTTTT 434  0.1 gTIM3_4 CACATCTTCCCTTTGACTGTG 435  0.8 gTIM3_5 GACTGTGTCCTGCTGCTGCTG 436  0.8 gTIM3_6 TAAGTAGTAGCAGCAGCAGCA 799 53.7 gTIM3_7 CTTGTAAGTAGTAGCAGCAGC  58 64.4 gTIM3_8 TCTCTCTATGCAGGGTCCTCA 437  0.1 gTIM3_9 TACACCCCAGCCGCCCCAGGG 438  1.0 gTIM3_10 CCCCAGCAGACGGGCACGAGG 175  7.3 gTIM3_11 GCCCCAGCAGACGGGCACGAG 439  0.6 gTIM3_12 AATGTGGCAACGTGGTGCTCA  84 21.9 gTIM3_13 ATCAGTCCTGAGCACCACGTT 187  1.5 gTIM3_14 CATCAGTCCTGAGCACCACGT 440  0.1 gTIM3_15 GCCAGTATCTGGATGTCCAAT 181  2.9 gTIM3_16 CGGAAATCCCCATTTAGCCAG 441  0.4 gTIM3_17 GCGGAAATCCCCATTTAGCCA 442  0.1 gTIM3_18 CGCAAAGGAGATGTGTCCCTG  86 14.4 gTIM3_19 GATCCGGCAGCAGTAGATCCC 178  5.1 gTIM3_20 TCATCATTCATTATGCCTGGG 443  0.1 gTIM3_21 AGGTTAAATTTTTCATCATTC 444  0.1 gTIM3_22 ATGACCAACTTCAGGTTAAAT 445  0.1 gTIM3_23 ACCTGAAGTTGGTCATCAAAC 184  2.2 gTIM3_24 TGTTGTTTCTGACATTAGCCA 446  0.7 gTIM3_25 TGACATTAGCCAAGGTCACCC  85 15.7 gTIM3_26 GAAAGGCTGCAGTGAAGTCTC 447  0.1 gTIM3_27 ACTGCAGCCTTTCCAAGGATG 182  2.6 gTIM3_28 CCAAGGATGCTTACCACCAGG 185  1.9 gTIM3_29 CAAGGATGCTTACCACCAGGG  80 59.8 gTIM3_30 CCACCAGGGGACATGGCCCAG  83 22.1 gTIM3_31 TATAGCAGAGACACAGACACT 448  0.3 gTIM3_32 TATCAGGGAGGCTCCCCAGTG 800 22.4 gTIM3_33 CTGTTAGATTTATATCAGGGA 449  1.4 gTIM3_34 TGTTTCCATAGCAAATATCCA 177  5.6 gTIM3_35 CATAGCAAATATCCACATTGG 450  1.0 gTIM3_36 CGGGACTCTGGAGCAACCATC 180  3.3 gTIM3_37 AAAATTAAAGCGCCGAAGATA 451  0.2 gTIM3_38 CATTTGAAAATTAAAGCGCCG 452  0.1 gTIM3_39 TGTTTCCCCCTTACTAGGGTA 453  0.7 gTIM3_40 GTTTCCCCCTTACTAGGGTAT 186  1.7 gTIM3_41 CCCCTTACTAGGGTATTCTCA 183  2.2 gTIM3_42 CTAGGGTATTCTCATAGCAAA 174  8.5 gTIM3_43 AATTCTGTATCTTCTCTTTGC 454  0.7 gTIM3_44 ATTTCCACAGCCTCATCTCTT 455  0.4 gTIM3_45 TTTCCACAGCCTCATCTCTTT 456  1.0 gTIM3_46 CACAGCCTCATCTCTTTGGCC 457  0.5 gTIM3_47 GCCAACCTCCCTCCCTCAGGA 176  6.0 gTIM3_48 CCAATCCTGAGGGAGGGAGGT 179  4.5 gTIM3_49 CTTCTGAGCGAATTCCCTCTG 458  0.7 gTIM3_50 ATATACGTTCTCTTCAATGGT 459  0.5 gTIM3_51 GGGTTGTCGCTTTGCAATGCC 460  0.5

TABLE 12 Tested crRNAs Targeting Human LAG3 Gene SEQ  crRNA Spacer Sequence ID NO % Indel gLAG3_1 CTGTTTCTGCAGCCGCTTTGG 461  0.2 gLAG3_2 TGCAGCCGCTTTGGGTGGCTC 462  0.2 gLAG3_3 ACCTGGAGCCACCCAAAGCGG 195  3.1 gLAG3_4 GCTCACCTAGTGAAGCCTCTC 463  1.3 gLAG3_5 TGCGAAGAGCAGGGGTCACTT 464  0.8 gLAG3_6 GGGTGCATACCTGTCTGGCTG  59 52.4 gLAG3_7 CCGCCCAGTGGCCCGCCCGCT 465 N.D. gLAG3_8 TCGCTATGGCTGCGCCCAGCC 466  0.1 gLAG3_9 TCCTTGCACAGTGACTGCCAG 467 N.D. gLAG3_10 CACAGTGACTGCCAGCCCCCC 468 N.D. gLAG3_11 GAACTGCTCCTTCAGCCGCCC 469  0.1 gLAG3_12 AGCCGCCCTGACCGCCCAGCC 470  0.1 gLAG3_13 CGCTAAGTGGTGATGGGGGGA 197  2.3 gLAG3_14 CCGCTAAGTGGTGATGGGGGG 471  0.3 gLAG3_15 GCGGAAAGCTTCCTCTTCCTG 472  1.0 gLAG3_16 GGGCAGGAAGAGGAAGCTTTC 191  6.4 gLAG3_17 CTCTTCCTGCCCCAAGTCAGC 473  1.3 gLAG3_18 AACGTCTCCATCATGTATAAC 474  1.1 gLAG3_19 CTTTTCTCTTCAGGTCTGGAG 475  0.2 gLAG3_20 CTCTTCAGGTCTGGAGCCCCC 476  0.2 gLAG3_21 ACAGTGTACGCTGGAGCAGGT 477  0.1 gLAG3_22 GCAGTGAGGAAAGACCGGGTC 198  2.1 gLAG3_23 CTCACTGCCAAGTGGACTCCT 478  0.4 gLAG3_24 ACCCTTCGACTAGAGGATGTG 479  0.8 gLAG3_25 CCCTTCGACTAGAGGATGTGA 196  2.7 gLAG3_26 GACTAGAGGATGTGAGCCAGG 480  1.0 gLAG3_27 CCACCTGAGGCTGACCTGTGA 193  3.4 gLAG3_28 CCCACCTGAGGCTGACCTGTG 481  0.8 gLAG3_29 TACTCTTTTCAGTGACTCCCA 482  0.3 gLAG3_30 CAGTGACTCCCAAATCCTTTG 483  0.1 gLAG3_31 CCCAGGGATCCAGGTGACCCA 194  3.1 gLAG3_32 GGGTCACCTGGATCCCTGGGG 484  0.2 gLAG3_33 GGTCACCTGGATCCCTGGGGA  88 17.1 gLAG3_34 GTGAGGTGACTCCAGTATCTG 485  0.7 gLAG3_35 TGAGGTGACTCCAGTATCTGG 188  9.3 gLAG3_36 GTGTGGAGCTCTCTGGACACC 486  0.9 gLAG3_37 TGTGGAGCTCTCTGGACACCC 190  6.9 gLAG3_38 TCAGGACCTTGGCTGGAGGCA  87 17.7 gLAG3_39 GCTGGAGGCACAGGAGGCCCA 487  0.3 gLAG3_40 CCCAGCCTTGGCAATGCCAGC 488  0.8 gLAG3_41 CCAGCCTTGGCAATGCCAGCT 189  8.3 gLAG3_42 GCAATGCCAGCTGTACCAGGG 489  0.6 gLAG3_43 TTGGAGCAGCAGTGTACTTCA 490  0.8 gLAG3_44 ACAGAGCTGTCTAGCCCAGGT 491  0.4 gLAG3_45 CTCCATAGGTGCCCAACGCTC 492  1.3 gLAG3_46 TCCATAGGTGCCCAACGCTCT 192  4.0 gLAG3_47 TCATCCTTGGTGTCCTTTCTC 493  0.4 gLAG3_48 GTGTCCTTTCTCTGCTCCTTT 494  0.1 gLAG3_49 CTCTGCTCCTTTTGGTGACTG 495  0.2 gLAG3_50 TCTGCTCCTTTTGGTGACTGG 496  0.1 gLAG3_51 TGGTGACTGGAGCCTTTGGCT 497  0.6 gLAG3_52 GGTGACTGGAGCCTTTGGCTT 498  0.2 gLAG3_53 GGCTTTCACCTTTGGAGAAGA 499  0.1 gLAG3_54 GCTTTCACCTTTGGAGAAGAC 500  0.2 gLAG3_55 CTCTAAGGCAGAAAATCGTCT 501  0.1 gLAG3_56 CTGCCTTAGAGCAAGGGATTC 502  0.1 gLAG3_57 GAGCAAGGGATTCACCCTCCG 503  0.2

TABLE 13 Tested crRNAs Targeting Human PDCD1 Gene SEQ  crRNA Spacer Sequence ID NO % Indel gPD_1 AACCTGACCTGGGACAGTTTC 504  0.2 gPD_2 CCTTCCGCTCACCTCCGCCTG 89 46.9 gPD_3 CGCTCACCTCCGCCTGAGCAG 505  1.0 gPD_4 TCCACTGCTCAGGCGGAGGTG 506  0.6 gPD_5 TCCCCAGCCCTGCTCGTGGTG 507  1.2 gPD_6 GGTCACCACGAGCAGGGCTGG 508  0.7 gPD_7 ACCTGCAGCTTCTCCAACACA 509  0.2 gPD_8 GCACGAAGCTCTCCGATGTGT  90 41.7 gPD_9 TCCAACACATCGGAGAGCTTC 510  0.2 gPD_10 GTGCTAAACTGGTACCGCATG 511  0.2 gPD_11 TCCGTCTGGTTGCTGGGGCTC 512  0.1 gPD_12 CCCGAGGACCGCAGCCAGCCC 513  0.4 gPD_13 CGTGTCACACAACTGCCCAAC 514  0.5 gPD_14 CACATGAGCGTGGTCAGGGCC 515  0.1 gPD_15 GATCTGCGCCTTGGGGGCCAG 516  0.1 gPD_16 ATCTGCGCCTTGGGGGCCAGG 517  1.2 gPD_17 GGGGCCAGGGAGATGGCCCCA 518  0.6 gPD_18 GTGCCCTTCCAGAGAGAAGGG 201  1.7 gPD_19 TGCCCTTCCAGAGAGAAGGGC 519  0.9 gPD_20 CAGAGAGAAGGGCAGAAGTGC 199  2.5 gPD_21 TGCCCTTCTCTCTGGAAGGGC 520  1.4 gPD_22 GAACTGGCCGGCTGGCCTGGG 200  1.7 gPD_23 TCTGCAGGGACAATAGGAGCC  60 57.6 gPD_24 CTCCTCAAAGAAGGAGGACCC 521  0.1 gPD_25 TCCTCAAAGAAGGAGGACCCC 522  0.5 gPD_26 TCTCGCCACTGGAAATCCAGC 523  0.2 gPD_27 CAGTGGCGAGAGAAGACCCCG  92 23.7 gPD_28 CCTAGCGGAATGGGCACCTCA 524  0.1 gPD_29 CTAGCGGAATGGGCACCTCAT  91 30.3 gPD_30 GCCCCTCTGACCGGCTTCCTT 525  0.3

TABLE 14 Tested crRNAs Targeting Human PTPN6 Gene SEQ  crRNA Spacer Sequence ID NO % Indel gPTPN6_1 ACCGAGACCTCAGTGGGCTGG  96 58.2 gPTPN6_2 AGCAGGGTCTCTGCATCCAGC 526  0.3 gPTPN6_4 CTGGCTCGGCCCAGTCGCAAG 208  4.3 gPTPN6_5 TCCCCTCCATACAGGTCATAG 803 14.8 gPTPN6_6 TATGACCTGTATGGAGGGGAG  61 83.4 gPTPN6_7 CGACTCTGACAGAGCTGGTGG 801 78.1 gPTPN6_8 AGGTGGATGATGGTGCCGTCG 209  3.5 gPTPN6_9 CCTGACGCTGCCTTCTCTAGG 527  0.8 9PTPN6_10 TCTAGGTGGTACCATGGCCAC 212  2.4 gPTPN6_11 GCCTGCAGCAGCGTCTCTGCC 528  0.2 gPTPN6_12 TTGTGCGTGAGAGCCTCAGCC 100 29.4 gPTPN6_13 GTGCTTTCTGTGCTCAGTGAC 529  0.8 gPTPN6_14 GGCTGGTCACTGAGCACAGAA 104 10.4 gPTPN6_15 CTGTGCTCAGTGACCAGCCCA 530  0.5 9PTPN6_16 TGTGCTCAGTGACCAGCCCAA  98 37.5 9PTPN6_17 ATGTGGGTGACCCTGAGCGGG 531  0.9 gPTPN6_18 CCTCGCACATGACCTTGATGT 532  1.4 gPTPN6_19 GCTCCCCCCAGGGTGGACGCT 103 13.5 gPTPN6_20 GAGACCTTCGACAGCCTCACG 202  9.7 gPTPN6_21 GACAGCCTCACGGACCTGGTG 533  0.5 gPTPN6_22 AAGAAGACGGGGATTGAGGAG 101 22.3 gPTPN6_23 TTGTTCAGTTCCAACACTCGG 534  0.1 gPTPN6_24 GCTGTATCCTCGGACTCCTGC 535  0.4 gPTPN6_25 CCCACCCACATCTCAGAGTTT  99 34.8 gPTPN6_26 CAGAAGCAGGAGGTGAAGAAC 802 77.5 gPTPN6_27 CAGACGCTGGTGCAAGTTCTT 536  0.3 gPTPN6_28 CACCAGCGTCTGGAAGGGCAG 205  5.4 gPTPN6_29 TTCTCTGGCCGCTGCCCTTCC 537  0.1 gPTPN6_30 ATGTAGTTGGCATTGATGTAG 538  0.2 gPTPN6_31 CGTCCAGAACCAGCTGCTAGG 539  0.3 gPTPN6_32 TGGCAGATGGCGTGGCAGGAG 207  4.4 gPTPN6_33 TCCACCTCTCGGGTGGTCATG 540  0.7 gPTPN6_34 CTCCACCTCTCGGGTGGTCAT 541  1.2 gPTPN6_35 CCAGAACAAATGCGTCCCATA 542  0.2 gPTPN6_36 CAGAACAAATGCGTCCCATAC 543  0.5 gPTPN6_37 TGGGCCCTACTCTGTGACCAA  97  51.3 gPTPN6_38 TATTCGGTTGTGTCATGCTCC 544  0.1 gPTPN6_39 CAGGTCTCCCCGCTGGACAAT 213  1.6 gPTPN6_40 GGGAGACCTGATTCGGGAGAT 210  3.4 gPTPN6_41 CTGGACCAGATCAACCAGCGG 203  8.4 gPTPN6_42 CTGCCGCTGGTTGATCTGGTC 206  5.3 gPTPN6_43 CCTGCCGCTGGTTGATCTGGT 545  0.3 gPTPN6_44 CCCAGCGCCGGCATCGGCCGC 546 N.D. gPTPN6_45 GTGGAGATGTTCTCCATGAGC 547 N.D. gPTPN6_46 ACTGCCCCCCACCCAGGCCTG  93 80.3 gPTPN6_47 TACTGCGCCTCCGTCTGCACC 548  0.1 gPTPN6_48 AATGAACTGGGCGATGGCCAC 211  3.3 gPTPN6_49 TTCTTAGTGGTTTCAATGAAC 549  0.1 gPTPN6_50 GCATGGGCATTCTTCATGGCT 550 N.D. gPTPN6_51 GACGAGGTGCGGGAGGCCTTG 551 N.D. gPTPN6_52 GAGTCTAGTGCAGGGACCGTG 552 0.1 gPTPN6_53 CCCCCCTGCACCCGGCTGCAG 204 7.0 gPTPN6_54 TGTCTGCAGCCGGGTGCAGGG 553 0.9 gPTPN6_55 TCCTCCCTCTTGTTCTTAGTG 554 0.0 gPTPN6_56 CTCCTCCCTCTTGTTCTTAGT 555 0.1 gPTPN6_57 TTCACTTTCTCCTCCCTCTTG 556 0.2

TABLE 15 Tested crRNAs Targeting Human TIGIT Gene SEQ  crRNA Spacer Sequence ID NO % Indel gTIGIT_1 CCTGAGGCGAGGGGAGCCTGC 557  0.2 gTIGIT_2 AGGCCTTACCTGAGGCGAGGG  62 81.7 gTIGIT_3 GTCCTCTTCCCTAGGAATGAT 558  1.3 gTIGIT_4 TATTGTGCCTGTCATCATTCC 559  1.0 gTIGIT_5 TCTGCAGAAATGTTCCCCGTT 560  1.1 gTIGIT_6 CTCTGCAGAAATGTTCCCCGT 561  0.1 gTIGIT_7 TGCAGAGAAAGGTGGCTCTAT 215  6.0 gTIGIT_8 TGCCGTGGTGGAGGAGAGGTG 562  0.3 gTIGIT_9 TGGCCATTTGTAATGCTGACT 563  0.8 gTIGIT_10 TAATGCTGACTTGGGGTGGCA 216  1.6 gTIGIT_11 GGGTGGCACATCTCCCCATCC 214  9.7 gTIGIT_12 AAGGATGGGGAGATGTGCCAC 564  0.4 gTIGIT_13 AAGGATCGAGTGGCCCCAGGT 565  0.2 gTIGIT_14 TGCATCTATCACACCTACCCT 566  1.4 gTIGIT_15 TAGGACCTCCAGGAAGATTCT 567  0.4 gTIGIT_16 CTAGGACCTCCAGGAAGATTC 568  0.5 gTIGIT_17 CTCCAGCAGGAATACCTGAGC 569  0.8 gTIGIT_18 GTCCTCCCTCTAGTGGCTGAG 105 72.4 gTIGIT_19 GAGCCATGGCCGCGACGCTGG 570  0.9 gTIGIT_20 TAGTCAACGCGACCACCACGA 571  0.1 gTIGIT_21 CTAGTCAACGCGACCACCACG 572  0.1 gTIGIT_22 TAGTTTGTTTGTTTTTAGAAG 573  0.6 gTIGIT_23 TTTGTTTTTAGAAGAAAGCCC 574  1.0 gTIGIT_24 TTTTTAGAAGAAAGCCCTCAG 575  0.4 gTIGIT_25 TAGAAGAAAGCCCTCAGAATC 576  1.2 gTIGIT_26 CACAGAATGGATTCTGAGGGC 577  0.3 gTIGIT_27 CTCCTGAGGTCACCTTCCACA 217  1.6 gTIGIT_28 CTGGGGGTGAGGGAGCACTGG 578  0.5 gTIGIT_29 TGCCTGGACACAGCTTCCTGG 579  0.3 gTIGIT_30 TGTAACTCAGGACATTGAAGT 580  0.5 gTIGIT_31 AATGTCCTGAGTTACAGAAGC 581  0.5

TABLE 16 Tested crRNAs Targeting Human TRAC Gene SEQ crRNA Spacer Sequence ID NO % Indel gTRAC001 TGTTTTTAATGTGACTCTCAT 237  1.8 gTRAC002 GTGTTTTTAATGTGACTCTCA 582  0.4 gTRAC003 CGTAGGATTTTGTGTTTTTAA 583  0.1 gTRAC004 CTTAGTGCTGAGACTCATTCT 584  0.7 gTRAC005 CCTTAGTGCTGAGACTCATTC 585  0.6 gTRAC006 TGAGGGTGAAGGATAGACGCT  63 81.8 gTRAC007 ATAAACTGTAAAGTACCAAAC 239  1.7 gTRAC008 TTTGGTACTTTACAGTTTATT 586  0.2 gTRAC009 GTACTTTACAGTTTATTAAAT 238  1.7 gTRAC010 CAGTTTATTAAATAGATGTTT 587  0.5 gTRAC011 TTAAATAGATGTTTATATGGA 588  0.0 gTRAC012 TATGGAGAAGCTCTCATTTCT 110 46.7 gTRAC013 TTTCTCAGAAGAGCCTGGCTA 225  5.8 gTRAC014 TCAGAAGAGCCTGGCTAGGAA 127 16.6 gTRAC015 ACCTGCAAAATGAATATGGTG 589  0.0 gTRAC016 GCAGGTGAAATTCCTGAGATG 590  0.2 gTRAC017 CAGGTGAAATTCCTGAGATGT 804 63.6 gTRAC018 CTCGATATAAGGCCTTGAGCA 120 26.0 gTRAC019 AACTATAAATCAGAACACCTG 228  4.5 gTRAC020 GAACTATAAATCAGAACACCT 224  6.4 gTRAC021 TAGTTCAAAACCTCTATCAAT 117 27.7 gTRAC022 TGGTATGTTGGCATTAAGTTG 591  1.0 gTRAC023 CCAACTTAATGCCAACATACC 592  1.4 gTRAC024 CTTTGCTGGGCCTTTTTCCCA 593  1.0 gTRAC025 CTGGGCCTTTTTCCCATGCCT 227  4.6 gTRAC026 TCCCATGCCTGCCTTTACTCT 594  0.6 gTRAC027 CCCATGCCTGCCTTTACTCTG 595  0.7 gTRAC028 CCATGCCTGCCTTTACTCTGC 129 15.3 gTRAC029 CTCTGCCAGAGTTATATTGCT 128 15.8 gTRAC030 ATAGGATCTTCTTCAAAACCC 235  2.2 gTRAC031 TTTAATAGGATCTTCTTCAAA 596  0.3 gTRAC032 ATTTAATAGGATOTTCTTCAA 597  0.1 gTRAC033 GAAGAAGATCCTATTAAATAA 236  2.0 gTRAC034 AAGAAGATCCTATTAAATAAA 598  0.1 gTRAC035 AGGTTTCCTTGAGTGGCAGGC 220  7.5 gTRAC036 CTTGAGTGGCAGGCCAGGCCT 230  4.4 gTRAC037 AGTGAACGTTCACGGCCAGGC 599  0.7 gTRAC038 TACGGGAAATAGCATCTTAGA 114 40.7 gTRAC039 TAAGATGCTATTTCCCGTATA 111 45.8 gTRAC040 CCGTATAAAGCATGAGACCGT 124 21.5 gTRAC041 CCCCAACCCAGGCTGGAGTCC 125 18.7 gTRAC042 CCTCTTTGCCCCAACCCAGGC 219  7.6 gTRAC043 GAGTCTCTCAGCTGGTACACG 121 25.9 gTRAC044 AGAATCAAAATCGGTGAATAG 221  7.4 gTRAC045 TTTGAGAATCAAAATCGGTGA 600  1.3 gTRAC046 TGACACATTTGTTTGAGAATC 601  0.2 gTRAC047 GATTCTCAAACAAATGTGTCA 602  0.1 gTRAC048 ATTCTCAAACAAATGTGTCAC 229  4.5 gTRAC049 TCTGTGATATACACATCAGAA 118 27.6 gTRAC050 GTCTGTGATATACACATCAGA 130 11.4 gTRAC055 CACATGCAAAGTCAGATTTGT 603  1.0 gTRAC056 CATGTGCAAACGCCTTCAACA 231  3.9 gTRAC057 GTGCCTTCGCAGGCTGTTTCC 604  0.9 gTRAC058 CTTGCTTCAGGAATGGCCAGG 116 27.8 gTRAC059 GACATCATTGACCAGAGCTCT 805 50.1 gTRAC060 AGACATCATTGACCAGAGCTC 605  1.3 gTRAC061 GTGGCAATGGATAAGGCCGAG 115 38.8 gTRAC062 GGTGGCAATGGATAAGGCCGA 223  6.5 gTRAC063 TTAGTAAAAAGAGGGTTTTGG 606  1.4 gTRAC064 TACTAAGAAACAGTGAGCCTT 232  3.5 gTRAC065 ACTAAGAAACAGTGAGCCTTG 607  0.2 gTRAC066 CTAAGAAACAGTGAGCCTTGT 218  9.5 gTRAC067 CCGTGTCATTCTCTGGACTGC 112 45.4 gTRAC068 CCCGTGTCATTCTCTGGACTG 226  5.3 gTRAC069 TCCCGTGTCATTCTCTGGACT 608  1.0 gTRAC070 TTCCCGTGTCATTCTCTGGAC 609  0.3 gTRAC071 CTCAGACTGTTTGCCCCTTAC 233  3.4 gTRAC072 CCCCTTACTGCTCTTCTAGGC 222  6.9 gTRAC073 GCAGACAGGGAGAAATAAGGA 106 66.9 gTRAC074 GGCAGACAGGGAGAAATAAGG 119 27.1 gTRAC075 TGGCAGACAGGGAGAAATAAG 122 25.2 gTRAC076 TTGGCAGACAGGGAGAAATAA 126 16.7 gTRAC077 TCCCTGTCTGCCAAAAAATCT 610  1.1 gTRAC078 CCAGCTCACTAAGTCAGTCTC 109 47.4 gTRAC079 ATTCCTCCACTTCAACACCTG 113 45.4 gTRAC080 AATTCCTCCACTTCAACACCT 611  0.5 gTRAC081 TAATTCCTCCACTTCAACACC 234  2.3 gTRAC082 CCAGCTGACAGATGGGCTCCC 123 21.5 gTRAC083 CCCAGCTGACAGATGGGCTCC 241  1.6 gTRAC084 GACTTTTCCCAGCTGACAGAT 240  1.6 gTRAC085 TCAACCCTGAGTTAAAACACA 612  0.5 gTRAC086 CTCAACCCTGAGTTAAAACAC 613  0.2 gTRAC087 TCCTGAAGGTAGCTGTTTTCT 614  0.2 gTRAC088 GTCCTGAAGGTAGCTGTTTTC 615  0.1 gTRAC089 AACTCAGGGTTGAGAAAACAG 616  0.7 gTRAC090 ACTCAGGGTTGAGAAAACAGC 617  0.1

TABLE 17 Tested crRNAs Targeting Human TRBC1/TRBC2 Genes SEQ  crRNA Spacer Sequence ID NO % Indel gTRBC1+2_1 AGCCATCAGAAGCAGAGATCT 705 66.40 (TRBC1); 74.7 (TRBC2) gTRBC1+2_3 CGCTGTCAAGTCCAGTTCTAC 706 71.28 (TRBC1) gTRBC2_7 CCCTGTTTTCTTTCAGACTGT 707  0.09 gTRBC2_8 CTTTCAGACTGTGGCTTCACC 708  0.24 gTRBC2_9 TTTCAGACTGTGGCTTCACCT 709  0.24 gTRBC2_10 CAGACTGTGGCTTCACCTCCG 710  0.16 gTRBC2_11 AGACTGTGGCTTCACCTCCGG 711 19.97 gTRBC2_12 CCGGAGGTGAAGCCACAGTCT 712 33.14 gTRBC2_13 TCAACAGAGTCTTACCAGCAA 713  1.20 gTRBC2_14 CCAGCAAGGGGTCCTGTCTGC 714  6.69 gTRBC2_15 CTAGGGAAGGCCACCTTGTAT 715 21.74 gTRBC2_16 TATGCCGTGCTGGTCAGTGCC 716  0.20 gTRBC2_17 CCATGGCCATCAGCACGAGGG 717  1.75 gTRBC2_18 CCTAGCAAGATCTCATAGAGG 718  0.37 gTRBC2_19 CACAGGTCAAGAGAAAGGATT 719  1.58 gTRBC2_21 GAGCTAGCCTCTGGAATCCTT 720 11.89

TABLE 18 Tested crRNAs Targeting Human CARD11 Gene SEQ  crRNA Spacer Sequence ID NO % Indel gCARD11_1 TAGTACCGCTCCTGGAAGGTT 721 1.37 gCARD11_2 ATCTTGTAGTACCGCTCCTGG 722 0.07 gCARD11_3 CTTCATCTTGTAGTACCGCTC 723 0.08

TABLE 19 Tested crRNAs Targeting Human CD247 gene SEQ crRNA Spacer Sequence ID NO % Indel gCD247_1 TGTGTTGCAGTTCAGCAGGAG 724 55.77 gCD247_2 CGTTATAGAGCTGGTTCTGGC 725  0.20 gCD247_3 CGGAGGGTCTACGGCGAGGCT 726 20.79 gCD247_4 TTATCTGTTATAGGAGCTCAA 727 12.31 gCD247_5 TCTGTTATAGGAGCTCAATCT 728  0.24 gCD247_6 TCCAAAACATCGTACTCCTCT 729  0.34 gCD247_7 CCCCCATCTCAGGGTCCCGGC 730  6.43 gCD247_8 GACAAGAGACGTGGCCGGGAC 731 40.95 gCD247_9 TCTCCCTCTAACGTCTTCCCG 732  4.13 gCD247_10 CTGAGGGTTCTTCCTTCTCTG 733  0.05 gCD247_11 CCGTTGTCTTTCCTAGCAGAG 734  1.18 gCD247_12 CTAGCAGAGAAGGAAGAACCC 735 70.64 gCD247_13 TGCAGTTCCTGCAGAAGAGGG 736  4.93 gCD247_14 TGCAGGAACTGCAGAAAGATA 737  2.91 gCD247_15 ATCCCAATCTCACTGTAGGCC 738 31.12 gCD247_16 CATCCCAATCTCACTGTAGGC 739  0.10 gCD247_17 CTCATTTCACTCCCAAACAAC 740  0.30 gCD247_18 TCATTTCACTCCCAAACAACC 741 44.34 gCD247_19 ACTCCCAAACAACCAGCGCCG 742 43.17 gCD247_20 TTTTCTGATTTGCTTTCACGC 743  0.10 gCD247_21 TGATTTGCTTTCACGCCAGGG 744  5.23 gCD247_22 CTTTCACGCCAGGGTCTCAGT 745  8.24 gCD247_23 ACGCCAGGGTCTCAGTACAGC 746  0.30

TABLE 20 Tested crRNAs Targeting Human IL7R Gene SEQ  crRNA Spacer Sequence ID NO % Indel gIL7R_1 CTTTCCAGGGGAGATGGATCC 747  0.25 gIL7R_2 CCAGGGGAGATGGATCCTATC 748  8.35 gIL7R_3 CAGGGGAGATGGATCCTATCT 749 87.87 gIL7R_4 CTAACCATCAGCATTTTGAGT 750  0.11 gIL7R_5 GAGTTTTTTCTCTGTCGCTCT 751  0.07 gIL7R_6 AGTTTTTTCTCTGTCGCTCTG 752  0.06 gIL7R_7 TCTGTCGCTCTGTTGGTCATC 753  2.61 gIL7R_8 CATAACACACAGGCCAAGATG 754 25.83

TABLE 21 Tested crRNAs Targeting Human LCK Gene SEQ  crRNA Spacer Sequence ID NO % Indel gLCK1_1 ATGTCCTTTCACCCATCAACC 755  0.06 gLCK1_2 CACCCATCAACCCGTAGGGAT 756  0.17 gLCK1_3 ACCCATCAACCCGTAGGGATG 757 16.21

TABLE 22 Tested crRNAs Targeting Human PLCG1 Gene SEQ  crRNA Spacer Sequence ID NO % Indel gPLCG1_1 CTCATACACCACGAAGCGCAG 758 0.09 gPLCG1_2 CCTTTCTGCGCTTCGTGGTGT 759 5.14 gPLCG1_3 CTGCGCTTCGTGGTGTATGAG 760 0.05 gPLCG1_4 TGCGCTTCGTGGTGTATGAGG 761 1.91 gPLCG1_5 GTGGTGTATGAGGAAGACATG 762 3.53

TABLE 23 Tested crRNAs Targeting Certain Other Human Genes SEQ crRNA Spacer Sequence ID NO % Indel gDHODH_1 TTGCAGAAGCGGGCCCAGGAT 770   0.60 gDHODH_2 TTGCAGAAGCGGGCCCAGGAT 771    0.59 gDHODH_3 TATGCTGAACACCTGATGCCG 772  74.94 gPLK1_1 CCAGGGTCGGCCGGTGCCCGT 773  29.06 gPLK1_2 GCCGGTGGAGCCGCCGCCGGA 774   2.01 gPLK1_3 TGGGCAAGGGCGGCTTTGCCA 775    2.26 gPLK1_4 GGGCAAGGGCGGCTTTGCCAA 776  28.24 gPLK1_5 GGCAAGGGCGGCTTTGCCAAG 777  28.41 gPLK1_6 CCAAGTGCTTCGAGATCTCGG 778   2.07 gPLK1_7 CATGGACATCTTCTCCCTCTG 779  90.07 gPLK1_8 TCGAGGACAACGACTTCGTGT 780   0.16 gPLK1_9 CGAGGACAACGACTTCGTGTT 781   6.84 gPLK1_10 GAGGACAACGACTTCGTGTTC 782   8.52 gMVD_1 CAGTTAAAAACCACCACAACA 783   1.42 gMVD_2 GCTGAATGGCCGGGAGGAGGA 784  14.06 gMVD_3 TGGAGTGGCAGATGGGAGAGC 785  63.22 gTUBB_1 AACCATGAGGGAAATCGTGCA 786   2.61 gTUBB_2 ACCATGAGGGAAATCGTGCAC 787  68.40 gTUBB_3 TTCTCTGTAGGTGGCAAATAT 788  18.67 gU6_1 GTCCTTTCCACAAGATATATA 763 68.1 gU6_2 GATTTCTTGGCTTTATATATC 764   0.71 gU6_3 TTGGCTTTATATATCTTGTGG 765   2.83 gU6_4 GCTTTATATATCTTGTGGAAA 766   0.37 gu6_5 ATATATCTTGTGGAAAGGACG 767   0.39 gU6_6 TATATCTTGTGGAAAGGACGA 768   0.39 gU6_7 TGGAAAGGACGAAACACCGTG 769   0.24

To provide sufficient targeting to the target nucleotide sequence, the spacer sequence can be 16 or more nucleotides in length. In certain embodiments, the spacer sequence is at least 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, or 75 nucleotides in length. In certain embodiments, the spacer sequence is shorter than or equal to 75, 50, 45, 40, 35, 30, 25, or 20 nucleotides in length. Shorter spacer sequence may be desirable for reducing off-target events. Accordingly, in certain embodiments, the spacer sequence is shorter than or equal to 21, 20, 19, 18, or 17 nucleotides. In certain embodiments, the spacer sequence is 17-30 nucleotides in length, e.g., 17-21, 17-22, 17-23, 17-24, 17-25, 17-30, 20-21, 20-22, 20-23, 20-24, 20-25, or 20-30 nucleotides in length. In certain embodiments, the spacer sequence is 19-22 nucleotides in length, for example 20 to 21 nucleotides in length. In certain embodiments, the spacer sequence is 21 nucleotides in length. In certain embodiments, the spacer sequence is 20 nucleotides in length.

In certain embodiments, the spacer sequence comprises a portion of a spacer sequence listed in Table 1, 2, or 3, wherein the portion is 16, 17, 18, 19, or 20 nucleotides in length. In certain embodiments, the spacer sequence comprises nucleotides 1-16, 1-17, 1-18, 1-19, or 1-20 of a spacer sequence listed in Table 1, 2, or 3. In specific embodiments, the spacer sequence consists of nucleotides 1-16, 1-17, 1-18, 1-19, or 1-20 of a spacer sequence listed in Table 1, 2, or 3.

In certain embodiments, the spacer sequence comprises a portion of a spacer sequence listed in Table 1-2 or 3, wherein the portion is 16, 17, 18, 19, or 20 nucleotides in length. In certain embodiments, the spacer sequence comprises nucleotides 1-16, 1-17, 1-18, 1-19, or 1-20 of a spacer sequence listed in Table 1, 2, or 3. In specific embodiments, the spacer sequence consists of nucleotides 1-16, 1-17, 1-18, 1-19, or 1-20 of a spacer sequence listed in any one of Tables 1-23.

In certain embodiments, the spacer sequence is 21 nucleotides in length. In certain embodiments, the spacer sequence consists of a spacer sequence shown in Table 1, 2, or 3.

In certain embodiments, the spacer sequence is 21 nucleotides in length. In certain embodiments, the spacer sequence consists of a spacer sequence shown in any one of Tables 1-23.

In certain embodiments, the spacer sequence, where it is longer than 21 nucleotides in length, comprises a spacer sequence shown in Table 1, 2, or 3 and one or more nucleotides. In certain embodiments, the one or more nucleotides are 3′ to the spacer sequence shown in Table 1, 2, or 3.

In certain embodiments, the spacer sequence, where it is longer than 21 nucleotides in length, comprises a spacer sequence shown in Table 1, 2, or 3 and one or more nucleotides. In certain embodiments, the one or more nucleotides are 3′ to the spacer sequence shown in any one of Tables 1-3.

In certain embodiments, the spacer sequence is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% complementary to the target nucleotide sequence. In certain embodiments, the spacer sequence is 100% complementary to the target nucleotide sequence in the seed region (5-10 base pairs proximal to the PAM). In certain embodiments, the spacer sequence is 100% complementary to the target nucleotide sequence. The spacer sequences listed in Tables 1-3 are designed to be 100% complementary to the wild-type sequence of the corresponding target gene. Accordingly, it is contemplated that a spacer sequence useful for targeting a gene listed in Table 1, 2, or 3 can be at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a corresponding spacer sequence listed in Table 1, 2, or 3, or a portion thereof disclosed herein. In certain embodiments, the spacer sequence is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides different from a sequence listed in Table 1, 2, or 3. In certain embodiments, the spacer sequence is 100% identical to a sequence listed in Table 1, 2, or 3 in the seed region (at least 5 base pairs proximal to the PAM). It has been reported that compared to DNA binding, DNA cleavage is less tolerant to mismatches between the spacer sequence and the target nucleotide sequence (see, Klein et al. (2018) Cell Reports, 22: 1413). Accordingly, in certain embodiments, a guide nucleic acid to be used with a Cas nuclease comprises a spacer sequence 100% complementary to the target nucleotide sequence. In certain embodiments, a guide nucleic acid to be used with a Cas nuclease comprises a spacer sequence listed in Table 1, 2, or 3, or a portion thereof disclosed herein.

In certain embodiments, the spacer sequence is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% complementary to the target nucleotide sequence. In certain embodiments, the spacer sequence is 100% complementary to the target nucleotide sequence in the seed region (at least 5 base pairs proximal to the PAM). In certain embodiments, the spacer sequence is 100% complementary to the target nucleotide sequence. The spacer sequences listed in any one of Tables 1-23 are designed to be 100% complementary to the wild-type sequence of the corresponding target gene. Accordingly, it is contemplated that a spacer sequence useful for targeting a gene listed in Table 1, 2, or 3 can be at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a corresponding spacer sequence listed in any one of Tables 1-23, or a portion thereof disclosed herein. In certain embodiments, the spacer sequence is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides different from a sequence listed in any one of Tables 1-23. In certain embodiments, the spacer sequence is 100% identical to a sequence listed in any one of Tables 1-23 in the seed region (at least 5 base pairs proximal to the PAM). It has been reported that compared to DNA binding, DNA cleavage is less tolerant to mismatches between the spacer sequence and the target nucleotide sequence (see, Klein et al. (2018) Cell Reports, 22: 1413). Accordingly, in certain embodiments, a guide nucleic acid to be used with a Cas nuclease comprises a spacer sequence 100% complementary to the target nucleotide sequence. In certain embodiments, a guide nucleic acid to be used with a Cas nuclease comprises a spacer sequence listed in any one of Table 1-23, or a portion thereof disclosed herein.

The present invention also provides guide nucleic acids targeting human DHODH, PLK1, MVD, TUBB, or U6 gene comprising the spacer sequences provided below in Table 25. DHODH, PLK1, MVD, and TUBB are known to be essential genes. It is contemplated that the guide nucleic acids targeting these genes, particularly the ones that edit the respective genomic locus at hight efficiency (e.g., at least 50%, at least 60%, at least 70%, at least 80%, or at least 90%), can be used as positive controls for assessing transfection efficiency and other experimental processes. The spacer sequences targeting U6 in Table 25 are designed to hybridize with the promoter region of human U6 gene and can be used to assess expression of an inserted gene from the endogenous U6 promoter.

In certain embodiments, the 3′ end of the targeter stem sequence is linked by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides to the 5′ end of the spacer sequence. In certain embodiments, the targeter stem sequence and the spacer sequence are adjacent to each other, directly linked by an internucleotide bond. In certain embodiments, the targeter stem sequence and the spacer sequence are linked by one nucleotide, e.g., a uridine. In certain embodiments, the targeter stem sequence and the spacer sequence are linked by two or more nucleotides. In certain embodiments, the targeter stem sequence and the spacer sequence are linked by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides.

In certain embodiments, the targeter nucleic acid further comprises an additional nucleotide sequence 5′ to the targeter stem sequence. In certain embodiments, the additional nucleotide sequence comprises at least 1 (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50) nucleotides. In certain embodiments, the additional nucleotide sequence consists of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides. In certain embodiments, the additional nucleotide sequence consists of 2 nucleotides. In certain embodiments, the additional nucleotide sequence is reminiscent to the loop or a fragment thereof (e.g., one, two, three, or four nucleotides at or near the 3′ end of the loop) in a crRNA of a corresponding single guide CRISPR-Cas system. It is understood that an additional nucleotide sequence 5′ to the targeter stem sequence is dispensable. Accordingly, in certain embodiments, the targeter nucleic acid does not comprise any additional nucleotide 5′ to the targeter stem sequence.

In certain embodiments, the targeter nucleic acid further comprises an additional nucleotide sequence containing one or more nucleotides at or near the 3′ end that does not hybridize with the target nucleotide sequence. The additional nucleotide sequence may protect the targeter nucleic acid from degradation by 3′-5′ exonuclease. In certain embodiments, the additional nucleotide sequence is no more than 100 nucleotides in length. In certain embodiments, the additional nucleotide sequence is no more than 90, 80, 70, 60, 50, 40, 30, 20, or 10 nucleotides in length. In certain embodiments, the additional nucleotide sequence is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides in length. In certain embodiments, the additional nucleotide sequence is 5-100, 5-50, 5-40, 5-30, 5-25, 5-20, 5-15, 5-10, 10-100, 10-50, 10-40, 10-30, 10-25, 10-20, 10-15, 15-100, 15-50, 15-40, 15-30, 15-25, 15-20, 20-100, 20-50, 20-40, 20-30, 20-25, 25-100, 25-50, 25-40, 25-30, 30-100, 30-50, 30-40, 40-100, 40-50, or 50-100 nucleotides in length.

In certain embodiments, the additional nucleotide sequence forms a hairpin with the spacer sequence. Such secondary structure may increase the specificity of the engineered, non-naturally occurring system (see, Kocak et al. (2019) NAT. BIOTECH. 37: 657-66). In certain embodiments, the free energy change during the hairpin formation is greater than or equal to −20 kcal/mol, −15 kcal/mol, −14 kcal/mol, −13 kcal/mol, −12 kcal/mol, −11 kcal/mol, or −10 kcal/mol. In certain embodiments, the free energy change during the hairpin formation is greater than or equal to −5 kcal/mol, −6 kcal/mol, −7 kcal/mol, −8 kcal/mol, −9 kcal/mol, −10 kcal/mol, −11 kcal/mol, −12 kcal/mol, −13 kcal/mol, −14 kcal/mol, or −15 kcal/mol. In certain embodiments, the free energy change during the hairpin formation is in the range of −20 to −10 kcal/mol, −20 to −11 kcal/mol, −20 to −12 kcal/mol, −20 to −13 kcal/mol, −20 to −14 kcal/mol, −20 to −15 kcal/mol, −15 to −10 kcal/mol, −15 to −11 kcal/mol, −15 to −12 kcal/mol, −15 to −13 kcal/mol, −15 to −14 kcal/mol, −14 to −10 kcal/mol, −14 to −11 kcal/mol, −14 to −12 kcal/mol, −14 to −13 kcal/mol, −13 to −10 kcal/mol, −13 to −11 kcal/mol, −13 to −12 kcal/mol, −12 to −10 kcal/mol, −12 to −11 kcal/mol, or −11 to −10 kcal/mol. In other embodiments, the targeter nucleic acid does not comprise any nucleotide 3′ to the spacer sequence.

In certain embodiments, the modulator nucleic acid further comprises an additional nucleotide sequence 3′ to the modulator stem sequence. In certain embodiments, the additional nucleotide sequence comprises at least 1 (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50) nucleotides. In certain embodiments, the additional nucleotide sequence consists of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50 nucleotides. In certain embodiments, the additional nucleotide sequence consists of 1 nucleotide (e.g., uridine). In certain embodiments, the additional nucleotide sequence consists of 2 nucleotides. In certain embodiments, the additional nucleotide sequence is reminiscent to the loop or a fragment thereof (e.g., one, two, three, or four nucleotides at or near the 5′ end of the loop) in a crRNA of a corresponding single guide CRISPR-Cas system. It is understood that an additional nucleotide sequence 3′ to the modulator stem sequence is dispensable. Accordingly, in certain embodiments, the modulator nucleic acid does not comprise any additional nucleotide 3′ to the modulator stem sequence.

It is understood that the additional nucleotide sequence 5′ to the targeter stem sequence and the additional nucleotide sequence 3′ to the modulator stem sequence, if present, may interact with each other. For example, although the nucleotide immediately 5′ to the targeter stem sequence and the nucleotide immediately 3′ to the modulator stem sequence do not form a Watson-Crick base pair (otherwise they would constitute part of the targeter stem sequence and part of the modulator stem sequence, respectively), other nucleotides in the additional nucleotide sequence 5′ to the targeter stem sequence and the additional nucleotide sequence 3′ to the modulator stem sequence may form one, two, three, or more base pairs (e.g., Watson-Crick base pairs). Such interaction may affect the stability of the complex comprising the targeter nucleic acid and the modulator nucleic acid.

The stability of a complex comprising a targeter nucleic acid and a modulator nucleic acid can be assessed by the Gibbs free energy change (AG) during the formation of the complex, either calculated or actually measured. Where all the predicted base pairing in the complex occurs between a base in the targeter nucleic acid and a base in the modulator nucleic acid, i.e., there is no intra-strand secondary structure, the AG during the formation of the complex correlates generally with the AG during the formation of a secondary structure within the corresponding single guide nucleic acid. Methods of calculating or measuring the AG are known in the art. An exemplary method is RNAfold (rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi) as disclosed in Gruber et al. (2008) NUCLEIC ACIDS RES., 36(Web Server issue): W70-W74. Unless indicated otherwise, the ΔG values in the present disclosure are calculated by RNAfold for the formation of a secondary structure within a corresponding single guide nucleic acid. In certain embodiments, the ΔG is lower than or equal to −1 kcal/mol, e.g., lower than or equal to −2 kcal/mol, lower than or equal to −3 kcal/mol, lower than or equal to −4 kcal/mol, lower than or equal to −5 kcal/mol, lower than or equal to −6 kcal/mol, lower than or equal to −7 kcal/mol, lower than or equal to −7.5 kcal/mol, or lower than or equal to −8 kcal/mol. In certain embodiments, the ΔG is greater than or equal to −10 kcal/mol, e.g., greater than or equal to −9 kcal/mol, greater than or equal to −8.5 kcal/mol, or greater than or equal to −8 kcal/mol. In certain embodiments, the ΔG is in the range of −10 to −4 kcal/mol. In certain embodiments, the ΔG is in the range of −8 to −4 kcal/mol, −7 to −4 kcal/mol, −6 to −4 kcal/mol, −5 to −4 kcal/mol, −8 to −4.5 kcal/mol, −7 to −4.5 kcal/mol, −6 to −4.5 kcal/mol, or −5 to −4.5 kcal/mol, for example −8 kcal/mol, −7 kcal/mol, −6 kcal/mol, −5 kcal/mol, −4.9 kcal/mol, −4.8 kcal/mol, −4.7 kcal/mol, −4.6 kcal/mol, −4.5 kcal/mol, −4.4 kcal/mol, −4.3 kcal/mol, −4.2 kcal/mol, −4.1 kcal/mol, or −4 kcal/mol.

It is understood that the ΔG may be affected by a sequence in the targeter nucleic acid that is not within the targeter stem sequence, and/or a sequence in the modulator nucleic acid that is not within the modulator stem sequence. For example, one or more base pairs (e.g., Watson-Crick base pair) between an additional sequence 5′ to the targeter stem sequence and an additional sequence 3′ to the modulator stem sequence may reduce the ΔG, i.e., stabilize the nucleic acid complex. In certain embodiments, the nucleotide immediately 5′ to the targeter stem sequence comprises a uracil or is a uridine, and the nucleotide immediately 3′ to the modulator stem sequence comprises a uracil or is a uridine, thereby forming a nonconventional U-U base pair.

In certain embodiments, the modulator nucleic acid comprises a nucleotide sequence referred to herein as a “5′ sequence”, e.g., a tail sequence, positioned 5′ to the modulator stem sequence. Where the CRISPR system is a type V-A CRISPR system, the 5′ sequence, e.g., a tail sequence, in a modified dual guide system is reminiscent of the nucleotide sequence positioned 5′ to the stem-loop structure of the scaffold sequence in a crRNA (the single guide). Accordingly, the 5′ sequence, e.g., a tail sequence, can comprise the corresponding nucleotide sequences when a modified dual guide system is engineered from a single guide system. In certain embodiments, one or more nucleotides or internucleotide linkages at or near the 5′ end of the 5′ sequence, e.g., tail sequence, can be modified, e.g., chemically modified.

Without being bound by theory, it is contemplated that or near the 5′ sequence, e.g., tail sequence, may participate in the formation of the CRISPR-Cas complex. For example, in certain embodiments, the 5′ sequence, e.g., tail sequence, forms a pseudoknot structure with the modulator stem sequence, which is recognized by the Cas protein (see, Yamano et al. (2016) CELL, 165: 949). In certain embodiments, the 5′ sequence, e.g., tail sequence, is at least 3 (e.g., at least 4 or at least 5) nucleotides in length. In certain embodiments, the 5′ sequence, e.g., tail sequence, is 3, 4, or 5 nucleotides in length. In certain embodiments, the nucleotide at or near the 3′ end of the 5′ sequence, e.g., tail sequence, comprises a uracil or is a uridine. In certain embodiments, the second nucleotide in the 5′ sequence, e.g., tail sequence, the position counted from the 3′ end, comprises a uracil or is a uridine. In certain embodiments, the third nucleotide in the 5′ sequence, e.g., tail sequence, the position counted from the 3′ end, comprises an adenine or is an adenosine. This third nucleotide may form a base pair (e.g., a Watson-Crick base pair) with a nucleotide 5′ to the modulator stem sequence. Accordingly, in certain embodiments, the modulator nucleic acid comprises a uridine or a uracil-containing nucleotide 5′ to the modulator stem sequence. In certain embodiments, the 5′ sequence, e.g., tail sequence, comprises the nucleotide sequence of 5′-AUU-3′. In certain embodiments, the 5′ sequence, e.g., tail sequence, comprises the nucleotide sequence of 5′-AAUU-3′. In certain embodiments, the 5′ sequence, e.g., tail sequence, comprises the nucleotide sequence of 5′-UAAUU-3′. In certain embodiments, the 5′ sequence, e.g., tail sequence, is positioned immediately 5′ to the modulator stem sequence.

In certain embodiments, the targeter nucleic acid and/or the modulator nucleic acid are designed to reduce the degree of secondary structure other than the hybridization between the targeter stem sequence and the modulator stem sequence. In certain embodiments, at most 75%, 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or fewer of the nucleotides of the targeter nucleic acid and/or the modulator nucleic acid participate in self-complementary base pairing when optimally folded. Optimal folding may be determined by any suitable polynucleotide folding algorithm. Some programs are based on calculating the minimal Gibbs free energy. An example of one such algorithm is mFold, as described by Zuker and Stiegler (Nucleic Acids Res. 9 (1981), 133-148). Another example folding algorithm is the online webserver RNAfold, developed at Institute for Theoretical Chemistry at the University of Vienna, using the centroid structure prediction algorithm (see e.g., A. R. Gruber et al., 2008, Cell 106(1): 23-24; and PA Carr and GM Church, 2009, Nature Biotechnology 27(12): 1151-62).

The targeter nucleic acid is directed to a specific target nucleotide sequence, and the donor template is designed to modify the target nucleotide sequence or a sequence nearby. It is understood, therefore, that association of the targeter or modulator nucleic acid with a donor template can increase editing efficiency and reduce off-targeting. In a multiplex method (e.g., as disclosed in the “Multiplex Methods” subsection of section II infra), association of a donor template with a modulator nucleic acid allows combination of a targeter nucleic acid library with a donor template library, making designs of screening or selection assays more efficient and flexible. Accordingly, in certain embodiments, the modulator nucleic acid further comprises a donor template-recruiting sequence capable of hybridizing with a donor template (see FIG. 1C). Donor templates are described in the “Donor Templates” subsection of section II infra. The donor template and donor template-recruiting sequence can be designed such that they bear sequence complementarity. In certain embodiments, the donor template-recruiting sequence is at least 90% (e.g., at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) complementary to at least a portion of the donor template. In certain embodiments, the donor template-recruiting sequence is 100% complementary to at least a portion of the donor template. In certain embodiments, where the donor template comprises an engineered sequence not homologous to the sequence to be repaired, the donor template-recruiting sequence is capable of hybridizing with the engineered sequence in the donor template. In certain embodiments, the donor template-recruiting sequence is at least 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 nucleotides in length. In certain embodiments, the donor template-recruiting sequence is positioned at or near the 5′ end of the modulator nucleic acid. In certain embodiments, the donor template-recruiting sequence is linked to the 5′ sequence, e.g., tail sequence, if present, or to the modulator stem sequence, of the modulator nucleic acid through an internucleotide bond or a nucleotide linker.

In certain embodiments, a guide nucleic acid as described herein is associated with a donor template comprising a single strand oligodeoxynucleotide (ssODN).

In certain embodiments, the modulator nucleic acid further comprises an editing enhancer sequence, which increases the efficiency of gene editing and/or homology-directed repair (HDR). Exemplary editing enhancer sequences are described in Park et al. (2018) NAT. COMMUN. 9: 3313. In certain embodiments, the editing enhancer sequence is positioned 5′ to the 5′ sequence, e.g., tail sequence, if present, or 5′ to the modulator stem sequence. In certain embodiments, the editing enhancer sequence is 1-50, 4-50, 9-50, 15-50, 25-50, 1-25, 4-25, 9-25, 15-25, 1-15, 4-15, 9-15, 1-9, 4-9, or 1-4 nucleotides in length. In certain embodiments, the editing enhancer sequence is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, or 55 nucleotides in length. The editing enhancer sequence is designed to minimize homology to the target nucleotide sequence or any other sequence that the engineered, non-naturally occurring system may be contacted to, e.g., the genome sequence of a cell into which the engineered, non-naturally occurring system is delivered. In certain embodiments, the editing enhancer is designed to minimize the presence of hairpin structure. The editing enhancer can comprise one or more of the chemical modifications disclosed herein.

The modulator and/or targeter nucleic acids can further comprise a protective nucleotide sequence that prevents or reduces nucleic acid degradation. In certain embodiments, the protective nucleotide sequence is at least 5 (e.g., at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, or at least 50) nucleotides in length. The length of the protective nucleotide sequence increases the time for an exonuclease to reach the 5′ sequence, e.g., tail sequence, modulator stem sequence, targeter stem sequence, and/or spacer sequence, thereby protecting these portions of the modulator and/or targeter nucleic acids from degradation by an exonuclease. In certain embodiments, the protective nucleotide sequence forms a secondary structure, such as a hairpin or a tRNA structure, to reduce the speed of degradation by an exonuclease (see, for example, Wu et al. (2018) CELL. MOL. LIFE SCI., 75(19): 3593-3607). Secondary structures can be predicted by methods known in the art, such as the online webserver RNAfold developed at University of Vienna using the centroid structure prediction algorithm (see, Gruber et al. (2008) NUCLEIC ACIDS RES., 36: W70). Certain chemical modifications, which may be present in the protective nucleotide sequence, can also prevent or reduce nucleic acid degradation, as disclosed in the “RNA Modifications” subsection.

A protective nucleotide sequence is typically located at or near the 5′ end, at or near the 3′ end, or at both ends, of the modulator or targeter nucleic acid. In certain embodiments, the modulator nucleic acid comprises a protective nucleotide sequence at or near the 5′ end, optionally through a nucleotide linker. In certain embodiments, the modulator nucleic acid comprises a protective nucleotide sequence at or near the 3′ end. In certain embodiments, the modulator nucleic acid comprises a protective nucleotide sequence at or near the 5′ end. In certain embodiments, the modulator nucleic acid comprises a protective nucleotide sequence at or near the 3′ end.

As described above, various nucleotide sequences can be present in the 5′ portion of a modulator nucleic acid, including but not limited to a donor template-recruiting sequence, an editing enhancer sequence, a protective nucleotide sequence, and a linker connecting such sequence to the 5′ sequence, e.g., tail sequence, if present, or to the modulator stem sequence. It is understood that the functions of donor template recruitment, editing enhancement, protection against degradation, and linkage are not exclusive to each other, and one nucleotide sequence can have one or more of such functions. For example, in certain embodiments, the modulator nucleic acid comprises a nucleotide sequence that is both a donor template-recruiting sequence and an editing enhancer sequence. In certain embodiments, the modulator nucleic acid comprises a nucleotide sequence that is both a donor template-recruiting sequence and a protective sequence. In certain embodiments, the modulator nucleic acid comprises a nucleotide sequence that is both an editing enhancer sequence and a protective sequence. In certain embodiments, the modulator nucleic acid comprises a nucleotide sequence that is a donor template-recruiting sequence, an editing enhancer sequence, and a protective sequence. In certain embodiments, the nucleotide sequence 5′ to the 5′ sequence, e.g., tail sequence, if present, or 5′ to the modulator stem sequence is 1-90, 1-80, 1-70, 1-60, 1-50, 1-40, 1-30, 1-20, 1-10, 10-90, 10-80, 10-70, 10-60, 10-50, 10-40, 10-30, 10-20, 20-90, 20-80, 20-70, 20-60, 20-50, 20-40, 20-30, 30-90, 30-80, 30-70, 30-60, 30-50, 30-40, 40-90, 40-80, 40-70, 40-60, 40-50, 50-90, 50-80, 50-70, 50-60, 60-90, 60-80, 60-70, 70-90, 70-80, or 80-90 nucleotides in length.

In certain embodiments, the engineered, non-naturally occurring system further comprises one or more compounds (e.g., small molecule compounds) that enhance HDR and/or inhibit NHEJ. Exemplary compounds having such functions are described in Maruyama et al. (2015) NAT BIOTECHNOL. 33(5): 538-42; Chu et al. (2015) NAT BIOTECHNOL. 33(5): 543-48; Yu et al. (2015) CELL STEM CELL 16(2): 142-47; Pinder et al. (2015) NUCLEIC ACIDS RES. 43(19): 9379-92; and Yagiz et al. (2019) COMMUN. BIOL. 2: 198. In certain embodiments, the engineered, non-naturally occurring system further comprises one or more compounds selected from the group consisting of DNA ligase IV antagonists (e.g., SCR7 compound, Ad4 E1B55K protein, and Ad4 E4orf6 protein), RAD51 agonists (e.g., RS-1), DNA-dependent protein kinase (DNA-PK) antagonists (e.g., NU7441 and KU0060648), β3-adrenergic receptor agonists (e.g., L755507), inhibitors of intracellular protein transport from the ER to the Golgi apparatus (e.g., brefeldin A), and any combinations thereof.

The sequences of the modulator nucleic acid and the targeter nucleic acid should be compatible with the Cas protein. Exemplary sequences that are operative with certain type V-A Cas proteins are provided in Table 24. It is understood that these sequences are merely illustrative, and other guide nucleic acid sequences may also be used with these Cas proteins.

TABLE 24 Type V-A Cas Protein and Corresponding Guide Nucleic Acid Sequences Modulator Targeter Stem Cas Protein¹ Sequence² Sequence PAM³ MAD7 (SEQ ID NO: UAAUUUCUAC (SEQ GUAGA (SEQ ID 5′ TTTN 1) ID NO: 15) NO: 21) MAD7 (SEQ ID NO: AUCUAC (SEQ ID GUAGA (SEQ ID 5′ TTTN 1) NO: 791) NO: 21) MAD7 (SEQ ID NO: GGAAUUUCUAC (SEQ GUAGA (SEQ ID 5′ TTTN 1) ID NO: 102) NO: 21) MAD7 (SEQ ID NO: UAAUUCCCAC (SEQ GUGGG (SEQ ID 5′ TTTN 1) ID NO: 792) NO: 22) MAD2 (SEQ ID NO: AUCUAC (SEQ ID GUAGA (SEQ ID 5′ TTTN 2) NO: 791) NO: 21) AsCpf1 (SEQ ID UAAUUUCUAC (SEQ GUAGA (SEQ ID 5′ TTTN NO: 3) ID NO: 15) NO: 21) LbCpf1 (SEQ ID UAAUUUCUAC (SEQ GUAGA (SEQ ID 5′ TTTN NO: 4) ID NO: 15) NO: 21) FnCpf1 (SEQ ID UAAUUUUCUACU (SEQ GUAGA (SEQ ID 5′ TTN NO: 5) ID NO: 18) NO: 21) Prevotella AAUUUCUAC (SEQ ID GUAGA (SEQ ID 5′ TTTC bryantii Cpf1 NO: 19) NO: 21) (SEQ ID NO: 6) Proteocatella AAUUUCUAC (SEQ ID GUAGA (SEQ ID 5′ TTTC sphenisci Cpf1 NO: 19) NO: 21) (SEQ ID NO: 7) Anaerovibrio sp. AAUUUCUAC (SEQ ID GUAGA (SEQ ID 5′ TTTC RM50 Cpf1 (SEQ ID NO: 19) NO: 21) NO: 8) Moraxella caprae GAAUUUCUAC (SEQ GUAGA (SEQ ID 5′ TTTC Cpf1 (SEQ ID NO: ID NO: 20) NO: 21) 9) Lachnospiraceae GAAUUUCUAC (SEQ GUAGA (SEQ ID 5′ TTTC bacterium COE1 ID NO: 20) NO: 21) Cpf1 (SEQ ID NO: 10) Eubacterium GAAUUUCUAC (SEQ GUAGA (SEQ ID 5′ TTTC coprostanoligenes ID NO: 20) NO: 21) Cpf1 (SEQ ID NO: 11) Smithella sp. GAAUUUCUAC (SEQ GUAGA (SEQ ID 5′ TTTC SCADC Csm1 (SEQ ID NO: 20) NO: 21) ID NO: 12) Sulfuricurvum sp. GAAUUUCUAC (SEQ GUAGA (SEQ ID 5′ TTTC Csm1 (SEQ ID NO: ID NO: 20) NO: 21) 13) Microgenomates GAAUUUCUAC (SEQ GUAGA (SEQ ID 5′ TTTC (Roizmanbacteria) ID NO: 20) NO: 21) bacterium Csm1 (SEQ ID NO: 14) ¹The amino acid sequences of the Cas proteins are provided at the end of the specification. ²It is understood that a “modulator sequence” listed herein may constitute the nucleotide sequence of a modulator nucleic acid. Alternatively, additional nucleotide sequences can be comprised in the modulator nucleic acid 5′ and/or 3′ to a “modulator sequence” listed herein. ³In the consensus PAM sequences, N represents A, C, G, or T. When the PAM sequence is preceded by “5′,” it means that the PAM is immediately upstream from the target nucleotide sequence when using the non-target strand (i.e., the strand not hybridized with the spacer sequence) as the coordinate.

In certain embodiments, the targeter nucleic acid of the engineered, non-naturally occurring system comprises a targeter stem sequence listed in Table 24. In certain embodiments, the targeter nucleic acid and the modulator nucleic acid of the engineered, non-naturally occurring system comprise, respectively, a targeter stem sequence and a modulator sequence listed in the same line of Table 24. It is understood that one or more 3′ or 5′ ends of a modulator sequence may contain chemical modifications, and/or 3′ end of targeter stem sequence or 5′ end of a targeter stem sequence, depending on orientation, may contain one or more chemical modifications. In certain embodiments, the engineered, non-naturally occurring system further comprises a Cas nuclease comprising the amino acid sequence set forth in the SEQ ID NO listed in the same line of Table 24. In certain embodiments, the engineered, non-naturally occurring system is useful for targeting, editing, or modifying a nucleic acid comprising a target nucleotide sequence close or adjacent to (e.g., immediately downstream of) a PAM listed in the same line of Table 24 when using the non-target strand (i.e., the strand not hybridized with the spacer sequence) as the coordinate.

In certain embodiments, the engineered, non-naturally occurring system is tunable or inducible. For example, in certain embodiments, the targeter nucleic acid, the modulator nucleic acid, and/or the Cas protein can be introduced to the target nucleotide sequence at different times, the system becoming active only when all components are present. In certain embodiments, the amounts of the targeter nucleic acid, the modulator nucleic acid, and/or the Cas protein can be titrated to achieve desirable efficiency and specificity. In certain embodiments, excess amount of a nucleic acid comprising the targeter stem sequence or the modulator stem sequence can be added to the system, thereby dissociating the complex of the targeter nucleic and modulator nucleic acid and turning off the system.

C. Cas Proteins

In certain embodiments, compositions and methods provided herein include a Cas protein, e.g., a Cas nuclease. The present invention also provides an engineered, non-naturally occurring system comprising a guide nucleic acid (e.g., a dual guide nucleic acid) disclosed herein, for example a guide nucleic acid described in section IA, IA1, and IB. In certain embodiments, the engineered, non-naturally occurring system further comprises the Cas nuclease, such as a Type I, II, III, IV, V, or VI nuclease, in some cases a Type V nuclease, for example, a Type V-A, V-C, or V-D Cas nuclease, such as a Type VA nuclease, including but not limited to a Cpf1 nuclease, derivative, or variant; a MAD nuclease, derivative, or variant; a ART nuclease, derivative, or variant; a Csm1 nuclease, derivative, or variant; or an ABW nuclease, derivative, or variant; specific examples are provided in this section. In certain embodiments, the modified guide nucleic acid and the Cas nuclease are present in a ribonucleoprotein (RNP) complex. In certain embodiments, the system also includes an editing sequence (donor sequence or donor template) having a change in sequence relative to the sequence of a target region.

The terms “CRISPR-Associated protein,” “Cas protein,” and “Cas,” as used interchangeably herein, can include a naturally occurring Cas protein or an engineered Cas protein. Non-limiting examples of Cas protein engineering includes but are not limited to mutations and modifications of the Cas protein that alter the activity of the Cas, alter the PAM specificity, broaden the range of recognized PAMs, and/or reduce the ability to modify one or more off-target loci as compared to a corresponding unmodified Cas. In certain embodiments, the altered activity of the engineered Cas comprises altered ability (e.g., specificity or kinetics) to bind the naturally occurring crRNA or engineered modified dual guide nucleic acids, altered ability (e.g., specificity or kinetics) to bind the target nucleotide sequence, altered processivity of nucleic acid scanning, and/or altered effector (e.g., nuclease) activity. A Cas protein having the nuclease activity is referred to as a “CRISPR-Associated nuclease” or “Cas nuclease,” as used interchangeably herein. In certain cases, as will be clear from context, a Cas nuclease lacking nuclease activity can also be referred to as a Cas nuclease.

The Cas nuclease that a complex comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating can be any suitable Cas nuclease, such as a Type I, II, III, IV, V, or VI nuclease, such as a Type V nuclease. In certain embodiments, provided herein are methods and compositions that include a modified guide nucleic acid, e.g., RNA, as described herein, for example in section IA or section IA1, and a Type I, II, III, IV, V, or VI nuclease. In certain embodiments, provided herein are methods and compositions that include a modified guide nucleic acid, e.g., RNA, as described herein, for example in section IA, IA1, or IB and a Type V, nuclease.

In certain embodiments, the Cas nuclease that a complex comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating is a type V-A, type V-C, or type V-D Cas nuclease. In certain embodiments, the Cas nuclease is a type V-A nuclease. In certain embodiments, the Cas nuclease is a Type V-E nuclease. In certain embodiments, the Cas nuclease is a MAD, ART, or ABW nuclease, as described herein. In certain embodiments, provided herein are methods and compositions that include a modified guide nucleic acid, e.g., RNA, as described herein, for example in section IA, IA1, or IB, and a Type V-A, Type V-C, Type V-E, or Type V-D Cas nuclease.

In certain embodiments, a nuclease that a complex comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating can be a Type V-A Cas nuclease. When a Type V-A Cas nuclease is used with a split gRNA as described herein, it may be considered a Type V-E Cas nuclease, and “Type V-A” may be considered equivalent to “Type V-E” herein in this context. In certain embodiments, the type V-A Cas nuclease comprises Cpf1 or a variant or derivative thereof, a MAD nuclease or a variant or derivative thereof, a Csm1 nuclease or a variant or derivative thereof, an ART nuclease or variant or derivative thereof, or an ABW nuclease or variant or derivative thereof. In certain embodiments, a composition comprises a Type V-A nuclease and a modified guide nucleic acid, e.g., modified dual guide RNA, as described herein, e.g., in Section IA, IA1, or IB.

In certain embodiments, the type V-A Cas nucleases comprises Cpf1 or a derivative thereof. Cpf1 proteins are known in the art and are described in U.S. Pat. Nos. 9,790,490 and 10,113,179. Cpf1 orthologs can be found in various bacterial and archaeal genomes. For example, in certain embodiments, the Cpf1 protein is derived from Francisella novicida U112 (Fn), Acidaminococcus sp. BV3L6 (As), Lachnospiraceae bacterium ND2006 (Lb), Lachnospiraceae bacterium MA2020 (Lb2), Candidatus Methanoplasma termitum (CMt), Moraxella bovoculi 237 (Mb), Porphyromonas crevioricanis (Pc), Prevotella disiens (Pd), Francisella tularensis 1, Francisella tularensis subsp. novicida, Prevotella albensis, Lachnospiraceae bacterium MC2017 1, Butyrivibrio proteoclasticus, Peregrinibacteria bacterium GW2011_GWA2_33_10, Parcubacteria bacterium GW2011_GWC2_44_17, Smithella sp. SCADC, Eubacterium eligens, Leptospira inadai, Porphyromonas macacae, Prevotella bryantii (Pb), Proteocatella sphenisci (Ps), Anaerovibrio sp. RM50 (As2), Moraxella caprae (Mc), Lachnospiraceae bacterium COE1 (Lb3), or Eubacterium coprostanoligenes (Ec).

In certain embodiments, the type V-A Cas nuclease comprises AsCpfl or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 3. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 3.

AsCpf1 (SEQ ID NO: 3) MTQFEGFTNLYQVSKTLRFELIPQGKTLKHIQEQGFIEEDKARNDHYKELK PIIDRIYKTYADQCLQLVQLDWENLSAAIDSYRKEKTEETRNALIEEQATY RNAIHDYFIGRTDNLTDAINKRHAEIYKGLFKAELFNGKVLKQLGTVTTTE HENALLRSFDKFTTYFSGFYENRKNVFSAEDISTAIPHRIVQDNFPKFKEN CHIFTRLITAVPSLREHFENVKKAIGIFVSTSIEEVFSFPFYNQLLTQTQI DLYNQLLGGISREAGTEKIKGLNEVLNLAIQKNDETAHIIASLPHRFIPLF KQILSDRNTLSFILEEFKSDEEVIQSFCKYKTLLRNENVLETAEALFNELN SIDLTHIFISHKKLETISSALCDHWDTLRNALYERRISELTGKITKSAKEK VQRSLKHEDINLQEIISAAGKELSEAFKQKTSEILSHAHAALDQPLPTTLK KQEEKEILKSQLDSLLGLYHLLDWFAVDESNEVDPEFSARLTGIKLEMEPS LSFYNKARNYATKKPYSVEKFKLNFQMPTLASGWDVNKEKNNGAILFVKNG LYYLGIMPKQKGRYKALSFEPTEKTSEGFDKMYYDYFPDAAKMIPKCSTQL KAVTAHFQTHTTPILLSNNFIEPLEITKEIYDLNNPEKEPKKFQTAYAKKT GDQKGYREALCKWIDFTRDFLSKYTKTTSIDLSSLRPSSQYKDLGEYYAEL NPLLYHISFQRIAEKEIMDAVETGKLYLFQIYNKDFAKGHHGKPNLHTLYW TGLFSPENLAKTSIKLNGQAELFYRPKSRMKRMAHRLGEKMLNKKLKDQKT PIPDTLYQELYDYVNHRLSHDLSDEARALLPNVITKEVSHEIIKDRRFTSD KFFFHVPITLNYQAANSPSKFNQRVNAYLKEHPETPIIGIDRGERNLIYIT VIDSTGKILEQRSLNTIQQFDYQKKLDNREKERVAARQAWSVVGTIKDLKQ GYLSQVIHEIVDLMIHYQAVVVLENLNFGFKSKRTGIAEKAVYQQFEKMLI DKLNCLVLKDYPAEKVGGVLNPYQLTDQFTSFAKMGTQSGFLFYVPAPYTS KIDPLTGFVDPFVWKTIKNHESRKHFLEGFDFLHYDVKTGDFILHFKMNRN LSFQRGLPGFMPAWDIVFEKNETQFDAKGTPFIAGKRIVPVIENHRFTGRY RDLYPANELIALLEEKGIVFRDGSNILPKLLENDDSHAIDTMVALIRSVLQ MRNSNAATGEDYINSPVRDLNGVCFDSRFQNPEWPMDADANGAYHIALKGQ LLLNHLKESKDLKLQNGISNQDWLAYIQELRN

In certain embodiments, the type V-A Cas nuclease comprises LbCpf1 or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 4. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 4.

LbCpf1 (SEQ ID NO: 4) MSKLEKFTNCYSLSKTLRFKAIPVGKTQENIDNKRLLVEDEKRAEDYKGVK KLLDRYYLSFINDVLHSIKLKNLNNYISLFRKKTRTEKENKELENLEINLR KEIAKAFKGNEGYKSLFKKDIIETILPEFLDDKDEIALVNSFNGFTTAFTG FFDNRENMFSEEAKSTSIAFRCINENLTRYISNMDIFEKVDAIFDKHEVQE IKEKILNSDYDVEDFFEGEFFNFVLTQEGIDVYNAIIGGFVTESGEKIKGL NEYINLYNQKTKQKLPKFKPLYKQVLSDRESLSFYGEGYTSDEEVLEVFRN TLNKNSEIFSSIKKLEKLFKNFDEYSSAGIFVKNGPAISTISKDIFGEWNV IRDKWNAEYDDIHLKKKAVVTEKYEDDRRKSFKKIGSFSLEQLQEYADADL SVVEKLKEIIIQKVDEIYKVYGSSEKLFDADFVLEKSLKKNDAVVAIMKDL LDSVKSFENYIKAFFGEGKETNRDESFYGDFVLAYDILLKVDHIYDAIRNY VTQKPYSKDKFKLYFQNPQFMGGWDKDKETDYRATILRYGSKYYLAIMDKK YAKCLQKIDKDDVNGNYEKINYKLLPGPNKMLPKVFFSKKWMAYYNPSEDI QKIYKNGTFKKGDMFNLNDCHKLIDFFKDSISRYPKWSNAYDFNFSETEKY KDIAGFYREVEEQGYKVSFESASKKEVDKLVEEGKLYMFQIYNKDFSDKSH GTPNLHTMYFKLLFDENNHGQIRLSGGAELFMRRASLKKEELVVHPANSPI ANKNPDNPKKTTTLSYDVYKDKRFSEDQYELHIPIAINKCPKNIFKINTEV RVLLKHDDNPYVIGIDRGERNLLYIVVVDGKGNIVEQYSLNEIINNFNGIR IKTDYHSLLDKKEKERFEARQNWTSIENIKELKAGYISQVVHKICELVEKY DAVIALEDLNSGFKNSRVKVEKQVYQKFEKMLIDKLNYMVDKKSNPCATGG ALKGYQITNKFESFKSMSTQNGFIFYIPAWLTSKIDPSTGFVNLLKTKYTS IADSKKFISSFDRIMYVPEEDLFEFALDYKNFSRTDADYIKKWKLYSYGNR IRIFRNPKKNNVFDWEEVCLTSAYKELFNKYGINYQQGDIRALLCEQSDKA FYSSFMALMSLMLQMRNSITGRTDVDFLISPVKNSDGIFYDSRNYEAQENA ILPKNADANGAYNIARKVLWAIGQFKKAEDEKLDKVKIAISNKEWLEYAQT SVKH

In certain embodiments, the type V-A Cas nuclease comprises FnCpf1 or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 5.

FnCpf1 (SEQ ID NO: 5) MSIYQEFVNKYSLSKTLRFELIPQGKTLENIKARGLILDDEKRAKDYKKAK QIIDKYHQFFIEEILSSVCISEDLLQNYSDVYFKLKKSDDDNLQKDFKSAK DTIKKQISEYIKDSEKFKNLFNQNLIDAKKGQESDLILWLKQSKDNGIELF KANSDITDIDEALEIIKSFKGWTTYFKGFHENRKNVYSSNDIPTSIIYRIV DDNLPKFLENKAKYESLKDKAPEAINYEQIKKDLAEELTFDIDYKTSEVNQ RVFSLDEVFEIANFNNYLNQSGITKFNTIIGGKFVNGENTKRKGINEYINL YSQQINDKTLKKYKMSVLFKQILSDTESKSFVIDKLEDDSDVVTTMQSFYE QIAAFKTVEEKSIKETLSLLFDDLKAQKLDLSKIYFKNDKSLTDLSQQVFD DYSVIGTAVLEYITQQIAPKNLDNPSKKEQELIAKKTEKAKYLSLETIKLA LEEFNKHRDIDKQCRFEEILANFAAIPMIFDEIAQNKDNLAQISIKYQNQG KKDLLQASAEDDVKAIKDLLDQTNNLLHKLKIFHISQSEDKANILDKDEHF YLVFEECYFELANIVPLYNKIRNYITQKPYSDEKFKLNFENSTLANGWDKN KEPDNTAILFIKDDKYYLGVMNKKNNKIFDDKAIKENKGEGYKKIVYKLLP GANKMLPKVFFSAKSIKFYNPSEDILRIRNHSTHTKNGSPQKGYEKFEFNI EDCRKFIDFYKQSISKHPEWKDFGFRFSDTQRYNSIDEFYREVENQGYKLT FENISESYIDSVVNQGKLYLFQIYNKDFSAYSKGRPNLHTLYWKALFDERN LQDVVYKLNGEAELFYRKQSIPKKITHPAKEAIANKNKDNPKKESVFEYDL IKDKRFTEDKFFFHCPITINFKSSGANKFNDEINLLLKEKANDVHILSIDR GERHLAYYTLVDGKGNIIKQDTFNIIGNDRMKTNYHDKLAAIEKDRDSARK DWKKINNIKEMKEGYLSQVVHEIAKLVIEYNAIVVFEDLNFGFKRGRFKVE KQVYQKLEKMLIEKLNYLVFKDNEFDKTGGVLRAYQLTAPFETFKKMGKQT GIIYYVPAGFTSKICPVTGFVNQLYPKYESVSKSQEFFSKFDKICYNLDKG YFEFSFDYKNFGDKAAKGKWTIASFGSRLINFRNSDKNHNWDTREVYPTKE LEKLLKDYSIEYGHGECIKAAICGESDKKFFAKLTSVLNTILQMRNSKTGT ELDYLISPVADVNGNFFDSRQAPKNMPQDADANGAYHIGLKGLMLLGRIKN NQEGKKLNLVIKNEEYFEFVQNRNN

In certain embodiments, the type V-A Cas nuclease comprises Prevotella bryantii Cpf1 (PbCpf1) or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 6. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 6.

Prevotella bryantii Cpf1 (PbCpf1)  (SEQ ID NO: 6) MQINNLKIIYMKFTDFTGLYSLSKTLRFELKPIGKTLENIKKAGLLEQDQH RADSYKKVKKIIDEYHKAFIEKSLSNFELKYQSEDKLDSLEEYLMYYSMKR IEKTEKDKFAKIQDNLRKQIADHLKGDESYKTIFSKDLIRKNLPDFVKSDE ERTLIKEFKDFTTYFKGFYENRENMYSAEDKSTAISHRIIHENLPKFVDNI NAFSKIILIPELREKLNQIYQDFEEYLNVESIDEIFHLDYFSMVMTQKQIE VYNAIIGGKSTNDKKIQGLNEYINLYNQKHKDCKLPKLKLLFKQILSDRIA ISWLPDNFKDDQEALDSIDTCYKNLLNDGNVLGEGNLKLLLENIDTYNLKG IFIRNDLQLTDISQKMYASWNVIQDAVILDLKKQVSRKKKESAEDYNDRLK KLYTSQESFSIQYLNDCLRAYGKTENIQDYFAKLGAVNNEHEQTINLFAQV RNAYTSVQAILTTPYPENANLAQDKETVALIKNLLDSLKRLQRFIKPLLGK GDESDKDERFYGDFTPLWETLNQITPLYNMVRNYMTRKPYSQEKIKLNFEN STLLGGWDLNKEHDNTAIILRKNGLYYLAIMKKSANKIFDKDKLDNSGDCY EKMVYKLLPGANKMLPKVFFSKSRIDEFKPSENIIENYKKGTHKKGANFNL ADCHNLIDFFKSSISKHEDWSKFNFHFSDTSSYEDLSDFYREVEQQGYSIS FCDVSVEYINKMVEKGDLYLFQIYNKDFSEFSKGTPNMHTLYWNSLFSKEN LNNIIYKLNGQAEIFFRKKSLNYKRPTHPAHQAIKNKNKCNEKKESIFDYD LVKDKRYTVDKFQFHVPITMNFKSTGNTNINQQVIDYLRTEDDTHIIGIDR GERHLLYLVVIDSHGKIVEQFTLNEIVNEYGGNIYRTNYHDLLDTREQNRE KARESWQTIENIKELKEGYISQVIHKITDLMQKYHAVVVLEDLNMGFMRGR QKVEKQVYQKFEEMLINKLNYLVNKKADQNSAGGLLHAYQLTSKFESFQKL GKQSGFLFYIPAWNTSKIDPVTGFVNLFDTRYESIDKAKAFFGKFDSIRYN ADKDWFEFAFDYNNFTTKAEGTRTNWTICTYGSRIRTFRNQAKNSQWDNEE IDLTKAYKAFFAKHGINIYDNIKEAIAMETEKSFFEDLLHLLKLTLQMRNS ITGTTTDYLISPVHDSKGNFYDSRICDNSLPANADANGAYNIARKGLMLIQ QIKDSTSSNRFKFSPITNKDWLIFAQEKPYLND

In certain embodiments, the type V-A Cas nuclease comprises Proteocatella sphenisci Cpf1(PsCpf1) or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 7. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 7.

Proteocatella sphenisci Cpf1 (PsCpf1)  (SEQ ID NO: 7) MENFKNLYPINKTLRFELRPYGKTLENFKKSGLLEKDAFKANSRRSMQAII DEKFKETIEERLKYTEFSECDLGNMTSKDKKITDKAATNLKKQVILSFDDE IFNNYLKPDKNIDALFKNDPSNPVISTFKGFTTYFVNFFEIRKHIFKGESS GSMAYRIIDENLTTYLNNIEKIKKLPEELKSQLEGIDQIDKLNNYNEFITQ SGITHYNEIIGGISKSENVKIQGINEGINLYCQKNKVKLPRLTPLYKMILS DRVSNSFVLDTIENDTELIEMISDLINKTEISQDVIMSDIQNIFIKYKQLG NLPGISYSSIVNAICSDYDNNFGDGKRKKSYENDRKKHLETNVYSINYISE LLTDTDVSSNIKMRYKELEQNYQVCKENFNATNWMNIKNIKQSEKTNLIKD LLDILKSIQRFYDLFDIVDEDKNPSAEFYTWLSKNAEKLDFEFNSVYNKSR NYLTRKQYSDKKIKLNFDSPTLAKGWDANKEIDNSTIIMRKFNNDRGDYDY FLGIWNKSTPANEKIIPLEDNGLFEKMQYKLYPDPSKMLPKQFLSKIWKAK HPTTPEFDKKYKEGRHKKGPDFEKEFLHELIDCFKHGLVNHDEKYQDVFGF NLRNTEDYNSYTEFLEDVERCNYNLSFNKIADTSNLINDGKLYVFQIWSKD FSIDSKGTKNLNTIYFESLFSEENMIEKMFKLSGEAEIFYRPASLNYCEDI IKKGHHHAELKDKFDYPIIKDKRYSQDKFFFHVPMVINYKSEKLNSKSLNN RTNENLGQFTHIIGIDRGERHLIYLTVVDVSTGEIVEQKHLDEIINTDTKG VEHKTHYLNKLEEKSKTRDNERKSWEAIETIKELKEGYISHVINEIQKLQE KYNALIVMENLNYGFKNSRIKVEKQVYQKFETALIKKFNYIIDKKDPETYI HGYQLTNPITTLDKIGNQSGIVLYIPAWNTSKIDPVTGFVNLLYADDLKYK NQEQAKSFIQKIDNIYFENGEFKFDIDFSKWNNRYSISKTKWTLTSYGTRI QTFRNPQKNNKWDSAEYDLTEEFKLILNIDGTLKSQDVETYKKFMSLFKLM LQLRNSVTGTDIDYMISPVTDKTGTHFDSRENIKNLPADADANGAYNIARK GIMAIENIMNGISDPLKISNEDYLKYIQNQQE

In certain embodiments, the type V-A Cas nuclease comprises Anaerovibrio sp. RM50 Cpf1 (As2Cpf1) or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 8. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 8.

Anaerovibrio sp. RM50 Cpf1 (As2Cpf1)  (SEQ ID NO: 8) MVAFIDEFVGQYPVSKTLRFEARPVPETKKWLESDQCSVLFNDQKRNEYYG VLKELLDDYYRAYIEDALTSFTLDKALLENAYDLYCNRDTNAFSSCCEKLR KDLVKAFGNLKDYLLGSDQLKDLVKLKAKVDAPAGKGKKKIEVDSRLINWL NNNAKYSAEDREKYIKAIESFEGFVTYLTNYKQARENMFSSEDKSTAIAFR VIDQNMVTYFGNIRIYEKIKAKYPELYSALKGFEKFFSPTAYSEILSQSKI DEYNYQCIGRPIDDADFKGVNSLINEYRQKNGIKARELPVMSMLYKQILSD RDNSFMSEVINRNEEAIECAKNGYKVSYALFNELLQLYKKIFTEDNYGNIY VKTQPLTELSQALFGDWSILRNALDNGKYDKDIINLAELEKYFSEYCKVLD ADDAAKIQDKFNLKDYFIQKNALDATLPDLDKITQYKPHLDAMLQAIRKYK LFSMYNGRKKMDVPENGIDFSNEFNAIYDKLSEFSILYDRIRNFATKKPYS DEKMKLSFNMPTMLAGWDYNNETANGCFLFIKDGKYFLGVADSKSKNIFDF KKNPHLLDKYSSKDIYYKVKYKQVSGSAKMLPKVVFAGSNEKIFGHLISKR ILEIREKKLYTAAAGDRKAVAEWIDFMKSAIAIHPEWNEYFKFKFKNTAEY DNANKFYEDIDKQTYSLEKVEIPTEYIDEMVSQHKLYLFQLYTKDFSDKKK KKGTDNLHTMYWHGVFSDENLKAVTEGTQPIIKLNGEAEMFMRNPSIEFQV THEHNKPIANKNPLNTKKESVFNYDLIKDKRYTERKFYFHCPITLNFRADK PIKYNEKINRFVENNPDVCIIGIDRGERHLLYYTVINQTGDILEQGSLNKI SGSYTNDKGEKVNKETDYHDLLDRKEKGKHVAQQAWETIENIKELKAGYLS QVVYKLTQLMLQYNAVIVLENLNVGFKRGRTKVEKQVYQKFEKAMIDKLNY LVFKDRGYEMNGSYAKGLQLTDKFESFDKIGKQTGCIYYVIPSYTSHIDPK TGFVNLLNAKLRYENITKAQDTIRKFDSISYNAKADYFEFAFDYRSFGVDM ARNEWVVCTCGDLRWEYSAKTRETKAYSVTDRLKELFKAHGIDYVGGENLV SHITEVADKHFLSTLLFYLRLVLKMRYTVSGTENENDFILSPVEYAPGKFF DSREATSTEPMNADANGAYHIALKGLMTIRGIEDGKLHNYGKGGENAAWFK FMQNQEYKNNG

In certain embodiments, the type V-A Cas nuclease comprises Moraxella caprae Cpf1 (McCpf1) or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 9. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 9.

Moraxella caprae Cpf1 (McCpf1) (SEQ ID NO: 9) MLFQDFTHLYPLSKTMRFELKPIGKTLEHIHAKNFLSQDETMADMYQKVKA ILDDYHRDFIADMMGEVKLTKLAEFYDVYLKFRKNPKDDGLQKQLKDLQAV LRKEIVKPIGNGGKYKAGYDRLFGAKLFKDGKELGDLAKFVIAQEGESSPK LAHLAHFEKFSTYFTGFHDNRKNMYSDEDKHTAITYRLIHENLPRFIDNLQ ILATIKQKHSALYDQIINELTASGLDVSLASHLDGYHKLLTQEGITAYNTL LGGISGEAGSRKIQGINELINSHHNQHCHKSERIAKLRPLHKQILSDGMGV SFLPSKFADDSEMCQAVNEFYRHYADVFAKVQSLFDGFDDHQKDGIYVEHK NLNELSKQAFGDFALLGRVLDGYYVDVVNPEFNERFAKAKTDNAKAKLTKE KDKFIKGVHSLASLEQAIEHYTARHDDESVQAGKLGQYFKHGLAGVDNPIQ KIHNNHSTIKGFLERERPAGERALPKIKSGKNPEMTQLRQLKELLDNALNV AHFAKLLTTKTTLDNQDGNFYGEFGALYDELAKIPTLYNKVRDYLSQKPFS TEKYKLNFGNPTLLNGWDLNKEKDNFGIILQKDGCYYLALLDKAHKKVFDN APNTGKNVYQKMIYKLLPGPNKMLPKVFFAKSNLDYYNPSAELLDKYAQGT HKKGNNFNLKDCHALIDFFKAGINKHPEWQHFGFKFSPTSSYQDLSDFYRE VEPQGYQVKFVDINADYINELVEQGQLYLFQIYNKDFSPKAHGKPNLHTLY FKALFSKDNLANPIYKLNGEAQIFYRKASLDMNETTIHRAGEVLENKNPDN PKKRQFVYDIIKDKRYTQDKFMLHVPITMNFGVQGMTIKEFNKKVNQSIQQ YDEVNVIGIDRGERHLLYLTVINSKGEILEQRSLNDITTASANGTQMTTPY HKILDKREIERLNARVGWGEIETIKELKSGYLSHVVHQISQLMLKYNAIVV LEDLNFGFKRGRFKVEKQIYQNFENALIKKLNHLVLKDEADDEIGSYKNAL QLTNNFTDLKSIGKQTGFLFYVPAWNTSKIDPETGFVDLLKPRYENIAQSQ AFFGKFDKICYNADKDYFEFHIDYAKFTDKAKNSRQIWKICSHGDKRYVYD KTANQNKGATKGINVNDELKSLFARHHINDKQPNLVMDICQNNDKEFHKSL IYLLKTLLALRYSNASSDEDFILSPVANDEGMFFNSALADDTQPQNADANG AYHIALKGLWVLEQIKNSDDLNKVKLAIDNQTWLNFAQNR

In certain embodiments, the type V-A Cas nuclease comprises Lachnospiraceae bacterium COE1 Cpf1 (Lb3Cpf1) or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 10. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 10.

Lb3Cpf1  (SEQ ID NO: 10) MHENNGKIADNFIGIYPVSKTLRFELKPVGKTQEYIEKHGILDEDLKRAGD YKSVKKIIDAYHKYFIDEALNGIQLDGLKNYYELYEKKRDNNEEKEFQKIQ MSLRKQIVKRFSEHPQYKYLFKKELIKNVLPEFTKDNAEEQTLVKSFQEFT TYFEGFHQNRKNMYSDEEKSTAIAYRVVHQNLPKYIDNMRIFSMILNTDIR SDLTELFNNLKTKMDITIVEEYFAIDGFNKVVNQKGIDVYNTILGAFSTDD NTKIKGLNEYINLYNQKNKAKLPKLKPLFKQILSDRDKISFIPEQFDSDTE VLEAVDMFYNRLLQFVIENEGQITISKLLTNFSAYDLNKIYVKNDTTISAI SNDLFDDWSYISKAVRENYDSENVDKNKRAAAYEEKKEKALSKIKMYSIEE LNFFVKKYSCNECHIEGYFERRILEILDKMRYAYESCKILHDKGLINNISL CQDRQAISELKDFLDSIKEVQWLLKPLMIGQEQADKEEAFYTELLRIWEEL EPITLLYNKVRNYVTKKPYTLEKVKLNFYKSTLLDGWDKNKEKDNLGIILL KDGQYYLGIMNRRNNKIADDAPLAKTDNVYRKMEYKLLTKVSANLPRIFLK DKYNPSEEMLEKYEKGTHLKGENFCIDDCRELIDFFKKGIKQYEDWGQFDF KFSDTESYDDISAFYKEVEHQGYKITFRDIDETYIDSLVNEGKLYLFQIYN KDFSPYSKGTKNLHTLYWEMLFSQQNLQNIVYKLNGNAEIFYRKASINQKD VVVHKADLPIKNKDPQNSKKESMFDYDIIKDKRFTCDKYQFHVPITMNFKA LGENHFNRKVNRLIHDAENMHIIGIDRGERNLIYLCMIDMKGNIVKQISLN EIISYDKNKLEHKRNYHQLLKTREDENKSARQSWQTIHTIKELKEGYLSQV IHVITDLMVEYNAIVVLEDLNFGFKQGRQKFERQVYQKFEKMLIDKLNYLV DKSKGMDEDGGLLHAYQLTDEFKSFKQLGKQSGFLYYIPAWNTSKLDPTTG FVNLFYTKYESVEKSKEFINNFTSILYNQEREYFEFLFDYSAFTSKAEGSR LKWTVCSKGERVETYRNPKKNNEWDTQKIDLTFELKKLFNDYSISLLDGDL REQMGKIDKADFYKKFMKLFALIVQMRNSDEREDKLISPVLNKYGAFFETG KNERMPLDADANGAYNIARKGLWIIEKIKNTDVEQLDKVKLTISNKEWLQY AQEHIL

In certain embodiments, the type V-A Cas nuclease comprises Eubacterium coprostanoligenes Cpf1 (EcCpf1) or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 11. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 11.

Eubacterium coprostanoligenes Cpf1 (EcCpf1)  (SEQ ID NO: 11) MDFFKNDMYFLCINGIIVISKLFAYLFLMYKRGVVMIKDNFVNVYSLSKTI RMALIPWGKTEDNFYKKFLLEEDEERAKNYIKVKGYMDEYHKNFIESALNS VVLNGVDEYCELYFKQNKSDSEVKKIESLEASMRKQISKAMKEYTVDGVKI YPLLSKKEFIRELLPEFLTQDEEIETLEQFNDFSTYFQGFWENRKNIYTDE EKSTGVPYRCINDNLPKFLDNVKSFEKVILALPQKAVDELNANFNGVYNVD VQDVFSVDYFNFVLSQSGIEKYNNIIGGYSNSDASKVQGLNEKINLYNQQI AKSDKSKKLPLLKPLYKQILSDRSSLSFIPEKFKDDNEVLNSINVLYDNIA ESLEKANDLMSDIANYNTDNIFISSGVAVTDISKKVFGDWSLIRNNWNDEY ESTHKKGKNEEKFYEKEDKEFKKIKSFSVSELQRLANSDLSIVDYLVDESA SLYADIKTAYNNAKDLLSNEYSHSKRLSKNDDAIELIKSFLDSIKNYEAFL KPLCGTGKEESKDNAFYGAFLECFEEIRQVDAVYNKVRNHITQKPYSNDKI KLNFQNPQFLAGWDKNKERAYRSVLLRNGEKYYLAIMEKGKSKLFEDFPED ESSPFEKIDYKLLPEPSKMLPKVFFATSNKDLFNPSDEILNIRATGSFKKG DSFNLDDCHKFIDFYKASIENHPDWSKFDFDFSETNDYEDISKFFKEVSDQ GYSIGYRKISESYLEEMVDNGSLYMFQLYNKDFSENRKSKGTPNLHTLYFK MLFDERNLEDVVYKLSGGAEMFYRKPSIDKNEMIVHPKNQPIDNKNPNNVK KTSTFEYDIVKDMRYTKPQFQLHLPIVLNFKANSKGYINDDVRNVLKNSED TYVIGIDRGERNLVYACVVDGNGKLVEQVPLNVIEADNGYKTDYHKLLNDR EEKRNEARKSWKTIGNIKELKEGYISQVVHKICQLVVKYDAVIAMEDLNSG FVNSRKKVEKQVYQKFERMLTQKLNYLVDKKLDPNEMGGLLNAYQLTNEAT KVRNGRQDGIIFYIPAWLTSKIDPTTGFVNLLKPKYNSVSASKEFFSKFDE IRYNEKENYFEFSFNYDNFPKCNADFKREWTVCTYGDRIRTFRDPENNNKF NSEVVVLNDEFKNLFVEFDIDYTDNLKEQILAMDEKSFYKKLMGLLSLTLQ MRNSISKNVDVDYLISPVKNSNGEFYDSRNYDITSSLPCDADSNGAYNIAR KGLWAINQIKQADDETKANISIKNSEWLQYAQNCDEV

In certain embodiments, the type V-A Cas nuclease is not Cpf1. In certain embodiments, the type V-A Cas nuclease is not AsCpfl.

In certain embodiments, the type V-A Cas nuclease comprises MAD1, MAD2, MAD3, MAD4, MAD5, MAD6, MAD7, MAD8, MAD9, MAD10, MAD11, MAD12, MAD13, MAD14, MAD15, MAD16, MAD17, MAD18, MAD19, or MAD20, or derivatives or variants thereof. MAD1-MAD20 are known in the art and are described in U.S. Pat. No. 9,982,279.

In certain embodiments, the type V-A Cas nuclease comprises MAD7 or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 1. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 1.

MAD7  (SEQ ID NO: 1) MNNGTNNFQNFIGISSLQKTLRNALIPTETTQQFIVKNGIIKEDELRGENR QILKDIMDDYYRGFISETLSSIDDIDWTSLFEKMEIQLKNGDNKDTLIKEQ TEYRKAIHKKFANDDRFKNMFSAKLISDILPEFVIHNNNYSASEKEEKTQV IKLFSRFATSFKDYFKNRANCFSADDISSSSCHRIVNDNAEIFFSNALVYR RIVKSLSNDDINKISGDMKDSLKEMSLEEIYSYEKYGEFITQEGISFYNDI CGKVNSFMNLYCQKNKENKNLYKLQKLHKQILCIADTSYEVPYKFESDEEV YQSVNGFLDNISSKHIVERLRKIGDNYNGYNLDKIYIVSKFYESVSQKTYR DWETINTALEIHYNNILPGNGKSKADKVKKAVKNDLQKSITEINELVSNYK LCSDDNIKAETYTHEISHILNNFEAQELKYNPEIHLVESELKASELKNVLD VIMNAFHWCSVFMTEELVDKDNNFYAELEETYDETYPVISLYNLVRNYVTQ KPYSTKKIKLNFGIPTLADGWSKSKEYSNNAIILMRDNLYYLGIFNAKNKP DKKIIEGNTSENKGDYKKMIYNLLPGPNKMIPKVFLSSKTGVETYKPSAYI LEGYKQNKHIKSSKDFDITFCHDLIDYFKNCIAIHPEWKNFGFDFSDTSTY EDISGFYREVELQGYKIDWTYISEKDIDLLQEKGQLYLFQIYNKDFSKKST GNDNLHTMYLKNLFSEENLKDIVLKLNGEAEIFFRKSSIKNPIIHKKGSIL VNRTYEAEEKDQFGNIQIVRKNIPENIYQELYKYFNDKSDKELSDEAAKLK NVVGHHEAATNIVKDYRYTYDKYFLHMPITINFKANKTGFINDRILQYIAK EKDLHVIGIDRGERNLIYVSVIDTCGNIVEQKSFNIVNGYDYQIKLKQQEG ARQIARKEWKEIGKIKEIKEGYLSLVIHEISKMVIKYNAIIAMEDLSYGFK KGRFKVERQVYQKFETMLINKLNYLVFKDISITENGGLLKGYQLTYIPDKL KNVGHQCGCIFYVPAAYTSKIDPTTGFVNIFKFKDLTVDAKREFIKKFDSI RYDSEKNLFCFTFDYNNFITQNTVMSKSSWSVYTYGVRIKRRFVNGRFSNE SDTIDITKDMEKTLEMTDINWRDGHDLRQDIIDYEIVQHIFEIFRLTVQMR NSLSELEDRDYDRLISPVLNENNIFYDSAKAGDALPKDADANGAYCIALKG LYEIKQITENWKEDGKFSRDKLKISNKDWFDFIQNKRYL

In certain embodiments, the type V-A Cas nuclease comprises MAD2 or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 2. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 2

MAD2  (SEQ ID NO: 2) MSSLTKFTNKYSKQLTIKNELIPVGKTLENIKENGLIDGDEQLNENYQKAK IIVDDFLRDFINKALNNTQIGNWRELADALNKEDEDNIEKLQDKIRGIIVS KFETFDLFSSYSIKKDEKIIDDDNDVEEEELDLGKKTSSFKYIFKKNLFKL VLPSYLKTTNQDKLKIISSFDNFSTYFRGFFENRKNIFTKKPISTSIAYRI VHDNFPKFLDNIRCFNVWQTECPQLIVKADNYLKSKNVIAKDKSLANYFTV GAYDYFLSQNGIDFYNNIIGGLPAFAGHEKIQGLNEFINQECQKDSELKSK LKNRHAFKMAVLFKQILSDREKSFVIDEFESDAQVIDAVKNFYAEQCKDNN VIFNLLNLIKNIAFLSDDELDGIFIEGKYLSSVSQKLYSDWSKLRNDIEDS ANSKQGNKELAKKIKTNKGDVEKAISKYEFSLSELNSIVHDNTKFSDLLSC TLHKVASEKLVKVNEGDWPKHLKNNEEKQKIKEPLDALLEIYNTLLIFNCK SFNKNGNFYVDYDRCINELSSVVYLYNKTRNYCTKKPYNTDKFKLNFNSPQ LGEGFSKSKENDCLTLLFKKDDNYYVGIIRKGAKINFDDTQAIADNTDNCI FKMNYFLLKDAKKFIPKCSIQLKEVKAHFKKSEDDYILSDKEKFASPLVIK KSTFLLATAHVKGKKGNIKKFQKEYSKENPTEYRNSLNEWIAFCKEFLKTY KAATIFDITTLKKAEEYADIVEFYKDVDNLCYKLEFCPIKTSFIENLIDNG DLYLFRINNKDFSSKSTGTKNLHTLYLQAIFDERNLNNPTIMLNGGAELFY RKESIEQKNRITHKAGSILVNKVCKDGTSLDDKIRNEIYQYENKFIDTLSD EAKKVLPNVIKKEATHDITKDKRFTSDKFFFHCPLTINYKEGDTKQFNNEV LSFLRGNPDINIIGIDRGERNLIYVTVINQKGEILDSVSFNTVTNKSSKIE QTVDYEEKLAVREKERIEAKRSWDSISKIATLKEGYLSAIVHEICLLMIKH NAIVVLENLNAGFKRIRGGLSEKSVYQKFEKMLINKLNYFVSKKESDWNKP SGLLNGLQLSDQFESFEKLGIQSGFIFYVPAAYTSKIDPTTGFANVLNLSK VRNVDAIKSFFSNFNEISYSKKEALFKFSFDLDSLSKKGFSSFVKFSKSKW NVYTFGERIIKPKNKQGYREDKRINLTFEMKKLLNEYKVSFDLENNLIPNL TSANLKDTFWKELFFIFKTTLQLRNSVTNGKEDVLISPVKNAKGEFFVSGT HNKTLPQDCDANGAYHIALKGLMILERNNLVREEKDTKKIMAISNVDWFEY VQKRRGVL

In certain embodiments, the type V-A Cas nucleases comprises Csm1. Csm1 proteins are known in the art and are described in U.S. Pat. No. 9,896,696. Csm1 orthologs can be found in various bacterial and archaeal genomes. For example, in certain embodiments, the Csm1 protein is derived from Smithella sp. SCADC (Sm), Sulfuricurvum sp. (Ss), or Microgenomates (Roizmanbacteria) bacterium (Mb).

In certain embodiments, the type V-A Cas nuclease comprises SmCsm1 or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 12. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 12.

Smithella sp. SCADC Csm1  (SEQ ID NO: 12) MEKYKITKTIRFKLLPDKIQDISRQVAVLQNSTNAEKKNNLLRLVQRGQEL PKLLNEYIRYSDNHKLKSNVTVHFRWLRLFTKDLFYNWKKDNTEKKIKISD VVYLSHVFEAFLKEWESTIERVNADCNKPEESKTRDAEIALSIRKLGIKHQ LPFIKGFVDNSNDKNSEDTKSKLTALLSEFEAVLKICEQNYLPSQSSGIAI AKASFNYYTINKKQKDFEAEIVALKKQLHARYGNKKYDQLLRELNLIPLKE LPLKELPLIEFYSEIKKRKSTKKSEFLEAVSNGLVFDDLKSKFPLFQTESN KYDEYLKLSNKITQKSTAKSLLSKDSPEAQKLQTEITKLKKNRGEYFKKAF GKYVQLCELYKEIAGKRGKLKGQIKGIENERIDSQRLQYWALVLEDNLKHS LILIPKEKTNELYRKVWGAKDDGASSSSSSTLYYFESMTYRALRKLCFGIN GNTFLPEIQKELPQYNQKEFGEFCFHKSNDDKEIDEPKLISFYQSVLKTDF VKNTLALPQSVFNEVAIQSFETRQDFQIALEKCCYAKKQIISESLKKEILE NYNTQIFKITSLDLQRSEQKNLKGHTRIWNRFWTKQNEEINYNLRLNPEIA IVWRKAKKTRIEKYGERSVLYEPEKRNRYLHEQYTLCTTVTDNALNNEITF AFEDTKKKGTEIVKYNEKINQTLKKEFNKNQLWFYGIDAGEIELATLALMN KDKEPQLFTVYELKKLDFFKHGYIYNKERELVIREKPYKAIQNLSYFLNEE LYEKTFRDGKFNETYNELFKEKHVSAIDLTTAKVINGKIILNGDMITFLNL RILHAQRKIYEELIENPHAELKEKDYKLYFEIEGKDKDIYISRLDFEYIKP YQEISNYLFAYFASQQINEAREEEQINQTKRALAGNMIGVIYYLYQKYRGI ISIEDLKQTKVESDRNKFEGNIERPLEWALYRKFQQEGYVPPISELIKLRE LEKFPLKDVKQPKYENIQQFGIIKFVSPEETSTTCPKCLRRFKDYDKNKQE GFCKCQCGFDTRNDLKGFEGLNDPDKVAAFNIAKRGFEDLQKYK

In certain embodiments, the type V-A Cas nuclease comprises SsCsm1 or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 13. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 13.

Sulfuricurvum sp. Csm1  (SEQ ID NO: 13) MLHAFTNQYQLSKTLRFGATLKEDEKKCKSHEELKGFVDISYENMKSSATI AESLNENELVKKCERCYSEIVKFHNAWEKIYYRTDQIAVYKDFYRQLSRKA RFDAGKQNSQLITLASLCGMYQGAKLSRYITNYWKDNITRQKSFLKDFSQQ LHQYTRALEKSDKAHTKPNLINFNKTFMVLANLVNEIVIPLSNGAISFPNI SKLEDGEESHLIEFALNDYSQLSELIGELKDAIATNGGYTPFAKVTLNHYT AEQKPHVFKNDIDAKIRELKLIGLVETLKGKSSEQIEEYFSNLDKFSTYND RNQSVIVRTQCFKYKPIPFLVKHQLAKYISEPNGWDEDAVAKVLDAVGAIR SPAHDYANNQEGFDLNHYPIKVAFDYAWEQLANSLYTTVTFPQEMCEKYLN SIYGCEVSKEPVFKFYADLLYIRKNLAVLEHKNNLPSNQEEFICKINNTFE NIVLPYKISQFETYKKDILAWINDGHDHKKYTDAKQQLGFIRGGLKGRIKA EEVSQKDKYGKIKSYYENPYTKLTNEFKQISSTYGKTFAELRDKFKEKNEI TKITHFGIIIEDKNRDRYLLASELKHEQINHVSTILNKLDKSSEFITYQVK SLTSKTLIKLIKNHTTKKGAISPYADFHTSKTGFNKNEIEKNWDNYKREQV LVEYVKDCLTDSTMAKNQNWAEFGWNFEKCNSYEDIEHEIDQKSYLLQSDT ISKQSIASLVEGGCLLLPIINQDITSKERKDKNQFSKDWNHIFEGSKEFRL HPEFAVSYRTPIEGYPVQKRYGRLQFVCAFNAHIVPQNGEFINLKKQIENF NDEDVQKRNVTEFNKKVNHALSDKEYVVIGIDRGLKQLATLCVLDKRGKIL GDFEIYKKEFVRAEKRSESHWEHTQAETRHILDLSNLRVETTIEGKKVLVD QSLTLVKKNRDTPDEEATEENKQKIKLKQLSYIRKLQHKMQTNEQDVLDLI NNEPSDEEFKKRIEGLISSFGEGQKYADLPINTMREMISDLQGVIARGNNQ TEKNKIIELDAADNLKQGIVANMIGIVNYIFAKYSYKAYISLEDLSRAYGG AKSGYDGRYLPSTSQDEDVDFKEQQNQMLAGLGTYQFFEMQLLKKLQKIQS DNTVLRFVPAFRSADNYRNILRLEETKYKSKPFGVVHFIDPKFTSKKCPVC SKTNVYRDKDDILVCKECGFRSDSQLKERENNIHYIHNGDDNGAYHIALKS VENLIQMK

In certain embodiments, the type V-A Cas nuclease comprises MbCsm1 or a variant thereof. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 14. In certain embodiments, the type V-A Cas protein comprises the amino acid sequence set forth in SEQ ID NO: 14.

Microgenomates (Roizmanbacteria) bacterium Csm1  (SEQ ID NO: 14) MEIQELKNLYEVKKTVRFELKPSKKKIFEGGDVIKLQKDFEKVQKFFLDIF VYKNEHTKLEFKKKREIKYTWLRTNTKNEFYNWRGKSDTGKNYALNKIGFL AEEILRWLNEWQELTKSLKDLTQREEHKQERKSDIAFVLRNFLKRQNLPFI KDFFNAVIDIQGKQGKESDDKIRKFREEIKEIEKNLNACSREYLPTQSNGV LLYKASFSYYTLNKTPKEYEDLKKEKESELSSVLLKEIYRRKRFNRTTNQK DTLFECTSDWLVKIKLGKDIYEWTLDEAYQKMKIWKANQKSNFIEAVAGDK LTHQNFRKQFPLFDASDEDFETFYRLTKALDKNPENAKKIAQKRGKFFNAP NETVQTKNYHELCELYKRIAVKRGKIIAEIKGIENEEVQSQLLTHWAVIAE ERDKKFIVLIPRKNGGKLENHKNAHAFLQEKDRKEPNDIKVYHFKSLTLRS LEKLCFKEAKNTFAPEIKKETNPKIWFPTYKQEWNSTPERLIKFYKQVLQS NYAQTYLDLVDFGNLNTFLETHFTTLEEFESDLEKTCYTKVPVYFAKKELE TFADEFEAEVFEITTRSISTESKRKENAHAEIWRDFWSRENEEENHITRLN PEVSVLYRDEIKEKSNTSRKNRKSNANNRFSDPRFTLATTITLNADKKKSN LAFKTVEDINIHIDNFNKKFSKNFSGEWVYGIDRGLKELATLNVVKFSDVK NVFGVSQPKEFAKIPIYKLRDEKAILKDENGLSLKNAKGEARKVIDNISDV LEEGKEPDSTLFEKREVSSIDLTRAKLIKGHIISNGDQKTYLKLKETSAKR RIFELFSTAKIDKSSQFHVRKTIELSGTKIYWLCEWQRQDSWRTEKVSLRN TLKGYLQNLDLKNRFENIETIEKINHLRDAITANMVGILSHLQNKLEMQGV IALENLDTVREQSNKKMIDEHFEQSNEHVSRRLEWALYCKFANTGEVPPQI KESIFLRDEFKVCQIGILNFIDVKGTSSNCPNCDQESRKTGSHFICNFQNN CIFSSKENRNLLEQNLHNSDDVAAFNIAKRGLEIVKV

In certain embodiments, the type V-A Cas nuclease comprises an ART nuclease or a variant thereof. In general, such nucleases sequences have <60% AA sequence similarity to Cas12a, <60% AA sequence similarity to a positive control nuclease, and >80% query cover. In certain embodiments, the Type V-A nuclease comprises an ART1, ART2, ART3, ART4, ART5, ART6, ART7, ART8, ART9, ART10, ART11, ART12, ART13, ART14, ART15, ART16, ART17, ART18, ART19, ART20, ART21, ART22, ART23, ART24, ART25, ART26, ART27, ART28, ART28, ART30, ART31, ART32, ART33, ART34, ART35, or ART11* (i.e., ART11 L679F, i.e., ART11 wherein leucine (L) at amino acid position 679 is replaced with phenylalanine (F)) nuclease, as shown in Table 25 and Appendix A. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence designated for the individual ART nuclease as shown in Table 25 and Appendix A. In certain embodiments, provided is a nucleic acid-guided nuclease comprising a nucleic acid-guided nuclease polypeptide having at least 85% identity to an amino acid sequence represented by SEQ ID NOs: 950-984 or a nucleic acid encoding a nucleic acid-guided nuclease polypeptide comprising at least 85% identity with the polynucleotide represented by SEQ ID NOs: 808-949. In certain embodiments, provided is a nucleic acid-guided nuclease comprising a polypeptide having at least 90% identity to the amino acid sequence represented by SEQ ID NOs: 950-958, 968-970, 972, 973, 976, 978-982, or 984, wherein the polypeptide does not contain a peptide motif of YLFQIYNKDF (SEQ ID NO: 806). In certain embodiments, provided is a nucleic acid-guided nuclease comprising a nucleic acid encoding a polypeptide having at least 90% identity to nucleic acids represented by SEQ ID NOs: 808-845 wherein an encoded polypeptide does not contain a peptide motif of YLFQIYNKDF (SEQ ID NO: 806). In certain embodiments, provided is a nucleic acid-guided nuclease wherein the polypeptide comprises at least 90% identity with the amino acid sequence represented by SEQ ID NOs: 950, 951, 954, 955, 957, or 958. In certain embodiments, provided is a nucleic acid-guided nuclease, wherein the polypeptide comprises a polypeptide comprising at least 90% identity with the amino acid sequence represented by SEQ ID NO: 951.

TABLE 25 Exemplary ART nucleases SEQ ID NO SEQ ID NO % AA correspon correspon to ding to ding to % AA to positive Protein Amino nucleic Cpf1 control ART Reference Acid acid (<80% (<60% Name Number sequences sequence desired) desired) ART1 WP 11842511 950 808 30.838 32.54 3.1 ART2 WP 13701302 951 812 34.189 33.07 8.1 ART3 WP 07304385 952 818 35.982 36.72 3.1 ART4 WP 11873440 953 822 30.519 51.64 5.1 ART5 WP 14668378 954 826 30.114 32.31 5.1 ART6 WP 11788226 955 830 29.421 33.49 3.1 ART7 OYP43732.1 956 834 26.323 28.64 ART8 TSC78600.1 957 838 25.379 23.01 ART9 WP 09439081 958 842 26.323 28.62 6.1 ART10 WP 10450576 959 846 31.291 32.59 5.1 ART11 WP 15162288 960 850 30.654 35.55 7.1 ART12 HAW84277.1 961 854 34.872 31.33 ART13 WP 11922772 962 858 34.993 31.55 6.1 ART14 WP 11808015 963 8 62 32.551 35.33 6.1 ART15 WP 04670074 964 866 31.456 33.92 4.1 ART16 WP 11524786 965 870 31.136 34.25 1.1 ART17 WP 06249910 966 874 31.136 34.17 8.1 ART18 WP 15432695 967 878 31.113 33.28 3.1 ART19 WP 11774722 968 882 30.764 32.47 1.1 ART20 WP 11821109 969 886 30.986 32.29 1.1 ART21 WP 11816303 970 890 31.134 32.54 1.1 ART22 WP 11500608 971 894 30.044 31.55 5.1 ART23 HCS95801.1 972 898 30.37 51.64 ART24 WP 08954109 973 902 30.933 33.11 0.1 ART25 WP 12012311 974 906 29.978 48.88 5.1 ART26 WP 11787429 975 910 29.904 48.49 4.1 ART27 WP 11795143 976 904 29.421 33.03 2.1 ART28 WP 10897793 977 918 32.099 32.69 0.1 ART29 WP 11788647 978 922 29.643 33.41 6.1 ART30 WP 10107097 979 926 29.027 32.95 5.1 ART31 WP 11794931 980 930 29.198 33.18 7.1 ART32 WP 11812831 981 934 29.198 33.18 0.1 ART33 WP 13815764 982 938 27.273 29.89 9.1 ART34 WP 13576474 983 942 27.004 25 9.1 ART35 OYP46450.1 984 946 26.709 29.51

In certain embodiments, the type V-A Cas nuclease comprises an ABW nuclease or a variant thereof. See International (PCT) Publication No. WO2021/108324. Exemplary amino acid and nucleic acid sequences are shown in Table 26. In certain embodiments, the Type V-A nuclease comprises an ABW1, ABW 2, ABW3, ABW4, ABW5, ABW6, ABW7, ABW8, or ABW 9 nuclease, as shown in Table 26. In certain embodiments, the type V-A Cas protein comprises an amino acid sequence at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence designated for the individual ABW nuclease as shown in Table 26.

TABLE 26 Sequences of exemplary engineered ABW nucleases Engineered Amino Acid Engineered Sequence Nucleotide Sequence ABW1 MGHHHHHHSSGLVPRGSG ATGGGCCACCATCATCATCATCATAGCAGCGGCCTG TMAAFDKFIHQYQVSKTL GTGCCGCGCGGCAGCGGTACCATGGCGGCGTTCGAT RFALIPQGKTLENTKNNV AAGTTCATCCATCAATATCAAGTAAGCAAAACCCTC LQEDDERQKNYEKVKPIL CGTTTTGCACTTATTCCGCAGGGGAAAACCTTGGAG DRIYKVFAEESLKDCSVD AATACAAAAAATAACGTACTCCAGGAAGATGATGAG WNDLNACLDAYQKNPSAD CGTCAGAAAAATTACGAAAAAGTCAAACCTATCCTT KRQKVKAAQDALRDEIAG GATCGTATTTATAAGGTATTCGCTGAGGAAAGCCTG YFTGKQYANGKNKNAVKE AAAGATTGCAGCGTTGACTGGAATGACCTCAATGCA KEQAELYKDIFSKKIFDG TGTCTGGATGCTTACCAAAAAAATCCTAGCGCGGAT TVTNNKLPQVNLSAEETE AAGCGTCAGAAGGTGAAAGCCGCGCAGGACGCGTTG LLGCFDKFTTYFVGFYQN CGGGACGAAATTGCCGGTTATTTTACAGGGAAACAA RENVFSGEDIATAIPHRI TACGCGAACGGGAAGAACAAAAATGCCGTTAAGGAG VQDNFPKFRENCRIYQDL AAAGAGCAGGCAGAATTGTATAAGGATATCTTTAGC IKNEPALKPLLQQAAAAV AAAAAGATCTTTGATGGGACCGTAACGAACAACAAA MAQNPKGIYQPRKSLDDI TTGCCACAGGTCAACCTTTCAGCCGAAGAAACAGAG FVIPFYNHLLLQDDIDYF TTATTAGGCTGTTTTGATAAATTCACAACATATTTC NQILGGISGAAGQKKIQG GTCGGCTTTTACCAGAACCGTGAGAACGTATTTTCA LNETINLFMQQHPQEADK GGGGAGGATATTGCTACAGCTATTCCGCATCGGATC LKKKKIRHRFIPLYKQIL GTCCAGGATAATTTTCCTAAATTCCGGGAAAACTGT SDRTSFSFIPEAFSNSQE CGGATTTATCAGGACTTAATCAAAAATGAACCTGCC ALDGIETFKKSLKKNDTF CTTAAACCGCTGCTTCAGCAAGCAGCGGCCGCGGTG GALERLIQNLASLDLKYV ATGGCCCAGAATCCAAAGGGGATCTATCAACCACGT YLSNKKVNEISQALYGEW AAGAGTCTGGACGATATTTTTGTCATTCCGTTTTAT HCIQDVLKQDFSLESLIQ AACCATCTCCTCTTACAGGATGATATTGATTATTTC INPQNSSNGFLATLTDEG AATCAAATCTTAGGCGGCATTTCGGGGGCAGCCGGT KKRISQCRNVLGNPLPVK CAGAAAAAAATCCAGGGTTTAAATGAAACAATTAAT LADDQDKAQVKNQLDTLL CTGTTTATGCAACAGCACCCACAAGAAGCCGATAAG AAVHYLEWFKADPDLETD TTAAAGAAAAAAAAGATTCGTCATCGGTTTATTCCG PNFTVPFEKIWEELVPLL CTGTATAAACAAATTCTCTCTGACCGTACGTCTTTC SLYSKVRNFVTKKPYSTA TCGTTCATCCCTGAAGCTTTTTCCAATTCTCAGGAA KFKLNFANPTLADGWDIH GCGTTAGACGGCATTGAGACATTCAAAAAGTCTCTT KESDNGALLFEKGGLYYL AAGAAGAATGACACATTCGGCGCGTTGGAGCGGCTG GIMNPKDKPNFKSYQGAE ATTCAAAATCTTGCTTCCCTGGACCTGAAATACGTG PYYQKMVYRFFPDCSKTI TATTTATCGAACAAGAAGGTCAATGAGATTTCGCAG PKCSTQRKDVKKYFEDHP GCATTATACGGCGAATGGCACTGCATCCAAGACGTC QATSYQIHDSKKEKFRQD CTCAAGCAAGATTTCAGCCTTGAGAGCCTGATCCAG FFEIPREIYELNNTTYGT ATCAACCCACAAAATTCTAGCAATGGTTTCCTGGCC GKSKYKKFQTQYYQKTQD ACACTTACCGACGAAGGCAAGAAACGTATCTCCCAA KSGYQKALRKWIDFSKKF TGTCGTAACGTACTGGGGAATCCTCTTCCAGTCAAG LQTYVSTSIFDFKGLRPS CTTGCGGATGATCAAGACAAAGCGCAAGTCAAAAAC KDYQDLGEFYKDVNSRCY CAATTGGATACATTACTGGCTGCTGTACACTATCTC RVTFEKIRVQDIHEAVKN GAGTGGTTCAAGGCAGATCCAGACCTGGAAACAGAC GQLYLFQLYNKDFSPKSH CCTAACTTCACTGTTCCTTTCGAAAAGATCTGGGAG GLPNLHTLYWKAVFDPEN GAATTGGTTCCTTTACTTTCACTGTACTCTAAAGTT LKDPIVKLNGQAELFYRP CGGAATTTTGTTACAAAGAAGCCATATTCTACAGCT KSNMQIIQHKTGEEIVNK AAATTTAAACTGAACTTTGCTAACCCGACATTAGCG KLKDGTPVPDDIYREISA GATGGGTGGGATATTCACAAGGAAAGTGATAACGGC YVQGKCQGNLSPEAEKWL GCGCTCCTGTTTGAAAAGGGTGGTTTGTATTACTTG PSVTIKKAAHDITKDRRF GGTATCATGAACCCTAAAGATAAGCCTAATTTTAAA TEDKFFFHVPITLNYQSS TCCTATCAGGGTGCAGAGCCATACTATCAGAAGATG GKPTAFNSQVNDFLTEHP GTGTACCGTTTTTTTCCTGACTGTTCGAAGACCATC ETNIIGIDRGERNLIYAV CCAAAATGCAGCACCCAACGTAAGGATGTAAAAAAG VITPDGKILEQKSENVIH TACTTCGAAGACCACCCTCAAGCGACCTCATACCAG DFDYHESLSQREKQRVAA ATCCACGACTCAAAGAAAGAGAAGTTTCGTCAGGAT RQAWTAIGRIKDLKEGYL TTTTTTGAGATCCCTCGGGAGATTTACGAGCTTAAT SLVVHEIAQMMIKYQAVV AACACCACATACGGCACAGGTAAGTCTAAATATAAA VLENLNTGFKRVRGGISE AAATTCCAGACCCAGTATTACCAGAAGACTCAGGAT KAVYQQFEKMLIEKLNFL AAGTCAGGCTATCAGAAAGCACTTCGCAAATGGATT VFKDRAINQEGGVLKAYQ GACTTTTCCAAAAAGTTTCTTCAAACATACGTCAGT LTDSFTSFAKLGNQSGFL ACTTCCATTTTTGATTTCAAAGGTCTCCGTCCTTCG FYIPSAYTSKIDPGTGFV AAGGATTATCAGGACTTAGGCGAGTTCTATAAAGAC DPFIWSHVTASEENRNEF GTTAATTCGCGTTGTTACCGTGTGACGTTCGAGAAA LKGFDSLKYDAQSSAFVL ATTCGCGTACAGGACATCCACGAAGCAGTCAAAAAT HFKMKSNKQFQKNNVEGF GGGCAACTGTATCTCTTCCAATTATATAATAAGGAC MPEWDICFEKNEEKISLQ TTCTCACCTAAAAGCCATGGGTTGCCTAATCTTCAC GSKYTAGKRIIFDSKKKQ ACTCTCTATTGGAAAGCCGTGTTCGATCCTGAGAAC YMECFPQNELMKALQDVG TTGAAGGACCCTATCGTAAAACTTAATGGCCAAGCT ITWNTGNDIWQDVLKQAS GAGTTATTCTATCGGCCGAAATCCAACATGCAAATC TDTGFRHRMINLIRSVLQ ATCCAACATAAGACCGGGGAGGAGATTGTGAACAAA MRSSNGATGEDYINSPVM AAGCTGAAGGACGGCACCCCGGTTCCTGATGATATC DLDGRFFDTRAGIRDLPL TACCGCGAAATCAGTGCTTACGTCCAGGGGAAATGT DADANGAYHIALKGRMVL CAAGGCAACTTATCCCCGGAGGCAGAGAAGTGGCTC ERIRSQKNTAIKNTDWLY CCAAGTGTCACAATCAAGAAAGCCGCCCATGATATC AIQEERNGAPKRPAATKK ACAAAGGATCGTCGCTTTACCGAAGATAAGTTTTTC AGQAKKKKASGSGAGSPK TTTCATGTCCCTATTACACTGAACTATCAGAGTTCA KKRKVEDPKKKRKV GGCAAGCCGACGGCATTCAACTCGCAAGTAAACGAT (SEQ ID NO: 789) TTCTTGACCGAGCACCCTGAGACAAATATCATCGGC ATTGATCGGGGTGAACGTAACTTGATTTATGCCGTT GTAATCACTCCAGATGGCAAGATTCTCGAACAGAAA TCTTTTAACGTGATCCACGACTTTGATTATCATGAA TCCCTGTCCCAGCGGGAAAAACAGCGGGTAGCAGCG CGTCAGGCTTGGACAGCGATTGGTCGCATCAAGGAT CTCAAGGAAGGTTACCTGTCGCTTGTGGTGCACGAA ATTGCTCAAATGATGATCAAATACCAAGCAGTCGTC GTATTAGAAAACCTCAACACGGGCTTTAAGCGTGTG CGCGGTGGTATCAGTGAGAAGGCCGTCTACCAACAG TTCGAAAAAATGTTGATTGAAAAATTGAACTTCCTG GTATTTAAAGATCGGGCAATCAATCAGGAAGGCGGG GTTCTCAAAGCTTACCAGCTGACAGACTCGTTTACG TCTTTTGCAAAGTTAGGTAACCAGTCCGGTTTCCTG TTCTACATCCCGTCCGCCTACACCAGCAAAATCGAC CCTGGTACGGGCTTCGTCGATCCTTTTATCTGGTCT CACGTGACCGCTTCTGAGGAAAATCGGAATGAATTT TTAAAGGGCTTTGATAGCTTGAAATATGACGCCCAA TCATCCGCCTTTGTACTGCATTTCAAGATGAAATCC AATAAGCAATTTCAGAAGAACAATGTTGAAGGTTTC ATGCCGGAATGGGATATCTGCTTCGAGAAAAACGAG GAAAAGATTTCCTTGCAGGGTAGTAAGTATACAGCC GGTAAACGCATTATTTTCGACTCCAAAAAGAAGCAA TACATGGAGTGCTTCCCGCAGAATGAGCTCATGAAA GCACTGCAGGACGTAGGCATCACCTGGAACACGGGC AACGATATCTGGCAGGATGTCCTTAAACAAGCGAGC ACAGATACAGGGTTTCGTCACCGGATGATCAACCTG ATCCGTTCAGTGCTCCAGATGCGGTCCAGTAATGGT GCGACCGGGGAGGATTACATCAATTCACCTGTGATG GATCTGGACGGCCGTTTTTTCGACACTCGGGCGGGG ATTCGTGATCTGCCATTGGATGCCGACGCCAACGGC GCATACCACATCGCTTTAAAAGGGCGTATGGTACTC GAACGCATTCGCTCCCAAAAGAATACCGCGATTAAG AACACTGACTGGTTATACGCAATCCAAGAGGAACGT AACGGCGCGCCAAAAAGGCCGGCGGCCACGAAAAAG GCCGGCCAGGCAAAAAAGAAAAAGGCTAGCGGCAGC GGCGCCGGATCCCCAAAGAAGAAAAGGAAGGTTGAA GACCCCAAGAAAAAGAGGAAGGTGTGATAA (SEQ ID NO: 790) ABW2 MGHHHHHHSSGLVPRGSG ATGGGCCACCATCATCATCATCATAGCAGCGGCCTG TMKEFTNQYSLTKTLRFE GTGCCGCGCGGCAGCGGTACCATGAAGGAGTTTACC LRPVGETAEKIEDFKSGG AACCAATATTCCTTAACCAAGACCCTGCGGTTCGAG LKQTVEKDRERTEAYKQL TTGCGGCCAGTCGGCGAAACAGCAGAAAAGATCGAA KEVIDSYHRDFIEQAFAR GATTTTAAATCGGGCGGGCTCAAGCAAACAGTGGAA QQTLSEEDFKQTYQLYKE AAGGATCGTGAGCGTACAGAAGCGTATAAGCAGTTG AQKEKDGETLTKQYEHLR AAAGAGGTTATTGACTCCTATCATCGTGACTTCATT KKIAAMFSKATKEWAVMG GAGCAAGCTTTTGCGCGCCAGCAGACGCTGTCCGAG ENNELIGKNKESKLYQWL GAGGATTTTAAACAAACATATCAACTGTACAAAGAG EKNYRAGRIEKEEFDHNA GCCCAGAAAGAGAAGGATGGGGAAACATTAACAAAG GLIEYFEKFSTYFVGFDK CAGTACGAGCATTTACGGAAGAAAATCGCAGCTATG NRANMYSKEAKATAISFR TTCAGCAAGGCTACGAAGGAATGGGCCGTTATGGGG TINENMVKHFDNCQRLEK GAGAATAACGAATTGATCGGGAAAAACAAAGAGTCA IKSKYPDLAEELKDFEEF AAGTTGTATCAGTGGCTGGAGAAGAACTACCGCGCA FKPSYFINCMNQSGIDYY GGTCGCATCGAAAAAGAGGAATTCGACCATAATGCG NISAIGGKDEKDQKANMK GGCTTAATCGAATACTTCGAGAAATTTTCCACATAT INLFTQKNHLKGSDKPPF TTCGTAGGTTTTGACAAAAATCGTGCGAATATGTAT FAKLYKQILSDREKSVVI TCAAAGGAGGCAAAGGCGACCGCAATTTCCTTCCGG DEFEKDSELTEALKNVFS ACGATTAATGAGAACATGGTCAAGCATTTCGATAAT KDGLINEEFFTKLKSALE TGCCAGCGGCTCGAGAAGATTAAATCTAAATATCCT NEMLPEYQGQLYIRNAFL GATTTGGCCGAGGAGCTGAAGGATTTTGAGGAGTTT TKISANIWGSGSWGIIKD TTTAAACCTAGCTATTTCATTAATTGTATGAATCAA AVTQAAENNFTRKSDKEK TCGGGTATCGACTACTACAATATCAGCGCGATCGGC YAKKDFYSIAELQQAIDE GGTAAGGATGAAAAGGATCAGAAAGCGAATATGAAG YIPTLENGVQNASLIEYF ATCAACCTTTTCACGCAAAAAAATCATTTAAAGGGC RKMNYKPRGSEEDAGLIE AGTGATAAACCACCATTTTTTGCTAAGCTCTACAAG EINNNLRQAGIVLNQAEL CAAATTTTGAGTGACCGGGAGAAGTCCGTGGTAATC GSGKQREENIEKIKNLLD GACGAGTTCGAAAAGGACAGCGAATTGACAGAGGCA SVLNLERFLKPLYLEKEK CTCAAAAACGTGTTTTCCAAGGACGGTTTGATCAAT MRPKAANLNKDFCESFDP GAGGAGTTTTTTACAAAGTTAAAAAGTGCATTAGAA LYEKLKTFFKLYNKVRNY AATTTTATGTTGCCTGAATATCAAGGTCAACTCTAC ATKKPYSKDKFKINFDTA ATCCGTAACGCTTTCCTTACGAAGATCAGCGCAAAC TLLYGWSLDKETANLSVI ATTTGGGGCTCTGGTTCTTGGGGCATCATCAAGGAC FRKREKFYLGIINRYNSQ GCAGTTACCCAGGCTGCGGAAAACAATTTCACGCGT IFNYKIAGSESEKGLERK AAGTCTGACAAGGAAAAGTATGCCAAGAAAGACTTC RSLQQKVLAEEGEDYFEK TATTCCATTGCTGAACTCCAGCAGGCTATTGATGAA MVYHLLLGASKTIPKCST TACATTCCTACTCTGGAGAACGGGGTTCAAAACGCA QLKEVKAHFQKSSEDYII TCACTCATCGAGTACTTTCGCAAAATGAATTACAAA QSKSFAKSLTLTKEIFDL CCACGCGGTTCTGAAGAAGACGCAGGCTTGATCGAA NNLRYNTETGEISSELSD GAAATTAATAACAACCTGCGTCAGGCTGGGATCGTC TYPKKFQKGYLTQTGDVS CTGAATCAAGCCGAGCTGGGGTCTGGTAAGCAGCGG GYKTALHKWIDFCKEFLR GAAGAGAATATTGAAAAAATTAAGAACTTATTAGAT CYRNTEIFTFHFKDTKEY TCGGTTTTGAATCTCGAACGTTTCTTAAAGCCACTT ESLDEFLKEVDSSGYEIS TACTTGGAGAAAGAGAAAATGCGTCCAAAAGCTGCT FDKIKASYINEKVNAGEL AACCTGAATAAGGATTTTTGTGAGTCATTTGATCCA YLFEIYNKDFSEYSKGKP CTTTACGAGAAACTGAAAACGTTTTTCAAGCTCTAC NLHTIYWKSLFETQNLLD AATAAAGTACGTAACTACGCAACAAAGAAACCATAC KTAKLNGKAEIFFRPRSI TCAAAGGACAAATTTAAGATCAATTTTGATACCGCT KHNDKIIHRAGETLKNKN ACGTTATTATATGGGTGGAGTTTGGATAAGGAAACC PLNEKPSSRFDYDITKDR GCGAATCTCAGCGTCATTTTCCGTAAACGCGAAAAA RFTKDKFFLHCPITLNFK TTCTATTTGGGTATCATCAACCGGTACAATAGCCAG QDKPVRFNEQVNLYLKDN ATTTTCAATTATAAGATTGCGGGCAGTGAGAGCGAG PDVNIIGIDRGERHLLYY AAAGGGTTAGAGCGTAAGCGGTCGCTGCAGCAAAAG TLINQNGEILQQGSLNRI GTGCTTGCAGAGGAGGGTGAAGATTATTTTGAGAAA GEEESRPTDYHRLLDERE ATGGTATACCACCTGCTGCTTGGCGCGTCGAAAACT KQRQQARETWKAVEGIKD ATTCCGAAATGCTCGACACAGTTGAAAGAAGTAAAA LKAGYLSRVVHKLAGLMV GCACACTTTCAAAAGTCATCAGAAGATTATATTATC QNNAIVVLEDLNKGFKRG CAATCCAAATCATTTGCAAAGTCATTAACATTAACA RFAVEKQVYQNFEKALIQ AAAGAGATCTTTGACTTAAATAATCTGCGGTATAAC KLNYLVFKEVNSKDAPGH ACAGAAACGGGCGAAATTAGTTCCGAGCTTTCTGAT YLKAYQLTAPFISFEKLG ACATATCCGAAGAAGTTCCAGAAGGGGTATCTCACA TQSGFLFYVRAWNTSKID CAAACAGGCGACGTTTCGGGTTACAAAACTGCTCTG PATGFTDQIKPKYKNQKQ CATAAGTGGATTGATTTCTGCAAAGAGTTCTTGCGT AKDFMSSFDSVRYNRKEN TGCTATCGTAATACGGAGATCTTCACGTTCCATTTC YFEFEADFEKLAQKPKGR AAGGACACGAAGGAGTACGAGTCGTTAGATGAGTTC TRWTICSYGQERYSYSPK TTGAAAGAAGTGGATAGTTCAGGTTATGAGATTTCA ERKFVKHNVTQNLAELFN TTCGATAAGATCAAAGCCTCTTATATCAACGAGAAG SEGISFDSGQCFKDEILK GTTAATGCAGGCGAGCTGTACTTGTTCGAGATCTAT VEDASFFKSIIFNLRLLL AATAAAGATTTCTCCGAGTATTCCAAAGGTAAGCCA KLRHTCKNAEIERDFIIS AATCTGCATACCATTTATTGGAAAAGTCTCTTCGAG PVKGNNSSFFDSRIAEQE ACTCAAAACTTGCTGGATAAAACAGCGAAACTCAAC NITSIPQNADANGAYNIA GGCAAGGCAGAGATCTTCTTCCGGCCACGTTCGATC LKGLMNLHNISKDGKAKL AAACACAACGACAAAATCATCCACCGTGCGGGCGAA IKDEDWIEFVQKRKFAAA ACACTTAAGAATAAAAACCCGCTCAATGAAAAGCCT KRPAATKKAGQAKKKKAS AGTTCGCGTTTCGATTACGATATTACGAAAGATCGT GSGAGSPKKKRKVEDPKK CGTTTTACGAAAGACAAATTTTTTTTACACTGCCCT KRKV (SEQ ID NO: ATTACGTTAAACTTTAAGCAGGACAAGCCTGTTCGC 16) TTTAATGAACAAGTCAACTTATACTTAAAAGACAAT CCAGACGTGAATATTATCGGTATCGATCGTGGTGAG CGTCACTTGCTTTATTACACTTTGATCAATCAGAAT GGTGAGATCTTACAGCAGGGTTCACTTAATCGCATT GGTGAGGAAGAATCTCGGCCTACGGACTACCATCGG TTACTCGATGAGCGTGAAAAGCAGCGTCAACAAGCA CGGGAGACGTGGAAAGCAGTAGAAGGGATTAAGGAC TTAAAAGCTGGGTATCTTTCACGGGTTGTACATAAA CTTGCAGGTTTAATGGTACAAAACAACGCAATTGTC GTTCTGGAAGATCTTAACAAGGGTTTTAAGCGCGGT CGTTTCGCTGTTGAGAAACAGGTGTACCAGAACTTC GAAAAAGCACTTATTCAAAAGCTTAACTATTTAGTG TTCAAGGAGGTCAACTCTAAAGACGCCCCTGGCCAC TATTTGAAGGCATATCAGCTTACGGCCCCTTTCATC TCGTTCGAAAAATTGGGTACTCAGAGCGGTTTCCTT TTTTATGTGCGCGCATGGAATACCTCGAAGATCGAC CCGGCGACGGGTTTTACCGACCAAATCAAACCAAAG TATAAAAACCAAAAACAAGCTAAAGACTTCATGTCA AGCTTCGACTCTGTCCGGTACAACCGCAAGGAAAAT TATTTTGAATTCGAGGCGGACTTTGAAAAACTGGCA CAGAAACCTAAGGGGCGCACCCGCTGGACGATTTGT TCCTATGGCCAGGAACGGTACTCTTACTCCCCAAAA GAACGGAAGTTTGTAAAGCACAACGTTACACAAAAT CTTGCTGAGCTTTTTAATTCAGAGGGTATCTCGTTC GACTCCGGGCAGTGTTTCAAGGATGAGATCCTGAAG GTCGAGGATGCCAGTTTCTTTAAGTCTATTATTTTC AATCTTCGCCTCCTTCTCAAGCTTCGTCACACTTGC AAGAACGCCGAGATCGAACGTGATTTCATCATTTCT CCTGTCAAGGGGAACAATTCGTCCTTTTTTGACTCC CGTATTGCCGAACAAGAAAATATCACCAGCATTCCA CAGAATGCTGATGCAAACGGTGCATACAACATCGCG CTGAAGGGCCTGATGAACCTCCATAATATCTCTAAG GACGGCAAGGCAAAATTAATTAAGGATGAAGATTGG ATCGAATTTGTCCAAAAACGCAAGTTCGCGGCCGCA AAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCA AAAAAGAAAAAGGCTAGCGGCAGCGGCGCCGGATCC CCAAAGAAGAAAAGGAAGGTTGAAGACCCCAAGAAA AAGAGGAAGGTGTGATAA (SEQ ID NO: 17) ABW3 MGHHHHHHSSGLVPRGSL ATGGGCCACCATCATCATCATCATAGCAGCGGCCTG QMKTLSDFTNLFPLSKTL GTGCCGCGCGGCAGCCTGCAGATGAAGACCTTGTCT RFKLIPIGNTLKNIEASG GATTTTACCAATCTGTTCCCTTTATCTAAGACTCTC ILDEDRHRAESYVKVKAI CGTTTCAAGCTGATTCCAATCGGCAACACGCTCAAG IDEYHKAFIDRVLSDTCL AACATTGAAGCTAGTGGCATCCTTGACGAGGATCGC QTESIGKHNSLEEFFFYY CACCGCGCGGAGTCCTATGTCAAGGTCAAGGCCATC QIGAKSEQQKKTFKKIQD ATCGACGAATATCATAAAGCTTTCATCGATCGGGTC ALRKQIADSLTKDKHFSR CTGTCGGATACTTGCCTCCAGACGGAATCTATCGGC IDKKELIQEDLIQFVRDG AAACACAACAGTCTCGAGGAATTCTTTTTCTACTAC EDAAEKTSLISEFQNFTV CAAATTGGTGCAAAAAGTGAACAGCAGAAAAAGACG YFTGFHENRQNMYSPDEK TTTAAAAAGATTCAAGACGCCTTGCGCAAACAAATC STAIAYRLINENLPKFVD GCAGATAGCCTCACCAAGGACAAACATTTTTCACGG NMKVFDRIAASELASCFD ATTGATAAAAAAGAATTGATCCAAGAGGATTTGATC ELYHNFEEYLQVERLHDI CAGTTTGTGCGCGATGGGGAGGATGCCGCTGAAAAG FSLDYFNLLLTQKHIDVY ACGTCTCTGATTTCCGAATTTCAAAATTTCACAGTT NALIGGKATETGEKIKGL TATTTTACCGGGTTTCATGAGAATCGCCAGAACATG NEYINLYNQRHKQEKLPK TACAGTCCGGACGAGAAGTCCACGGCCATCGCATAT FKMLFKQILTDREAISWL CGCTTAATTAACGAGAATCTCCCAAAATTCGTAGAC PRQFDDNSQLLSAIEQCY AACATGAAAGTTTTTGACCGTATCGCGGCGTCCGAA NHLSTYTLKDGSLKYLLE TTGGCATCGTGTTTCGACGAATTATACCACAACTTC NLHTYDTEKIFIRNDSLL GAGGAATACCTCCAAGTGGAGCGGTTACATGATATC TEISQRHYGSWSILPEAI TTTAGTTTGGACTATTTCAATCTGCTTCTCACGCAG KRHLERANPQKRRETYEA AAACATATCGACGTCTATAATGCTCTGATCGGTGGG YQSRIEKAFKAYPGFSIA AAGGCAACCGAAACCGGGGAAAAGATCAAGGGCTTA FLNGCLTETGKESPSIES AATGAATACATCAATCTCTACAATCAACGTCACAAG YFESLGAVETETSQQENW CAGGAAAAACTGCCAAAATTCAAGATGTTATTCAAG FARIANAYTDFREMQNRL CAAATTCTTACCGACCGTGAGGCAATCAGCTGGTTG HATDVPLAQDAEAVARIK CCACGCCAATTTGACGATAATAGTCAGTTACTCTCA KLLDALKGLQLFIKPLLD GCCATTGAACAGTGTTATAACCACCTTTCGACCTAC TGEEAEKDERFYGDFTEF ACACTCAAGGATGGGTCACTCAAATACCTGTTAGAA WNELDTITPLYNMVRNYL AACCTGCATACATACGATACTGAAAAGATCTTCATC TRKPYSEEKIKLNFQNPT CGCAATGACAGTTTACTTACGGAAATCTCCCAACGG LLNGWDLNKEVDNTSVIL CATTACGGTTCGTGGTCGATTTTACCAGAAGCTATC RRNGRYYLAIMHRNHRRV AAACGTCATCTCGAGCGCGCGAACCCGCAAAAACGG FSQYPGTERGDCYEKMEY CGCGAAACATACGAGGCCTATCAATCTCGCATTGAG KLLPGANKMLPKVFFSKS AAGGCCTTTAAGGCATATCCGGGGTTTTCAATTGCT RIDEFNPSEELLARYQQG TTCCTCAATGGGTGTTTAACAGAGACAGGTAAGGAG THKKGENFNLHDCHALID TCGCCATCCATCGAAAGCTATTTTGAAAGTCTGGGT FFKDSIEKHEEWRNFHFK GCTGTCGAAACAGAGACCTCTCAGCAGGAAAACTGG FSDTSSYTDMSGFYREIE TTTGCCCGCATCGCAAACGCTTATACGGACTTTCGT TQGYKLSFVPVACEYIDE GAAATGCAAAATCGGCTGCACGCCACTGACGTGCCG LVRDGKIFLFQIYNKDFS TTGGCTCAAGACGCTGAGGCAGTGGCCCGGATCAAG TYSKGKPNMHTLYWEMLF AAGCTGTTAGATGCACTGAAAGGCCTGCAATTATTC DERNLMNVVYKLNGQAEI ATTAAGCCTCTTTTGGATACTGGCGAAGAAGCAGAG FFRKASLSARHPEHPAGL AAAGATGAACGGTTCTATGGGGACTTTACCGAATTC PIKKKQAPTEESCFPYDL TGGAACGAGTTAGACACTATCACGCCATTGTACAAT IKNKRYTVDQFQFHVPIT ATGGTACGGAACTATCTCACGCGTAAGCCTTATAGT INFKATGTSNINPSVTDY GAAGAAAAAATCAAGCTCAATTTCCAGAATCCGACA IRTADDLHIIGIDRGERH TTACTGAACGGTTGGGATTTGAACAAAGAGGTAGAT LLYLVVIDSQGRICEQFS AATACATCTGTCATCCTCCGCCGGAATGGTCGTTAT LNEIVTQYQGHQYRTDYH TATCTTGCCATCATGCACCGCAACCACCGGCGTGTA ALLQKKEDERQKARQSWQ TTTTCACAGTATCCAGGCACAGAACGTGGCGATTGT SIENIKELKEGYLSQVVH TATGAGAAAATGGAATATAAACTGCTTCCGGGCGCC KVSELMIKYKAIVVLEDL AACAAGATGCTCCCAAAAGTCTTCTTCTCTAAATCA NAGFKRSRQKVEKQVYQK CGCATCGATGAATTCAACCCTAGCGAAGAATTATTA FEKMLIDKLNYLVFKTAE GCACGTTACCAGCAAGGTACCCACAAGAAGGGTGAG ADQPGGLLHAYQLTNKFE AATTTTAATTTACACGACTGCCATGCCTTGATTGAT SFKKMGKQSGFLFYIPAW TTTTTTAAAGACTCTATTGAGAAACATGAAGAATGG NTSKIDPTTGFVNLFDTR CGTAACTTTCATTTTAAATTTAGTGATACGTCCAGT YENVDKSRAFFGKFDSIR TACACCGACATGAGCGGCTTTTATCGTGAAATCGAA YRADKGTFEWTFDYNNFH ACACAGGGTTACAAGTTGTCATTTGTGCCAGTGGCG KKAEGTRSSWCLSSHGNR TGTGAATACATCGATGAGTTGGTACGTGATGGCAAA VRTFRNPAKNNQWDNEEI ATCTTTTTGTTCCAGATCTATAATAAGGACTTTTCG DLTQAFRDLFEAWGIEIT ACCTACTCTAAGGGCAAGCCAAATATGCACACTCTT SNLKEAICNQSEKKFFSE TATTGGGAAATGCTTTTCGACGAGCGGAACCTGATG LFELFKLMIQLRNSVTGT AACGTGGTGTATAAACTCAATGGCCAAGCAGAGATC NIDYMVSPVENHYGTFFD TTTTTTCGTAAAGCATCACTGAGCGCACGTCACCCT SRTCDSSLPANADANGAY GAGCACCCGGCAGGGTTGCCAATTAAAAAAAAACAG NIARKGLMLARRIQATPE GCCCCGACGGAAGAATCTTGTTTCCCATATGATCTC NDPISLTLSNKEWLRFAQ ATTAAGAATAAGCGGTATACAGTTGACCAGTTTCAG GLDETTTYEAAAKRPAAT TTTCACGTGCCAATTACTATTAATTTTAAAGCAACT KKAGQAKKKKASGSGAGS GGGACTTCAAATATCAACCCGTCGGTCACTGATTAT PKKKRKVEDPKKKRKV ATTCGTACGGCCGATGACCTCCATATCATTGGCATT (SEQ ID NO: 29) GATCGCGGTGAGCGCCATTTACTTTATTTAGTGGTG ATTGACTCACAAGGGCGCATCTGTGAACAGTTTTCC TTAAACGAGATCGTAACGCAATACCAAGGTCACCAG TACCGTACAGATTATCATGCTCTCTTGCAGAAAAAA GAGGATGAACGGCAAAAAGCTCGCCAGTCTTGGCAA TCGATCGAAAACATCAAGGAATTAAAAGAGGGGTAT CTGAGCCAAGTAGTGCACAAGGTTTCTGAACTGATG ATCAAATATAAAGCAATTGTGGTGTTGGAAGATTTA AATGCTGGGTTCAAGCGGAGTCGGCAGAAGGTTGAA AAGCAAGTGTATCAAAAATTTGAGAAGATGCTGATC GACAAACTTAACTATCTTGTGTTCAAGACCGCAGAA GCTGACCAACCTGGCGGCCTCCTGCACGCATACCAA TTAACAAATAAATTTGAGTCATTCAAGAAAATGGGG AAGCAAAGTGGCTTCCTCTTCTACATTCCTGCATGG AACACGTCTAAAATCGACCCGACCACGGGCTTTGTC AACCTTTTTGATACCCGGTATGAGAACGTAGACAAA TCCCGTGCCTTCTTCGGCAAATTCGATAGCATCCGC TACCGTGCGGACAAGGGCACGTTCGAGTGGACGTTC GATTATAATAACTTTCACAAAAAGGCCGAAGGTACG CGGTCGAGCTGGTGTTTGTCTTCTCATGGTAACCGG GTCCGTACTTTCCGCAATCCTGCGAAAAACAACCAA TGGGACAACGAAGAGATCGACTTAACACAAGCGTTC CGCGATCTGTTTGAAGCTTGGGGGATCGAGATCACT TCGAACTTAAAAGAGGCCATTTGCAACCAGTCTGAG AAGAAATTCTTTTCTGAGCTTTTCGAACTGTTCAAA CTTATGATCCAGCTGCGGAACTCAGTGACAGGCACG AATATCGACTATATGGTGAGCCCAGTCGAGAATCAC TACGGCACGTTCTTCGATTCGCGCACATGCGATTCG TCTCTGCCGGCTAACGCTGACGCTAATGGTGCTTAT AATATTGCCCGTAAGGGGTTAATGCTGGCTCGCCGC ATTCAGGCTACCCCTGAGAATGATCCGATCTCCTTA ACATTGAGCAACAAAGAGTGGTTACGCTTTGCACAG GGGCTCGATGAGACAACAACCTACGAGGCGGCCGCA AAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCA AAAAAGAAAAAGGCTAGCGGCAGCGGCGCCGGATCC CCAAAGAAGAAAAGGAAGGTTGAAGACCCCAAGAAA AAGAGGAAGGTGTGATAA (SEQ ID NO: 30) ABW4 MGHHHHHHSSGLVPRGSG ATGGGCCACCATCATCATCATCATAGCAGCGGCCTG TMKNMESFINLYPVSKTL GTGCCGCGCGGCAGCGGTACCATGAAGAACATGGAG RFELKPIGKTLETFSRWI TCTTTTATTAATTTATATCCGGTTTCGAAAACTTTA EELKEKEAIELKETGNLL CGTTTTGAGTTAAAGCCTATTGGCAAAACACTCGAA AQDEHRAESYKKVKKILD ACTTTCTCCCGCTGGATCGAAGAGTTGAAAGAGAAA EYHKWFITESLQNTKLNG GAGGCTATTGAGCTGAAAGAAACTGGCAACCTGTTG LDVFYHNYMLPKKEDHEK GCGCAGGATGAGCATCGGGCCGAGTCTTATAAGAAG KAFASCQDNLRKQIVNAF GTCAAAAAAATTCTTGACGAATATCATAAATGGTTC RQETGLENKLSGKELFKD ATCACTGAAAGCCTCCAGAACACAAAGTTAAATGGG SKEEVALLKAIVPYFDNK TTGGACGTTTTTTATCATAACTATATGCTCCCGAAG TLENIGVKSNEGALLLIE AAAGAGGACCATGAGAAGAAAGCTTTTGCTTCGTGT EFKDFTTYFGGFHENRKN CAAGATAATCTCCGTAAGCAAATTGTAAACGCGTTT MYSDEAKSTAVAFRLIHE CGTCAAGAAACCGGTTTATTTAACAAACTGTCAGGC NLPRFIDNKKVFEEKIMN AAAGAACTGTTTAAAGATTCGAAGGAAGAGGTTGCA SELKDKFPEILKELEQIL CTGTTGAAAGCCATTGTACCGTATTTCGATAACAAG QVNEIEEMFQLDYFNDTL ACTCTGGAAAACATTGGTGTTAAGAGTAATGAAGGG IQNGIDVYNHLIGGYAEE GCTCTCCTTTTAATTGAAGAGTTCAAGGATTTTACC GKKKIQGLNEHINLYNQI ACGTATTTCGGTGGCTTCCATGAGAATCGCAAAAAT QKEKNKRIPRLKPLYKQI ATGTATAGCGACGAAGCAAAATCAACAGCGGTTGCC LSDRETASFVIEAFENDG TTTCGTCTTATTCACGAAAATTTGCCGCGCTTCATT ELLESLEKSYRLLQQEVF GACAATAAGAAGGTCTTCGAAGAGAAAATCATGAAT TPEGKEGLANLLAAIAES AGTGAATTAAAGGATAAATTTCCAGAGATTTTGAAG ETHKIFLKNDLGLTEISQ GAGCTGGAACAGATTCTGCAAGTCAACGAGATTGAA QIYESWSLIEEAWNKQYD GAGATGTTTCAGCTCGACTATTTTAACGACACATTG NKQKKVTETETYVDNRKK ATCCAGAATGGCATCGATGTCTATAACCATTTGATC AFKSIKSFSIAEVEEWVK GGCGGCTACGCCGAGGAAGGCAAGAAAAAAATTCAA ALGNEKHKGKSVATYFKS GGGCTTAACGAGCATATTAACCTCTATAACCAGATC LGKTDEKVSLIEQVENNY CAGAAGGAGAAGAATAAGCGTATCCCGCGGCTGAAA NIIKDLLNTPYPPSKDLA CCACTCTATAAGCAAATTTTGAGTGATCGCGAAACC QQKDDVEKIKNYLDSLKA GCCTCATTTGTTATCGAGGCGTTTGAGAACGATGGC LQRFIKPLLGSGEESDKD GAGTTATTAGAATCATTGGAGAAGTCATATCGCTTA AHFYGEFTAFWDVLDKVT CTGCAGCAGGAGGTCTTTACGCCTGAAGGTAAAGAA PLYNKVRNYMTKKPYSTE GGTCTGGCGAATTTACTCGCAGCAATCGCTGAAAGC KFKLNFENSYFLNGWAQD GAGACACACAAGATCTTTCTGAAGAACGACTTGGGT YETKAGLIFLKDGNYFLA CTCACCGAGATCTCTCAACAAATTTATGAATCATGG INNKKLDEKEKKQLKTNY TCGCTGATTGAAGAGGCATGGAATAAACAATATGAC EKNPAKRIILDFQKPDNK AACAAACAGAAGAAAGTTACGGAGACAGAGACATAT NIPRLFIRSKGDNFAPAV GTGGACAATCGGAAAAAGGCTTTCAAGTCCATCAAG EKYNLPISDVIDIYDEGK AGCTTTAGCATCGCAGAGGTTGAGGAATGGGTGAAA FKTEYRKINEPEYLKSLH GCACTTGGGAATGAGAAACACAAGGGCAAAAGCGTG KLIDYFKLGFSKHESYKH GCAACCTATTTTAAAAGTCTCGGGAAGACTGACGAA YSFSWKKTHEYENIAQFY AAAGTTAGCCTTATTGAACAGGTAGAGAACAATTAT HDVEVSCYQVLDENINWD AATATCATCAAGGACCTTTTGAACACACCGTATCCT SLMEYVEQNKLYLFQIYN CCTTCGAAGGACTTGGCCCAGCAAAAAGATGACGTT KDFSPNSKGTPNMHTLYW GAAAAAATCAAAAATTATTTGGACTCTCTGAAGGCC KMLFNPDNLKDVVYKLNG CTCCAGCGGTTCATTAAGCCATTGTTGGGTAGCGGG QAEVFYRKASIKKENKIV GAGGAATCCGATAAAGATGCGCACTTTTATGGTGAG HKANDPIDNKNELNKKKQ TTTACCGCTTTCTGGGATGTGCTCGACAAAGTAACC NTFEYDIVKDKRYTVDKF CCACTCTACAATAAAGTCCGCAACTATATGACTAAG QFHVPITLNFKAEGLNNL AAACCTTATAGCACAGAGAAATTTAAGCTGAATTTT NSKVNEYIKECDDLHIIG GAAAATAGTTACTTTTTGAATGGTTGGGCACAGGAC IDRGERHLLYLSLIDMKG TACGAGACAAAAGCGGGGCTTATCTTCTTGAAGGAC NIVKQFSLNEIVNEHKGN GGCAATTACTTCCTTGCCATCAATAATAAGAAATTA TYRTNYHNLLDKREKERE GATGAAAAGGAGAAAAAACAGCTCAAGACTAATTAT KERESWKTIETIKELKEG GAGAAGAATCCTGCGAAGCGTATCATCTTAGACTTT YISQVVHKITQLMIEYNA CAGAAGCCAGACAATAAGAACATTCCTCGCTTGTTC IVVLEDLNFGFKRGRFKV ATTCGCAGTAAAGGCGACAATTTCGCTCCTGCAGTA EKQVYQKFEKMLIDKLNY GAAAAGTATAATCTTCCGATCTCTGACGTTATTGAC LVDKKKEANESGGTLKAY ATCTATGACGAGGGGAAGTTTAAGACTGAGTATCGC QLTDSYADFMKYKKKQCG AAAATTAACGAGCCGGAATATCTCAAATCTCTCCAT FLFYVPAWNTSKIDPTTG AAGCTGATTGACTACTTCAAACTTGGGTTCTCCAAG FVNLFDTHYVNVSKAQEF CATGAATCCTACAAGCATTATTCTTTTTCATGGAAG FSKFKSIRYNAANNYFEF AAAACACATGAGTATGAGAACATCGCCCAGTTTTAC EVTDYFSFSGKAEGTKQN CACGACGTGGAGGTCTCTTGCTATCAGGTGCTCGAC WIICTHGTRIINFRNPEK GAAAATATTAACTGGGATTCCCTCATGGAGTATGTA NSQWDNKEVVITDEFKKL GAACAGAACAAATTGTACTTGTTCCAGATTTATAAC FEKHGIDYKNSSDLKGQI AAAGACTTCTCCCCAAACTCGAAAGGCACTCCGAAT ASQSEKAFFHNEKKDTKD ATGCACACTTTGTACTGGAAGATGTTGTTTAATCCG PDGLLQLFKLALQMRNSF GATAATCTTAAGGACGTGGTCTATAAGCTGAACGGT IKSEEDYLVSPVMNDEGE CAGGCTGAAGTATTCTACCGGAAGGCGAGTATTAAG FFDSRKAQPNQPENADAN AAAGAAAACAAGATTGTCCACAAGGCGAACGACCCT GAYNIAMKGKWVVKQIRE ATTGACAATAAAAACGAGTTGAATAAGAAAAAGCAA SEDLDKLKLAISNKEWLN AATACATTTGAATACGACATCGTCAAAGATAAACGG FAQRSAAAKRPAATKKAG TATACAGTGGATAAGTTTCAATTCCATGTTCCTATC QAKKKKASGSGAGSPKKK ACGCTCAACTTTAAAGCTGAAGGCCTGAATAACTTG RKVEDPKKKRKV (SEQ AATAGCAAAGTTAACGAATACATCAAAGAGTGTGAC ID NO: 42) GACCTTCACATTATTGGCATCGACCGGGGTGAACGG CACCTCTTGTATCTGAGCCTCATCGATATGAAAGGT AACATTGTAAAGCAATTTAGTCTTAACGAGATCGTT AATGAGCACAAGGGGAACACGTACCGCACGAACTAT CATAACCTCTTGGACAAACGTGAAAAGGAACGTGAA AAAGAGCGCGAGTCATGGAAAACCATTGAGACCATC AAAGAGCTGAAAGAAGGCTATATTAGTCAAGTAGTA CATAAAATCACTCAGTTAATGATCGAATATAATGCG ATCGTTGTACTCGAAGACCTGAATTTCGGCTTCAAA CGCGGCCGGTTCAAGGTGGAGAAGCAAGTGTATCAA AAATTTGAGAAGATGTTAATTGATAAACTGAACTAC TTGGTCGATAAGAAGAAGGAAGCCAATGAGAGTGGC GGGACACTCAAAGCCTACCAGCTTACCGATAGTTAC GCTGACTTCATGAAGTACAAGAAAAAGCAATGCGGC TTCCTGTTTTATGTCCCGGCCTGGAACACTTCCAAA ATCGATCCTACTACTGGGTTCGTGAATCTGTTTGAC ACACATTATGTCAATGTTAGTAAGGCCCAGGAATTT TTCTCGAAATTCAAGTCAATTCGCTACAACGCGGCC AACAACTATTTCGAGTTTGAAGTAACAGATTATTTT TCCTTCAGTGGTAAAGCTGAGGGCACCAAGCAGAAT TGGATCATTTGCACCCATGGCACCCGCATTATCAAT TTTCGTAACCCGGAAAAAAATTCGCAGTGGGATAAT AAGGAAGTAGTGATCACAGATGAATTCAAGAAACTG TTTGAGAAGCACGGCATTGACTACAAAAATAGTTCC GACCTCAAGGGGCAGATCGCCTCTCAATCGGAGAAG GCGTTTTTTCATAACGAAAAAAAAGATACAAAGGAC CCAGATGGCCTTCTGCAGCTTTTTAAACTGGCGCTG CAGATGCGGAACTCTTTCATTAAGAGCGAAGAGGAC TACTTAGTATCTCCTGTGATGAACGACGAAGGTGAA TTCTTTGACTCGCGCAAAGCCCAGCCTAATCAGCCA GAGAACGCTGATGCTAATGGGGCGTACAATATTGCA ATGAAAGGGAAATGGGTTGTTAAGCAAATCCGCGAA TCGGAGGACCTCGACAAGCTGAAACTGGCAATCTCA AATAAAGAATGGTTGAACTTCGCCCAGCGCTCCGCG GCCGCAAAAAGGCCGGCGGCCACGAAAAAGGCCGGC CAGGCAAAAAAGAAAAAGGCTAGCGGCAGCGGCGCC GGATCCCCAAAGAAGAAAAGGAAGGTTGAAGACCCC AAGAAAAAGAGGAAGGTGTGATAA (SEQ ID NO: 43) ABW5 MGHHHHHHSSGLVPRGSG ATGGGCCACCATCATCATCATCATAGCAGCGGCCTG TMKNILEQFVGLYPLSKT GTGCCGCGCGGCAGCGGTACCATGAAGAACATCTTA LRFELKPLGKTLEHIEKK GAGCAGTTTGTCGGCTTATATCCGTTGTCTAAAACA GLIAQDEQRAEEYKLVKD CTTCGGTTTGAGCTTAAACCTTTGGGTAAGACGTTG IIDRYHKAFIHMCLKHFK GAACATATTGAGAAAAAAGGCTTGATTGCCCAAGAC LKMYSEQGYDSLEEYRKL GAACAGCGGGCGGAGGAGTACAAATTGGTTAAAGAT ASISKRNEKEEQQFDKVK ATTATTGATCGCTACCACAAGGCTTTTATTCATATG ENLRKQIVDAFKNGGSYD TGCTTAAAACATTTTAAGCTCAAGATGTACAGTGAA DLFKKELIQKHLPRFIEG CAAGGGTATGATAGCTTGGAGGAGTACCGCAAGCTT EEEKRIVDNFNKFTTYFT GCGTCAATTTCCAAACGCAACGAGAAAGAGGAGCAG GFHENRKNMYSDEKESTA CAATTTGACAAAGTCAAGGAAAATCTTCGTAAGCAA IAYRLIHENLPLFLDNMK ATTGTCGACGCGTTTAAAAATGGCGGGAGTTATGAT SFAKIAESEVAARFTEIE GATCTGTTTAAGAAAGAATTGATCCAGAAACACCTC TAYRTYLNVEHISELFTL CCACGTTTTATTGAGGGTGAAGAAGAAAAACGTATC DYFSTVLTQEQIEVYNNI GTTGACAACTTCAACAAGTTCACGACCTATTTTACT IGGRVDDDNVKIQGLNEY GGTTTTCATGAAAATCGCAAGAATATGTATAGTGAC VNLYNQQQKDRSKRLPLL GAAAAGGAATCGACGGCTATTGCTTATCGTCTCATT KSLYKMILSDRIAISWLP CACGAAAACTTGCCATTGTTTTTGGATAACATGAAG EEFKSDKEMIEAINNMHD AGCTTCGCTAAGATCGCCGAATCGGAAGTGGCTGCT DLKDILAGDNEDSLKSLL CGTTTTACCGAAATCGAAACCGCTTACCGGACATAC QHIGQYDLSKIYIANNPG TTGAACGTAGAACACATTAGTGAACTGTTCACCCTC LTDISQQMFGCYDVFTNG GACTATTTTAGCACGGTTTTGACGCAAGAACAAATC IKQELRNSITPSKKEKAD GAAGTATATAATAACATTATCGGCGGGCGCGTCGAC NEIYEERINKMFKSEKSF GACGACAACGTAAAGATCCAAGGGTTGAATGAGTAC SIAYLNSLPHPKTDAPQK GTAAATTTATATAATCAGCAGCAGAAGGACCGGTCT NVEDYFALLGTCNQNDEQ AAGCGCTTACCGCTTCTTAAGTCCCTCTACAAAATG PINLFAQIEMARLVASDI ATCTTATCCGATCGTATTGCAATTTCGTGGTTACCT LAGRHVNLNQSENDIKLI GAGGAGTTCAAATCCGATAAGGAGATGATTGAAGCA KDLLDAYKALQHFVKPLL ATTAACAACATGCATGACGACCTGAAGGACATTCTG GSGDEAEKDNEFDARLRA GCAGGCGACAACGAAGACTCGCTTAAGTCCTTACTG AWNALDIVTPLYNKVRNW CAGCATATTGGCCAATACGATCTCTCGAAAATCTAC LTRKPYSTEKIKLNFENA ATTGCGAACAATCCGGGCCTGACAGATATCTCACAA QLLGGWDQNKEPDCTSVL CAAATGTTCGGGTGTTATGACGTCTTTACTAATGGG LRKDGMYYLAIMDKKANH ATCAAGCAGGAGCTCCGGAACAGTATTACCCCTTCA AFDCDCLPSDGACFEKID AAAAAGGAGAAAGCCGATAACGAAATCTACGAGGAG YKLLPGANKMLPKVFFSK CGGATTAACAAAATGTTTAAAAGTGAGAAGAGTTTC SRIKEFSPSESIIAAYKK TCAATTGCCTACCTGAATTCGTTGCCGCACCCAAAG GTHKKGPNFSLSDCHRLI ACGGATGCGCCTCAAAAAAATGTTGAGGATTATTTT DFFKASIDKHEDWSKFRF GCTCTCCTGGGGACTTGCAATCAAAACGATGAACAG RFSDTKTYEDISGFYREV CCGATTAATTTGTTTGCCCAAATTGAGATGGCACGC EQQGYMLGFRKVSEAFVN TTAGTCGCCTCTGATATTCTCGCAGGCCGGCACGTT KLVDEGKLYLFHIWNKDF AATTTGAACCAATCTGAGAATGATATCAAGTTAATC SKHSKGTPNLHTIYWKML AAGGATCTGTTAGATGCTTACAAGGCTCTGCAGCAT FDEKNLTDVIYKLNGQAE TTCGTCAAACCACTCCTTGGCTCGGGTGACGAGGCT VFYRKKSLDLNKTTTHKA GAGAAAGATAACGAGTTCGATGCACGCCTCCGTGCG HAPITNKNTQNAKKGSVF GCTTGGAATGCGTTGGACATTGTTACACCACTCTAT DYDIIKNRRYTVDKFQFH AACAAGGTTCGGAACTGGCTGACCCGCAAACCATAT VPITLNFKATGRNYINEH TCTACAGAAAAAATCAAGCTTAATTTCGAAAACGCC TQEAIRNNGIEHIIGIDR CAACTTCTGGGGGGTTGGGATCAGAACAAAGAACCG GERHLLYLSLIDLKGNIV GATTGCACATCAGTCCTCCTTCGGAAGGATGGGATG KQMTLNDIVNEYNGRTYA TACTATTTAGCGATCATGGATAAAAAGGCGAATCAC TNYKDLLATREGERTDAR GCCTTTGACTGTGACTGCTTACCGTCTGACGGGGCC RNWQKIENIKEIKEGYLS TGTTTCGAGAAAATTGACTACAAGCTGCTCCCGGGC QVVHILSKMMVDYKAIVV GCGAATAAAATGTTGCCGAAAGTTTTTTTTTCTAAA LEDLNTGFMRNRQKIERQ AGCCGCATCAAAGAATTTTCCCCTTCGGAATCGATC VYEKFEKMLIDKLNCYVD ATCGCTGCTTATAAAAAGGGGACTCATAAAAAAGGG KQKDADETGGALHPLQLT CCGAATTTCAGTCTCTCTGATTGTCATCGCTTGATT NKFESFRKLGKQSGWLFY GACTTTTTTAAGGCTAGCATTGATAAGCACGAAGAT IPAWNTSKIDPVTGFVNM TGGTCAAAATTTCGTTTTCGCTTCTCAGATACCAAA LDTRYENADKARCFFSKF ACGTATGAAGACATCAGTGGTTTCTACCGTGAAGTA DSIRYNADKDWFEFAMDY GAACAGCAAGGCTATATGCTGGGTTTTCGTAAAGTC SKFTDKAKDTYTWWTLCS TCTGAGGCCTTTGTGAATAAACTCGTTGATGAAGGT YGTRIKTFRNPAKNNLWD AAGTTATACTTATTCCATATCTGGAACAAAGACTTT NEEVVLTDEFKKVFAAAG AGTAAGCACTCCAAAGGTACACCTAATCTCCACACT IDVHENLKEAICALTDKK ATTTATTGGAAAATGCTCTTCGATGAGAAAAATCTC YLEPLMRLMTLLVQMRNS ACTGACGTCATCTACAAACTGAATGGGCAGGCTGAA ATNSETDYLLSPVADESG GTATTCTACCGTAAAAAAAGTCTGGATCTTAATAAG MFYDSREGKETLPKDADA ACAACTACTCACAAGGCACATGCCCCAATCACCAAT NGAYNIARKGLWTIRRIQ AAAAATACCCAAAACGCAAAGAAGGGTAGTGTTTTC ATNCEEKVNLVLSNREWL GATTACGATATCATCAAAAATCGTCGCTACACAGTG QFAQQKPYLNDAAAKRPA GACAAATTCCAGTTCCACGTCCCTATCACCTTAAAT ATKKAGQAKKKKASGSGA TTTAAGGCAACAGGTCGTAATTACATTAATGAGCAC GSPKKKRKVEDPKKKRKV ACTCAAGAGGCAATCCGTAATAATGGCATCGAACAT (SEQ ID NO: 55) ATCATTGGCATCGACCGTGGGGAGCGTCACTTGCTT TACTTGTCGCTCATTGATCTGAAGGGTAATATCGTC AAGCAGATGACCCTTAATGATATTGTCAATGAATAT AATGGTCGGACTTATGCGACGAACTACAAGGACTTG CTGGCAACACGGGAGGGTGAGCGTACGGACGCTCGG CGCAACTGGCAGAAGATTGAAAATATTAAAGAAATC AAGGAAGGTTACCTTAGCCAGGTGGTGCACATCTTG AGTAAAATGATGGTCGACTACAAGGCTATCGTTGTT CTGGAAGACTTGAATACAGGCTTCATGCGGAATCGT CAAAAAATCGAACGTCAAGTATATGAGAAGTTCGAA AAAATGTTAATTGACAAGCTGAACTGCTATGTTGAC AAACAAAAGGATGCTGACGAGACGGGCGGTGCCCTC CACCCGCTGCAGCTGACAAACAAATTTGAGTCGTTT CGTAAGTTAGGTAAGCAGAGTGGTTGGCTTTTTTAC ATCCCAGCATGGAACACTTCGAAAATCGACCCAGTT ACTGGGTTCGTGAACATGTTAGACACGCGCTACGAG AACGCCGATAAGGCGCGGTGTTTCTTCTCGAAATTC GATTCCATCCGGTATAACGCTGACAAAGATTGGTTT GAGTTTGCTATGGATTACAGTAAGTTCACTGATAAA GCGAAAGATACTTACACGTGGTGGACTCTGTGTTCC TATGGGACGCGTATTAAAACTTTTCGTAATCCGGCT AAGAATAATTTGTGGGATAATGAGGAGGTTGTCCTT ACTGATGAGTTCAAGAAAGTTTTCGCAGCGGCAGGT ATTGATGTCCATGAGAACCTTAAGGAAGCGATCTGT GCTCTGACAGATAAAAAGTATCTTGAACCACTCATG CGTCTCATGACCCTGCTCGTTCAAATGCGGAACTCT GCTACTAACTCCGAAACAGACTATTTACTTTCACCA GTTGCTGACGAGTCAGGGATGTTCTATGACTCCCGC GAAGGGAAGGAAACACTGCCAAAAGATGCGGACGCC AACGGTGCATATAACATTGCCCGTAAGGGCCTCTGG ACCATCCGGCGGATTCAAGCCACCAACTGTGAGGAG AAAGTTAACTTAGTCCTCAGTAATCGTGAATGGTTG CAGTTTGCCCAGCAGAAACCATATCTGAATGATGCG GCCGCAAAAAGGCCGGCGGCCACGAAAAAGGCCGGC CAGGCAAAAAAGAAAAAGGCTAGCGGCAGCGGCGCC GGATCCCCAAAGAAGAAAAGGAAGGTTGAAGACCCC AAGAAAAAGAGGAAGGTGTGATAA (SEQ ID NO: 56) ABW 6 MGHHHHHHSSGLVPRGSG ATGGGCCACCATCATCATCATCATAGCAGCGGCCTG TMIYRENFKRKKEKIEMN GTGCCGCGCGGCAGCGGTACCATGATCTACCGTGAG TGFNDFTNLSSVTKTLCN AATTTTAAGCGGAAAAAGGAGAAGATTGAAATGAAC RLIPTEITAKYIKEHGVI ACTGGGTTTAATGACTTCACTAATTTGAGTTCCGTG EADQERNMMSQELKNILN ACCAAGACGTTATGCAACCGGTTGATCCCAACAGAA DFYRSFLNENLVKVHELD ATTACCGCAAAGTACATTAAGGAGCATGGGGTAATT FKPLFTEMKKYLETKDNK GAGGCGGACCAAGAACGGAACATGATGAGTCAAGAG EALEKAQDDMRKAIHDIF CTGAAAAATATCTTGAATGACTTTTACCGGAGTTTC ESDDRYKKMFKAEITASI CTGAACGAGAACCTTGTGAAGGTGCACGAACTTGAT LPEFILHNGAYSAEEKEE TTCAAGCCGTTATTCACCGAGATGAAAAAGTACCTC KMQVVKMFNGFMTSFSAF GAAACAAAAGATAACAAGGAAGCACTCGAAAAGGCC FTNRENCESKEKISSSAC CAGGACGACATGCGGAAGGCAATCCATGATATCTTT YRIVDDNAKIHFDNIRIY GAAAGTGATGACCGCTACAAAAAAATGTTCAAGGCT KNIANKFDYEIEMIEKIE GAGATCACGGCGTCGATTTTGCCTGAATTCATTCTT EAAGGADIRNIFSYNFDH CATAACGGGGCATATTCAGCCGAAGAAAAGGAGGAG FAFNHFVSQDDISFYNYV AAAATGCAAGTAGTCAAGATGTTCAATGGCTTTATG VGGINKFMNLYCQATKEK ACGTCTTTCTCAGCATTCTTTACGAATCGTGAGAAT LSPYKLRHLHKQILCIEE TGTTTCTCCAAAGAAAAGATCAGCTCCTCCGCATGT SLYDVPAKFNCDEDVYAA TACCGTATTGTTGATGACAACGCGAAAATCCATTTC VNDFLNNVRTKSVIERLQ GATAACATTCGTATTTATAAAAATATCGCCAACAAG MLGKNADSYDLDKIYISK TTCGATTATGAAATTGAAATGATCGAGAAGATCGAA KHFTNISQTLYRDESVIN GAGGCGGCGGGGGGTGCCGACATTCGTAATATCTTC TALTMSYIDTLPGKGKTK TCGTACAACTTTGACCACTTTGCATTCAATCATTTC EKKAASMAKNTELISLGE GTTAGTCAAGATGATATCTCATTCTACAATTATGTT IDKLVDKYNLCPDKAAST GTTGGTGGTATTAACAAGTTTATGAACTTGTATTGT RSLIRSISDIVADYKANP CAAGCCACCAAAGAGAAATTATCGCCTTATAAACTG LTMNSGIPLAENETEIAV CGTCACCTTCACAAACAGATTCTGTGTATTGAGGAA LKEAIEPFMDIFRWCAKF AGCCTCTATGACGTGCCAGCGAAGTTTAATTGTGAT KTDEPVDKDTDFYTELED GAGGACGTATATGCAGCTGTCAACGATTTTCTTAAT INDEIHSIVSLYNRTRNY AACGTTCGGACGAAATCAGTAATTGAACGCTTGCAA VTKKPYNTDKFGLYFGTS ATGCTCGGCAAAAATGCAGACAGTTACGACCTGGAT SFASGWSESKEFTNNAIL AAAATTTATATCTCTAAAAAGCACTTCACCAATATC LAKDDKFYLGVFNAKNKP TCTCAAACTTTATATCGCGACTTCTCTGTGATCAAC AKSIIKGHDTIQDGDYKK ACTGCCCTCACTATGTCTTATATCGATACTCTTCCG MVYSLLTGPNKMLPHMFI GGTAAGGGGAAAACCAAGGAAAAAAAGGCAGCATCG SSSKAVPVYGLTDELLSD ATGGCCAAAAACACCGAACTTATTTCGTTAGGCGAA YKKGRHLKTSKNFDIDYC ATTGATAAGTTGGTGGATAAATATAACCTCTGTCCA HKLIDYFKHCLALYTDWD GATAAGGCAGCTAGCACTCGTAGCCTCATTCGGTCT CFNFKFSDTESYNDIGEF ATTAGCGACATCGTCGCTGACTACAAGGCAAACCCT YKEVAEQGYYMNWTYIGS CTTACAATGAATAGTGGGATTCCGTTGGCAGAGAAC DDIDSLQENGQLYLFQIY GAGACAGAAATCGCGGTGTTAAAAGAGGCGATCGAG NKDFSEKSFGKPSKHTAI CCTTTTATGGATATCTTCCGGTGGTGTGCTAAGTTT LRSLFSDENVADPVIKLC AAAACCGACGAGCCTGTCGATAAGGATACAGATTTC GGTEVFFRPKSIKTPVVH TACACGGAGTTAGAAGACATTAACGATGAAATCCAT KKGSILVSKTYNAQEMDE AGTATTGTCAGTCTTTATAACCGGACCCGGAATTAT NGNIITVRKCVPDDVYME GTCACTAAAAAGCCGTACAACACAGATAAGTTCGGT LYGYYNNSGTPLSAEALK CTGTATTTTGGCACTTCGTCGTTCGCATCGGGTTGG YKDIVDHRTAPYDIIKDR AGCGAGAGCAAAGAGTTTACTAACAACGCAATTTTG RYTEDEFFINMPVSLNYK TTAGCCAAGGATGACAAGTTTTACCTCGGCGTGTTC AENRRVNVNEMALKYIAQ AACGCAAAAAACAAGCCAGCAAAATCGATTATCAAA TKDTYIIGIDRGERNLLY GGGCATGACACAATCCAAGATGGTGATTATAAGAAA VSVIDTDGNIVEQKSLNI ATGGTGTATTCACTGCTCACCGGGCCAAATAAGATG INNVDYQAKLKQVEIMRK CTTCCTCACATGTTTATCTCGAGCAGTAAAGCGGTT LARQNWKQGVKIADLKKG CCTGTTTACGGGCTCACTGACGAGCTTCTCAGCGAC YLSQAVHEVAELVIKYNG TATAAGAAAGGTCGCCACCTTAAGACATCCAAGAAT IVVMEDLNSRFKEKRSKI TTCGACATTGATTACTGTCACAAACTTATCGATTAC ERGVYQQFETSLIKTLNY TTCAAACATTGTCTCGCTTTGTATACTGATTGGGAT LTFKDRKPLEAGGIANGY TGCTTCAACTTCAAATTCTCTGATACGGAGTCCTAC QLTYIPESLKNVGSQCGC AATGATATCGGCGAGTTCTACAAAGAGGTTGCCGAG ILYVPAAYTSKIDPTTGF CAAGGCTACTACATGAACTGGACATATATCGGGTCG VTLFKFKDISSEKAKTDE GACGATATCGATTCGCTGCAGGAAAACGGCCAGCTC IGRFDCIRYDAEKDLFAF TATCTTTTTCAAATTTATAACAAAGATTTCAGCGAA EFDYDNFETYETCARTKW AAGTCATTCGGTAAACCGTCTAAACATACGGCCATC CAYTYGTRVKKTFRNRKF CTGCGTAGCTTATTCAGCGATGAAAACGTGGCCGAC VSEVIIDITEEIKKTLAA CCAGTCATTAAACTGTGTGGGGGGACCGAAGTTTTT TDINWIDSHDIKQEIIDY TTCCGGCCGAAGTCTATTAAGACACCAGTAGTACAT ALSSHIFEMFKLTVQMRN AAAAAAGGCAGCATCCTCGTATCCAAAACCTATAAC SLCESKDREYDKFVSPIL GCACAAGAAATGGACGAGAATGGTAATATCATCACC NASGKFFDTDAADKSLPI GTGCGGAAGTGTGTTCCAGACGACGTCTATATGGAG EADANDAYGIAMKGLYNV CTCTACGGCTATTACAACAACTCTGGGACGCCTCTG LQVKNNWAEGEKFKFSRL TCCGCCGAAGCTTTGAAATACAAGGATATTGTGGAC SNEDWFNFMQKRAAAKRP CACCGCACGGCTCCGTACGACATTATCAAGGACCGG AATKKAGQAKKKKASGSG CGTTACACCGAAGACGAATTTTTCATCAACATGCCG AGSPKKKRKVEDPKKKRK GTGTCATTGAATTATAAAGCGGAAAACCGCCGTGTT V (SEQ ID NO: 68) AATGTGAACGAAATGGCCTTAAAATACATCGCACAG ACCAAGGACACCTACATCATTGGCATCGATCGGGGC GAACGTAATCTGTTGTATGTGAGCGTTATCGATACT GACGGCAATATCGTTGAGCAAAAGAGTCTCAATATC ATCAATAACGTGGATTATCAAGCCAAATTAAAGCAA GTGGAAATCATGCGTAAACTGGCCCGTCAGAATTGG AAGCAGGGGGTAAAGATTGCAGACCTGAAAAAGGGC TACCTGTCACAAGCGGTACATGAAGTCGCGGAACTT GTAATTAAATACAACGGGATTGTTGTAATGGAGGAC TTAAACTCCCGCTTCAAAGAGAAGCGTTCTAAAATT GAACGCGGCGTCTACCAACAGTTTGAGACATCATTA ATCAAGACATTGAATTATTTGACGTTCAAAGATCGC AAACCGTTAGAAGCCGGGGGCATTGCGAATGGTTAT CAATTAACTTATATTCCGGAGTCTCTTAAAAATGTG GGCTCTCAGTGCGGCTGTATCTTGTATGTGCCAGCA GCCTACACCTCGAAGATCGACCCTACCACTGGTTTC GTCACCTTGTTCAAATTCAAAGACATTTCGAGCGAG AAAGCTAAAACGGATTTTATTGGTCGGTTCGACTGC ATCCGTTATGATGCAGAAAAGGACCTTTTCGCATTT GAATTCGATTATGACAACTTTGAGACTTATGAGACT TGTGCGCGTACCAAATGGTGTGCATATACATACGGG ACTCGGGTGAAGAAAACTTTCCGGAATCGGAAATTC GTGTCAGAGGTGATCATCGACATCACTGAAGAGATC AAGAAGACCCTTGCAGCGACCGATATTAATTGGATT GACAGTCACGACATCAAACAAGAGATCATCGACTAT GCCCTTAGCAGCCATATTTTTGAAATGTTCAAATTA ACGGTACAGATGCGTAACAGCCTTTGCGAGAGTAAA GATCGCGAGTACGACAAGTTCGTCTCACCTATTCTC AACGCGTCGGGCAAATTTTTCGACACCGATGCCGCT GATAAAAGTCTGCCTATTGAAGCTGATGCGAACGAT GCGTATGGTATTGCTATGAAAGGGTTGTATAATGTT TTACAAGTCAAAAACAACTGGGCGGAGGGCGAGAAA TTTAAGTTCTCCCGTTTAAGCAACGAAGATTGGTTC AACTTCATGCAAAAGCGGGCGGCCGCAAAAAGGCCG GCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAA AAGGCTAGCGGCAGCGGCGCCGGATCCCCAAAGAAG AAAAGGAAGGTTGAAGACCCCAAGAAAAAGAGGAAG GTGTGATAA (SEQ ID NO: 69) ABW 7 MGHHHHHHSSGLVPRGSL ATGGGCCACCATCATCATCATCATAGCAGCGGCCTG QMTMDYGNGQFERRAPLT GTGCCGCGCGGCAGCCTGCAGATGACAATGGATTAC KTITLRLKPIGETRETIR GGTAACGGTCAATTTGAGCGGCGCGCCCCGCTCACC EQKLLEQDAAFRKLVETV AAGACAATCACTCTCCGGTTGAAACCGATCGGGGAG TPIVDDCIRKIADNALCH ACCCGTGAGACGATTCGCGAGCAAAAGCTCCTCGAA FGTEYDFSCLGNAISKND CAAGATGCTGCATTCCGTAAACTTGTTGAAACTGTC SKAIKKETEKVEKLLAKV ACCCCTATCGTGGATGATTGTATCCGGAAAATTGCT LTENLPDGLRKVNDINSA GACAACGCTTTGTGTCATTTTGGCACGGAATATGAT AFIQDTLTSFVQDDADKR TTCTCCTGTTTAGGTAATGCCATCTCAAAAAATGAC VLIQELKGKTVLMQRFLT AGCAAAGCGATTAAGAAAGAGACCGAAAAAGTAGAG TRITALTVWLPDRVFENF AAGCTGTTGGCCAAGGTTCTGACAGAGAACTTGCCA NIFIENAEKMRILLDSPL GACGGTCTGCGTAAAGTCAACGATATTAACAGCGCG NEKIMKFDPDAEQYASLE GCTTTTATTCAGGACACACTGACATCATTCGTCCAG FYGQCLSQKDIDSYNLII GACGATGCTGACAAACGTGTGTTAATTCAAGAGTTA SGIYADDEVKNPGINEIV AAGGGCAAAACTGTGTTAATGCAACGCTTTTTAACA KEYNQQIRGDKDESPLPK ACCCGGATTACTGCATTGACTGTATGGCTCCCTGAC LKKLHKQILMPVEKAFFV CGGGTGTTTGAGAACTTCAACATTTTTATCGAAAAT RVLSNDSDARSILEKILK GCTGAAAAGATGCGCATCTTGCTCGACTCACCATTG DTEMLPSKITEAMKEADA AATGAAAAGATCATGAAGTTCGATCCGGATGCTGAA GDIAVYGSRLHELSHVIY CAATACGCGAGTTTGGAATTCTATGGTCAATGTCTG GDHGKLSQIIYDKESKRI TCCCAGAAGGATATTGATTCGTACAACCTCATCATT SELMETLSPKERKESKKR TCCGGGATTTATGCCGATGATGAGGTCAAGAACCCA LEGLEEHIRKSTYTFDEL GGTATCAATGAAATTGTTAAGGAATACAACCAGCAA NRYAEKNVMAAYIAAVEE ATTCGCGGGGATAAGGATGAGTCACCTTTACCTAAA SCAEIMRKEKDLRTLLSK CTGAAAAAGTTGCATAAACAAATTTTGATGCCTGTC EDVKIRGNRHNTLIVKNY GAGAAGGCATTTTTCGTTCGGGTACTCAGTAATGAT FNAWTVFRNLIRILRRKS TCTGATGCTCGTTCAATTTTAGAAAAAATCTTGAAG EAEIDSDFYDVLDDSVEV GATACTGAGATGTTGCCTTCTAAGATCATTGAAGCG LSLTYKGENLCRSYITKK ATGAAAGAAGCAGACGCTGGGGACATCGCTGTATAT IGSDLKPEIATYGSALRP GGTTCACGTTTGCACGAGTTAAGCCACGTAATCTAT NSRWWSPGEKFNVKFHTI GGCGATCACGGGAAGCTCTCTCAGATTATCTATGAT VRRDGRLYYFILPKGAKP AAGGAGTCGAAACGCATCAGCGAGCTCATGGAAACG VELEDMDGDIECLQMRKI TTATCGCCTAAGGAGCGCAAAGAGTCAAAGAAACGC PNPTIFLPKLVFKDPEAF TTGGAGGGTCTGGAAGAACATATCCGGAAGTCGACA FRDNPEADEFVFLSGMKA TATACCTTCGACGAGCTTAATCGTTATGCGGAAAAG PVTITRETYEAYRYKLYT AACGTCATGGCTGCCTACATCGCGGCCGTGGAGGAA VGKLRDGEVSEEEYKRAL AGCTGCGCCGAAATTATGCGTAAGGAGAAGGACTTA LQVLTAYKEFLENRMIYA CGCACGCTTCTTAGTAAGGAGGATGTCAAGATTCGT DLNFGFKDLEEYKDSSEF GGTAATCGCCACAATACGTTAATTGTTAAGAACTAC IKQVETHNTFMCWAKVSS TTCAATGCCTGGACTGTCTTCCGGAATTTGATCCGC SQLDDLVKSGNGLLFEIW ATCCTCCGGCGGAAATCCGAGGCGGAGATCGACTCA SERLESYYKYGNEKVLRG GATTTCTATGACGTCTTGGATGACTCTGTGGAAGTT YEGVLLSILKDENLVSMR TTATCGCTCACATATAAAGGTGAAAACTTGTGCCGG TLLNSRPMLVYRPKESSK TCTTACATTACGAAGAAGATCGGGAGCGATTTAAAG PMVVHRDGSRVVDRFDKD CCAGAGATTGCTACCTATGGTTCCGCCTTGCGCCCT GKYIPPEVHDELYRFFNN AATTCACGGTGGTGGTCACCGGGCGAGAAGTTTAAC LLIKEKLGEKARKILDNK GTAAAGTTCCACACCATTGTTCGCCGGGACGGTCGC KVKVKVLESERVKWSKFY CTTTATTATTTCATCTTGCCGAAAGGTGCCAAACCT DEQFAVTFSVKKNADCLD GTCGAGCTCGAAGATATGGATGGGGACATCGAATGC TTKDLNAEVMEQYSESNR TTGCAAATGCGCAAGATTCCGAATCCGACTATTTTC LILIRNTTDILYYLVLDK CTTCCAAAATTGGTTTTCAAGGACCCAGAGGCCTTC NGKVLKQRSLNIINDGAR TTCCGCGACAATCCAGAGGCAGATGAATTCGTTTTT DVDWKERFRQVTKDRNEG CTTTCGGGTATGAAAGCTCCAGTGACCATCACGCGT YNEWDYSRTSNDLKEVYL GAAACCTATGAGGCGTATCGCTACAAACTTTATACA NYALKEIAEAVIEYNAIL GTTGGGAAGTTACGCGACGGTGAAGTGAGCGAAGAA IIEKMSNAFKDKYSFLDD GAGTATAAACGTGCGTTGTTACAAGTATTGACCGCC VTFKGFETKLLAKLSDLH TATAAGGAATTCTTAGAGAATCGGATGATCTACGCA FRGIKDGEPCSFTNPLQL GATCTGAACTTTGGCTTTAAAGATCTCGAAGAATAC CQNDSNKILQDGVIFMVP AAAGACTCGTCAGAATTTATCAAACAAGTCGAAACT NSMTRSLDPDTGFIFAIN CACAACACTTTTATGTGCTGGGCTAAGGTCAGTAGC DHNIRTKKAKLNFLSKFD AGTCAGCTCGACGACCTGGTCAAGAGCGGGAACGGG QLKVSSEGCLIMKYSGDS TTACTGTTCGAAATCTGGTCAGAACGGTTGGAGTCC LPTHNTDNRVWNCCCNHP TATTACAAATATGGCAACGAGAAGGTGCTGCGTGGG ITNYDRETKKVEFIEEPV TACGAGGGCGTTCTTTTGAGTATCCTTAAGGACGAG EELSRVLEENGIETDTEL AACCTCGTGAGCATGCGGACGCTGCTTAATTCTCGG NKLNERENVPGKVVDAIY CCGATGCTCGTCTACCGCCCTAAAGAATCATCCAAG SLVLNYLRGTVSGVAGQR CCGATGGTCGTTCACCGGGACGGTAGCCGCGTCGTT AVYYSPVTGKKYDISFIQ GATCGGTTCGATAAGGATGGGAAGTATATTCCACCA AMNLNRKCDYYRIGSKER GAGGTACACGACGAATTATACCGGTTCTTTAACAAT GEWTDFVAQLINAAAKRP TTGCTTATTAAGGAAAAGCTCGGCGAGAAAGCGCGC AATKKAGQAKKKKASGSG AAAATTTTAGACAACAAAAAAGTAAAAGTAAAGGTA AGSPKKKRKVEDPKKKRK TTGGAATCTGAACGTGTAAAGTGGTCAAAGTTTTAT V (SEQ ID NO: 81) GATGAACAGTTTGCAGTTACATTCTCTGTTAAAAAG AATGCAGACTGTCTGGATACCACGAAAGATCTCAAT GCCGAAGTTATGGAGCAGTATTCCGAATCGAACCGG CTTATCCTGATCCGCAATACCACTGACATCTTGTAT TATCTTGTACTTGATAAGAATGGGAAAGTGCTGAAA CAACGCTCATTGAATATCATTAACGACGGGGCTCGC GACGTTGATTGGAAAGAGCGTTTTCGGCAGGTAACA AAAGATCGTAACGAAGGCTATAACGAGTGGGACTAC TCGCGGACTAGCAACGATTTGAAAGAGGTCTATCTG AATTATGCATTGAAGGAGATTGCCGAAGCGGTAATC GAATACAACGCAATTTTGATTATTGAAAAAATGTCG AATGCCTTCAAGGATAAGTACTCCTTTTTGGATGAT GTTACCTTCAAAGGTTTTGAGACCAAACTTCTTGCG AAGCTCTCTGACTTGCATTTCCGGGGTATTAAAGAT GGGGAGCCATGTTCGTTTACGAACCCGTTACAGTTA TGTCAGAACGACTCAAACAAAATTTTACAAGACGGT GTGATTTTCATGGTCCCTAACAGCATGACGCGCAGT CTGGACCCTGACACTGGGTTCATTTTTGCGATTAAC GATCACAACATCCGCACTAAGAAAGCGAAGTTAAAC TTCCTTAGTAAATTCGATCAGCTGAAAGTGTCATCA GAGGGCTGTTTAATCATGAAATATTCGGGGGACTCC CTTCCTACACACAACACAGATAATCGTGTATGGAAC TGTTGTTGCAATCACCCGATCACCAACTACGACCGC GAGACGAAAAAGGTCGAATTCATCGAGGAGCCAGTG GAAGAGTTGAGTCGCGTCTTAGAAGAGAATGGGATT GAGACAGATACGGAACTTAACAAGCTTAACGAGCGC GAGAATGTTCCGGGCAAGGTAGTAGATGCCATCTAT TCTCTGGTGTTGAATTACTTGCGTGGTACCGTGTCC GGCGTTGCAGGCCAACGGGCGGTCTACTATTCCCCT GTGACGGGGAAAAAATATGATATTTCGTTTATCCAA GCAATGAATCTGAATCGTAAGTGCGATTACTACCGG ATCGGGAGCAAAGAACGCGGCGAATGGACGGATTTT GTAGCGCAGTTAATTAACGCGGCCGCAAAAAGGCCG GCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAA AAGGCTAGCGGCAGCGGCGCCGGATCCCCAAAGAAG AAAAGGAAGGTTGAAGACCCCAAGAAAAAGAGGAAG GTGTGATAA (SEQ ID NO: 82) ABW8 MGHHHHHHSSGLVPRGSG ATGGGCCACCATCATCATCATCATAGCAGCGGCCTG TMCYDLNNIKTKLREREV GTGCCGCGCGGCAGCGGTACCATGTGCTACGACTTA ETMGNNMDNSFEPFIGGN AACAACATCAAGACAAAGTTACGTGAACGCGAAGTC SVSKTLRNELRVGSEYTG GAAACTATGGGCAATAACATGGATAATAGCTTCGAG KHIKECAIIAEDAVKAEN CCTTTTATTGGCGGTAATAGTGTCTCTAAAACACTT QYIVKEMMDDFYRDFINR CGGAATGAGCTGCGTGTAGGTTCCGAATATACTGGT KLDALQGINWEQLFDIMK AAACACATTAAAGAGTGCGCGATCATTGCAGAGGAC KAKLDKSNKVSKELDKIQ GCCGTGAAGGCGGAGAACCAGTACATCGTAAAAGAG ESTRKEIGKIFSSDPIYK ATGATGGACGACTTTTACCGTGACTTCATTAATCGC DMLKADMISKILPEYIVD AAACTTGACGCCTTGCAGGGTATTAATTGGGAGCAG KYGDAASRIEAVKVFYGF CTTTTTGACATTATGAAGAAGGCGAAATTGGATAAG SGYFIDFWASRKNVFSDK TCGAATAAAGTCAGCAAAGAGTTAGACAAGATTCAA NIASAIPHRIVNVNARIH GAGTCTACGCGGAAAGAAATCGGGAAAATCTTCTCA LDNITAFNRIAEIAGDEV TCCGATCCAATCTATAAAGACATGCTCAAAGCGGAC AGIAEDACAYLQNMSLED ATGATCAGCAAAATTCTGCCAGAGTATATTGTCGAC VFTGACYGEFICQKDIDR AAATACGGTGATGCAGCCTCGCGGATCGAAGCTGTA YNNICGVINQHMNQYCQN AAGGTGTTTTACGGCTTTTCGGGTTATTTTATCGAC KKISRSKFKMERLHKQIL TTCTGGGCATCGCGCAAGAACGTCTTCTCAGATAAG CRSESGFEIPIGFQTDGE AACATCGCGTCGGCCATTCCGCACCGGATTGTCAAT VIDAINSFSTILEEKDIL GTGAACGCTCGGATCCATCTGGACAACATCACGGCC DRLRTLSQEVTGYDMERI TTCAACCGTATCGCAGAAATTGCAGGGGATGAAGTC YVSSKAFESVSKYIDHKW GCCGGCATTGCTGAAGATGCTTGTGCTTACCTGCAG DVIASSMYNYFSGAVRGK AATATGAGCTTAGAGGATGTATTCACGGGGGCCTGC DDKKDVKIQTEIKKIKSC TACGGTGAGTTCATCTGTCAGAAGGATATTGATCGT SLLDLKKLVDMYYKMDGM TACAATAACATTTGCGGTGTTATCAACCAGCACATG CLEHEATEYVAGITEILV AATCAATACTGCCAAAACAAAAAGATCTCACGCTCA DFNYKTFDMDDSVKMIQN AAATTTAAGATGGAACGTCTGCACAAACAGATCTTA EHMINEIKEYLDTYMSIY TGTCGCTCTGAGAGTGGTTTTGAGATCCCGATTGGG HWAKDFMIDELVDRDMEF TTTCAAACCGACGGGGAGGTAATCGATGCTATCAAC YSELDEIYYDLSDIVPLY TCCTTTTCTACGATTCTTGAAGAGAAAGATATCTTG NKVRNYVTQKPYSQDKIK GATCGTCTGCGCACTTTGTCGCAGGAGGTAACAGGT LNFGSPTLANGWSKSKEF TATGACATGGAGCGTATCTATGTAAGTTCCAAGGCG DNNVVVLLRDEKIYLAIL TTTGAGTCTGTATCAAAGTACATCGATCACAAATGG NVGNKPSKDIMAGEDRRR GACGTAATTGCTTCTTCCATGTACAATTACTTTTCT SDTDYKKMNYYLLPGASK GGGGCTGTTCGTGGGAAGGACGACAAGAAAGATGTC TLPHVFISSNAWKKSHGI AAGATTCAGACGGAAATTAAAAAGATTAAGTCATGT PDEIMYGYNQNKHLKSSP TCGTTATTGGACCTCAAAAAGCTGGTAGATATGTAT NFDLEFCRKLIDYYKECI TATAAAATGGATGGGATGTGTTTAGAGCACGAAGCG DSYPNYQIFNFKFAATET ACGGAGTACGTGGCAGGTATTACGGAGATCCTGGTT YNDISEFYKDVERQGYKI GACTTTAACTATAAGACCTTCGACATGGATGATTCC EWSYISEDDINQMDRDGQ GTTAAGATGATTCAAAATGAGCACATGATTAATGAA IYLFQIYNKDFAPNSKGM ATTAAAGAATATTTAGATACCTATATGTCTATCTAT QNLHTLYLKNIFSEENLS CATTGGGCGAAGGACTTTATGATCGATGAGCTCGTA DVVIKLNGEAELFFRKSS GATCGCGACATGGAATTCTACAGTGAGCTCGATGAA IQHKRGHKKGSVLVNKTY ATCTATTATGATTTGTCCGACATCGTACCACTGTAT KTTEKTENGQGEIEVIES AATAAAGTCCGCAACTACGTCACGCAAAAACCGTAT VPDQCYLELVKYWSEGGV TCCCAGGATAAAATCAAGTTAAACTTTGGCAGCCCA GQLSEEASKYKDKVSHYA ACCTTAGCAAACGGTTGGAGCAAGTCGAAAGAATTT ATMDIVKDRRYTEDKFFI GATAACAACGTTGTAGTATTGTTGCGTGACGAAAAG HMPITINFKADNRNNVNE ATTTATCTGGCCATCTTAAATGTGGGGAATAAACCG KVLKFIAENDDLHVIGID TCAAAGGATATCATGGCGGGCGAAGACCGTCGTCGC RGERNLLYVSVIDSRGRI TCCGATACTGATTACAAGAAAATGAATTACTATCTG VEQKSFNIVENYESSKNV CTCCCTGGGGCAAGCAAAACCCTGCCACACGTTTTT IRRHDYRGKLVNKEHYRN ATCTCTTCAAATGCATGGAAGAAATCCCACGGTATC EARKSWKEIGKIKEIKEG CCTGACGAGATTATGTACGGCTATAACCAAAATAAG YLSQVIHEISKLVLKYNA CATTTAAAATCTTCGCCAAACTTCGACTTAGAGTTT IIVMEDLNYGFKRGRFKV TGTCGCAAGCTGATCGATTATTACAAAGAATGTATT ERQVYQKFETMLINKLAY GACAGCTATCCTAACTATCAGATCTTCAATTTCAAA LVDKSRAVDEPGGLLKGY TTCGCCGCTACGGAAACTTACAACGATATTTCGGAG QLTYVPDNLGELGSQCGI TTCTACAAAGATGTTGAACGTCAGGGGTACAAGATT IFYVPAAYTSKIDPVTGF GAATGGTCGTACATTTCCGAGGACGATATTAATCAG VDVFDFKAYSNAEARLDF ATGGATCGTGACGGCCAGATTTATCTTTTTCAAATC INKLDCIRYDAPRNKFEI TACAACAAGGATTTTGCCCCAAACTCTAAGGGCATG AFDYGNFRTHHTTLAKTS CAGAATTTACATACACTCTATTTAAAAAATATTTTT WTIFIHGDRIKKERGSYG TCAGAGGAAAACCTCTCTGATGTCGTCATTAAACTG WKDEIIDIEARIRKLFED AATGGCGAGGCTGAGCTCTTCTTCCGCAAGAGCTCG TDIEYADGHNLIGDINEL ATCCAACATAAACGCGGTCATAAGAAGGGTAGTGTG ESPIQKKFVGELFDIIRF TTGGTAAATAAGACCTATAAAACCACAGAAAAAACT TVQLRNSKSEKYDGTEKE GAAAATGGTCAAGGCGAAATTGAAGTAATCGAGAGC YDKIISPVMDEEGVFFTT GTGCCGGACCAGTGTTACCTGGAGCTTGTTAAGTAC DSYIRADGTELPKDADAN TGGTCAGAGGGTGGTGTAGGTCAGTTGTCAGAAGAG GAYCIALKGLYDVLAVKK GCTTCCAAATACAAAGATAAAGTCAGCCACTACGCT YWKEGEKFDRKLLAITNY GCAACAATGGATATTGTCAAGGACCGGCGGTACACG NWFDFIQNRRFAAAKRPA GAGGATAAGTTCTTTATTCACATGCCGATTACGATT ATKKAGQAKKKKASGSGA AATTTTAAAGCTGATAACCGGAACAATGTCAACGAG GSPKKKRKVEDPKKKRKV AAAGTGCTGAAGTTTATTGCAGAAAACGATGATCTC (SEQ ID NO: 94) CACGTTATTGGTATTGACCGTGGGGAACGTAATCTC CTGTACGTCTCAGTAATTGATTCACGTGGGCGTATT GTTGAGCAGAAGTCGTTTAATATTGTTGAGAATTAC GAGAGCAGTAAAAATGTGATCCGCCGCCATGATTAT CGTGGGAAATTAGTAAATAAAGAGCACTATCGTAAT GAGGCACGTAAGAGCTGGAAAGAAATCGGCAAAATC AAGGAGATCAAAGAAGGTTATCTCAGTCAAGTTATC CATGAGATTAGTAAGTTGGTATTAAAGTATAACGCC ATCATCGTGATGGAAGATCTTAATTATGGCTTCAAA CGCGGGCGGTTTAAAGTCGAGCGGCAGGTATACCAG AAGTTCGAGACCATGCTTATTAACAAATTAGCCTAC TTAGTGGACAAATCACGCGCGGTAGACGAACCGGGT GGGTTATTAAAAGGCTACCAGCTGACATACGTGCCA GATAACTTGGGTGAACTGGGGTCCCAGTGCGGGATC ATTTTTTATGTGCCAGCAGCATACACTTCGAAAATC GATCCTGTTACGGGCTTTGTAGACGTGTTTGATTTT AAGGCATACTCCAATGCCGAAGCACGTTTAGATTTC ATCAATAAACTGGACTGCATCCGGTATGACGCGCCG CGTAACAAGTTTGAAATTGCTTTCGACTACGGTAAC TTCCGGACTCATCATACAACCCTTGCAAAGACTAGC TGGACTATTTTTATTCACGGCGACCGTATTAAAAAG GAGCGCGGTTCTTACGGCTGGAAGGACGAAATTATC GATATCGAGGCCCGTATTCGTAAGCTGTTTGAAGAC ACAGACATCGAATACGCCGATGGTCACAATTTGATC GGTGACATTAACGAGCTCGAGAGTCCAATTCAAAAG AAATTCGTTGGTGAGCTGTTCGACATTATCCGTTTC ACTGTCCAACTGCGCAACAGCAAAAGTGAGAAATAT GACGGCACCGAAAAGGAGTATGACAAAATTATTTCG CCGGTAATGGACGAGGAGGGGGTTTTCTTTACAACC GACAGTTATATCCGCGCAGATGGTACTGAATTACCT AAAGATGCTGATGCTAACGGGGCCTATTGTATCGCG CTGAAGGGTCTTTACGACGTGCTCGCGGTAAAGAAA TATTGGAAGGAGGGGGAGAAGTTCGATCGGAAGTTA CTTGCCATCACCAATTACAACTGGTTTGATTTCATT CAGAATCGTCGCTTCGCGGCCGCAAAAAGGCCGGCG GCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAG GCTAGCGGCAGCGGCGCCGGATCCCCAAAGAAGAAA AGGAAGGTTGAAGACCCCAAGAAAAAGAGGAAGGTG TGATAA (SEQ ID NO: 95) ABW9 MGHHHHHHSSGLVPRGSG ATGGGGCATCACCACCACCACCACTCGTCGGGTCTT TMSDRLDVLTNQYPLSKT GTTCCACGTGGTTCTGGTACCATGTCTGATCGCCTG LRFELKPVGATADWIRKH GACGTGCTTACTAACCAATACCCATTATCGAAAACT NVIRYHNGKLVGKDAIRF TTGCGCTTCGAATTGAAGCCGGTTGGAGCCACAGCT QNYKYLKKMLDEMHRLFL GACTGGATTCGCAAACACAACGTTATCCGCTATCAT QQALVLEPNSNQAQELTA AATGGTAAACTGGTTGGAAAGGATGCGATCCGTTTT LLRAIENNYCNNNDLLAG CAAAATTATAAGTATCTGAAGAAAATGCTTGATGAG DYPSLSTDKTIKISNGLS ATGCATCGCTTATTTCTTCAGCAAGCACTGGTGTTG KLTTDLFDKKFEDWAYQY GAGCCAAATAGCAACCAGGCGCAGGAGTTGACCGCA KEDMPNFWRQDIAELEQK CTGCTGCGTGCTATTGAGAATAATTATTGCAACAAC LQVSANAKDQKFYKGIIK AACGACCTGCTGGCGGGCGATTATCCCAGCCTCTCT KLKNKIQKSELKAETHKG ACCGATAAGACCATTAAAATCAGCAACGGCCTTAGC LYSPTESLQLLEWLVRRG AAGCTGACCACGGATCTGTTCGATAAGAAGTTCGAA DIKLTYLEIGKENEKLNE GACTGGGCATACCAATACAAAGAAGATATGCCCAAT LVPLVELKDIHRNFNNFA TTCTGGCGTCAAGATATTGCGGAATTAGAGCAAAAG TYLSGFSKNRENVYSTKF CTTCAGGTGAGTGCGAACGCAAAAGATCAAAAGTTC DRRSGYKATSVIARTFEQ TACAAAGGGATCATCAAGAAGCTGAAGAATAAGATC NLMFCLGNIAKWHKVTEF CAGAAGTCTGAACTGAAAGCGGAAACGCACAAGGGC INQANNYELLQEHGIDWN TTATACTCACCTACGGAGTCACTGCAACTGCTGGAG KQIAALEHKLDVCLAEFF TGGCTGGTACGTCGTGGCGATATTAAACTGACTTAC ALNNFSQTLAQQGIEKYN TTAGAGATTGGTAAAGAGAACGAGAAACTTAATGAA QVLAGIAEIAGQPKTQGL CTGGTCCCGCTGGTCGAACTTAAGGACATTCATCGC NELINLARQKLSAKRSQL AATTTCAATAATTTCGCCACATATCTTTCTGGCTTC PTLQLLYKQILSKGDKPF AGCAAGAATCGTGAGAATGTGTACTCAACCAAATTT IDDFKSDQELIAELNEFV GATCGTCGTTCGGGTTATAAAGCCACCAGTGTAATC SSQIHGEHGAIKLINHEL GCACGCACGTTCGAACAGAATTTAATGTTCTGTCTT ESFINEARAAQQQIYVPK GGTAACATTGCCAAGTGGCACAAGGTGACAGAATTC DKLTELSLLLTGSWQAIN ATCAACCAGGCGAACAATTACGAGCTCCTGCAGGAG QWRYKLFDQKQLDKQQKQ CACGGCATCGATTGGAATAAGCAAATTGCCGCGCTG YSFSLAQVERWLATEVEQ GAACACAAACTGGACGTGTGTCTCGCAGAGTTCTTC QNFYQTEKERQQHKDTQP GCGCTTAATAACTTCTCACAAACCCTTGCACAACAG ANVTTSSDGHSILTAFEQ GGTATCGAAAAGTATAACCAGGTCTTGGCCGGCATC QVQTLLTNICVAAEKYRQ GCCGAGATTGCAGGCCAACCCAAGACCCAGGGCCTG LSDNLTAIDKQRESESSK AACGAACTCATTAACCTGGCCCGTCAGAAATTGTCT GFEQIAVIKTLLDACNEL GCCAAACGCTCACAACTGCCTACGTTGCAACTCCTT NHFLARFTVNKKDKLPED TACAAACAAATCTTAAGCAAGGGTGATAAGCCATTC RAEFWYEKLQAYIDAFPI ATCGACGATTTTAAAAGCGACCAAGAGTTGATCGCC YELYNKVRNYLSKKPFST GAATTAAATGAGTTTGTAAGCAGCCAGATTCACGGA EKVKINFDNSHFLSGWTA GAGCATGGTGCAATCAAATTAATTAATCACGAACTT DYERHSALLFKFNENYLL GAAAGCTTTATCAATGAAGCCCGTGCAGCGCAGCAA GVVNENLSSEEEEKLKLV CAGATTTATGTGCCCAAGGACAAGCTTACCGAATTA GGEEHAKRFIYDFQKIDN AGTCTTCTCTTAACGGGCAGTTGGCAAGCTATTAAT SNPPRVFIRSKGSSFAPA CAATGGCGTTACAAACTGTTCGACCAGAAACAGCTG VEKYQLPIGDIIDIYDQG GATAAACAACAGAAACAATATTCATTTAGCCTGGCC KFKTEHKKKNEAEFKDSL CAGGTTGAACGCTGGCTGGCAACTGAGGTTGAGCAA VRLIDYFKLGFSRHDSYK CAAAACTTCTACCAAACCGAAAAGGAGCGCCAGCAG HYPFKWKASHQYSDIAEF CATAAAGATACGCAGCCGGCGAACGTCACCACCAGC YAHTASFCYTLKEENINF AGCGATGGACACAGCATTTTAACAGCATTTGAGCAA NVLRELSSAGKVYLFEIY CAGGTGCAGACCTTATTAACCAACATCTGTGTTGCT NKDFSKNKRGQGRDNLHT GCCGAGAAATATCGCCAATTAAGTGATAATCTCACA SYWKLLFSAENLKDVVLK GCCATCGATAAACAACGCGAGAGCGAATCAAGTAAG LNGQAEIFYRPASLAETK GGATTCGAGCAAATCGCGGTGATTAAAACCTTGCTG AYTHKKGEVLKHKAYSKV GACGCGTGTAACGAGCTGAATCACTTTCTGGCACGC WEALDSPIGTRLSWDDAL TTCACGGTCAACAAGAAGGACAAACTCCCCGAAGAT KIPSITEKTNHNNQRVVQ CGCGCAGAATTTTGGTATGAAAAGTTACAAGCGTAC YNGQEIGRKAEFAIIKNR ATTGACGCGTTTCCGATCTACGAGCTGTATAATAAA RYSVDKFLFHCPITLNFK GTGCGTAATTACTTAAGCAAGAAGCCGTTTAGCACT ANGQDNINARVNQFLANN GAGAAAGTCAAAATTAATTTTGACAATTCCCATTTC KKINIIGIDRGEKHLLYI CTGTCGGGTTGGACGGCGGACTATGAGCGTCACAGC SVINQQGEVLHQESENTI GCCTTATTATTCAAATTTAATGAAAATTACCTGCTG TNSYQTANGEKRQVVTDY GGTGTAGTGAATGAGAACTTAAGCAGCGAGGAAGAA HQKLDMSEDKRDKARKSW GAAAAGCTGAAGCTCGTGGGCGGCGAAGAACATGCC STIENIKELKAGYLSHVV AAGCGCTTCATTTATGATTTTCAGAAAATCGACAAC HRLAQLIIEFNAIVALED TCAAACCCACCGCGCGTTTTCATTCGTAGCAAGGGG LNHGFKRGRFKIEKQVYQ TCATCGTTCGCACCTGCGGTCGAAAAGTATCAGTTA KFEKALIDKLSYLAFKDR CCGATTGGCGATATCATTGACATTTACGATCAGGGT TSCLETGHYLNAFQLTSK AAATTTAAGACAGAACACAAGAAGAAGAATGAGGCC FKGFNNLGKQSGILFYVN GAGTTTAAAGACAGTCTGGTACGTTTGATCGATTAT ADYTSTTDPLTGYIKNVY TTTAAGCTGGGCTTCTCTCGCCATGACAGCTATAAG KTYSSVKDSTEFWQRFNS CACTACCCATTCAAGTGGAAAGCCAGTCATCAATAT IRYIASENRFEFSYDLAD AGCGACATTGCGGAATTTTACGCTCATACCGCCTCA LKQKSLESKTKQTPLAKT TTTTGTTACACGCTTAAGGAAGAAAACATCAATTTT QWTVSSHVTRSYYNQQTK AACGTTCTGCGTGAGTTGTCGTCGGCGGGCAAAGTA QHELFEVTARIQQLLSKA TATCTCTTCGAAATTTACAATAAGGATTTCTCAAAG EISYQHQNDLIPALASCQ AACAAGCGCGGCCAAGGACGCGACAACTTGCATACC SKALHKELIWLFNSILTM AGTTATTGGAAGTTGCTGTTCTCGGCTGAGAACCTG RVTDSSKPSATSENDFIL AAGGATGTTGTGCTGAAATTAAACGGCCAAGCGGAG SPVAPYFDSRNLNKQLPE ATCTTTTACCGCCCAGCGTCTTTGGCCGAAACCAAG NGDANGAYNIARKGIMLL GCCTACACCCATAAGAAAGGGGAAGTACTGAAACAT ERIGDFVPEGNKKYPDLL AAGGCTTATAGCAAAGTGTGGGAAGCCCTGGATTCT IRNNDWQNFVQRPEMVNK CCCATTGGCACCCGCCTGAGCTGGGACGATGCTTTA QKKKLVKLKTEYSNGSLF AAGATCCCGTCTATTACCGAGAAGACCAATCACAAT NDLAFKAAAKRPAATKKA AATCAGCGTGTTGTCCAGTACAACGGCCAAGAAATT GQAKKKKASGSGAGSPKK GGCCGCAAAGCGGAGTTCGCTATTATCAAGAACCGC KRKVEDPKKKRKV (SEQ CGTTATTCCGTCGATAAATTCCTCTTTCACTGCCCG ID NO: 107) ATTACACTCAACTTCAAGGCGAACGGCCAGGACAAC ATTAACGCACGCGTTAATCAATTCCTGGCAAATAAC AAGAAGATCAACATTATTGGAATTGACCGTGGTGAA AAGCATTTACTGTATATCAGCGTGATTAATCAACAA GGCGAAGTCCTGCATCAGGAAAGCTTCAATACAATC ACGAATTCATATCAGACCGCCAATGGCGAGAAACGC CAAGTAGTCACTGACTATCACCAGAAGTTGGACATG AGCGAGGACAAACGCGATAAAGCACGTAAGAGCTGG AGTACAATCGAAAATATCAAAGAGCTGAAGGCGGGG TATCTGAGCCACGTTGTACATCGCCTCGCGCAACTG ATTATCGAATTTAATGCCATTGTTGCGTTGGAAGAT CTTAACCACGGGTTCAAACGCGGACGTTTTAAAATC GAAAAGCAAGTGTATCAGAAGTTCGAAAAGGCGCTG ATCGACAAATTGAGCTACTTAGCGTTTAAGGATCGC ACGTCGTGTCTGGAAACTGGACATTACTTGAATGCC TTTCAATTAACCTCAAAGTTCAAAGGCTTTAACAAC CTTGGCAAGCAATCCGGGATTTTGTTCTACGTTAAC GCCGATTACACGAGCACCACGGATCCCTTAACAGGC TATATTAAGAACGTATACAAAACCTACTCCTCGGTG AAGGATTCGACCGAATTTTGGCAGCGCTTTAACTCT ATCCGCTATATTGCGAGCGAGAACCGTTTTGAATTT AGCTACGACTTAGCGGACCTGAAACAGAAGTCGCTC GAGAGTAAAACCAAACAGACCCCTCTCGCCAAGACC CAATGGACGGTCTCTAGCCACGTTACCCGTTCCTAT TACAACCAGCAGACGAAGCAACATGAGTTATTCGAA GTGACAGCGCGCATTCAGCAATTGCTTAGCAAAGCA GAAATCAGCTATCAACATCAAAACGACTTGATCCCT GCGTTAGCATCATGTCAAAGTAAGGCGTTACACAAG GAGTTGATTTGGCTGTTCAACAGCATCCTGACTATG CGCGTCACGGACTCAAGCAAACCGTCCGCGACCTCG GAGAATGATTTTATCCTGAGCCCGGTAGCGCCGTAC TTCGACTCCCGCAATCTGAATAAGCAGCTGCCGGAA AACGGCGACGCGAACGGCGCATACAATATCGCTCGT AAAGGTATCATGCTTCTGGAACGTATCGGGGACTTC GTCCCGGAAGGTAACAAGAAGTACCCCGATTTACTG ATCCGCAATAATGACTGGCAGAATTTTGTACAACGC CCGGAGATGGTGAACAAGCAGAAGAAGAAACTCGTG AAGTTGAAAACGGAATACTCTAATGGCAGCCTCTTC AATGATTTGGCGTTTAAGGCCGCAGCTAAGCGCCCC GCCGCGACTAAGAAAGCGGGTCAAGCGAAGAAGAAG AAAGCGTCGGGGTCGGGAGCGGGCAGTCCGAAGAAG AAGCGTAAAGTAGAGGATCCGAAGAAGAAACGCAAA GTATAATAA (SEQ ID NO: 108)

In some embodiments, nuclease constructs disclosed herein can have a polypeptide sequence having at least 85% homology to the polypeptide represented by SEQ ID NO: 94 (ABW8), 29 (ABW3), 81 (ABW7), 107 (ABW9), 3 (ABW1), 16 (ABW2), 42 (ABW4), 55 (ABW5), and/or 68 (AWBW6) of International (PCT) Publication No. WO2021/108324. In some embodiments, nuclease constructs herein can have a polynucleotide sequence at least 85% homologous to the polynucleotide encoding the polypeptide having a polynucleotide represented by SEQ ID NO: 95-104 (ABW8 variants 1-10), 30-39 (ABW3 variants 1-10), 82-91 (ABW7 variants 1-10), 108-117 (ABW9 variants 1-10), 4-13 (ABW1 variants 1-10), 17-26 (ABW2 variants 1-10), 43-52 (ABW4 variants 1-10), 56-65 (ABW5 variants 1-10), and/or 69-78 (ABW6 variants 1-10)) of International (PCT) Publication No. WO2021/108324.

In some embodiments, nuclease constructs herein having a polypeptide of at least 85% homology to the polypeptide represented SEQ ID NO: 94) of International (PCT) Publication No. WO2021/108324. (ABW8) can have increased activity and/or editing accuracy compared to other nuclease constructs. In some embodiments, nuclease constructs herein having a polypeptide of at least 85% homology to the polypeptide represented by SEQ ID NO: 94 (ABW8), 29 (ABW3), 81 (ABW7) and/or 107 (ABW9) can have increased enzymatic activity and/or editing efficiency and/or accuracy compared to other nuclease constructs such as control nuclease constructs or native sequence-containing nucleases.

In some embodiments, nuclease constructs disclosed herein having a polynucleotide encoding a polypeptide having a polynucleotide of at least 85% homology to a polynucleotide represented by SEQ ID NO: 95-104 (ABW8 variants 1-10) can have increased enzymatic activity and/or editing efficiency and/or accuracy compared to control nuclease constructs or nuclease constructs having native sequences. In some embodiments, nuclease constructs disclosed herein having a polynucleotide encoding a polypeptide of at least 85% homology to a polynucleotide represented by SEQ ID NO: 95-104 (ABW8 variants 1-10), 30-39 (ABW3 variants 1-10) or 82-91 (ABW7 variants 1-10) can have increased activity (e.g., editing and/or efficiency) compared to control nuclease constructs or other nuclease constructs.

More type V-A Cas nucleases and their corresponding naturally occurring CRISPR-Cas systems can be identified by computational and experimental methods known in the art, e.g., as described in U.S. Pat. No. 9,790,490 and Shmakov et al. (2015) MOL. CELL, 60: 385. Exemplary computational methods include analysis of putative Cas proteins by homology modeling, structural BLAST, PSI-BLAST, or HHPred, and analysis of putative CRISPR loci by identification of CRISPR arrays. Exemplary experimental methods include in vitro cleavage assays and in-cell nuclease assays (e.g., the Surveyor assay) as described in Zetsche et al. (2015) CELL, 163: 759.

In certain embodiments, the Cas nuclease directs cleavage of one or both strands at the target locus, such as the target strand (i.e., the strand having the target nucleotide sequence that hybridizes with a single guide nucleic acid or modified dual guide nucleic acids) and/or the non-target strand. In certain embodiments, the Cas nuclease directs cleavage of one or both strands within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more nucleotides from the first or last nucleotide of the target nucleotide sequence or its complementary sequence. In certain embodiments, the cleavage is staggered, i.e. generating sticky ends. In certain embodiments, the cleavage generates a staggered cut with a 5′ overhang. In certain embodiments, the cleavage generates a staggered cut with a 5′ overhang of 1 to 5 nucleotides, e.g., of 4 or 5 nucleotides. In certain embodiments, the cleavage site is distant from the PAM, e.g., the cleavage occurs after the 18th nucleotide on the non-target strand and after the 23rd nucleotide on the target strand.

In certain embodiments, the engineered, non-naturally occurring system of the present invention further comprises the Cas nuclease that a complex comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating. In other embodiments, the engineered, non-naturally occurring system of the present invention further comprises a Cas protein that is related to the Cas nuclease that a complex comprising the targeter nucleic acid and the modulator nucleic acid is capable of activating. For example, in certain embodiments, the Cas protein comprises an amino acid sequence at least 80% (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the Cas nuclease. In certain embodiments, the Cas protein comprises a nuclease-inactive mutant of the Cas nuclease. In certain embodiments, the Cas protein further comprises an effector domain.

In certain embodiments, the Cas protein lacks substantially all DNA cleavage activity. Such a Cas protein can be generated by introducing one or more mutations to an active Cas nuclease (e.g., a naturally occurring Cas nuclease). A mutated Cas protein is considered to lack substantially all DNA cleavage activity when the DNA cleavage activity of the protein has at most 25%, at most 10%, at most 5%, at most 1%, at most 0.1%, at most 0.01%, or less of the DNA cleavage activity of the corresponding non-mutated form, for example, nil or negligible as compared with the non-mutated form. Thus, the Cas protein may comprise one or more mutations (e.g., a mutation in the RuvC domain of a type V-A Cas protein) and be used as a generic DNA binding protein with or without fusion to an effector domain. Exemplary mutations include D908A, E993A, and D1263A with reference to the amino acid positions in AsCpfl; D832A, E925A, and D1180A with reference to the amino acid positions in LbCpf1; and D917A, E1006A, and D1255A with reference to the amino acid position numbering of the FnCpf1. More mutations can be designed and generated according to the crystal structure described in Yamano et al. (2016) CELL, 165: 949.

It is understood that the Cas protein, rather than losing nuclease activity to cleave all DNA, may lose the ability to cleave only the target strand or only the non-target strand of a double-stranded DNA, thereby being functional as a nickase (see, Gao et al. (2016) CELL RES., 26: 901). Accordingly, in certain embodiments, the Cas nuclease is a Cas nickase. In certain embodiments, the Cas nuclease has the activity to cleave the non-target strand but lacks substantially the activity to cleave the target strand, e.g., by a mutation in the Nuc domain. In certain embodiments, the Cas nuclease has the cleavage activity to cleave the target strand but lacks substantially the activity to cleave the non-target strand.

In other embodiments, the Cas nuclease has the activity to cleave a double-stranded DNA and result in a double-strand break.

Cas proteins that lack substantially all DNA cleavage activity or have the ability to cleave only one strand may also be identified from naturally occurring systems. For example, certain naturally occurring CRISPR-Cas systems may retain the ability to bind the target nucleotide sequence but lose entire or partial DNA cleavage activity in eukaryotic (e.g., mammalian or human) cells. Such type V-A proteins are disclosed, for example, in Kim et al. (2017) ACS SYNTH. BIOL. 6(7): 1273-82 and Zhang et al. (2017) CELL DISCOV. 3:17018.

The activity of the Cas protein (e.g., Cas nuclease) can be altered, thereby creating an engineered Cas protein. In certain embodiments, the altered activity of the engineered Cas protein comprises increased targeting efficiency and/or decreased off-target binding. While not wishing to be bound by theory, it is hypothesized that off-target binding can be recognized by the Cas protein, for example, by the presence of one or more mismatches between the spacer sequence and the target nucleotide sequence, which may affect the stability and/or conformation of the CRISPR-Cas complex. In certain embodiments, the altered activity comprises modified binding, e.g., increased binding to the target locus (e.g., the target strand or the non-target strand) and/or decreased binding to off-target loci. In certain embodiments, the altered activity comprises altered charge in a region of the protein that associates with a single guide nucleic acid or dual guide nucleic acids, e.g., modified dual guide nucleic acids as described herein. In certain embodiments, the altered activity of the engineered Cas protein comprises altered charge in a region of the protein that associates with the target strand and/or the non-target strand. In certain embodiments, the altered activity of the engineered Cas protein comprises altered charge in a region of the protein that associates with an off-target locus. The altered charge can include decreased positive charge, decreased negative charge, increased positive charge, and increased negative charge. For example, decreased negative charge and increased positive charge may generally strengthen the binding to the nucleic acid(s) whereas decreased positive charge and increased negative charge may weaken the binding to the nucleic acid(s). In certain embodiments, the altered activity comprises increased or decreased steric hindrance between the protein and a single guide nucleic acid or dual guide nucleic acids, e.g., modified dual guide nucleic acids as described herein. In certain embodiments, the altered activity comprises increased or decreased steric hindrance between the protein and the target strand and/or the non-target strand. In certain embodiments, the altered activity comprises increased or decreased steric hindrance between the protein and an off-target locus. In certain embodiments, the modification or mutation comprises a substitution of Lys, His, Arg, Glu, Asp, Ser, Gly, or Thr. In certain embodiments, the modification or mutation comprises a substitution with Gly, Ala, Ile, Glu, or Asp. In certain embodiments, the modification or mutation comprises an amino acid substitution in the groove between the WED and RuvC domain of the Cas protein (e.g., a type V-A Cas protein).

In certain embodiments, the altered activity of the engineered Cas protein comprises increased nuclease activity to cleave the target locus. In certain embodiments, the altered activity of the engineered Cas protein comprises decreased nuclease activity to cleave an off-target locus. In certain embodiments, the altered activity of the engineered Cas protein comprises altered helicase kinetics. In certain embodiments, the engineered Cas protein comprises a modification that alters formation of the CRISPR complex.

In certain embodiments, a protospacer adjacent motif (PAM) or PAM-like motif directs binding of the Cas protein complex to the target locus. Many Cas proteins have PAM specificity. The precise sequence and length requirements for the PAM differ depending on the Cas protein used. PAM sequences are typically 2-5 base pairs in length and are adjacent to (but located on a different strand of target DNA from) the target nucleotide sequence. PAM sequences can be identified using any suitable method, e.g., a method known in the art, such as testing cleavage, targeting, or modification of oligonucleotides having the target nucleotide sequence and different PAM sequences.

In one embodiment, the Cas protein is MAD7 and the PAM is TTTN, wherein N is A, C, G, or T. In one embodiment, the Cas protein is MAD7 and the PAM is CTTN, wherein N is A, C, G, or T. In another embodiment, the Cas protein is AsCpfl and the PAM is TTTN, wherein N is A, C, G, or T. In another embodiment, the Cas protein is FnCpf1 and the PAM is 5′ TTN, wherein N is A, C, G, or T. PAM sequences for certain other type V-A Cas proteins are disclosed in Zetsche et al. (2015) CELL, 163: 759 and U.S. Pat. No. 9,982,279. Further, engineering of the PAM Interacting (PI) domain of a Cas protein may allow programing of PAM specificity, improve target site recognition fidelity, and increase the versatility of the engineered, non-naturally occurring system. Exemplary approaches to alter the PAM specificity of Cpf1 is described in Gao et al. (2017) NAT. BIOTECHNOL., 35: 789.

In certain embodiments, the engineered Cas protein comprises a modification that alters the Cas protein specificity in concert with modification to targeting range. Cas mutants can be designed to have increased target specificity as well as accommodating modifications in PAM recognition, for example by choosing mutations that alter PAM specificity (e.g., in the PI domain) and combining those mutations with groove mutations that increase (or if desired, decrease) specificity for the on-target locus versus off-target loci. The Cas modifications described herein can be used to counter loss of specificity resulting from alteration of PAM recognition, enhance gain of specificity resulting from alteration of PAM recognition, counter gain of specificity resulting from alteration of PAM recognition, or enhance loss of specificity resulting from alteration of PAM recognition.

In certain embodiments, the engineered Cas protein comprises one or more nuclear localization signal (NLS) motifs. In certain embodiments, the engineered Cas protein comprises at least 2 (e.g., at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10) NLS motifs. Non-limiting examples of NLS motifs include: the NLS of SV40 large T-antigen, having the amino acid sequence of PKKKRKV (SEQ ID NO: 23); the NLS from nucleoplasmin, e.g., the nucleoplasmin bipartite NLS having the amino acid sequence of KRPAATKKAGQAKKKK (SEQ ID NO: 24); the c-myc NLS, having the amino acid sequence of PAAKRVKLD (SEQ ID NO: 25) or RQRRNELKRSP (SEQ ID NO: 26); the hRNPA1 M9 NLS, having the amino acid sequence of NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO: 27); the importin-α IBB domain NLS, having the amino acid sequence of RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO: 28); the myoma T protein NLS, having the amino acid sequence of VSRKRPRP (SEQ ID NO: 793) or PPKKARED (SEQ ID NO: 794); the human p53 NLS, having the amino acid sequence of PQPKKKPL (SEQ ID NO: 31); the mouse c-abl IV NLS, having the amino acid sequence of SALIKKKKKMAP (SEQ ID NO: 32); the influenza virus NS1 NLS, having the amino acid sequence of DRLRR (SEQ ID NO: 33) or PKQKKRK (SEQ ID NO: 34); the hepatitis virus δ antigen NLS, having the amino acid sequence of RKLKKKIKKL (SEQ ID NO: 35); the mouse Mx1 protein NLS, having the amino acid sequence of REKKKFLKRR (SEQ ID NO: 36); the human poly(ADP-ribose) polymerase NLS, having the amino acid sequence of KRKGDEVDGVDEVAKKKSKK (SEQ ID NO: 37); the human glucocorticoid receptor NLS, having the amino acid sequence of RKCLQAGMNLEARKTKK (SEQ ID NO: 38), and synthetic NLS motifs such as PAAKKKKLD (SEQ ID NO: 39).

In general, the one or more NLS motifs are of sufficient strength to drive accumulation of the Cas protein in a detectable amount in the nucleus of a eukaryotic cell. The strength of nuclear localization activity may derive from the number of NLS motif(s) in the Cas protein, the particular NLS motif(s) used, the position(s) of the NLS motif(s), or a combination of these factors. In certain embodiments, the engineered Cas protein comprises at least 1 (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10) NLS motif(s) at or near the N-terminus (e.g., within at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the N-terminus). In certain embodiments, the engineered Cas protein comprises at least 1 (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10) NLS motif(s) at or near the C-terminus (e.g., within at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, 50, or more amino acids along the polypeptide chain from the C-terminus). In certain embodiments, the engineered Cas protein comprises at least 1 (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10) NLS motif(s) at or near the C-terminus and at least 1 (e.g., at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10) NLS motif(s) at or near the N-terminus. In certain embodiments, the engineered Cas protein comprises one, two, or three NLS motifs at or near the C-terminus. In certain embodiments, the engineered Cas protein comprises one NLS motif at or near the N-terminus and one, two, or three NLS motifs at or near the C-terminus. In certain embodiments, the engineered Cas protein comprises a nucleoplasmin NLS at or near the C-terminus.

Detection of accumulation in the nucleus may be performed by any suitable technique. For example, a detectable marker may be fused to the nucleic acid-targeting protein, such that location within a cell may be visualized. Cell nuclei may also be isolated from cells, the contents of which may then be analyzed by any suitable process for detecting the protein, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulation in the nucleus may also be determined indirectly, such as by an assay that detects the effect of the nuclear import of a Cas protein complex (e.g., assay for DNA cleavage or mutation at the target locus, or assay for altered gene expression activity) as compared to a control not exposed to the Cas protein or exposed to a Cas protein lacking one or more of the NLS motifs.

The Cas protein may comprise a chimeric Cas protein, e.g., a Cas protein having enhanced function by being a chimera. Chimeric Cas proteins may be new Cas proteins containing fragments from more than one naturally occurring Cas proteins or variants thereof. For example, fragments of multiple type V-A Cas homologs (e.g., orthologs) may be fused to form a chimeric Cas protein. In certain embodiments, the chimeric Cas protein comprises fragments of Cpf1 orthologs from multiple species and/or strains.

In certain embodiments, the Cas protein comprises one or more effector domains. The one or more effector domains may be located at or near the N-terminus of the Cas protein and/or at or near the C-terminus of the Cas protein. In certain embodiments, an effector domain comprised in the Cas protein is a transcriptional activation domain (e.g., VP64), a transcriptional repression domain (e.g., a KRAB domain or an SID domain), an exogenous nuclease domain (e.g., FokI), a deaminase domain (e.g., cytidine deaminase or adenine deaminase), or a reverse transcriptase domain (e.g., a high fidelity reverse transcriptase domain). Other activities of effector domains include but are not limited to methylase activity, demethylase activity, transcription release factor activity, translational initiation activity, translational activation activity, translational repression activity, histone modification (e.g., acetylation or demethylation) activity, single-stranded RNA cleavage activity, double-strand RNA cleavage activity, single-strand DNA cleavage activity, double-strand DNA cleavage activity, and nucleic acid binding activity.

In certain embodiments, the Cas protein comprises one or more protein domains that enhance homology-directed repair (HDR) and/or inhibit non-homologous end joining (NHEJ). Exemplary protein domains having such functions are described in Jayavaradhan et al. (2019) NAT. COMMUN. 10(1): 2866 and Janssen et al. (2019) MOL. THER. NUCLEIC ACIDS 16: 141-54. In certain embodiments, the Cas protein comprises a dominant negative version of p53-binding protein 1 (53BP1), for example, a fragment of 53BP1 comprising a minimum focus forming region (e.g., amino acids 1231-1644 of human 53BP1). In certain embodiments, the Cas protein comprises a motif that is targeted by APC-Cdh1, such as amino acids 1-110 of human Geminin, thereby resulting in degradation of the fusion protein during the HDR non-permissive G1 phase of the cell cycle.

In certain embodiments, the Cas protein comprises an inducible or controllable domain. Non-limiting examples of inducers or controllers include light, hormones, and small molecule drugs. In certain embodiments, the Cas protein comprises a light inducible or controllable domain. In certain embodiments, the Cas protein comprises a chemically inducible or controllable domain.

In certain embodiments, the Cas protein comprises a tag protein or peptide for ease of tracking or purification. Non-limiting examples of tag proteins and peptides include fluorescent proteins (e.g., green fluorescent protein (GFP), YFP, RFP, CFP, mCherry, tdTomato), HIS tags (e.g., 6×His tag), hemagglutinin (HA) tag, FLAG tag, and Myc tag.

In certain embodiments, the Cas protein is conjugated to a non-protein moiety, such as a fluorophore useful for genomic imaging. In certain embodiments, the Cas protein is covalently conjugated to the non-protein moiety. The terms “CRISPR-Associated protein,” “Cas protein,” “Cas,” “CRISPR-Associated nuclease,” and “Cas nuclease” as used herein can include such conjugates despite the presence of one or more non-protein moieties.

II. METHODS OF TARGETING, EDITING, AND/OR MODIFYING GENOMIC DNA

The engineered, non-naturally occurring systems disclosed herein are useful for targeting, editing, and/or modifying a target nucleic acid, such as a DNA (e.g., genomic DNA) in a cell or organism. Accordingly, in one aspect, the present invention provides a method of modifying a target nucleic acid (e.g., DNA) having a target nucleotide sequence, the method comprising contacting the target nucleic acid with the engineered, non-naturally occurring system disclosed herein, for example in sections IA, IA1, IB, or IC, thereby resulting in modification of the target nucleic acid.

The engineered, non-naturally occurring system can be contacted with the target nucleic acid as a complex. Accordingly, in certain embodiments, the method comprises contacting the target nucleic acid with a modified guide CRISPR-Cas complex, such as a modified dual guide CRISPR-Cas complex comprising (a) a targeter nucleic acid comprising (i) a spacer sequence designed to hybridize with the target nucleotide sequence with a 3′ end and (ii) a targeter stem sequence with, optionally, a 5′ end; (b) a modulator nucleic acid comprising a modulator stem sequence complementary to the targeter stem sequence with, optionally, a 3′ end and a 5′ end with, optionally, a 5′ sequence, e.g., tail sequence; and (c) a Cas protein, e.g., a Cas nuclease, wherein the targeter nucleic acid and the modulator nucleic acid are joined in certain embodiments and separate nucleic acids in other embodiments, and wherein one or more nucleotides or internucleotide linkages, such as 1-5 or more than 5 nucleotides or internucleotide linkages, e.g., 1, 2, 3, 4, 5 or more than 5 nucleotides or internucleotide linkages, at or near the 3′ end of the targeter nucleotide, at or near the 5′ end of the targeter stem sequence (if present), at or near the 3′ end of the modulator nucleic acid (if present), at or near the 5′ end of the 5′ sequence, e.g., tail sequence, or a combination thereof, are modified; thereby resulting in modification of the target nucleic acid. Exemplary modified guide nucleic acid CRISPR-Cas complexes are described in Section IC, using modified guide nucleic acids described in sections IA, IA1, and IB, and nucleases described in section IC, and any of these may be used under suitable conditions. In some cases, the targeter nucleic acid and the modulator nucleic acid form a complex that is capable of activating a Cas nuclease that, in a naturally occurring system, is activated by a single crRNA in the absence of a tracrRNA. In certain embodiments, the Cas protein comprises an amino acid sequence at least 80% (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the Cas nuclease.

In certain embodiments, the Cas nuclease is a Type I, II, III, IV, V, or V Cas nuclease. In certain embodiments, the Cas nuclease is a type V-A, type V-C, or type V-D Cas nuclease. In certain embodiments, the Cas nuclease is a type V-A Cas nuclease. In certain embodiments, the target nucleic acid further comprises a cognate PAM positioned relative to the target nucleotide sequence such that (a) the modified dual guide CRISPR-Cas complex binds the target nucleic acid; or (b) the Cas nuclease is activated when the modified guide CRISPR-Cas complex, e.g., modified dual guide CRISPR-Cas complex, binds the target nucleic acid.

The modified guide CRISPR-Cas complex, e.g., modified dual guide CRISPR-Cas complex may be delivered to a cell by introducing a pre-formed ribonucleoprotein (RNP) complex into the cell. Alternatively, one or more components of the modified guide CRISPR-Cas complex, e.g., modified dual guide CRISPR-Cas complex may be expressed in the cell; it will be appreciated that segments containing modified nucleotides should be introduced into the cells, but unmodified segments can be expressed in the cell. Exemplary methods of delivery are known in the art and described in, for example, U.S. Pat. Nos. 10,113,167, 8,697,359, 10,570,418, 11,125,739, 10,829,787, and 11,118,194, and U.S. Patent Application Publication Nos. 2015/0344912, 2018/0119140, and 2018/0282763.

It is understood that contacting a DNA (e.g., genomic DNA) in a cell with a modified dual guide CRISPR-Cas complex does not require delivery of all components of the complex into the cell. For examples, one or more of the components may be pre-existing in the cell. In certain embodiments, the cell (or a parental/ancestral cell thereof) has been engineered to express the Cas protein, and the targeter nucleic acid (or a nucleic acid comprising a regulatory element operably linked to a nucleotide sequence encoding the targeter nucleic acid) and the modulator nucleic acid (or a nucleic acid comprising a regulatory element operably linked to a nucleotide sequence encoding the modulator nucleic acid) are delivered into the cell, e.g., where one or the other, or both, contains one or more modified nucleotides or internucleotide linkages at or near the 3′ ends, at or near the 5′ ends, or at or near both ends. In certain embodiments, the cell (or a parental/ancestral cell thereof) has been engineered to express the modulator nucleic acid, and the Cas protein (or a nucleic acid comprising a regulatory element operably linked to a nucleotide sequence encoding the Cas protein) and the targeter nucleic acid (or a nucleic acid comprising a regulatory element operably linked to a nucleotide sequence encoding the targeter nucleic acid) are delivered into the cell, where the targeter nucleic acid contains one or more modified nucleotides at or near the 3′ and/or 5′ ends. In certain embodiments, the cell (or a parental/ancestral cell thereof) has been engineered to express the Cas protein and the targeter nucleic acid, and the modulator nucleic acid (or a nucleic acid comprising a regulatory element operably linked to a nucleotide sequence encoding the modulator nucleic acid) is delivered into the cell, where the modulator nucleic acid contains one or more modified nucleotides at or near the 3′ and/or 5′ ends.

In certain embodiments, the target DNA is in the genome of a target cell. Accordingly, in another aspect, the present invention provides a cell comprising the non-naturally occurring system or a CRISPR expression system described herein. In certain embodiments, the cell is an immune cell. In certain embodiments, the cell is a T cell. See following paragraph and section IVB for more potential cells to be modified. In addition, the present invention provides a cell whose genome has been modified by the modified dual guide CRISPR-Cas system or complex disclosed herein.

The target cells can be mitotic or post-mitotic cells from any organism, such as a bacterial cell, an archaeal cell, a cell of a single-cell eukaryotic organism, a plant cell, an algal cell, e.g., Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa, Sargassum patens C. Agardh, and the like, a fungal cell (e.g., a yeast cell), an animal cell, a cell from an invertebrate animal (e.g., fruit fly, enidarian, echinoderm, nematode, etc.), a cell from a vertebrate animal (e.g., fish, amphibian, reptile, bird, mammal), a cell from a mammal, a cell from a rodent, or a cell from a human. The types of target cells include but are not limited to a stem cell (e.g., an embryonic stem (ES) cell, an induced pluripotent stem (iPS) cell, a germ cell), a somatic cell (e.g., a fibroblast, a hematopoietic cell, a T lymphocyte (e.g., CD8⁺ T lymphocyte), an NK cell, a neuron, a muscle cell, a bone cell, a hepatocyte, a pancreatic cell), an in vitro or in vivo embryonic cell of an embryo at any stage (e.g., a 1-cell, 2-cell, 4-cell, 8-cell; stage zebrafish embryo). Cells may be from established cell lines or may be primary cells (i.e., cells and cells cultures that have been derived from a subject and allowed to grow in vitro for a limited number of passages of the culture). For example, primary cultures are cultures that may have been passaged within 0 times, 1 time, 2 times, 4 times, 5 times, 10 times, or 15 times, but not enough times to go through the crisis stage. Typically, the primary cell lines of the present invention are maintained for fewer than 10 passages in vitro. If the cells are primary cells, they may be harvested from an individual by any suitable method. For example, leukocytes may be harvested by apheresis, leukocytapheresis, or density gradient separation, while cells from tissues such as skin, muscle, bone marrow, spleen, liver, pancreas, lung, intestine, or stomach can be harvested by biopsy. The harvested cells may be used immediately, or may be stored under frozen conditions with a cryopreservative and thawed at a later time in a manner as commonly known in the art.

A. Ribonucleoprotein (RNP) Delivery and “Cas RNA” Delivery

The engineered, non-naturally occurring system disclosed herein can be delivered into a cell by suitable methods known in the art, including but not limited to ribonucleoprotein (RNP) delivery and “Cas RNA” delivery described below.

In certain embodiments, a modified guide CRISPR-Cas complex, e.g., modified dual guide CRISPR-Cas system including a targeter nucleic acid, a modulator nucleic acid, where the 5′ and/or 3′ ends of one or both of the targeter and modulator nucleic acids contain one or more, e.g., 1-5 or more than 5, such as 1, 2, 3, 4, 5, or more than 5 modified nucleotides or internucleotide linkages, and a Cas protein can be combined into a RNP complex and then delivered into the cell as a pre-formed complex. Exemplary modified guide nucleic acid CRISPR-Cas complexes are described in Section IC, using modified guide nucleic acids described in sections IA, IA1, and IB, and nucleases described in section IC, and any of these may be used under suitable conditions. This method is suitable for active modification of the genetic or epigenetic information in a cell during a limited time period. For example, where the Cas protein has nuclease activity to modify the genomic DNA of the cell, the nuclease activity only needs to be retained for a period of time to allow DNA cleavage, and prolonged nuclease activity may increase off-targeting. Similarly, certain epigenetic modifications can be maintained in a cell once established and can be inherited by daughter cells.

A “ribonucleoprotein” or “RNP,” as used herein, includes a complex comprising a nucleoprotein and a ribonucleic acid. A “nucleoprotein” as used herein includes a protein capable of binding a nucleic acid (e.g., RNA, DNA). Where the nucleoprotein binds a ribonucleic acid it is referred to as “ribonucleoprotein.” The interaction between the ribonucleoprotein and the ribonucleic acid may be direct, e.g., by covalent bond, or indirect, e.g., by non-covalent bond (e.g., electrostatic interactions (e.g., ionic bond, hydrogen bond, halogen bond), van der Waals interactions (e.g., dipole-dipole, dipole-induced dipole, London dispersion), ring stacking (pi effects), hydrophobic interactions, and the like). In certain embodiments, the ribonucleoprotein includes an RNA-binding motif non-covalently bound to the ribonucleic acid. For example, positively charged aromatic amino acid residues (e.g., lysine residues) in the RNA-binding motif may form electrostatic interactions with the negative nucleic acid phosphate backbones of the RNA.

To ensure efficient loading of the Cas protein, the targeter nucleic acid and the modulator nucleic acid can be provided in excess molar amount (e.g., at least 1 fold, at least 1.5 fold. at least 2 fold, at least 3 fold, at least 4 fold, or at least 5 fold) relative to the Cas protein. In certain embodiments, the targeter nucleic acid and the modulator nucleic acid are annealed under suitable conditions prior to complexing with the Cas protein. In other embodiments, the targeter nucleic acid, the modulator nucleic acid, and the Cas protein are directly mixed together to form an RNP.

A variety of delivery methods can be used to introduce an RNP disclosed herein into a cell. Exemplary delivery methods or vehicles include but are not limited to microinjection, liposomes (see, e.g., U.S. Pat. No. 10,829,787) such as molecular trojan horses liposomes that delivers molecules across the blood brain barrier (see, Pardridge et al. (2010) COLD SPRING HARB. PROTOC., doi:10.1101/pdb.prot5407), immunoliposomes, virosomes, microvesicles (e.g., exosomes and ARMMs), polycations, lipid:nucleic acid conjugates, electroporation, cell permeable peptides (see, U.S. Pat. No. 11,118,194), nanoparticles, nanowires (see, Shalek et al. (2012) NANO LETTERS, 12: 6498), exosomes, and perturbation of cell membrane (e.g., by passing cells through a constriction in a microfluidic system, see, U.S. Pat. No. 11,125,739). In certain embodiments the delivery method is electroporation. Where the target cell is a proliferating cell, the efficiency of RNP delivery can be enhanced by cell cycle synchronization (see, U.S. Pat. No. 10,570,418).

In other embodiments, the modified guide CRISPR-CAS system, e.g., modified dual guide CRISPR-Cas system is delivered into a cell in a “Cas RNA” approach, i.e., delivering a targeter nucleic acid, a modulator nucleic acid, where the 5′ and/or 3′ ends of one or both of the targeter and modulator nucleic acids contain one or more, e.g., 1-5 or more than 5, such as 1, 2, 3, 4, 5, or more than 5 modified nucleotides, and an RNA (e.g., messenger RNA (mRNA)) encoding a Cas protein. The RNA encoding the Cas protein can be translated in the cell and form a complex with the targeter nucleic acid and the modulator nucleic acid intracellularly. Similar to the RNP approach, RNAs have limited half-lives in cells, even though stability-increasing modification(s) can be made in one or more of the RNAs. Accordingly, the “Cas RNA” approach is suitable for active modification of the genetic or epigenetic information in a cell during a limited time period, such as DNA cleavage, and has the advantage of reducing off-targeting.

The mRNA can be produced by transcription of a DNA comprising a regulatory element operably linked to a Cas coding sequence. Given that multiple copies of Cas protein can be generated from one mRNA, the targeter nucleic acid and the modulator nucleic acid are generally provided in excess molar amount (e.g., at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 50 fold, or at least 100 fold) relative to the mRNA. In certain embodiments, the targeter nucleic acid and the modulator nucleic acid are annealed under suitable conditions prior to delivery into the cells. In other embodiments, the targeter nucleic acid and the modulator nucleic acid are delivered into the cells without annealing in vitro. In certain embodiments, a modified dual guide nucleic acid system is used. In certain embodiments, a modified single guide nucleic acid system is used.

A variety of delivery systems can be used to introduce an “Cas RNA” system into a cell. Non-limiting examples of delivery methods or vehicles include microinjection, biolistic particles, liposomes (see, e.g., U.S. Pat. No. 10,829,787) such as molecular trojan horses liposomes that delivers molecules across the blood brain barrier (see, Pardridge et al. (2010) COLD SPRING HARB. PROTOC., doi:10.1101/pdb.prot5407), immunoliposomes, virosomes, polycations, lipid:nucleic acid conjugates, electroporation, nanoparticles, nanowires (see, Shalek et al. (2012) NANO LETTERS, 12: 6498), exosomes, and perturbation of cell membrane (e.g., by passing cells through a constriction in a microfluidic system, see, U.S. Pat. No. 11,125,739). Specific examples of the “nucleic acid only” approach by electroporation are described in International (PCT) Publication No. WO2016/164356.

In other embodiments, the modified guide CRISPR-Cas system, e.g., modified dual guide CRISPR-Cas system is delivered into a cell in the form of a targeter nucleic acid, a modulator nucleic acid, where the 5′ and/or 3′ ends of one or both of the targeter and modulator nucleic acids contain one or more, e.g., 1-5 or more than 5, such as 1, 2, 3, 4, 5, or more than 5 modified nucleotides, and a DNA comprising a regulatory element operably linked to a Cas coding sequence. The DNA can be provided in a plasmid, viral vector, or any other form described in the “CRISPR Expression Systems” subsection. Such delivery method may result in constitutive expression of Cas protein in the target cell (e.g., if the DNA is maintained in the cell in an episomal vector or is integrated into the genome), and may increase the risk of off-targeting which is undesirable when the Cas protein has nuclease activity. Notwithstanding, this approach is useful when the Cas protein comprises a non-nuclease effector (e.g., a transcriptional activator or repressor). It is also useful for research purposes and for genome editing of plants.

B. CRISPR Expression Systems

In another aspect, the present invention provides a CRISPR expression system comprising: either (a) a nucleic acid comprising a first regulatory element operably linked to a nucleotide sequence encoding a targeter nucleic acid disclosed herein comprising (i) a spacer sequence designed to hybridize with a target nucleotide sequence and (ii) a targeter stem sequence; or (b) a nucleic acid comprising a second regulatory element operably linked to a nucleotide sequence encoding a modulator nucleic acid disclosed herein comprising a modulator stem sequence complementary to the targeter stem sequence, wherein a complex comprising the targeter nucleic acid and a modified modulator nucleic acid, as described herein, or a complex comprising a modified targeter nucleic acid, as described herein, and the modulator nucleic acid is capable of activating a Cas nuclease that, in a naturally occurring system, is activated by a single crRNA in the absence of a tracrRNA. Exemplary targeter and modulator nucleic acids are described in sections IA, IA1, and 1B.

In certain embodiments, the CRISPR expression system further comprises (c) a nucleic acid comprising a third regulatory element operably linked to a nucleotide sequence encoding a Cas protein disclosed herein. In certain embodiments, the Cas protein comprises an amino acid sequence at least 80% (e.g., at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) identical to the Cas nuclease, thereby resulting in modification of the target nucleic acid (e.g., DNA). In certain embodiments, the Cas protein and the Cas nuclease are identical, and the method results in cleavage of the target nucleic acid. In certain embodiments, the Cas nuclease is a Type I, II, III, IV, V, or VI nuclease. In certain embodiments the Cas nuclease is a Type V nuclease. In certain embodiments, the Cas nuclease is a type V-A, type V-C, or type V-D Cas nuclease. In certain embodiments, the Cas nuclease is a type V-A Cas nuclease. Exemplary Cas Nucleases are described in section IC.

As used in this context, the term “operably linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory element in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).

The form of elements (a), (b), and (c) of the CRISPR expression system described above may be independently selected from various nucleic acids such as DNA (e.g., modified DNA) and RNA (e.g., modified RNA). In certain embodiments, elements (a) and (b) are each in the form of DNA. In certain embodiments, the CRISPR expression system further comprises element (c) in the form of DNA. The third regulatory element can be a constitutive or inducible promoter that drives the expression of the Cas protein. In other embodiments, the CRISPR expression system further comprises element (c) in the form of RNA (e.g., mRNA).

Elements (a), (b), and/or (c) can be provided in one or more vectors. The term “vector,” as used herein, can include a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. Conventional viral and non-viral based gene transfer methods can be used to introduce nucleic acids in cells, such as prokaryotic cells, eukaryotic cells, mammalian cells, or target tissues. Non-viral vector delivery systems include DNA plasmids, RNA (e.g., a transcript of a vector described herein), naked nucleic acid, and nucleic acid complexed with a delivery vehicle, such as a liposome. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. Gene therapy procedures are known in the art and disclosed in Van Brunt (1988) BIOTECHNOLOGY, 6: 1149; Anderson (1992) SCIENCE, 256: 808; Nabel & Feigner (1993) TIBTECH, 11: 211; Mitani & Caskey (1993) TIBTECH, 11: 162; Dillon (1993) TIBTECH, 11: 167; Miller (1992) NATURE, 357: 455; Vigne, (1995) RESTORATIVE NEUROLOGY AND NEUROSCIENCE, 8: 35; Kremer & Perricaudet (1995) BRITISH MEDICAL BULLETIN, 51: 31; Haddada et al. (1995) CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, 199: 297; Yu et al. (1994) GENE THERAPY, 1: 13; and Doerfler and Bohm (Eds.) (2012) The Molecular Repertoire of Adenoviruses II: Molecular Biology of Virus-Cell Interactions. In certain embodiments, at least one of the vectors is a DNA plasmid. In certain embodiments, at least one of the vectors is a viral vector (e.g., retrovirus, adenovirus, or adeno-associated virus).

Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors and replication defective viral vectors) do not autonomously replicate in the host cell. Certain vectors, however, may be integrated into the genome of the host cell and thereby are replicated along with the host genome. A skilled person in the art will appreciate that different vectors may be suitable for different delivery methods and have different host tropism, and will be able to select one or more vectors suitable for the use.

The term “regulatory element,” as used herein, can include a transcriptional and/or translational control sequence, such as a promoter, enhancer, transcription termination signal (e.g., polyadenylation signal), internal ribosomal entry sites (IRES), protein degradation signal, and the like, that provide for and/or regulate transcription of a non-coding sequence (e.g., a targeter nucleic acid or a modulator nucleic acid) or a coding sequence (e.g., a Cas protein) and/or regulate translation of an encoded polypeptide. Such regulatory elements are described, for example, in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY, 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). A tissue-specific promoter may direct expression primarily in a desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g., liver, pancreas), or particular cell types (e.g., lymphocytes). Regulatory elements may also direct expression in a temporal-dependent manner, such as in a cell-cycle dependent or developmental stage-dependent manner, which may or may not also be tissue or cell-type specific. In certain embodiments, a vector comprises one or more pol III promoter (e.g., 1, 2, 3, 4, 5, or more pol III promoters), one or more pol II promoters (e.g., 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g., 1, 2, 3, 4, 5, or more pol I promoters), or combinations thereof. Examples of pol III promoters include, but are not limited to, U6 and H1 promoters. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with the CMV enhancer), the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1α promoter. Also encompassed by the term “regulatory element” are enhancer elements, such as WPRE; CMV enhancers; the R-U5′ segment in LTR of HTLV-I (see, Takebe et al. (1988) MOL. CELL. BIOL., 8: 466); SV40 enhancer; and the intron sequence between exons 2 and 3 of rabbit β-globin (see, O'Hare et al. (1981) PROC. NATL. ACAD. SCI. USA., 78: 1527). It will be appreciated by those skilled in the art that the design of the expression vector can depend on factors such as the choice of the host cell to be transformed, the level of expression desired, etc. A vector can be introduced into host cells to produce transcripts, proteins, or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., CRISPR transcripts, proteins, enzymes, mutant forms thereof, or fusion proteins thereof).

In certain embodiments, the nucleotide sequence encoding the Cas protein is codon optimized for expression in a eukaryotic host cell, e.g., a yeast cell, a mammalian cell (e.g., a mouse cell, a rat cell, or a human cell), or a plant cell. Various species exhibit particular bias for certain codons of a particular amino acid. Codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell is generally a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, at the “Codon Usage Database” available at kazusa.or.jp/codon/and these tables can be adapted in a number of ways (see, Nakamura et al. (2000) NUCL. ACIDS RES., 28: 292). Computer algorithms for codon optimizing a particular sequence for expression in a particular host cell, such as Gene Forge (Aptagen; Jacobus, Pa.), are also available. In certain embodiments, the codon optimization facilitates or improves expression of the Cas protein in the host cell.

C. Donor Templates

Cleavage of a target nucleotide sequence in the genome of a cell by the modified dual guide CRISPR-Cas system or complex disclosed herein can activate the DNA damage pathways, which may rejoin the cleaved DNA fragments by NHEJ or HDR. HDR requires a repair template, either endogenous or exogenous, to transfer the sequence information from the repair template to the target.

In certain embodiments, the engineered, non-naturally occurring system or CRISPR expression system further comprises a donor template. As used herein, the term “donor template” can include a nucleic acid designed to serve as a repair template at or near the target nucleotide sequence upon introduction into a cell or organism. In certain embodiments, the donor template is complementary to a polynucleotide comprising the target nucleotide sequence or a portion thereof. When optimally aligned, a donor template may overlap with one or more nucleotides of a target nucleotide sequences (e.g., at least 1, 5, 10, 15, 20, 25, 30, 35, 40, 50, 100, 500 or more nucleotides). The nucleotide sequence of the donor template is typically not identical to the genomic sequence that it replaces. Rather, the donor template may contain one or more substitutions, insertions, deletions, inversions or rearrangements with respect to the genomic sequence, so long as sufficient homology is present to support homology-directed repair. In certain embodiments, the donor template comprises a non-homologous sequence flanked by two regions of homology (i.e., homology arms), such that homology-directed repair between the target DNA region and the two flanking sequences results in insertion of the non-homologous sequence at the target region. In certain embodiments, the donor template comprises a non-homologous sequence of 10-100 nucleotides, 50-500 nucleotides, 100-1,000 nucleotides, 200-2,000 nucleotides, or 500-5,000 nucleotides in length positioned between two homology arms. In certain embodiments the donor template comprises a single stranded oligodeoxynucleotide (ssODN).

Generally, the homologous region(s) of a donor template has at least 50% sequence identity to a genomic sequence with which recombination is desired. The homology arms are designed or selected such that they are capable of recombining with the nucleotide sequences flanking the target nucleotide sequence under intracellular conditions. In certain embodiments, where HDR of the non-target strand is desired, the donor template comprises a first homology arm homologous to a sequence 5′ to the target nucleotide sequence and a second homology arm homologous to a sequence 3′ to the target nucleotide sequence. In certain embodiments, the first homology arm is at least 50% (e.g., at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to a sequence 5′ to the target nucleotide sequence. In certain embodiments, the second homology arm is at least 50% (e.g., at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to a sequence 3′ to the target nucleotide sequence. In certain embodiments, when the donor template sequence and a polynucleotide comprising a target nucleotide sequence are optimally aligned, the nearest nucleotide of the donor template is within at least 5, 10, 15, 20, 25, 50, 75, 100, 200, 300, 400, 500, 1000, 2000, 3000, 4000, or more nucleotides from the target nucleotide sequence.

In certain embodiments, the donor template further comprises an engineered sequence not homologous to the sequence to be repaired. Such engineered sequence can harbor a barcode and/or a sequence capable of hybridizing with a donor template-recruiting sequence disclosed herein.

In certain embodiments, the donor template further comprises one or more mutations relative to the genomic sequence, wherein the one or more mutations reduce or prevent cleavage, by the same CRISPR-Cas system, of the donor template or of a modified genomic sequence with at least a portion of the donor template sequence incorporated. In certain embodiments, in the donor template, the PAM adjacent to the target nucleotide sequence and recognized by the Cas nuclease is mutated to a sequence not recognized by the same Cas nuclease. In certain embodiments, in the donor template, the target nucleotide sequence (e.g., the seed region) is mutated. In certain embodiments, the one or more mutations are silent with respect to the reading frame of a protein-coding sequence encompassing the mutated sites.

The donor template can be provided to the cell as single-stranded DNA, single-stranded RNA, double-stranded DNA, or double-stranded RNA. It is understood that the modified dual guide CRISPR-Cas system disclosed herein may possess nuclease activity to cleave the target strand, the non-target strand, or both. When HDR of the target strand is desired, a donor template having a nucleic acid sequence complementary to the target strand is also contemplated.

The donor template can be introduced into a cell in linear or circular form. If introduced in linear form, the ends of the donor template may be protected (e.g., from exonucleolytic degradation) by methods known to those of skill in the art. For example, one or more dideoxynucleotide residues are added to the 3′ terminus of a linear molecule and/or self-complementary oligonucleotides are ligated to one or both ends (see, for example, Chang et al. (1987) PROC. NATL. ACAD SCI USA, 84: 4959; Nehls et al. (1996) SCIENCE, 272: 886; see also the chemical modifications for increasing stability and/or specificity of RNA disclosed supra). Additional methods for protecting exogenous polynucleotides from degradation include, but are not limited to, addition of terminal amino group(s) and the use of modified nucleotides such as, for example, phosphorothioates, phosphoramidates, and O-methyl ribose or deoxyribose residues. As an alternative to protecting the termini of a linear donor template, additional lengths of sequence may be included outside of the regions of homology that can be degraded without impacting recombination.

A donor template can be a component of a vector as described herein, contained in a separate vector, or provided as a separate polynucleotide, such as an oligonucleotide, linear polynucleotide, or synthetic polynucleotide. In certain embodiments, the donor template is a DNA. In certain embodiments, a donor template is in the same nucleic acid as a sequence encoding the targeter nucleic acid, a sequence encoding the modulator nucleic acid, and/or a sequence encoding the Cas protein, where applicable. In certain embodiments, a donor template is provided in a separate nucleic acid. A donor template polynucleotide may be of any suitable length, such as at least 50, 75, 100, 150, 200, 500, 1000, 2000, 3000, 4000, or more nucleotides in length, for example 50 to 500 nucleotides in length, such as 500 nucleotides in length.

A donor template can be introduced into a cell as an isolated nucleic acid. Alternatively, a donor template can be introduced into a cell as part of a vector (e.g., a plasmid) having additional sequences such as, for example, replication origins, promoters and genes encoding antibiotic resistance, that are not intended for insertion into the DNA region of interest. Alternatively, a donor template can be delivered by viruses (e.g., adenovirus, adeno-associated virus (AAV)). In certain embodiments, the donor template is introduced as an AAV, e.g., a pseudotyped AAV. The capsid proteins of the AAV can be selected by a person skilled in the art based upon the tropism of the AAV and the target cell type. For example, in certain embodiments, the donor template is introduced into a hepatocyte as AAV8 or AAV9. In certain embodiments, the donor template is introduced into a hematopoietic stem cell, a hematopoietic progenitor cell, or a T lymphocyte (e.g., CD8⁺ T lymphocyte) as AAV6 or an AAVHSC (see, U.S. Pat. No. 9,890,396). It is understood that the sequence of a capsid protein (VP1, VP2, or VP3) may be modified from a wild-type AAV capsid protein, for example, having at least 50% (e.g., at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%) sequence identity to a wild-type AAV capsid sequence.

The donor template can be delivered to a cell (e.g., a primary cell) by various delivery methods, such as a viral or non-viral method disclosed herein. In certain embodiments, a non-viral donor template is introduced into the target cell as a naked nucleic acid or in complex with a liposome or poloxamer. In certain embodiments, a non-viral donor template is introduced into the target cell by electroporation. In other embodiments, a viral donor template is introduced into the target cell by infection. The engineered, non-naturally occurring system can be delivered before, after, or simultaneously with the donor template (see, International (PCT) Application Publication No. WO2017/053729). A skilled person in the art can choose proper timing based upon the form of delivery (consider, for example, the time needed for transcription and translation of RNA and protein components) and the half-life of the molecule(s) in the cell. In particular embodiments, where the modified guide CRISPR-Cas system, e.g., modified dual guide CRISPR-Cas system including the Cas protein is delivered by electroporation (e.g., as an RNP), the donor template (e.g., as an AAV) is introduced into the cell within 4 hours (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 90, 120, 150, 180, 210, or 240 minutes) after the introduction of the engineered, non-naturally occurring system.

In certain embodiments, the donor template is conjugated covalently to the modulator nucleic acid. Covalent linkages suitable for this conjugation are known in the art and are described, for example, in U.S. Pat. No. 9,982,278 and Savic et al. (2018) ELIFE 7:e33761. In certain embodiments, the donor template is covalently linked to the modulator nucleic acid (e.g., the 5′ end of the modulator nucleic acid) through an internucleotide bond. In certain embodiments, the donor template is covalently linked to the modulator nucleic acid (e.g., the 5′ end of the modulator nucleic acid) through a linker.

In certain embodiments, the donor template contains an exogenous gene, e.g., CAR cassette, that is integrated at a targeted site in a host cell, e.g., an immune cell, e.g., a T cell, mediated through the action of a nucleic acid-guided nuclease complex, that results in a modified host cell, e.g., a CAR-T cell.

D. Efficiency and Specificity

The engineered, non-naturally occurring system of the present invention can have the advantage that the efficiency of nucleic acid targeting, cleavage, or modification can be increased or decreased by, for example, adjusting the hybridization of modified guide nucleic acids, e.g., modified dual guide nucleic acids, and the length of the spacer sequence.

In certain embodiments, the engineered, non-naturally occurring system has high efficiency. For example, in certain embodiments, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of a population of nucleic acids having the target nucleotide sequence and a cognate PAM, when contacted with the engineered, non-naturally occurring system, is targeted, cleaved, or modified. In certain embodiments, the genomes of at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of a population of cells, when contacted with the engineered, non-naturally occurring system, are targeted, cleaved, or modified.

It has been observed that the occurrence of on-target events and the occurrence of off-target events are generally correlated. For certain therapeutic purposes, low on-target efficiency can be tolerated and low off-target frequency is more desirable. For example, when editing or modifying a proliferating cell that will be delivered to a subject and proliferate in vivo, tolerance to off-target events is low. Prior to delivery, however, it is possible to assess the on-target and off-target events, thereby selecting one or more colonies that have the desired edit or modification and lack any undesired edit or modification.

The method disclosed herein is suitable for such use. In certain embodiments, when a population of nucleic acids having the target nucleotide sequence and a cognate PAM is contacted with the engineered, non-naturally occurring system disclosed herein, the frequency of off-target events (e.g., targeting, cleavage, or modification, depending on the function of the CRISPR-Cas system) is reduced by at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% relative to the frequency of off-target events when using the corresponding CRISPR system containing an unmodified guide nucleic acid, e.g., a guide nucleic acid consisting of the sequences of the targeter and modulator nucleic acids, but without modified nucleotides or internucleotide linkages under the same conditions. In certain cases, the frequency is relative to the frequency of off-target events when using the corresponding CRISPR system containing a single guide nucleic acid (e.g., a single crRNA consisting of the sequences of the targeter and modulator nucleic acids) under the same conditions. In certain embodiments, when genomic DNA having the target nucleotide sequence and a cognate PAM is contacted with the engineered, non-naturally occurring system disclosed herein in a population of cells, the frequency of off-target events (e.g., targeting, cleavage, or modification, depending on the function of the CRISPR-Cas system) is reduced by at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% % relative to the frequency of off-target events when using the corresponding CRISPR system containing an unmodified guide nucleic acid, e.g., a guide nucleic acid consisting of the sequences of the targeter and modulator nucleic acids, but without modified nucleotides or internucleotide linkages under the same conditions. In certain cases, the frequency is relative to the frequency of off-target events when using the corresponding CRISPR system containing a single guide nucleic acid (e.g., a single crRNA consisting of the sequences of the targeter and modulator nucleic acids) under the same conditions. In certain embodiments, when delivered into a population of cells comprising genomic DNA having the target nucleotide sequence and a cognate PAM, the frequency of off-target events (e.g., targeting, cleavage, or modification, depending on the function of the CRISPR-Cas system) in the cells receiving the engineered, non-naturally occurring system disclosed herein is reduced by at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% % relative to the frequency of off-target events when using the corresponding CRISPR system containing an unmodified guide nucleic acid, e.g., a guide nucleic acid consisting of the sequences of the targeter and modulator nucleic acids, but without modified nucleotides or internucleotide linkages under the same conditions. In certain cases, the frequency is relative to the frequency of off-target events when using the corresponding CRISPR system containing a single guide nucleic acid (e.g., a single crRNA consisting of the sequences of the targeter and modulator nucleic acids) under the same conditions. Methods of assessing off-target events were summarized in Lazzarotto et al. (2018) NAT PROTOC. 13(11): 2615-42, and include discovery of in situ Cas off-targets and verification by sequencing (DISCOVER-seq) as disclosed in Wienert et al. (2019) SCIENCE 364(6437): 286-89; genome-wide unbiased identification of double-stranded breaks (DSBs) enabled by sequencing (GUIDE-seq) as disclosed in Kleinstiver et al. (2016) NAT. BIOTECH. 34: 869-74; circularization for in vitro reporting of cleavage effects by sequencing (CIRCLE-seq) as described in Kocak et al. (2019) NAT. BIOTECH. 37: 657-66. In certain embodiments, the off-target events include targeting, cleavage, or modification at a given off-target locus (e.g., the locus with the highest occurrence of off-target events detected). In certain embodiments, the off-target events include targeting, cleavage, or modification at all the loci with detectable off-target events, collectively.

E. Multiplex Methods

The methods of targeting, editing, and/or modifying a genomic DNA disclosed herein can be conducted in multiplicity. For example, a library of targeter nucleic acids can be used to target multiple genomic loci; a library of donor templates can also be used to generate multiple insertions, deletions, and/or substitutions. The multiplex assay can be conducted in a screening method wherein each separate cell culture (e.g., in a well of a 96-well plate or a 384-well plate) is exposed to a different targeter nucleic acid or a different combination of targeter nucleic acid and donor template. The multiplex assay can also be conducted in a selection method wherein a cell culture is exposed to a mixed population of different targeter nucleic acids and/or donor templates, and the cells with desired characteristics (e.g., functionality) are enriched or selected by advantageous survival or growth, resistance to a certain agent, expression of a detectable protein (e.g., a fluorescent protein that is detectable by flow cytometry), etc.

In certain embodiments, the multiplex method employs a plurality of targeter nucleic acids that are capable of hybridizing with different target nucleotide sequences. In certain embodiments, the plurality of targeter nucleic acids comprise a common targeter stem sequence. In certain embodiments, the multiplex method employs a single modulator nucleic acid capable of hybridizing with the plurality of targeter nucleic acids. In certain embodiments, the multiplex method employs a single Cas protein (e.g., Cas nuclease) disclosed herein.

In certain embodiments, the multiplex method employs a plurality of targeter nucleic acids that are capable of hybridizing with different target nucleotide sequences that are close to or adjacent to different PAMs. In certain embodiments, the plurality of targeter nucleic acids comprise different targeter stem sequences. In certain embodiments, the multiplex method employs a plurality of modulator nucleic acids each capable of hybridizing with a different targeter nucleic acid. In certain embodiments, the multiplex method employs a plurality of Cas proteins (e.g., Cas nucleases) disclosed herein that have different PAM specificity.

In certain embodiments, the multiplex method further comprises introducing one or more donor templates into the population of cells. In certain embodiments, the multiplex method employs a plurality of modulator nucleic acids each comprising a different donor template-recruiting sequence, wherein each donor template-recruiting sequence is capable of hybridizing with a different donor template.

In certain embodiments, the plurality of targeter nucleic acids and/or the plurality of donor templates are designed for saturation editing. For example, in certain embodiments, each nucleotide position in a sequence of interest is systematically modified with each of all four traditional bases, A, T, G and C. In other embodiments, at least one sequence in each gene from a pool of genes of interest is modified, for example, according to a CRISPR design algorithm. In certain embodiments, each sequence from a pool of exogenous elements of interest (e.g., protein coding sequences, non-protein coding genes, regulatory elements) is inserted into one or more given loci of the genome.

It is understood that the multiplex methods suitable for the purpose of carrying out a screening or selection method, which is typically conducted for research purposes, may be different from the methods suitable for therapeutic purposes. For example, constitutive expression of certain elements (e.g., a Cas nuclease and/or a modulator nucleic acid) may be undesirable for therapeutic purposes due to the potential of increased off-targeting. Conversely, for research purposes, constitutive expression of a Cas nuclease and/or a modulator nucleic acid may be desirable. For example, the constitutive expression provides a large window during which other elements can be introduced. When a stable cell line is established for the constitutive expression, the number of exogenous elements that need to be co-delivered into a single cell is also reduced. Therefore, constitutive expression of certain elements can increase the efficiency and reduce the complexity of a screening or selection process. Inducible expression of certain elements of the system disclosed herein may also be used for research purposes given similar advantages. Expression may be induced by an exogenous agent (e.g., a small molecule) or by an endogenous molecule or complex present in a particular cell type (e.g., at a particular stage of differentiation). Methods known in the art, such as those described in the “CRISPR Expression Systems” subsection supra, can be used for constitutively or inducibly expressing one or more elements.

It is further understood that despite the need to introduce at least three elements—the targeter nucleic acid, the modulator nucleic acid, and the Cas protein—these three elements can be delivered into the cell as a single complex of pre-formed RNP. Therefore, the efficiency of the screening or selection process can also be achieved by pre-assembling a plurality of RNP complexes in a multiplex manner.

In certain embodiments, the method disclosed herein further comprises a step of identifying a targeter nucleic acid, a modulator nucleic acid, a Cas protein, a donor template, or a combination of two or more of these elements from the screening or selection process. A set of barcodes may be used, for example, in the donor template between two homology arms, to facilitate the identification. In specific embodiments, the method further comprises harvesting the population of cells; selectively amplifying a genomic DNA or RNA sample including the target nucleotide sequence(s) and/or the barcodes; and/or sequencing the genomic DNA or RNA sample and/or the barcodes that has been selectively amplified.

In another aspect, the present invention provides a library comprising a plurality of targeter nucleic acids disclosed herein, optionally further comprising one or more modulator nucleic acids disclosed herein. In another aspect, the present invention provides a library comprising a plurality of nucleic acids each comprising a regulatory element operably linked to a different targeter nucleic acid disclosed herein, optionally further comprising a regulatory element operably linked to a modulator nucleic acid disclosed herein. These libraries can be used in combination with one or more Cas proteins or Cas-coding nucleic acids disclosed herein, and/or one or more donor templates as disclosed herein for a screening or selection method.

III. PHARMACEUTICAL COMPOSITIONS

The present invention provides a composition (e.g., pharmaceutical composition) comprising an engineered, non-naturally occurring system or a eukaryotic cell disclosed herein. In certain embodiments, the composition comprises a complex of the targeter nucleic acid and the modulator nucleic acid. In certain embodiments, the composition comprises an RNP comprising the targeter nucleic acid, the modulator nucleic acid, and a Cas protein (e.g., the Cas nuclease that the targeter nucleic acid and the modulator nucleic acid are capable of activating or a related Cas protein). Targeter and modulator nucleic acids, and modifications thereto, are described in sections IA, IA1, and IB; Cas proteins, e.g., Cas nucleases, are described in section IC; RNPs are described in section IIA.

In addition, the present invention provides a method of producing a composition, the method comprising incubating the targeter nucleic acid and the modulator nucleic acid of an engineered, non-naturally occurring system disclosed herein under suitable conditions, thereby producing a composition (e.g., pharmaceutical composition) comprising a complex of the targeter nucleic acid and the modulator nucleic acid. In certain embodiments, the method further comprises incubating the targeter nucleic acid and the modulator nucleic acid with a Cas protein (e.g., the Cas nuclease that the targeter nucleic acid and the modulator nucleic acid are capable of activating or a related Cas protein), thereby producing a complex of the targeter nucleic acid, the modulator nucleic acid, and the Cas protein (e.g., an RNP). In certain embodiments, the method further comprises purifying the complex (e.g., the RNP).

For therapeutic use, an engineered, non-naturally occurring system, a CRISPR expression system, or a cell comprising such system or modified by such system disclosed herein is combined with a pharmaceutically acceptable carrier. The term “pharmaceutically acceptable” as used herein can include those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit-to-risk ratio.

The term “pharmaceutically acceptable carrier” as used herein can include buffers, carriers, and excipients suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable carriers include any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water, emulsions (e.g., such as an oil/water or water/oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see, e.g., Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, Pa. (1975). Pharmaceutically acceptable carriers include buffers, solvents, dispersion media, coatings, isotonic and absorption delaying agents, and the like, that are compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is known in the art.

In certain embodiments, a pharmaceutical composition disclosed herein comprises a salt, e.g., NaCl, MgCl₂, KCl, MgSO₄, etc.; a buffering agent, e.g., a Tris buffer, N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), 2-(N-Morpholino)ethanesulfonic acid (MES), IVIES sodium salt, 3-(N-Morpholino)propanesulfonic acid (MOPS), N-tris[Hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS), etc.; a solubilizing agent; a detergent, e.g., a non-ionic detergent such as Tween-20, etc.; a nuclease inhibitor; and the like. For example, in certain embodiments, a subject composition comprises a subject DNA-targeting RNA and a buffer for stabilizing nucleic acids.

In certain embodiments, a pharmaceutical composition may contain formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition. In such embodiments, suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen-sulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates or other organic acids); bulking agents (such as mannitol or glycine); chelating agents (such as ethylenediamine tetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides; and other carbohydrates (such as glucose, mannose or dextrins); proteins (such as serum albumin, gelatin or immunoglobulins); coloring, flavoring and diluting agents; emulsifying agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate, triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancing agents (such as sucrose or sorbitol); tonicity enhancing agents (such as alkali metal halides, preferably sodium or potassium chloride, mannitol sorbitol); delivery vehicles; diluents; excipients and/or pharmaceutical adjuvants (see, Remington's Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990).

In certain embodiments, a pharmaceutical composition may contain nanoparticles, e.g., polymeric nanoparticles, liposomes, or micelles (See Anselmo et al. (2016) BIOENG. TRANSL. MED. 1: 10-29). In certain embodiment, the pharmaceutical composition comprises an inorganic nanoparticle. Exemplary inorganic nanoparticles include, e.g., magnetic nanoparticles (e.g., Fe₃MnO₂) or silica. The outer surface of the nanoparticle can be conjugated with a positively charged polymer (e.g., polyethylenimine, polylysine, polyserine) which allows for attachment (e.g., conjugation or entrapment) of payload. In certain embodiment, the pharmaceutical composition comprises an organic nanoparticle (e.g., entrapment of the payload inside the nanoparticle). Exemplary organic nanoparticles include, e.g., SNALP liposomes that contain cationic lipids together with neutral helper lipids which are coated with polyethylene glycol (PEG) and protamine and nucleic acid complex coated with lipid coating. In certain embodiment, the pharmaceutical composition comprises a liposome, for example, a liposome disclosed in International (PCT) Publication No. WO2015/148863.

In certain embodiments, the pharmaceutical composition comprises a targeting moiety to increase target cell binding or update of nanoparticles and liposomes. Exemplary targeting moieties include cell specific antigens, monoclonal antibodies, single chain antibodies, aptamers, polymers, sugars, and cell penetrating peptides. In certain embodiments, the pharmaceutical composition comprises a fusogenic or endosome-destabilizing peptide or polymer.

In certain embodiments, a pharmaceutical composition may contain a sustained- or controlled-delivery formulation. Techniques for formulating sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. Sustained-release preparations may include, e.g., porous polymeric microparticles or semipermeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained release matrices may include polyesters, hydrogels, polylactides, copolymers of L-glutamic acid and gamma ethyl-L-glutamate, poly (2-hydroxyethyl-inethacrylate), ethylene vinyl acetate, or poly-D(−)-3-hydroxybutyric acid. Sustained release compositions may also include liposomes that can be prepared by any of several methods known in the art.

A pharmaceutical composition of the invention can be administered by a variety of methods known in the art. The route and/or mode of administration vary depending upon the desired results. Administration can be intravenous, intramuscular, intraperitoneal, or subcutaneous, or administered proximal to the site of the target. The pharmaceutically acceptable carrier should be suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (e.g., by injection or infusion). Depending on the route of administration, the active compound, i.e., the multispecific antibody of the invention, may be coated in a material to protect the compound from the action of acids and other natural conditions that may inactivate the compound.

Formulation components suitable for parenteral administration include a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as EDTA; buffers such as acetates, citrates or phosphates; and agents for the adjustment of tonicity such as sodium chloride or dextrose.

For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). The carrier should be stable under the conditions of manufacture and storage, and should be preserved against microorganisms. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol), and suitable mixtures thereof.

Pharmaceutical formulations preferably are sterile. Sterilization can be accomplished by any suitable method, e.g., filtration through sterile filtration membranes. Where the composition is lyophilized, filter sterilization can be conducted prior to or following lyophilization and reconstitution. In certain embodiments, a multispecific antibody is lyophilized, and then reconstituted in buffered saline, at the time of administration.

Pharmaceutical compositions of the invention can be prepared in accordance with methods well known and routinely practiced in the art. See, e.g., Remington: The Science and Practice of Pharmacy, Mack Publishing Co., 20th ed., 2000; and Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York, 1978. Pharmaceutical compositions are preferably manufactured under GMP conditions. Typically, a therapeutically effective dose or efficacious dose of the multispecific antibody of the invention is employed in the pharmaceutical compositions of the invention. The multispecific antibodies of the invention are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art. Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.

Actual dosage levels of the active ingredients in the pharmaceutical compositions of the invention can be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level depends upon a variety of pharmacokinetic factors including the activity of the particular compositions of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion of the particular compound being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compositions employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors.

IV. THERAPEUTIC USES

The engineered, non-naturally occurring system and CRISPR expression system disclosed herein are useful for targeting, editing, and/or modifying the genomic DNA in a cell or organism. These systems, as well as a cell comprising one of the systems or a cell whose genome has been modified by the engineered, non-naturally occurring system, can be used to treat a disease or disorder in which modification of genetic or epigenetic information is desirable. Accordingly, in another aspect, the present invention provides a method of treating a disease or disorder, the method comprising administering to a subject in need thereof an effective amount of a non-naturally occurring system, a CRISPR expression system, or a cell disclosed herein.

The term “subject” can include human and non-human animals. Non-human animals include all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, and reptiles. Except when noted, the terms “patient” or “subject” are used herein interchangeably.

The terms “treatment”, “treating”, “treat”, “treated”, and the like, as used herein, can include obtaining a desired pharmacologic and/or physiologic effect. The effect may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease or delaying the disease progression. “Treatment”, as used herein, covers any treatment of a disease in a mammal, e.g., in a human, and includes: (a) inhibiting the disease, i.e., arresting its development; and (b) relieving the disease, i.e., causing regression of the disease. It is understood that a disease or disorder may be identified by genetic methods and treated prior to manifestation of any medical symptom.

For therapeutic purposes, the method disclosed herein is particularly suitable for editing or modifying a proliferating cell, such as a stem cell (e.g., a hematopoietic stem cell), a progenitor cell (e.g., a hematopoietic progenitor cell or a lymphoid progenitor cell), or a memory cell (e.g., a memory T cell). Given that such cell is delivered to a subject and will proliferate in vivo, tolerance to off-target events is low. Prior to delivery, however, it is possible to assess the on-target and off-target events, thereby selecting one or more colonies that have the desired edit or modification and lack any undesired edit or modification. Therefore, lower editing or modifying efficiency can be tolerated for such cell. The engineered, non-naturally occurring system of the present invention has the advantage of increasing or decreasing the efficiency of nucleic acid cleavage by, for example, adjusting the hybridization of modified dual guide nucleic acids. As a result, it can be used to minimize off-target events when creating genetically engineered proliferating cells.

For minimization of toxicity and off-target effect, it is important to control the concentration of the modified guide CRISPR-Cas system, e.g., modified dual guide CRISPR-Cas system, delivered. Optimal concentrations can be determined by testing different concentrations in a cellular, tissue, or non-human eukaryote animal model and using deep sequencing to analyze the extent of modification at potential off-target genomic loci. The concentration that gives the highest level of on-target modification while minimizing the level of off-target modification can be selected for ex vivo or in vivo delivery.

B. Gene Therapies

It is understood that the engineered, non-naturally occurring system and CRISPR expression system disclosed herein can be used to treat a genetic disease or disorder, i.e., a disease or disorder associated with or otherwise mediated by an undesirable mutation in the genome of a subject.

Exemplary genetic diseases or disorders include age-related macular degeneration, adrenoleukodystrophy (ALD), Alagille syndrome, alpha-1-antitrypsin deficiency, argininemia, argininosuccinic aciduria, ataxia (e.g., Friedreich ataxia, spinocerebellar ataxias, ataxia telangiectasia, essential tremor, spastic paraplegia), autism, biliary atresia, biotinidase deficiency, carbamoyl phosphate synthetase I deficiency, carbohydrate deficient glycoprotein syndrome (CDGS), a central nervous system (CNS)-related disorder (e.g., Alzheimer's disease, amyotrophic lateral sclerosis (ALS), canavan disease (CD), ischemia, multiple sclerosis (MS), neuropathic pain, Parkinson's disease), Bloom's syndrome, cancer, Charcot-Marie-Tooth disease (e.g., peroneal muscular atrophy, hereditary motor sensory neuropathy), congenital hepatic porphyria, citrullinemia, Crigler-Najjar syndrome, cystic fibrosis (CF), Dentatorubro-Pallidoluysian Atrophy (DRPLA). Diabetes insipidus, Fabry, familial hypercholesterolemia (LDL receptor defect), Fanconi's anemia, fragile X syndrome, a fatty acid oxidation disorder, galactosemia, glucose-6-phosphate dehydrogenase (G6PD), glycogen storage diseases (e.g., type I (glucose-6-phosphatase deficiency, Von Gierke II (alpha glucosidase deficiency, Pompe), III (debrancher enzyme deficiency, Cori), IV (brancher enzyme deficiency, Anderson), V (muscle glycogen phosphorylase deficiency, McArdle), VII (muscle phosphofructokinase deficiency, Tauri), VI (liver phosphorylase deficiency, Hers), IX (liver glycogen phosphorylase kinase deficiency)), hemophilia A (associated with defective factor VIII), hemophilia B (associated with defective factor IX), Huntington's disease, glutaric aciduria, hypophosphatemia, Krabbe, lactic acidosis, Lafora disease, Leber's Congenital Amaurosis, Lesch Nyhan syndrome, a lysosomal storage disease, metachromatic leukodystrophy disease (MLD), mucopolysaccharidosis (MPS) (e.g., Hunter syndrome, Hurler syndrome, Maroteaux-Lamy syndrome, Sanfilippo syndrome, Scheie syndrome, Morquio syndrome, other, MPSI, MPSII, MPSIII, MSIV, MPS 7), a muscular/skeletal disorder (e.g., muscular dystrophy, Duchenne muscular dystrophy), myotonic Dystrophy (DM), neoplasia, N-acetylglutamate synthase deficiency, ornithine transcarbamylase deficiency, phenylketonuria, primary open angle glaucoma, retinitis pigmentosa, schizophrenia, Severe Combined Immune Deficiency (SCID), Spinobulbar Muscular Atrophy (SBMA), sickle cell anemia, Usher syndrome, Tay-Sachs disease, thalassemia (e.g, β-Thalassemia), trinucleotide repeat disorders, tyrosinemia, Wilson's disease, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease (CGD), X-linked severe combined immune deficiency, and xeroderma pigmentosum.

Genetic Disorders contemplated herein can include, but are not limited to:

-   -   Neoplasia: Genes linked to this disorder: PTEN; ATM; ATR; EGFR;         ERBB2; ERBB3; ERBB4; Notch1; Notch2; Notch3; Notch4; AKT; AKT2;         AKT3; HIF; HIFI a; HIF3a; Met; HRG; Bc12; PPAR alpha; PPAR         gamma; WT1 (Wilms Tumor); FGF Receptor Family members (5         members: 1, 2, 3, 4, 5); CDKN2a; APC; RB (retinoblastoma); MEN1;         VHL; BRCA1; BRCA2; AR (Androgen Receptor); TSG101; IGF; IGF         Receptor; Igf1 (4 variants); Igf2 (3 variants); Igf 1 Receptor;         Igf 2 Receptor; Bax; Bc12; caspases family (9 members: 1, 2, 3,         4, 6, 7, 8, 9, 12); Kras; Apc;     -   Age-related Macular Degeneration: Genes linked to these         disorders Abcr; Cc12; Cc2; cp (cemloplasmin); Timp3; cathepsinD;         Vidlr; Ccr2;     -   Schizophrenia Disorders: Genes linked to this disorder:         Neuregulinl (Nrgl); Erb4 (receptor for Neuregulin); Complexinl         (Cp1x1); Tph1 Tryptophan hydroxylase; Tph2 Tryptophan         hydroxylase 2; Neurexin 1; GSK3; GSK3a; GSK3b;     -   Trinucleotide Repeat Disorders: Genes linked to this disorder: 5         HTT (Huntington's Dx); SBMA/SMAX1/AR (Kennedy's Dx); FXN/X25         (Friedrich's Ataxia); ATX3 (Machado-Joseph's Dx); ATXN1 and         ATXN2 (spinocerebellar ataxias); DMPK (myotonic dystrophy);         Atrophin-1 and Atn1 (DRPLA Dx); CBP (Creb-BP—global         instability); VLDLR (Alzheimer's); Atxn7; Atxn10;     -   Fragile X Syndrome: Genes linked to this disorder: FMR2; FXR1;         FXR2; mGLURS;     -   Secretase Related Disorders: Genes linked to this disorder:         APH-1 (alpha and beta); Presenil n (Psenl); nicastrin (Ncstn);         PEN-2;     -   Others: Genes linked to this disorder: Nos1; Paip1; Nati; Nat2;     -   Prion—related disorders: Gene linked to this disorder: Prp;     -   ALS: Genes linked to this disorder: SOD1; ALS2; STEX; FUS;         TARDBP; VEGF (VEGF-a; VEGF-b; VEGF-c);     -   Drug addiction: Genes linked to this disorder: Prkce (alcohol);         Drd2; Drd4; ABAT (alcohol); GRIA2; GrmS; Grin1; Htr1b; Grin2a;         Drd3; Pdyn; Gria1 (alcohol);     -   Autism: Genes linked to this disorder: Mecp2; BZRAP1; MDGA2;         SemaSA; Neurexin 1; Fragile X (FMR2 (AFF2); FXR1; FXR2; MglurS);     -   Alzheimer's Disease Genes linked to this disorder: El; CHIP;         UCH; UBB; Tau; LRP; PICALM; Clusterin; PS1; SORL1; CR1; Vidlr;         Uba1; Uba3; CHIP28 (Aqp1, Aquaporin 1); Uch11; Uch13; APP;     -   Inflammation and Immune-related disorders Genes linked to this         disorder: IL-10; IL-1 (IL-la; IL-1b); IL-13; IL-17 (IL-17a         (CTLA8); IL-17b; IL-17c; IL-17d; IL-17f); 11-23; Cx3cr1; ptpn22;         TNFa; NOD2/CARD15 for IBD; IL-6; IL-12 (IL-12a; IL-12b); CTLA4;         Cx3c11, AAT deficiency/mutations, AIDS (KIR3DL1, NKAT3, NKB1,         ANIB11, KIR3DS1, IFNG, CXCL12, SDF1); Autoimmune         lymphoproliferative syndrome (TNFRSF6, APT1, FAS, CD95, ALPS1A);         Combined immunodeficiency, (IL2RG, SCIDX1, SCIDX, IMD4); HIV-1         (CCL5, SCYA5, D17S136E, TCP228), HIV susceptibility or infection         (IL10, CSIF, CMKBR2, CCR2, CMKBR5, CCCKR5 (CCR5));         Immunodeficiencies (CD3E, CD3G, AICDA, AID, HIGM2, TNFRSF5,         CD40, UNG, DGU, HIGM4, TNFSF5, CD40LG, HIGM1, IGM, FOXP3, IPEX,         AIID, XPID, PIDX, TNFRSF14B, TACI); Inflammation (IL-10, IL-1         (IL-la, IL-1b), IL-13, IL-17 (IL-17a (CTLA8), IL-17b, IL-17c,         IL-17d, IL-17f), 11-23, Cx3cr1, ptpn22, TNFa, NOD2/CARD15 for         IBD, IL-6, IL-12 (IL-12a, IL-12b), CTLA4, Cx3c11); Severe         combined immunodeficiencies (SCIDs)(JAK3, JAKL, DCLRE1C,         ARTEMIS, SCIDA, RAG1, RAG2, ADA, PTPRC, CD45, LCA, IL7R, CD3D,         T3D, IL2RG, SCIDX1, SCIDX, IMD4);     -   Parkinson's, Genes linked to this disorder: x-Synuclein; DJ-1;         LRRK2; Parkin; PINK1;     -   Blood and coagulation disorders: Genes linked to these         disorders: Anemia (CDAN1, CDA1, RPS19, DBA, PKLR, PK1, NT5C3,         UMPH I, PSN1, RHAG, RH50A, NRAMP2, SPTB, ALAS2, ANH I, ASB,         ABCB7, ABC7, ASAT); Bare lymphocyte syndrome (TAPBP, TPSN, TAP2,         ABCB3, PSF2, RINGI 1, MHC2TA, C2TA, RFX5, RFXAP, RFX5), Bleeding         disorders (TBXA2R, P2RX I, P2X I); Factor H and factor H-like 1         (HF1, CFH, HUS); Factor V and factor VIII (MCFD2); Factor VII         deficiency (F7); Factor X deficiency (F10); Factor XI deficiency         (F11); Factor XII deficiency (F12, HAF); Factor XIIIA deficiency         (F13A1, F13A); Factor XIIIB deficiency (F13B); Fanconi anemia         (FANCA, FACA, FA1, FA, FAA, FAAP95, FAAP90, F1134064, FANCB,         FANCC, FACC, BRCA2, FANCD1, FANCD2, FANCD, FACD, FAD, FANCE,         FACE, FANCF, XRCC9, FANCG, BRIP1, BACH1, FANCJ, PHF9, FANCL,         FANCM, ICIAA1596); Hemophagocytic lymphohistiocytosis disorders         (PRF1, HPLH2, UNC13D, MUNC13-4, HPLH3, HLH3, FHL3); Hemophilia A         (F8, F8C, HEMA);     -   Hemophilia B (F9, HEMB), Hemorrhagic disorders (PI, ATT, F5);         Leukocyde deficiencies and disorders (ITGB2, CD18, LCAMB, LAD,         EIF2B1, EIF2BA, EIF2B2, EIF2B3, EIF2B5, LVWM, CACH, CLE,         EIF2B4); Sickle cell anemia (HBB); Thalassemia (HBA2, HBB, HBD,         LCRB, HBA1);     -   Cell dysregulation and oncology disorders: Genes linked to these         disorders: B-cell non-Hodgkin lymphoma (BCL7A, BCL7); Leukemia         (TALI TCL5, SCL, TAL2, FLT3, NBS 1, NBS, ZNFNIAI, IK1, LYF1,         HOXD4, HOX4B, BCR, CML, PHL, ALL, ARNT, KRAS2, RASK2, GMPS,         AFIO, ARHGEFI2, LARG, KIAA0382, CALM, CLTH, CEBPA, CEBP, CHIC2,         BTL, FLT3, KIT, PBT, LPP, NPM1, NUP214, D9S46E, CAN, CAIN, RUNX         1, CBFA2, AML1, WHSC 1 LI, NSD3, FLT3, AF1Q, NPM 1, NUMA1,         ZNF145, PLZF, PML, MYL, STAT5B, AFI 0, CALM, CLTH, ARLI 1,         ARLTS1, P2RX7, P2X7, BCR, CML, PHL, ALL, GRAF, NFI, VRNF, WSS,         NFNS, PTPNI 1, PTP2C, SHP2, NS 1, BCL2, CCND1, PRAD1, BCL1,         TCRA, GATA1, GF 1, ERYF1, NFE1, ABL1, NQO1, DIA4, NMOR1, NUP2I4,         D9S46E, CAN, CAIN);     -   Metabolic, liver, kidney disorders: Genes linked to these         disorders: Amyloid neuropathy (TTR, PALS); Amyloidosis (APOA1,         APP, AAA, CVAP, AD1, GSN, FGA, LYZ, UR, PALS); Cirrhosis (KATI         8, KRT8, CaHlA, NAIC, TEX292, KIAA1988); Cystic fibrosis (CFTR,         ABCC7, CF, MRP7); Glycogen storage diseases (SLC2A2, GLUT2,         G6PC, G6PT, G6PT1, GAA, LAMP2, LAMPS, ΔGL, GDE, GBE1, GYS2,         PYGL, PFKM); Hepatic adenoma, 142330 (TCF1, HNF1A, MODY3),         Hepatic failure, early onset, and neurologic disorder (SCOD1,         SCO1), Hepatic lipase deficiency (LIPC), Hepatoblastoma, cancer         and carcinomas (CTNNB1, PDGFRL, PDGRL, PRLTS, AXIN1, AXIN,         CTNNB1, TP53, P53, LFS1, IGF2R, MPRI, MET, CASP8, MCH5;         Medullary cystic kidney disease (UMOD, HNFJ, FJHN, MCKD2,         ADMCKD2); Phenylketonuria (PAH, PKU1, QDPR, DHPR, PTS);         Polycystic kidney and hepatic disease (FCYT, PKHD1, ARPKD, PKD2,         PKD4, PKDTS, PRKCSH, G19P1, PCLD, SEC63);     -   Muscular/Skeletal Disorders: Genes linked to these disorders:         Becker muscular dystrophy (DMD, BMD, MYF6), Duchenne Muscular         Dystrophy (DMD, BMD); Emery-Dreifuss muscular dystrophy (LMNA,         LMN1, EMD2, FPLD, CMD1A, HGPS, LGMD1B, LMNA, LMN1, EMD2, FPLD,         CMD1A); Facioscapulohumeral muscular dystrophy (FSHMD1A,         FSHD1A); Muscular dystrophy (FKRP, MDC1C, LGMD2I, LAMA2, LAMM,         LARGE, KIAA0609, MDC1D, FCMD, TTID, MYOT, CAPN3, CANP3, DYSF,         LGMD2B, SGCG, LGMD2C, DMDA1, SCG3, SGCA, ADL, DAG2, LGMD2D,         DMDA2, SGCB, LGMD2E, SGCD, SGD, LGMD2F, CMD1L, TCAP, LGMD2G,         CMD1N, TRIM32, HT2A, LGMD2H, FKRP, MDC1C, LGMD2I, TTN, CMD1G,         TMD, LGMD2J, POMT1, CAV3, LGMD1C, SEPN1, SELN, RSMD1, PLEC1,         PLTN, EBS1); Osteopetrosis (LAPS, BMND1, LRP7, LR3, OPPG, VBCH2,         CLCN7, CLC7, OPTA2, OSTM1, GL, TCIRG1, TIRC7, 0C116, OPTB1);         Muscular atrophy (VAPB, VAPC, ALS8, SMN1, SMA1, SMA2, SMA3,         SMA4, BSCL2, SPG17, GARS, SMAD1, CMT2D, HEXB, IGHMBP2, SMUBP2,         CATF1, SMARD1);     -   Neurological and Neuronal disorders: Genes linked to these         disorders: ALS (SOD1, ALS2, STEX, FUS, TARDBP, VEGF (VEGF-a,         VEGF-b, VEGF-c); Alzheimer disease (APP, AAA, CVAP, AD1, APOE,         AD2, PSEN2, AD4, STM2, APBB2, FE65L1, NOS3, PLAU, URK, ACE,         DCPI, ACEI, MPO, PACIP1, PAXIPIL, PTIP, A2M, BLMH, BMH, PSEN1,         AD3); Autism (Mecp2, BZRAP I, MDGA2, Sema5A, Neurex 1, GLO1,         MECP2, RTT, PPMX, MRX16, MRX79, NLGN3, NLGN4, KIAA1260, AUTSX2);         Fragile X Syndrome (FMR2, FXR1, FXR2, mGLUR5); Huntington's         disease and disease like disorders (HD, IT15, PRNP, PRIP, JPH3,         JP3, HDL2, TBP, SCA17); Parkinson disease (NR4A2, NURR1, NOT,         TINUR, SNCAIP, TBP, SCA17, SNCA, NACP, PARK1, PARK4, DJ1, PARK7,         LRRK2, PARKS, PINK1, PARK6, UCHL1, PARKS, SNCA, NACP, PARK1,         PARK4, PRKN, PARK-2, PDJ, DBH, NDUFV2); Rett syndrome (MECP2,         RTT, PPMX, MRX16, MRX79, CDKL5, STK9, MECP2, RTT, PPMX, MRX16,         MRX79, x-Synuclein, DJ-1); Schizophrenia (Neuregulin1 (Nrg1),         Erb4 (receptor for Neuregulin), Comp1exin1 (Cp1x1), Tph1         Tryptophan hydroxylase, Tph2, Tryptophan hydroxylase 2, Neurexin         1, GSK3, GSK3a, GSK3b, 5-HTT (S1c6a4), COMT, DRD (Drd 1a),         SLC6A3, DAOA, DTNBP1, Dao (Dao1)); Secretase Related Disorders         (APH-1 (alpha and beta), Preseni I in (Psenl), nicastrin,         (Ncstn), PEN-2, Nos1, Parp1, Nat1, Nat2); Trinucleotide Repeat         Disorders (HTT (Huntington's Dx), SBMA/SMAX1/AR (Kennedy's Dx),         FXN/X25 (Friedrich's Ataxia), ATX3 (Machado-Joseph's Dx), ATXN1         and ATXN2 (spinocerebellar ataxias), DMPK (myotonic dystrophy),         Atrophin-1 and Atn1 (DRPLA Dx), CBP (Creb-BP—global         instability), VLDLR (Alzheimer's), Atxn7, Atxn10);     -   Occular-related disorders: Genes linked to these disorders:         Age-related macular degeneration (Aber, Cc12, Cc2, cp         (ceruloplasmin), Timp3, cathepsinD, Vld1r, Ccr2); Cataract         (CRYAA, CRYA1, CRYBB2, CRYB2, PITX3, BFSP2, CP49, CP47, CRYAA,         CRYA1, PAX6, AN2, MGDA, CRYBA1, CRYB1, CRYGC, CRYG3, CCL, LIM2,         MP19, CRYGD, CRYG4, BFSP2, CP49, CP47, HSF4, CTM, HSF4, CTM,         MIP, AQPO, CRYAB, CRYA2, CTPP2, CRYBB1, CRYGD, CRYG4, CRYBB2,         CRYB2, CRYGC, CRYG3, CCL, CRYAA, CRYA1, GJA8, CX50, CAE1, GJA3,         CX46, CZP3, CAE3, CCM1, CAM, KRIT1); Corneal clouding and         dystrophy (APOA1, TGFBI, CSD2, CDGG1, CSD, BIGH3, CDG2, TACSTD2,         TROP2, M1S1, VSX1, RINX, PPCD, PPD, KTCN, COL8A2, FECD, PPCD2,         PIP5K3, CFD); Cornea plana congenital (KERA, CNA2); Glaucoma         (MYOC, TIGR, GLC1A, JOAG, GPOA, OPTN, GLC1E, FIP2, HYPL, NRP,         CYP1B1, GLC3A, OPAL, NTG, NPG, CYP1B1, GLC3A); Leber congenital         amaurosis (CRB1, RP12, CRX, CORD2, CRD, RPGRIP1, LCA6, CORDS,         RPE65, RP20, AIPL1, LCA4, GUCY2D, GUC2D, LCA1, CORD6, RDH12,         LCA3); Macular dystrophy (ELOVL4, ADMD, STGD2, STGD3, RDS, RP7,         PRPH2, PRPH, AVMD, AOFMD, VMD2);     -   P13K/AKT Cellular Signaling disorders: Genes linked to these         disorders: PRKCE; ITGAM; ITGA5; IRAK1; PRKAA2; EIF2AK2; PTEN;         EIF4E; PRKCZ; GRK6; MAPK1; TSC1; PLK1; AKT2; IKBKB; PIK3CA;         CDK8; CDKN1B; NFKB2; BCL2; PIK3CB; PPP2R1A; MAPK8; BCL2L1;         MAPK3; TSC2; ITGA1; KRAS; EIF4EBP1; RELA; PRKCD; NOS3; PRKAA1;         MAPK9; CDK2; PPP2CA; PIM1; ITGB7; YWHAZ; ILK; TP53; RAF1; IKBKG;         RELB; DYRK1A; CDKN1A; ITGB1; MAP2K2; JAK1; AKT1; JAK2; PIK3R1;         CHUK; PDPK1; PPP2R5C; CTNNB1; MAP2K1; NFKB1; PAK3; ITGB3; CCND1;         GSK3A; FRAP1; SFN; ITGA2; TTK; CSNK1A1; BRAF; GSK3B; AKT3;         FOXO1; SOK; HS P9OAA1; RP S 6KB1;     -   ERK/MAPK Cellular Signaling disorders: Genes linked to these         disorders: PRKCE; ITGAM; ITGA5; HSPB1; IRAK1; PRKAA2; EIF2AK2;         RAC1; RAP1A; TLN1; EIF4E; ELK1; GRK6; MAPK1; RAC2; PLK1; AKT2;         PIK3CA; CDK8; CREB1; PRKCI; PTK2; FOS; RPS6KA4; PIK3CB; PPP2R1A;         PIK3C3; MAPK8; MAPK3; ITGA1; ETS1; KRAS; MYCN; EIF4EBP1; PPARG;         PRKCD; PRKAA1; MAPK9; SRC; CDK2; PPP2CA; PIM1; PIK3C2A; ITGB7;         YWHAZ; PPP1CC; KSR1; PXN; RAF1; FYN; DYRK1A; ITGB1; MAP2K2;         PAK4; PIK3R1; STAT3; PPP2R5C; MAP2K1; PAK3; ITGB3; ESR1; ITGA2;         MYC; TTK; CSNK1A1; CRKL; BRAE; ATF4; PRKCA; SRF; STAT1; SGK;     -   Glucocorticoid Receptor Cellular Signaling disorders: Genes         linked to these disorders: RAC1; TAF4B; EP300; SMAD2; TRAF6;         PCAF; ELK1; MAPK1; SMAD3; AKT2; IKBKB; NCOR2; UBE2I; PIK3CA;         CREB1; FOS; HSPA5; NFKB2; BCL2; MAP3K14; STAT5B; PIK3CB; PIK3C3;         MAPK8; BCL2L1; MAPK3; TSC22D3; MAPK10; NRIP1; KRAS; MAPK13;         RELA; STAT5A; MAPK9; NOS2A; PBX1; NR3C1; PIK3C2A; CDKN1C; TRAF2;         SERPINE1; NCOA3; MAPK14; TNF; RAF1; IKBKG; MAP3K7; CREBBP;         CDKN1A; MAP2K2; JAK1; IL8; NCOA2; AKT1; JAK2; PIK3R1; CHUK;         STAT3; MAP2K1; NFKB1; TGFBR1; ESR1; SMAD4; CEBPB; JUN; AR; AKT3;         CCL2; MMP 1; STAT1; IL6; HSP9OAA1;     -   Axonal Guidance Cellular Signaling disorders: Genes linked to         these disorders: PRKCE; ITGAM; ROCK1; ITGA5; CXCR4; ADAM12;         IGF1; RAC1; RAP1A; El F4E; PRKCZ; NRP1; NTRK2; ARHGEF7; SMO;         ROCK2; MAPK1; PGF; RAC2; PTPN11; GNAS; AKT2; PIK3CA; ERBB2;         PRKCI; PTK2; CFL1; GNAQ; PIK3CB; CXCL12; PIK3C3; WNT11; PRKD1;         GNB2L1; ABL1; MAPK3; ITGA1; KRAS; RHOA; PRKCD; PIK3C2A; ITGB7;         GLI2; PXN; VASP; RAF1; FYN; ITGB1; MAP2K2; PAK4; ADAM17; AKT1;         PIK3R1; GUI; WNT5A; ADAM10; MAP2K1; PAK3; ITGB3; CDC42; VEGFA;         ITGA2; EPHA8; CRKL; RND1; GSK3B; AKT3; PRKCA;     -   Ephrin Recptor Cellular Signaling disorders: Genes linked to         these disorders: PRKCE; ITGAM; ROCK1; ITGA5; CXCR4; IRAK1;         PRKAA2; EIF2AK2; RAC1; RAP1A; GRK6; ROCK2; MAPK1; PGF; RAC2;         PTPN11; GNAS; PLK1; AKT2; DOK1; CDK8; CREB1; PTK2; CFL1; GNAQ;         MAP3K14; CXCL12; MAPK8; GNB2L1; ABL1; MAPK3; ITGA1; KRAS; RHOA;         PRKCD; PRKAA1; MAPK9; SRC; CDK2; PIM1; ITGB7; PXN; RAF1; FYN;         DYRK1A; ITGB1; MAP2K2; PAK4, AKT1; JAK2; STAT3; ADAM10; MAP2K1;         PAK3; ITGB3; CDC42; VEGFA; ITGA2; EPHA8; TTK; CSNK1A1; CRKL;         BRAF; PTPN13; ATF4; AKT3; SGK;     -   Actin Cytoskeleton Cellular Signaling disorders: Genes linked to         these disorders: ACTN4; PRKCE; ITGAM; ROCK1; ITGA5; IRAK1;         PRKAA2; EIF2AK2; RAC1; INS; ARHGEF7; GRK6; ROCK2; MAPK1; RAC2;         PLK1; AKT2; PIK3CA; CDK8; PTK2; CFL1; PIK3CB; MYH9; DIAPH1;         PIK3C3; MAPK8; F2R; MAPK3; SLC9A1; ITGA1; KRAS; RHOA; PRKCD;         PRKAA1; MAPK9; CDK2; PIM1; PIK3C2A; ITGB7; PPP1CC; PXN; VIL2;         RAF1; GSN; DYRK1A; ITGB1; MAP2K2; PAK4; PIP5K1A; PIK3R1; MAP2K1;         PAK3; ITGB3; CDC42; APC; ITGA2; TTK; CSNK1A1; CRKL; BRAF; VAV3;         SGK;     -   Huntington's Disease Cellular Signaling disorders: Genes linked         to these disorders: PRKCE; IGF1; EP300; RCOR1; PRKCZ; HDAC4;         TGM2; MAPK1; CAPNS1; AKT2; EGFR; NCOR2; SP1; CAPN2; PIK3CA;         HDAC5; CREB1; PRKC1; HS PA5; REST; GNAQ; PIK3CB; PIK3C3; MAPK8;         IGF1R; PRKD1; GNB2L1; BCL2L1; CAPN1; MAPK3; CASP8; HDAC2;         HDAC7A; PRKCD; HDAC11; MAPK9; HDAC9; PIK3C2A; HDAC3; TP53;         CASP9; CREBBP; AKT1; PIK3R1; PDPK1; CASP1; APAF1; FRAP1; CASP2;         JUN; BAX; ATF4; AKT3; PRKCA; CLTC; SGK; HDAC6; CASP3;     -   Apoptosis Cellular Signaling disorders: Genes linked to these         disorders: PRKCE; ROCK1; BID; IRAK1; PRKAA2; EIF2AK2; BAK1;         BIRC4; GRK6; MAPK1; CAPNS1; PLK1; AKT2; IKBKB; CAPN2; CDK8; FAS;         NFKB2; BCL2; MAP3K14; MAPK8; BCL2L1; CAPN1; MAPK3; CASP8; KRAS;         RELA; PRKCD; PRKAA1; MAPK9; CDK2; PIM1; TP53; TNF; RAF1; IKBKG;         RELB; CASP9; DYRK1A; MAP2K2; CHUK; APAF1; MAP2K1; NFKB1; PAK3;         LMNA; CASP2; BIRC2; TTK; CSNK1A1; BRAF; BAX; PRKCA; SGK; CASP3:         BTRC3: PARPI;     -   B Cell Receptor Cellular Signaling disorders: Genes linked to         these disorders: RAC1; PTEN; LYN; ELK1; MAPK1; RAC2; PTPN11;         AKT2; IKBKB; PIK3CA; CREB1; SYK; NFKB2; CAMK2A; MAP3K14; PIK3CB;         PIK3C3; MAPK8; BCL2L1; ABL1; MAPK3; ETS1; KRAS; MAPK13; RELA;         PTPN6; MAPK9; EGR1; PIK3C2A; BTK; MAPK14; RAF1; IKBKG; RELB;         MAP3K7; MAP2K2; AKT1; PIK3R1; CHUK; MAP2K1; NFKB1; CDC42; GSK3A;         FRAP1; BCL6; BCL10; JUN; GSK3B; ATF4; AKT3; VAV3; RPS6KB1;     -   Leukocyte Extravasation Cellular Signaling disorders: Genes         linked to these disorders: ACTN4; CD44; PRKCE; ITGAM; ROCK1;         CXCR4; CYBA; RAC1; RAP1A; PRKCZ; ROCK2; RAC2; PTPN11; MMP14;         PIK3CA; PRKCI; PTK2; PIK3CB; CXCL12; PIK3C3; MAPK8; PRKD1; ABL1;         MAPK10; CYBB; MAPK13; RHOA; PRKCD; MAPK9; SRC; PIK3C2A; BTK;         MAPK14; NOX1; PXN; VIL2; VASP; ITGB1; MAP2K2; CTNND1; PIK3R1;         CTNNB1; CLDN1; CDC42; FUR; ITK; CRKL; VAV3; CTTN; PRKCA; MMP1;         MMP9;     -   Integrin Cellular Signaling disorders: Genes linked to these         disorders: ACTN4; ITGAM; ROCK1; ITGA5; RAC1; PTEN; RAP1A; TLN1;         ARHGEF7; MAPK1; RAC2; CAPNS1; AKT2; CAPN2; PIK3CA; PTK2; PIK3CB;         PIK3C3; MAPK8; CAV1; CAPN1; ABL1; MAPK3; ITGA1; KRAS; RHOA; SRC;         PIK3C2A; ITGB7; PPP1CC; ILK; PXN; VASP; RAF1; FYN; ITGB1;         MAP2K2; PAK4; AKT1; PIK3R1; TNK2; MAP2K1; PAK3; ITGB3; CDC42;         RND3; ITGA2; CRKL; BRAF; GSK3B; AKT3;     -   Acute Phase Response Cellular Signaling disorders: Genes linked         to these disorders: IRAK1; SOD2; MYD88; TRAF6; ELK1; MAPK1;         PTPN11; AKT2; IKBKB; PIK3CA; FOS; NFKB2; MAP3K14; PIK3CB; MAPK8;         RIPK1; MAPK3; IL6ST; KRAS; MAPK13; IL6R; RELA; SOCS1; MAPK9;         FTL; NR3C1; TRAF2; SERPINE1; MAPK14; TNF; RAF1; PDK1; IKBKG;         RELB; MAP3K7; MAP2K2; AKT1; JAK2; PIK3R1; CHUK; STAT3; MAP2K1;         NFKB1; FRAP1; CEBPB; JUN; AKT3; IL1R1; IL6;     -   PTEN Cellular Signaling disorders: Genes linked to these         disorders: ITGAM; ITGA5; RAC1; PTEN; PRKCZ; BCL2L11; MAPK1;         RAC2; AKT2; EGFR; IKBKB; CBL; PIK3CA; CDKN1B; PTK2; NFKB2; BCL2;         PIK3CB; BCL2L1; MAPK3; ITGA1; KRAS; ITGB7; ILK; PDGFRB; INSR;         RAF1; IKBKG; CASP9; CDKN1A; ITGB1; MAP2K2; AKT1; PIK3R1; CHUK;         PDGFRA; PDPK1; MAP2K1; NFKB1; ITGB3; CDC42; CCND1; GSK3A; ITGA2;         GSK3B; AKT3; FOXO1; CASP3;     -   p53 Cellular Signaling disorders: Genes linked to these         disorders: RPS6KB1 PTEN; EP300; BBC3; PCAF; FASN; BRCA1;         GADD45A; BIRC5; AKT2; PIK3CA; CHEK1; TP53INP1; BCL2; PIK3CB;         PIK3C3; MAPK8; THB S 1; ATR; BCL2L1; E2F1; PMAIP1; CHEK2;         TNFASF10B; TP73; RB1; HDAC9; CDK2; PIK3C2A; MAPK14; TP53; LRDD;         CDKN1A; HIPK2; AKT1; PIK3R1; RAM2B; APAF1; CTNNB1; SIRT1; CCND1;         PRKDC; ATM; SFN; CDKN2A; JUN; SNAI2; GSK3B; BAX; AKT3;     -   Aryl Hydrocarbon Receptor Cellular Signaling disorders: Genes         linked to these disorders: HSPB1; EP300; FASN; TGM2; RXRA;         MAPK1; NQO1; NCOR2; SP1; ARNT; CDKN1B; FOS; CHEK1; SMARCA4;         NFKB2; MAPK8; ALDH1A1; ATR; E2F1; MAPK3; NRIP1; CHEK2; RELA;         TP73; GSTP1; RB1; SRC; CDK2; AHR; NFE2L2; NCOA3; TP53; TNF;         CDKN1A; NCOA2; APAF1; NFKB1; CCND1; ATM; ESR1; CDKN2A; MYC; JUN;         ESR2; BAX; IL6; CYP1B1; HSP9OAA1;     -   Xenobiotic Metabolism Cellular Signaling disorders: Genes linked         to these disorders: PRKCE; EP300; PRKCZ; RXRA; MAPK1; NQO1;         NCOR2; PIK3CA; ARNT; PRKCI; NFKB2; CAMK2A; PIK3CB; PPP2R1A;         PIK3C3; MAPK8; PRKD1; ALDH1A1; MAPK3; NRIP1; KRAS; MAPK13;         PRKCD; GSTP1; MAPK9; NOS2A; ABCB1; AHR; PPP2CA; FTL; NFE2L2;         PIK3C2A; PPARGC1A; MAPK14; TNF; RAF1; CREBBP; MAP2K2; PIK3R1;         PPP2R5C; MAP2K1; NFKB1; KEAP1; PRKCA; EIF2AK3; IL6; CYP1B1;         HSP9OAA1;     -   SAPL/JNK Cellular Signaling disorders: Genes linked to these         disorders: PRKCE; IRAK1; PRKAA2; EIF2AK2; RAC1; ELK1; GRK6;         MAPK1; GADD45A; RAC2; PLK1; AKT2; PIK3CA; FADD; CDK8; PIK3CB;         PIK3C3; MAPK8; RIPK1; GNB2L1; IRS1; MAPK3; MAPK10; DAXX; KRAS;         PRKCD; PRKAA1; MAPK9; CDK2; PIM1, PIK3C2A; TRAF2; TP53; LCK;         MAP3K7; DYRK1A; MAP2K2; PIK3R1; MAP2K1; PAK3; CDC42; JUN; TTK;         CSNK1A1; CRKL; BRAF; SGK;     -   PPAr/RXR Cellular Signaling disorders: Genes linked to these         disorders: PRKAA2; EP300; INS; SMAD2; TRAF6; PPARA; FASN; RXRA;         MAPK1; SMAD3; GNAS; IKBKB; NCOR2; ABCA1; GNAQ; NFKB2; MAP3K14;         STAT5B; MAPK8; IASI; MAPK3; KRAS; RELA; PRKAA1; PPARGC1A; NCOA3;         MAPK14; INSR; RAF1; IKBKG; RELB; MAP3K7; CREBBP; MAP2K2; JAK2;         CHUK; MAP2K1; NFKB1; TGFBA1; SMAD4; JUN; IL1R1; PRKCA; IL6;         HSP9OAA1; ADIPOO;     -   NF-KB Cellular Signaling disorders: Genes linked to these         disorders: IRAK1; EIF2AK2; EP300; INS; MYD88; PRKCZ: TRAF6;         TBK1; AKT2; EGFR; IKBKB; PIK3CA; BTRC; NFKB2; MAP3K14; PIK3CB;         PIK3C3; MAPK8; RIPK1; HDAC2; KRAS; RELA; PIK3C2A; TRAF2; TLR4:         PDGFRB; TNF; INSR; LCK; IKBKG; RELB; MAP3K7; CREBBP; AKT1;         PIK3R1; CHUK; PDGFRA; NFKB1; TLR2; BCL10; GSK3B; AKT3; TNFAIP3;         IL1R1;     -   Neuregulin Cellular Signaling disorders: Genes linked to these         disorders: ERBB4; PRKCE; ITGAM; ITGA5: PTEN; PRKCZ; ELK1; MAPK1;         PTPN11; AKT2; EGFR; ERBB2; PRKCI; CDKN1B; STAT5B; PRKD1; MAPK3;         ITGA1; KRAS; PRKCD; STAT5A; SRC; ITGB7; RAF1; ITGB1; MAP2K2;         ADAM17; AKT1; PIK3R1; PDPK1; MAP2K1; ITGB3; EREG; FRAP1; PSEN1;         ITGA2; MYC; NRG1; CRKL; AKT3; PRKCA; HS P9OAA1; RPS6KB1;     -   Wnt and Beta catenin Cellular Signaling disorders: Genes linked         to these disorders: CD44; EP300; LRP6; DVL3; CSNK1E; GJA1; SMO;         AKT2; PIN1; CDH1; BTRC; GNAQ; MARK2; PPP2R1A; WNT11; SRC; DKK1;         PPP2CA; SOX6; SFRP2: ILK; LEF1; SOX9; TP53; MAP3K7; CREBBP;         TCF7L2; AKT1; PPP2R5C; WNT5A; LAPS; CTNNB1; TGFBR1; CCND1;         GSK3A; DVL1; APC; CDKN2A; MYC; CSNK1A1; GSK3B; AKT3; SOX2;     -   Insulin Receptor Signaling disorders: Genes linked to these         disorders: PTEN; INS; EIF4E; PTPN1; PRKCZ; MAPK1; TSC1; PTPN11;         AKT2; CBL; PIK3CA; PRKCI; PIK3CB; PIK3C3; MAPK8; IASI; MAPK3;         TSC2; KRAS; EIF4EBP1; SLC2A4; PIK3C2A; PPP1CC; INSR; RAF1; FYN;         MAP2K2; JAK1; AKT1; JAK2; PIK3R1; PDPK1; MAP2K1; GSK3A; FRAP1;         CRKL; GSK3B; AKT3; FOXO1; SGK; RPS6KB1;     -   IL-6 Cellular Signaling disorders: Genes linked to these         disorders: HSPB1; TRAF6; MAPKAPK2; ELK1; MAPK1; PTPN11; IKBKB;         FOS; NFKB2: MAP3K14; MAPK8; MAPK3; MAPK10; IL6ST; KRAS; MAPK13;         IL6R; RELA; SOCS1; MAPK9; ABCB1; TRAF2; MAPK14; TNF; RAF1;         IKBKG; RELB; MAP3K7; MAP2K2; IL8; JAK2; CHUK; STAT3; MAP2K1;         NFKB1; CEBPB; JUN; IL1R1; SRF; IL6;     -   Hepatic Cholestasis Cellular Signaling disorders: Genes linked         to these disorders: PRKCE; IRAK1; INS; MYD88; PRKCZ; TRAF6;         PPARA; RXRA; IKBKB; PRKCI; NFKB2; MAP3K14; MAPK8; PRKD1; MAPK10;         RELA; PRKCD; MAPK9; ABCB1; TRAF2; TLR4; TNF; INSR; IKBKG; RELB;         MAP3K7; IL8; CHUK; NR1H2; TJP2; NFKB1; ESR1; SREBF1; FGFR4; JUN;         IL1R1; PRKCA; IL6;     -   IGF-1 Cellular Signaling disorders: Genes linked to these         disorders: IGF1; PRKCZ; ELK1; MAPK1; PTPN11; NEDD4; AKT2;         PIK3CA; PRKCI; PTK2; FOS; PIK3CB; PIK3C3; MAPK8; IGF1R; IRS1;         MAPK3; IGFBP7; KRAS; PIK3C2A; YWHAZ; PXN; RAF1; CASP9; MAP2K2;         AKT1; PIK3R1; PDPK1; MAP2K1; IGFBP2; SFN; JUN; CYR61; AKT3;         FOXO1; SRF; CTGF; RPS6KB1;     -   NRF2-mediated Oxidative Stress Response Signaling disorders:         Genes linked to these disorders: PRKCE; EP300; SOD2; PRKCZ;         MAPK1; SQSTM1; NQO1; PIK3CA; PRKCI; FOS; PIK3CB; PIK3C3; MAPK8;         PRKD1; MAPK3; KRAS; PRKCD; GSTP1; MAPK9; FTL; NFE2L2; PIK3C2A;         MAPK14; RAF1; MAP3K7; CREBBP; MAP2K2; AKT1; PIK3R1; MAP2K1;         PPIB; JUN; KEAP1; GSK3B; ATF4; PRKCA; EIF2AK3; HSP9OAA1;     -   Hepatic Fibrosis/Hepatic Stellate Cell Activation Signaling         disorders: Genes linked to these disorders: EDN1; IGF1; KDR;         FLT1; SMAD2; FGFR1; MET; PGF; SMAD3; EGFR; FAS; CSF1; NFKB2;         BCL2; MYH9; IGF1R; IL6R; RELA; TLR4; PDGFRB; TNF; RELB; IL8;         PDGFRA; NFKB1; TGFBR1; SMAD4; VEGFA; BAX; IL1R1; CCL2; HGF;         MMP1; STAT1; IL6; CTGF; MMP9;     -   PPAR Signaling disorders: Genes linked to these disorders:         EP300; INS; TRAF6; PPARA; RXRA; MAPK1; IKBKB; NCOR2; FOS; NFKB2;         MAP3K14; STAT5B; MAPK3; NRIP1; KRAS; PPARG; RELA; STAT5A; TRAF2;         PPARGC1A; PDGFRB; TNF; INSR; RAF1; IKBKG; RELB; MAP3K7; CREBBP;         MAP2K2; CHUK; PDGFRA; MAP2K1; NFKB1; JUN; IL1R1; HSP9OAA1;     -   Fc Epsilon RI Signaling disorders: Genes linked to these         disorders: PRKCE; RAC1; PRKCZ; LYN; MAPK1; RAC2; PTPN11; AKT2;         PIK3CA; SYK; PRKCI; PIK3CB; PIK3C3; MAPK8; PRKD1; MAPK3; MAPK10;         KRAS; MAPK13; PRKCD; MAPK9; PIK3C2A; BTK; MAPK14; TNF; RAF1;         FYN; MAP2K2; AKT1; PIK3R1; PDPK1; MAP2K1; AKT3; VAV3; PRKCA;     -   G-Protein Coupled Receptor Signaling disorders: Genes linked to         these disorders: PRKCE; RAP1A; RGS16; MAPK1; GNAS; AKT2; IKBKB;         PIK3CA; CREB1; GNAQ; NFKB2; CAMK2A; PIK3CB; PIK3C3; MAPK3; KRAS;         RELA; SRC; PIK3C2A; RAF1; IKBKG; RELB; FYN; MAP2K2; AKT1;         PIK3R1; CHUK; PDPK1; STAT3; MAP2K1; NFKB1; BRAF; ATF4; AKT3;         PRKCA;     -   Inositol Phosphate Metabolism Signaling disorders: Genes linked         to these disorders: PRKCE; IRAK1; PRKAA2; EIF2AK2; PTEN; GRK6;         MAPK1; PLK1; AKT2; PIK3CA; CDK8; PIK3CB; PIK3C3; MAPK8; MAPK3;         PRKCD; PRKAA1; MAPK9; CDK2; PIK3C2A; DYRK1A; MAP2K2; PIP5K1A;         PIK3R1; MAP2K1; PAK3; ATM; TTK; CSNK1A1; BRAF; SGK;     -   PDGF Signaling disorders: Genes linked to these disorders:         EIF2AK2; ELK1; ABL2; MAPK1; PIK3CA; FOS; PIK3CB; PIK3C3; MAPK8;         CAV1; ABL1; MAPK3; KRAS; SRC; PIK3C2A; PDGFRB; RAF1; MAP2K2;         JAK1; JAK2; PIK3R1; PDGFRA; STAT3; SPHK1; MAP2K1; MYC; JUN;         CRKL; PRKCA; SRF; STAT1; SPHK2 VEGF Signaling disorders: Genes         linked to these disorders: ACTN4; ROCK1; KDR; FLT1; ROCK2;         MAPK1; PGF; AKT2; PIK3CA; ARNT; PTK2; BCL2; PIK3CB; PIK3C3;         BCL2L1; MAPK3; KRAS; HIF1A; NOS3; PIK3C2A; PXN; RAF1; MAP2K2;         ELAVL1; AKT1; PIK3R1; MAP2K1; SFN; VEGFA; AKT3; FOXO1; PRKCA;     -   Natural Killer Cell Signaling disorders: Genes linked to these         disorders: PRKCE; RAC1; PRKCZ; MAPK1; RAC2; PTPN11; KIR2DL3;         AKT2; PIK3CA; SYK; PRKCI; PIK3CB; PIK3C3; PRKD1; MAPK3; KRAS;         PRKCD; PTPN6; PIK3C2A; LCK; RAF1; FYN; MAP2K2; PAK4; AKT1;         PIK3R1; MAP2K1; PAK3; AKT3; VAV3; PRKCA;     -   Cell Cycle: G1/S Checkpoint Regulation Signaling disorders:         Genes linked to these disorders: HDAC4; SMAD3; SUV39H1; HDAC5;         CDKN1B; BTRC; ATR; ABL1; E2F1; HDAC2; HDAC7A; RB1; HDAC11;         HDAC9; CDK2; E2F2; HDAC3; TP53; CDKN1A; CCND1; E2F4; ATM; RBL2;         SMAD4; CDKN2A; MYC; NRG1; GSK3B; RBL1; HDAC6;     -   T Cell Receptor Signaling disorders: Genes linked to these         disorders: RAC1; ELK1; MAPK1; IKBKB; CBL; PIK3CA; FOS; NFKB2;         PIK3CB; PIK3C3; MAPK8; MAPK3; KRAS; RELA, PIK3C2A; BTK; LCK;         RAF1; IKBKG; RELB, FYN; MAP2K2; PIK3R1; CHUK; MAP2K1; NFKB1;         ITK; BCL10; JUN; VAV3;     -   Death Receptor disorders: Genes linked to these disorders:         CRADD; HSPB1; BID; BIRC4; TBK1; IKBKB; FADD; FAS; NFKB2; BCL2;         MAP3K14; MAPK8; RIPK1; CASP8; DAXX; TNFRSF10B; RELA; TRAF2; TNF;         IKBKG; RELB; CASP9; CHUK; APAF1; NFKB1; CASP2; BIRC2; CASP3;         BIRC3;     -   FGF Cell Signaling disorders: Genes linked to these disorders:         RAC1; FGFR1; MET; MAPKAPK2; MAPK1; PTPN11; AKT2; PIK3CA; CREB1;         PIK3CB; PIK3C3; MAPK8; MAPK3; MAPK13; PTPN6; PIK3C2A; MAPK14;         RAF1; AKT1; PIK3R1; STAT3; MAP2K1; FGFR4; CRKL; ATF4; AKT3;         PRKCA; HGF;     -   GM-CSF Cell Signaling disorders: Genes linked to these         disorders: LYN; ELK1; MAPK1; PTPN11; AKT2; PIK3CA; CAMK2A;         STAT5B; PIK3CB; PIK3C3; GNB2L1; BCL2L1; MAPK3; ETS1; KRAS;         RUNX1; PIM1; PIK3C2A; RAF1; MAP2K2; AKT1; JAK2; PIK3R1; STAT3;         MAP2K1; CCND1; AKT3; STAT1;     -   Amyotrophic Lateral Sclerosis Cell Signaling disorders: Genes         linked to these disorders: BID; IGF1; RAC1; BIRC4; PGF; CAPNS1;         CAPN2; PIK3CA; BCL2; PIK3CB; PIK3C3; BCL2L1; CAPN1; PIK3C2A;         TP53; CASP9; PIK3R1; RAB5A; CASP1; APAF1; VEGFA; BIRC2; BAX;         AKT3; CASP3; BIRC3 PTPN1; MAPK1; PTPN11; AKT2; PIK3CA; STAT5B;         PIK3CB; PIK3C3; MAPK3; KRAS; SOCS1; STAT5A; PTPN6; PIK3C2A;         RAF1; CDKN1A; MAP2K2; JAK1; AKT1; JAK2; PIK3R1; STAT3; MAP2K1;         FRAP1; AKT3; STAT1;     -   JAK/Stat Cell Signaling disorders: Genes linked to these         disorders: PTPN1; MAPK1; PTPN11; AKT2; PIK3CA; STAT5B; PIK3CB;         PIK3C3; MAPK3; KRAS; SOCS1; STAT5A; PTPN6; PIK3C2A; RAF1;         CDKN1A; MAP2K2; JAK1; AKT1; JAK2; PIK3R1; STAT3; MAP2K1; FRAP1;         AKT3; STAT1;     -   Nicotinate and Nicotinamide Metabolism Cell Signaling disorders:         Genes linked to these disorders: PRKCE; IRAK1; PRKAA2; EIF2AK2;         GRK6; MAPK1; PLK1; AKT2; CDK8; MAPK8; MAPK3; PRKCD; PRKAA1;         PBEF1; MAPK9; CDK2; DYRK1A; MAP2K2; MAP2K1; PAK3; NT5E; TTK;         CSNK1A1; BRAF; SGK;     -   Chemokine Cell Signaling disorders: Genes linked to these         disorders: CXCR4; ROCK2; MAPK1; PTK2; FOS; CFL1; GNAQ; CAMK2A;         CXCL12; MAPK8; MAPK3; KRAS; MAPK13; RHOA; CCR3; SRC; PPP1CC;         MAPK14; NOX1; RAF1; MAP2K2; MAP2K1; JUN; CCL2; PRKCA;     -   IL-2 Cell Signaling disorders: Genes linked to these disorders:         ELK1; MAPK1; PTPN11; AKT2; PIK3CA; SYK; FOS; STAT5B; PIK3CB;         PIK3C3; MAPK8; MAPK3; KRAS; SOCS1; STAT5A; PIK3C2A; LCK; RAF1;         MAP2K2; JAK1; AKT1; PIK3R1; MAP2K1; JUN; AKT3;     -   Synaptic Long Term Depression Signaling disorders: Genes linked         to these disorders: PRKCE; IGF1; PRKCZ; PRDX6; LYN; MAPK1; GNAS;         PRKCI; GNAQ; PPP2R1A; IGF1R; PRKD1; MAPK3; KRAS; GRN; PRKCD;         NOS3; NOS2A; PPP2CA; YWHAZ; RAF1; MAP2K2; PPP2R5C; MAP2K1;         PRKCA;     -   Estrogen Receptor Cell Signaling disorders: Genes linked to         these disorders: TAF4B; EP300; CARM1; PCAF; MAPK1; NCOR2;         SMARCA4; MAPK3; NRIP1; KRAS; SRC; NR3C1; HDAC3; PPARGC1A; RBM9;         NCOA3; RAF1; CREBBP; MAP2K2; NCOA2; MAP2K1; PRKDC; ESR1; ESR2;     -   Protein Ubiquitination Pathway Cell Signaling disorders: Genes         linked to these disorders: TRAF6; SMURF1; BIRC4; BRCA1; UCHL1;         NEDD4; CBL; UBE2I; BTRC; HSPA5; USP7; USP10; FBXW7; USP9X;         STUB1; USP22; B2M; BIRC2; PARK2; USP8; USP1; VHL; HSP9OAA1;         BIRC3;     -   IL-10 Cell Signaling disorders: Genes linked to these disorders:         TRAF6; CCR1; ELK1; IKBKB; SP1; FOS; NFKB2; MAP3K14; MAPK8;         MAPK13; RELA; MAPK14; TNF; IKBKG; RELB; MAP3K7; JAK1; CHUK;         STAT3; NFKB1; JUN; IL1R1; IL6;     -   VDR/RXR Activation Signaling disorders: Genes linked to these         disorders: PRKCE; EP300; PRKCZ; RXRA; GADD45A; HES1; NCOR2; SP1;         PRKCI; CDKN1B; PRKD1; PRKCD; RUNX2; KLF4; YY1; NCOA3; CDKN1A;         NCOA2; SPP1; LAPS; CEBPB; FOXO1; PRKCA;     -   TGF-beta Cell Signaling disorders: Genes linked to these         disorders: EP300; SMAD2; SMURF1; MAPK1; SMAD3; SMAD1; FOS;         MAPK8; MAPK3; KRAS; MAPK9; RUNX2; SERPINE1; RAF1; MAP3K7;         CREBBP; MAP2K2; MAP2K1; TGFBR1; SMAD4; JUN; SMAD5;     -   Toll-like Receptor Cell Signaling disorders: Genes linked to         these disorders: IRAK1; EIF2AK2; MYD88; TRAF6; PPARA; ELK1;         IKBKB; FOS; NFKB2; MAP3K14; MAPK8; MAPK13; RELA; TLR4; MAPK14;         IKBKG; RELB; MAP3K7; CHUK; NFKB1; TLR2; JUN;     -   p38 MAPK Cell Signaling disorders: Genes linked to these         disorders: HSPB1; IRAK1; TRAF6; MAPKAPK2; ELK1; FADD; FAS;         CREB1; DDIT3; RPS6KA4; DAXX; MAPK13; TRAF2; MAPK14; TNF; MAP3K7;         TGFBR1; MYC; ATF4; IL1R1; SRF; STAT1; and     -   Neurolrophin/TRK Cell Signaling disorders: Genes linked to these         disorders: NTRK2; MAPK1; PTPN11; PIK3CA; CREB1; FOS; PIK3CB;         PIK3C3; MAPK8; MAPK3; KRAS; PIK3C2A; RAF1; MAP2K2; AKT1; PIK3R1;         PDPK1; MAP2K1; CDC42; JUN; ATF4.

Other cellular dysfunction disorders linked to a genetic modification are contemplated herein for example, FXR/RXR Activation, Synaptic Long Term Potentiation, Calcium Signaling EGF Signaling, Hypoxia Signaling in the Cardiovascular System, LPS/IL-1 Mediated Inhibition of RXR Function LXR/RXR Activation, Amyloid Processing, IL-4 Signaling, Cell Cycle: G2/M DNA Damage Checkpoint Regulation, Nitric Oxide Signaling in the Cardiovascular System Purine Metabolism, cAMP-mediated Signaling, Mitochondrial Dysfunction Notch Signaling Endoplasmic Reticulum Stress Pathway Pyrimidine Metabolism, Parkinson's Signaling Cardiac & Beta Adrenergic Signaling Glycolysis/Gluconeogenesis Interferon Signaling Sonic Hedgehog Signaling Glycerophospholipid Metabolism, Phospholipid Degradation, Tryptophan Metabolism Lysine Degradation Nucleotide Excision Repair Pathway, Starch and Sucrose Metabolism, Aminosugars Metabolism Arachidonic Acid Metabolism, Circadian Rhythm Signaling, Coagulation System Dopamine Receptor Signaling, Glutathione Metabolism Glycerolipid Metabolism Linoleic Acid Metabolism Methionine Metabolism Pyruvate Metabolism Arginine and Praline Metabolism, Eicosanoid Signaling Fructose and Mannose Metabolism, Galactose Metabolism Stilbene, Coumarine and Lignin Biosynthesis Antigen Presentation Pathway, Biosynthesis of Steroids Butanoate Metabolism Citrate Cycle Fatty Acid Metabolism Glycerophosphol ipid Metabolism, Histidine Metabolism Inositol Metabolism Metabolism of Xenobiotics by Cytochrome p450, Methane Metabolism, Phenylalanine Metabolism, Propanoate Metabolism Selenoamino Acid Metabolism Sphingolipid Metabolism Aminophosphonate Metabolism, Androgen and Estrogen Metabolism Ascorbate and Aldarate Metabolism, Bile Acid Biosynthesis Cysteine Metabolism Fatty Acid Biosynthesis Glutamate Receptor Signaling, NRF2-mediated, Oxidative Stress Response Pentose Phosphate Pathway, Pentose and Glucuronate Interconversions, Retinol Metabolism Riboflavin Metabolism Tyrosine Metabolism Ubiquinone Biosynthesis Valine, Leucine and Isoleucine Degradation Glycine, Serine and Threonine Metabolism Lysine Degradation Pain/Taste, or Mitochondrial Function Developmental Neurology or combinations thereof.

Additional exemplary genetic diseases or disorders and associated information are available on the world wide web at kumc.edu/gec/support, genome.gov/10001200, and ncbi.nlm.nih.gov/booksNBK22183/. Additional exemplary genetic diseases or disorders, associated genetic mutations, and gene therapy approaches to treat genetic diseases or disorders are described in International (PCT) Publication Nos. WO2013/126794, WO2013/163628, WO2015/048577, WO2015/070083, WO2015/089354, WO2015/134812, WO2015/138510, WO2015/148670, WO2015/148860, WO2015/148863, WO2015/153780, WO2015/153789, and WO2015/153791, U.S. Pat. Nos. 89,568,28, 83,83,604, 9,273,296, 8,859,597, and 9,255,130, and U.S. Patent Publication Nos. 2009/0222937, 2009/0271881, 2010/0229252, 2010/0311124, 2011/0016540, 2011/0023139, 2011/0023144, 2011/0023145, 2011/0023146, 2011/0023153, 2011/0091441, 2012/0159653, and 2013/0145487.

B. Immune Cell Engineering

It is understood that the engineered, non-naturally occurring system and CRISPR expression system disclosed herein can be used to engineer an immune cell. Immune cells include but are not limited to lymphocytes (e.g., B lymphocytes or B cells, T lymphocytes or T cells, and natural killer cells), myeloid cells (e.g., monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes), and the stem and progenitor cells that can differentiate into these cell types (e.g., hematopoietic stem cells, hematopoietic progenitor cells, and lymphoid progenitor cells). The cells can include autologous cells derived from a subject to be treated, or alternatively allogenic cells derived from a donor. Cells are treated with a non-naturally occurring CRISPR-Cas system can be treated with a system that includes a modified targeter nucleic acid, a modified modulator nucleic acid, or both, as described in sections IA, IA1, and IB. Systems that include Cas proteins such as Cas nucleases are described in section IC. RNPs, Expression systems, donor templates, efficiency and specificity, and multiplex methods are described in sections IIA, B, C, D, and E, respectively.

It is understood that the guide nucleic acid, the engineered, non-naturally occurring system, and the CRISPR expression system disclosed herein can be used to treat any disease or disorder that can be improved by editing or modifying a target sequence; exemplary genes containing target sequences to be modified for therapeutic purposes include ADORA2A, B2M, CD3E, CD38, CD40LG, CD52, CIITA, CSF2, CTLA4, DCK, FAS, HAVCR2 (also called TIM3), LAG3, PDCD1 (also called PD-1), PTPN6, TIGIT, TRAC, TRBC1, TRBC2, TRBC1_2 (or TRBC1+2), CARD11, CD247, IL7R, LCK, PLCG1, ALPNR, BBS1, CALR, CD3G, CD58, COL17A1, DEFB134, ERAP1, ERAP2, IFNGR1, IFNGR2, JAK1, JAK2, mir-101-2, MLANA, PSMB5, PSMB8, PSMB9, PTCD2, RFX5, RFXANK, RFXAP, RPL23, SOX10, SRP54, STAT1, Tap1, TAP2, TAPBP, TWF1, CD3D, or NLRC5 gene in a cell.

In certain embodiments, the immune cell is a T cell, which can be, for example, a cultured T cell, a primary T cell, a T cell from a cultured T cell line (e.g., Jurkat, SupTi), or a T cell obtained from a mammal, for example, from a subject to be treated. If obtained from a mammal, the T cell can be obtained from numerous sources, including but not limited to blood, bone marrow, lymph node, the thymus, or other tissues or fluids. T cells can also be enriched or purified. The T cell can be any type of T cell and can be of any developmental stage, including but not limited to, CD4⁺/CD8⁺ double positive T cells, CD4⁺ helper T cells (e.g., Th1 and Th2 cells), CD8⁺ T cells (e.g., cytotoxic T cells), tumor infiltrating lymphocytes (TILs), memory T cells (e.g., central memory T cells and effector memory T cells), regulatory T cells, naive T cells, and the like.

In certain embodiments, an immune cell, e.g., a T cell, is engineered to express an exogenous gene. For example, in certain embodiments, an engineered CRISPR system disclosed herein may be used to engineer an immune cell to express an exogenous gene. For example, in certain embodiments, the guide nucleic acid, the engineered, non-naturally occurring system, and the CRISPR expression system disclosed herein may be used to engineer an immune cell to express an exogenous gene at the locus of a ADORA2A, B2M, CD3E, CD38, CD40LG, CD52, CIITA, CSF2, CTLA4, DCK, FAS, HAVCR2 (also called TIM3), LAG3, PDCD1 (also called PD-1), PTPN6, TIGIT, TRAC, TRBC1, TRBC2, TRBC1_2 (or TRBC1+2), CARD11, CD247, IL7R, LCK, PLCG1, ALPNR, BBS1, CALR, CD3G, CD58, COL17A1, DEFB134, ERAP1, ERAP2, IFNGR1, IFNGR2, JAK1, JAK2, mir-101-2, MLANA, PSMB5, PSMB8, PSMB9, PTCD2, RFX5, RFXANK, RFXAP, RPL23, SOX10, SRP54, STAT1, Tap1, TAP2, TAPBP, TWF1, CD3D, or NLRC5 gene. For example, in certain embodiments, an engineered CRISPR system disclosed herein may catalyze DNA cleavage at a gene locus, allowing for site-specific integration of the exogenous gene at the gene locus by HDR.

In certain embodiments, an immune cell, e.g., a T cell, is engineered to express a chimeric antigen receptor (CAR), i.e., the T cell comprises an exogenous nucleotide sequence encoding a CAR. As used herein, the term “chimeric antigen receptor” or “CAR” can include any artificial receptor including an antigen-specific binding moiety and one or more signaling chains derived from an immune receptor. CARs can comprise a single chain fragment variable (scFv) of an antibody specific for an antigen coupled via hinge and transmembrane regions to cytoplasmic domains of T cell signaling molecules, e.g., a T cell costimulatory domain (e.g., from CD28, CD137, OX40, ICOS, or CD27) in tandem with a T cell triggering domain (e.g., from CD3). A T cell expressing a chimeric antigen receptor is referred to as a CAR T cell. Exemplary CAR T cells include CD19 targeted CTL019 cells (see, Grupp et al. (2015) BLOOD, 126: 4983), 19-28z cells (see, Park et al. (2015) J. CLIN. ONCOL., 33: 7010), and KTE-C19 cells (see, Locke et al. (2015) BLOOD, 126: 3991). Additional exemplary CAR T cells are described in U.S. Pat. Nos. 8,399,645, 8,906,682, 7,446,190, 9,181,527, 9,272,002, 9,266,960, 10,253,086, 10,808,035, and 10,640,569, and International (PCT) Publication Nos. WO2013/142034, WO2015/120180, WO2015/188141, WO2016/120220, and WO2017/040945. Exemplary approaches to express CARs using CRISPR systems are described in Hale et al. (2017) MOL THER METHODS CLIN DEV., 4: 192, MacLeod et al. (2017) MOL THER, 25: 949, and Eyquem et al. (2017) NATURE, 543: 113.

In certain embodiments, an immune cell, e.g., a T cell, binds an antigen, e.g., a cancer antigen, through an endogenous T cell receptor (TCR). In certain embodiments, an immune cell, e.g., a T cell, is engineered to express an exogenous TCR, e.g., an exogenous naturally occurring TCR or an exogenous engineered TCR. T cell receptors comprise two chains referred to as the α- and β-chains, that combine on the surface of a T cell to form a heterodimeric receptor that can recognize MHC-restricted antigens. Each of α- and β-chain comprises a constant region and a variable region. Each variable region of the α- and β-chains defines three loops, referred to as complementary determining regions (CDRs) known as CDR₁, CDR₂, and CDR₃ that confer the T cell receptor with antigen binding activity and binding specificity.

In certain embodiments, a CAR or TCR binds a cancer antigen selected from B-cell maturation antigen (BCMA), mesothelin, prostate specific membrane antigen (PSMA), prostate stem cell antigen (PCSA), carbonic anhydrase IX (CAIX), carcinoembryonic antigen (CEA), CD5, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD49f, CD56, CD70, CD74, CD123, CD133, CD138, epithelial glycoprotein2 (EGP 2), epithelial glycoprotein-40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor-type tyrosine-protein kinase (FLT3), folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-a and β (FRa and β), Ganglioside G2 (GD2), Ganglioside G3 (GD3), epidermal growth factor receptor 2 (HER-2/ERB2), epidermal growth factor receptor vIII (EGFRvIII), ERB3, ERB4, human telom erase reverse transcriptase (hTERT), Interleukin-13 receptor subunit alpha-2 (IL-13Ra2), K-light chain, kinase insert domain receptor (KDR), Lewis A (CA19.9), Lewis Y (LeY), LI cell adhesion molecule (LICAM), melanoma-associated antigen 1 (melanoma antigen family A1, MAGE-A1), Mucin 16 (MUC-16), Mucin 1 (MUC-1; e.g., a truncated MUC-1), KG2D ligands, cancer-testis antigen NY-ESO-1, oncofetal antigen (h5T4), tumor-associated glycoprotein 72 (TAG-72), vascular endothelial growth factor R2 (VEGF-R2), Wilms tumor protein (WT-1), type 1 tyrosine-protein kinase transmembrane receptor (ROR1), B7-H3 (CD276), B7-H6 (Nkp30), Chondroitin sulfate proteoglycan-4 (CSPG4), DNAX Accessory Molecule (DNAM-1), Ephrin type A Receptor 2 (EpHA2), Fibroblast Associated Protein (FAP), Gp100/HLA-A2, Glypican 3 (GPC3), HA-IH, HERK-V, IL-1 IRa, Latent Membrane Protein 1 (LMP1), Neural cell-adhesion molecule (N-CAM/CD56), and Trail Receptor (TRAIL-R).

In certain embodiments, a genetic loci suitable for insertion of a exogenous gene is intergenic. In certain embodiments, introduction of an exogenous DNA into the genetic loci meadiated by the action on a nucleic acid-guided nucleases, e.g., a cas protein bound to a suitable gNA, results in no phenotypic side affects to the host cell. In certain embodiments, the exogenous gene and or genes inserted into the genetic loci demonstrate robust transcription. In certain embodiments, the transcription of the exogenous gene or genes doesn't affect the expression of neighboring upstream or down-stream genes. In certain embodiments, robust transcription of the exogenous gene or genes in the genetic loci is maintained in progeny after proliferation of the host cell.

Genetic loci suitable for insertion of a CAR- or exogenous TCR-encoding sequence include but are not limited to safe harbor loci (e.g., the AAVS1 locus), TCR subunit loci (e.g., the TCRa constant (TRAC) locus), and other loci associated with certain advantages (e.g., the CCR5 locus, the inactivation of which may prevent or reduce HIV infection). It is understood that insertion in the TRAC locus reduces tonic CAR signaling and enhances T cell potency (see, Eyquem et al. (2017) NATURE, 543: 113). Furthermore, inactivation of the endogenous TRAC gene may reduce a graft-versus-host disease (GVHD) response, thereby allowing use of allogeneic T cells as starting materials for preparation of CAR-T cells. Accordingly, in certain embodiments, an immune cell, e.g., a T cell, is engineered to have reduced expression of an endogenous TCR or TCR subunit, e.g., TCRa subunit constant (TRAC). The cell may be engineered to have partially reduced or no expression of the endogenous TCR or TCR subunit. For example, in certain embodiments, the immune cell, e.g., a T cell, is engineered to have less than 80% (e.g., less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5%) of the expression of the endogenous TCR or TCR subunit relative to a corresponding unmodified or parental cell. In certain embodiments, the immune cell, e.g., a T cell, is engineered to have no detectable expression of the endogenous TCR or TCR subunit. Exemplary approaches to reduce expression of TCRs using CRISPR systems are described in U.S. Pat. No. 9,181,527, Liu et al. (2017) CELL RES, 27: 154, Ren et al. (2017) CLIN CANCER RES, 23: 2255, Cooper et al. (2018) LEUKEMIA, 32: 1970, and Ren et al. (2017) ONCOTARGET, 8: 17002.

It is understood that certain immune cells, such as T cells, also express major histocompatibility complex (MHC) or human leukocyte antigen (HLA) genes, and inactivation of these endogenous gene may reduce a GVHD response, thereby allowing use of allogeneic T cells as starting materials for preparation of CAR-T cells. Accordingly, in certain embodiments, an immune cell, e.g., a T cell, is engineered to have reduced expression of one or more endogenous class I or class II MHCs or HLAs (e.g., beta 2-microglobulin (B2M), class II major histocompatibility complex transactivator (CIITA), HLA-E, and/or HLA-G). The cell may be engineered to have partially reduced or no expression of an endogenous MHC or HLA. For example, in certain embodiments, the immune cell, e.g., a T cell, is engineered to have less than less than 80% (e.g., less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5%) of the expression of endogenous MHC (e.g., B2M, CIITA, HLA-E, or HLA-G) relative to a corresponding unmodified or parental cell. In certain embodiments, the immune cell, e.g., a T cell, is engineered to have no detectable expression of an endogenous MHC (e.g., B2M, CIITA, HLA-E, or HLA-G). Exemplary approaches to reduce expression of MHCs using CRISPR systems are described in Liu et al. (2017) CELL RES, 27: 154, Ren et al. (2017) CLIN CANCER RES, 23: 2255, and Ren et al. (2017) ONCOTARGET, 8: 17002.

Other genes that may be inactivated to reduce a GVHD response include but are not limited to CD3, CD52, and deoxycytidine kinase (DCK). For example, inactivation of DCK may render the immune cells (e.g., T cells) resistant to purine nucleotide analogue (PNA) compounds, which are often used to compromise the host immune system in order to reduce a GVHD response during an immune cell therapy. In certain embodiments, the immune cell, e.g., a T cell, is engineered to have less than less than 80% (e.g., less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5%) of the expression of endogenous CD52 or DCK relative to a corresponding unmodified or parental cell.

In certain embodiments, an immune cell, e.g., a T cell, is engineered to have reduced expression of an endogenous gene. For example, in certain embodiments, an engineered CRISPR system disclosed herein may be used to engineer an immune cell to have reduced expression of an endogenous gene. For example, in certain embodiments, an engineered CRISPR system disclosed herein may result in DNA cleavage at a gene locus, thereby inactivating the targeted gene. In other embodiments, an engineered CRISPR system disclosed herein may be fused to an effector domain (e.g., a transcriptional repressor or histone methylase) to reduce the expression of the target gene.

It is understood that the activity of an immune cell (e.g., T cell) may be enhanced by inactivating or reducing the expression of an immune suppressor such as an immune checkpoint protein. Accordingly, in certain embodiments, an immune cell, e.g., a T cell, is engineered to have reduced expression of an immune checkpoint protein. Exemplary immune checkpoint proteins expressed by wild-type T cells include but are not limited to PDCD1 (PD-1), CSF2, CTLA4, ADORA2A (A2AR), B7-H3, B7-H4, BTLA, KIR, LAG3, HAVCR2 (TIM3), TIGIT, VISTA, PTPN6 (SHP-1), and FAS. The cell may be modified to have partially reduced or no expression of the immune checkpoint protein. For example, in certain embodiments, the immune cell, e.g., a T cell, is engineered to have less than 80% (e.g., less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5%) of the expression of the immune checkpoint protein relative to a corresponding unmodified or parental cell. In certain embodiments, the immune cell, e.g., a T cell, is engineered to have no detectable expression of the immune checkpoint protein. Exemplary approaches to reduce expression of immune checkpoint proteins using CRISPR systems are described in International (PCT) Publication No. WO2017/017184, Cooper et al. (2018) LEUKEMIA, 32: 1970, Su et al. (2016) ONCOIMMUNOLOGY, 6: e1249558, and Zhang et al. (2017) FRONT MED, 11: 554.

The immune cell can also be engineered to express an exogenous protein (besides an antigen-binding protein described above) at the locus of a human ADORA2A, B2M, CD3E, CD38, CD40LG, CD52, CIITA, CSF2, CTLA4, DCK, FAS, HAVCR2 (also called TIM3), LAG3, PDCD1 (also called PD-1), PTPN6, TIGIT, TRAC, TRBC1, TRBC2, TRBC1_2 (or TRBC1+2), CARD11, CD247, IL7R, LCK, PLCG1, ALPNR, BBS1, CALR, CD3 G, CD58, COL17A1, DEFB134, ERAP1, ERAP2, IFNGR1, IFNGR2, JAK1, JAK2, mir-101-2, MLANA, PSMB5, PSMB8, PSMB9, PTCD2, RFX5, RFXANK, RFXAP, RPL23, SOX10, SRP54, STAT1, Tap1, TAP2, TAPBP, TWF1, CD3D, or NLRC5 gene.

In certain embodiments, an immune cell, e.g., a T cell, is modified to express a dominant-negative form of an immune checkpoint protein. In certain embodiments, the dominant-negative form of the checkpoint inhibitor can act as a decoy receptor to bind or otherwise sequester the natural ligand that would otherwise bind and activate the wild-type immune checkpoint protein. Examples of engineered immune cells, for example, T cells containing dominant-negative forms of an immune suppressor are described, for example, in International (PCT) Publication No. WO2017/040945.

In certain embodiments, an immune cell, e.g., a T cell, is modified to express a gene (e.g., a transcription factor, a cytokine, or an enzyme) that regulates the survival, proliferation, activity, or differentiation (e.g., into a memory cell) of the immune cell. In certain embodiments, the immune cell is modified to express TET2, FOXO1, IL-12, IL-15, IL-18, IL-21, IL-7, GLUT1, GLUT3, HK1, HK2, GAPDH, LDHA, PDK1, PKM2, PFKFB3, PGK1, ENO1, GYS1, and/or ALDOA. In certain embodiments, the modification is an insertion of a nucleotide sequence encoding the protein operably linked to a regulatory element. In certain embodiments, the modification is a substitution of a single nucleotide polymorphism (SNP) site in the endogenous gene. In certain embodiments, an immune cell, e.g., a T cell, is modified to express a variant of a gene, for example, a variant that has greater activity than the respective wild-type gene. In certain embodiments, the immune cell is modified to express a variant of CARD11, CD247, IL7R, LCK, or PLCG1. For example, certain gain-of-function variants of IL7R were disclosed in Zenatti et al., (2011) NAT. GENET. 43(10):932-39. The variant can be expressed from the native locus of the respective wild-type gene by delivering an engineered system described herein for targeting the native locus in combination with a donor template that carries the variant or a portion thereof.

In certain embodiments, an immune cell, e.g., a T cell, is modified to express a protein (e.g., a cytokine or an enzyme) that regulates the microenvironment that the immune cell is designed to migrate to (e.g., a tumor microenvironment). In certain embodiments, the immune cell is modified to express CA9, CA12, a V-ATPase subunit, NHE1, and/or MCT-1.

In certain embodiments, provided is a method for treatment of a disease, e.g., a cancer, by administering to a subject suffering from the disease an effective amount of T cells modified to express a CAR specific to the disease using the modified guide nucleic acids and CRISPR-Cas systems described herein, e.g., in sections IA, IA1, IB, IC, and IVB. In certain embodiments, the T cells are autologous cells removed from the subject, treated to modify genomic DNA to express CAR, expanded, and administered to the subject; in certain embodiments, the T cells are allogeneic T cells that have been treated to modify genomic DNA to express CAR. In certain embodiments, the disease is a blood cancer, such as leukemia or lymphoma; in certain embodiments the disease is a solid tumor cancer.

V. KITS

It is understood that the engineered, non-naturally occurring system, the CRISPR expression system, and/or the library disclosed herein can be packaged in a kit suitable for use by a medical provider, researcher, and the like. Accordingly, in another aspect, the invention provides kits containing any one or more of the elements disclosed in the above systems, libraries, methods, and compositions. In certain embodiments, the kit comprises an engineered, non-naturally occurring system as disclosed herein and instructions for using the kit. The instructions may be specific to the applications and methods described herein. In certain embodiments, one or more of the elements of the system are provided in a solution. In certain embodiments, one or more of the elements of the system are provided in lyophilized form, and the kit further comprises a diluent. Elements may be provided individually or in combinations, and may be provided in any suitable container, such as a vial, a bottle, a tube, or immobilized on the surface of a solid base (e.g., chip or microarray). In certain embodiments, the kit comprises one or more of the nucleic acids and/or proteins described herein. In certain embodiments, the kit provides all elements of the systems of the invention.

In certain embodiments of a kit comprising the engineered, non-naturally occurring system, the targeter nucleic acid and the modulator nucleic acid, where one or more nucleotides at or near the 3′ and/or 5′ end of either or both, is modified, are provided in separate containers. In other embodiments, the targeter nucleic acid and the modulator nucleic acid are pre-complexed, and the complex is provided in a single container. In certain embodiments, the kit comprises a Cas protein or a nucleic acid comprising a regulatory element operably linked to a nucleic acid encoding a Cas protein provided in a separate container. In other embodiments, the kit comprises a Cas protein pre-complexed with the targeter nucleic acid and the modulator nucleic acid, and the complex is provided in a single container.

In order to target multiple target nucleotide sequences, e.g., for use in a screening or selection process, a kit may be provided comprising multiple targeter nucleic acids. Accordingly, in certain embodiments, the kit comprises a plurality of targeter nucleic acids as disclosed herein (e.g., in separate tubes or immobilized on the surface of a solid base such as a chip or a microarray), optionally one or more modulator nucleic acids as disclosed herein, and optionally a Cas protein or a regulatory element operably linked to a nucleic acid encoding a Cas protein as disclosed herein. Such kits are useful for identifying a targeter nucleic acid with the highest efficiency and/or specificity to target a given gene, for identifying a gene implicated in a physiological or pathological pathway, or for engineering a cell to achieve desired functionality in a multiplex assay. In certain embodiments, the kit further comprises one or more donor templates provided in one or more separate containers. In certain embodiments, the kit comprises a plurality of donor templates as disclosed herein (e.g., in separate tubes or immobilized on the surface of a solid base such as a chip or a microarray), one or more targeter nucleic acids disclosed herein, and one or more modulator nucleic acids as disclosed herein, and optionally a Cas protein or a regulatory element operably linked to a nucleic acid encoding a Cas protein as disclosed herein. Such kits are useful for identifying a donor template that introduces optimal genetic modification in a multiplex assay. The CRISPR expression systems as disclosed herein are also suitable for use in a kit.

In certain embodiments, a kit further comprises one or more reagents and/or buffers for use in a process utilizing one or more of the elements described herein. Reagents may be provided in any suitable container and may be provided in a form that is usable in a particular assay, or in a form that requires addition of one or more other components before use (e.g., in concentrate or lyophilized form). A buffer may be a reaction or storage buffer, including but not limited to a sodium carbonate buffer, a sodium bicarbonate buffer, a borate buffer, a Tris buffer, a MOPS buffer, a HEPES buffer, and combinations thereof. In some embodiments, the buffer is alkaline. In certain embodiments, the buffer has a pH from 6-9, 6.5-8.5, 7-8, 6.5-7.5, 6-8, 7.5-8.5, 7-9, 6.5-9.5, 6-10, 8-9, 7.5-9.5, 7-10, for example 7-8, such as 7.5. In certain embodiments, the kit further comprises a pharmaceutically acceptable carrier. In certain embodiments, the kit further comprises one or more devices or other materials for administration to a subject.

Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.

In the application, where an element or component is said to be included in and/or selected from a list of recited elements or components, it should be understood that the element or component can be any one of the recited elements or components, or the element or component can be selected from a group consisting of two or more of the recited elements or components.

Further, it should be understood that elements and/or features of a composition or a method described herein can be combined in a variety of ways without departing from the spirit and scope of the present invention, whether explicit or implicit herein. For example, where reference is made to a particular compound, that compound can be used in various embodiments of compositions of the present invention and/or in methods of the present invention, unless otherwise understood from the context. In other words, within this application, embodiments have been described and depicted in a way that enables a clear and concise application to be written and drawn, but it is intended and will be appreciated that embodiments may be variously combined or separated without parting from the present teachings and invention(s). For example, it will be appreciated that all features described and depicted herein can be applicable to all aspects of the invention(s) described and depicted herein.

The terms “a” and “an” and “the” and similar references in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. For example, the term “a cell” can include a plurality of cells, including mixtures thereof. Where the plural form is used for compounds, salts, and the like, this is taken to mean also a single compound, salt, or the like.

It should be understood that the expression “at least one of” includes individually each of the recited objects after the expression and the various combinations of two or more of the recited objects unless otherwise understood from the context and use. The expression “and/or” in connection with three or more recited objects should be understood to have the same meaning unless otherwise understood from the context.

The use of the term “include,” “includes,” “including,” “have,” “has,” “having,” “contain,” “contains,” or “containing,” including grammatical equivalents thereof, should be understood generally as open-ended and non-limiting, for example, not excluding additional unrecited elements or steps, unless otherwise specifically stated or understood from the context.

Where the use of the term “about” is before a quantitative value, the present invention also includes the specific quantitative value itself, unless specifically stated otherwise. As used herein, the term “about” refers to a ±10% variation from the nominal value unless otherwise indicated or inferred.

It should be understood that the order of steps or order for performing certain actions is immaterial so long as the present invention remain operable. Moreover, two or more steps or actions may be conducted simultaneously.

The use of any and all examples, or exemplary language herein, for example, “such as” or “including,” is intended merely to illustrate better the present invention and does not pose a limitation on the scope of the invention unless claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the present invention.

VI. EMBODIMENTS

In embodiment 1 provided herein is a composition comprising a synthetic guide nucleic acid (gNA) comprising (i) a targeter nucleic acid comprising: (a) a spacer sequence configured to hybridize with a target nucleotide sequence, and (b) a targeter stem sequence; and (ii) a modulator nucleic acid comprising (a) a modulator stem sequence complementary to the targeter stem sequence, and (b) a 5′ sequence; wherein either the targeter nucleic acid or the modulator nucleic acid, or both, comprise one or more modified nucleotides at or near its 3′ end, if present, at or near its 5′ end, if present, or both. In embodiment 2 provided herein is the composition of embodiment 1 wherein the synthetic gNA is a single polynucleotide. In embodiment 3 provided herein is the composition of embodiment 1 wherein the targeter nucleic acid and the modulator nucleic acid are separate nucleic acids. In embodiment 4 provided herein is the composition of any one of embodiments 1 through 3 wherein some or all of the gNA is RNA, e.g provided herein is a gRNA. In embodiment 5 provided herein is the composition of embodiment 4 wherein at least 50% of the nucleic acid is RNA. In embodiment 6 provided herein is the composition of embodiment 4 wherein at least 70% of the nucleic acid is RNA. In embodiment 7 provided herein is the composition of embodiment 4 wherein at least 90% of the nucleic acid is RNA. In embodiment 8 provided herein is the composition of embodiment 4 wherein at least 100% of the nucleic acid is RNA. In embodiment 9 provided herein is the composition of any one of embodiments 1 through 8 wherein the modified nucleotide comprises a chemical modification. In embodiment 10 provided herein is the composition of any one of embodiments 1 through 9 wherein the stem sequences are between one and ten nucleotides in length. In embodiment 11 provided herein is the composition of any one of embodiments 1 through 9 wherein the stem sequences are between two and nice nucleotides in length. In embodiment 12 provided herein is the composition of any one of embodiments 1 through 9 wherein the stem sequences are between four and six nucleotides in length. In embodiment 13 provided herein is the composition of any one of embodiments 1 through 12 wherein the stem sequences of the modulator and targeter nucleic acids share at least 80% sequence complementarity. In embodiment 14 provided herein is the composition of any one of embodiments 1 through 12 wherein the stem sequences of the modulator and targeter nucleic acids share at least 90% sequence complementarity. In embodiment 15 provided herein is the composition of any one of embodiments 1 through 12 wherein the stem sequences of the modulator and targeter nucleic acids share at least 95% sequence complementarity. In embodiment 16 provided herein is the composition of any one of embodiments 1 through 12 wherein the stem sequences of the modulator and targeter nucleic acids share 100% sequence complementarity. In embodiment 17 provided herein is the composition of embodiment 2 wherein the modification comprises a chemical modification in one or more nucleotides or internucleotide linkages at or near the 5′ end of the gNA. In embodiment 18 provided herein is the composition of embodiment 17 wherein the chemical modification comprises a chemical modification in at least one nucleotide or internucleotide linkage within ten nucleotides of the 5′ end. In embodiment 19 provided herein is the composition of embodiment 17 wherein the chemical modification comprises one to 17 phosphorothioate modifications within 17 internucleotide linkages of the 5′ end. In embodiment 20 provided herein is the composition of embodiment 19 wherein the chemical modification comprises one to ten phopshorothioate modifications within ten internucleotide linkages of the 5′ end. In embodiment 21 provided herein is the composition of embodiment 19 wherein the chemical modification comprises nine phosphorothioate modifications to the final nine internucleotide linkages of the 5′ end. In embodiment 22 provided herein is the composition of embodiment 17 wherein the chemical modification comprises one to five 2′-O-methoxy modifications to one or more nucleotides within five nucleotides of the 5′ end. In embodiment 23 provided herein is the composition of any one of embodiments 17 through 21 wherein the chemical modification comprises two 2′-O-methoxy modifications to the final two nucleotides of the 5′ end. In embodiment 24 provided herein is the composition of any one of embodiments 17 through 21 wherein the chemical modification comprises one 2′-O-methoxy modification to the 5′ terminal nucleotide. In embodiment 25 provided herein is the composition of any one of embodiments 17 through 24 wherein the chemical modification comprises a propanediol modification to the 5′ terminal nucleotide. In embodiment 26 provided herein is the composition of embodiment 17 wherein the modulator nucleic acid comprises any one of SEQ ID NOs: 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, or 1037. In embodiment 27 provided herein is the composition of embodiment 2 wherein the modification comprises a chemical modification in one or more nucleotides or internucleotide linkages at or near the 3′ end of the gNA. In embodiment 28 provided herein is the composition of any one of embodiments 17 through 25 wherein the chemical modification further comprises a chemical modification in one or more nucleotides or internucleotide linkages at or near the 3′ end of the gNA. In embodiment 29 provided herein is the composition of embodiment 27 or embodiment 28 wherein the chemical modification comprises a chemical modification in at least one nucleotide or internucleotide linkage within ten nucleotides of the 3′ end. In embodiment 30 provided herein is the composition of embodiment 27 or embodiment 28 wherein the chemical modification comprises one to 17 phosphorothioate modifications within 17 internucleotide linkages of the 3′ end. In embodiment 31 provided herein is the composition of embodiment 30 wherein the chemical modification comprises one to ten phopshorothioate modifications within ten internucleotide linkages of the 3′ end. In embodiment 32 provided herein is the composition of embodiment 30 wherein the chemical modification comprises nine phosphorothioate modifications to the final nine internucleotide linkages of the 3′ end. In embodiment 33 provided herein is the composition of any one of embodiments 27 through 32 wherein the chemical modification comprises one to five 2′-O-methoxy modifications to one or more nucleotides within five nucleotides of the 3′ end. In embodiment 34 provided herein is the composition of any one of embodiments 27 through 32 wherein the chemical modification comprises two 2′-O-methoxy modifications to the final two nucleotides of the 3′ end. In embodiment 35 provided herein is the composition of any one of embodiments 27 through 32 wherein the chemical modification comprises one 2′-O-methoxy modification to the last nucleotide of the 3′ end. In embodiment 36 provided herein is the composition of any one of embodiments 27 through 35 wherein the chemical modification comprises a propanediol modification to the 3′ terminal nucleotide. In embodiment 37 provided herein is the composition of embodiment 3 wherein the modulator nucleic acid is unmodified. In embodiment 38 provided herein is the composition of embodiment 3 wherein the modification comprises a chemical modification in one or more nucleotides or internucleotide linkages at or near the 5′ end of the modulator nucleic acid. In embodiment 39 provided herein is the composition of embodiment 38 wherein the chemical modification comprises a chemical modification in at least one nucleotide or internucleotide linkage within ten nucleotides of the 5′ end. In embodiment 40 provided herein is the composition of embodiment 38 wherein the chemical modification comprises one to 17 phosphorothioate modifications within 17 internucleotide linkages of the 5′ end. In embodiment 41 provided herein is the composition of embodiment 40 wherein the chemical modification comprises one to ten phopshorothioate modifications within ten internucleotide linkages of the 5′ end. In embodiment 42 provided herein is the composition of embodiment 40 wherein the chemical modification comprises nine phosphorothioate modifications to the final nine internucleotide linkages of the 5′ end. In embodiment 43 provided herein is the composition of any one of embodiments 38 through 42 wherein the chemical modification comprises one to five 2′-O-methoxy modifications to one or more nucleotides within five nucleotides of the 5′ end. In embodiment 44 provided herein is the composition of any one of embodiments 38 through 42 wherein the chemical modification comprises two 2′-O-methoxy modifications to the final two nucleotides of the 5′ end. In embodiment 45 provided herein is the composition of any one of embodiments 38 through 42 wherein the chemical modification comprises one 2′-O-methoxy modification to the 5′ end nucleotide. In embodiment 46 provided herein is the composition of any one of embodiments 38 through 45 wherein the chemical modification comprises a propanediol modification to the 5′ terminal nucleotide. In embodiment 47 provided herein is the composition of embodiment 38 wherein the modulator nucleic acid comprises any one of SEQ ID NOs: 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022, 1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, or 1037. In embodiment 48 provided herein is the composition of any one of embodiments 3 and embodiments 38 through 46 wherein the modification comprises a chemical modification to one or more nucleotides or internucleotide linkages at or near the 3′ end of the modulator nucleic acid. In embodiment 49 provided herein is the composition of embodiment 48 wherein the chemical modification comprises a chemical modification in at least one nucleotide or internucleotide linkage within ten nucleotides of the 3′ end. In embodiment 50 provided herein is the composition of embodiment 48 wherein the chemical modification comprises one 1 to 17 phosphorothioate modifications within 17 internucleotide linkages of the 3′ end. In embodiment 51 provided herein is the composition of embodiment 50 wherein the chemical modification comprises one to ten phopshorothioate modifications within ten internucleotide linkages of the 3′ end. In embodiment 52 provided herein is the composition of embodiment 50 wherein the chemical modification comprises nine phosphorothioate modifications to the final nine internucleotide linkages of the 3′ end. In embodiment 53 provided herein is the composition of any one of embodiments 3 and embodiments 38 through 52 wherein the chemical modification comprises one to five 2′-O-methoxy modifications to one or more nucleotides within five nucleotides of the 3′ end. In embodiment 54 provided herein is the composition of any one of embodiments 3 and embodiments 38 through 52 wherein the chemical modification comprises two 2′-O-methoxy modifications to the final two nucleotides of the 3′ end. In embodiment 55 provided herein is the composition of any one of embodiments 3 and embodiments 38 through 52 wherein the chemical modification comprises one 2′-O-methoxy modification to the last nucleotide of the 3′ end. In embodiment 56 provided herein is the composition of any one of embodiments 48 through 55 wherein the chemical modification comprises a propanediol modification to the 3′ terminal nucleotide. In embodiment 57 provided herein is the composition of any one of embodiments 3 and 38 through 56 wherein the targeter nucleic acid is unmodified. In embodiment 58 provided herein is the composition of any one of embodiments 37 through 56 wherein the chemical modification comprises a chemical modification in one or more nucleotides or internucleotide linkages at or near the 3′ end of the targeter nucleic acid. In embodiment 59 provided herein is the composition of embodiment 58 wherein the chemical modification comprises a chemical modification in at least one nucleotide or internucleotide linkage within ten nucleotides of the 3′ end. In embodiment 60 provided herein is the composition of embodiment 58 wherein the chemical modification comprises one to five 2′-O-methoxy-3′-phosphorothioate modifications within five nucleotides of the 3′ end. In embodiment 61 provided herein is the composition of embodiment 58 wherein the chemical modification comprises two 2′-O-methoxy-3′-phosphorothioate modifications to the final two nucleotides of the 3′ end. In embodiment 62 provided herein is the composition of embodiment 58 wherein the chemical modification comprises one through nine 2′-fluoro modifications to the final nine nucleotides of the 3′ end. In embodiment 63 provided herein is the composition of embodiment 58 wherein the chemical modification comprises five 2′-fluoro modifications to the final five nucleotides of the 3′ end. In embodiment 64 provided herein is the composition of any one of embodiments 58 through 63 wherein the chemical modification comprises a propanediol modification to the 3′ terminal nucleotide. In embodiment 65 provided herein is the composition of any one of embodiments 3, embodiments 37 through 56, and embodiments 58 through 64 wherein the modification comprises a chemical modification at or near the 5′ end of the targeter nucleic acid. In embodiment 66 provided herein is the composition of embodiment 65 wherein the chemical modification comprises a chemical modification in at least one nucleotide or internucleotide linkage within ten nucleotides of the 5′ end. In embodiment 67 provided herein is the composition of embodiment 65 wherein the chemical modification comprises one to five 2′-O-methoxy-3′-phosphorothioate modifications within five nucleotides of the 5′ end. In embodiment 68 provided herein is the composition of embodiment 65 wherein the chemical modification comprises two 2′-O-methoxy-3′-phosphorothioate modifications to the final two nucleotides of the 5′ end. In embodiment 69 provided herein is the composition of embodiment 65 wherein the chemical modification comprises one through nine 2′-fluoro modifications to one or more nucleotides within nine nucleotides of the 5′ end. In embodiment 70 provided herein is the composition of embodiment 65 wherein the chemical modification comprises five 2′-fluoro modification to the final five nucleotides of the 5′ end. In embodiment 71 provided herein is the composition of any one of embodiments 65 through 70 wherein the chemical modification comprises a propanediol modification to the 5′ terminal nucleotide. In embodiment 72 provided herein is the composition of embodiment 1, 9, 17, 18, 27, 28, 29, 38, 39, 48, 49, 58, 59, or 65 wherein the chemical modification is 2′-O-alkyl, 2′-O-methyl, a phosphorothioate, a phosphonoacetate, a thiophosphonoacetate, a 2′-O-methyl-3′-phosphorothioate, a 2′-O-methyl-3′-phosphonoacetate, a 2′-O-methyl-3′-thiophosphonoacetate, a 2′-deoxy-3′-phosphonoacetate, a 2′-deoxy-3′-thiophosphonoacetate, or a combination thereof. In embodiment 73 provided herein is a composition comprising a Cas nuclease complexed with a gNA of any of the previous embodiments. In embodiment 74 provided herein is the composition of embodiment 73 wherein the Cas nuclease comprises a Type V Cas nuclease. In embodiment 75 provided herein is the composition of embodiment 74, wherein the Cas nuclease comprises a type V-A, type V-C, or type V-D Cas nuclease. In embodiment 76 provided herein is the composition of embodiment 75, wherein the Cas nuclease comprises a type V-A Cas nuclease. In embodiment 77 provided herein is the composition of embodiment 76 wherein the Type V-A Cas nuclease comprises a MAD, Csm1, ART, ABW, or other Cpf1 nuclease, or derivative or variant thereof. In embodiment 78 provided herein is the composition of embodiment 77 wherein the nuclease comprises a sequence with at least 80% identity to any one of SEQ ID NOs: 3, 4, 5, 6, 7, 8, 9, 10, or 11. In embodiment 79 provided herein is the composition of embodiment 77 wherein the nuclease comprises a sequence with at least 80% identity to any one of SEQ ID NOs: 1 or 2. In embodiment 80 provided herein is the composition of embodiment 77 wherein the nuclease comprises a sequence with at least 80% identity to any one of SEQ ID NOs: 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, or 984. In embodiment 81 provided herein is the composition of embodiment 77 wherein the nuclease comprises a sequence with at least 80% identity to any one of SEQ ID NOs: 789, 16, 29, 42, 55, 68, 81, 94, or 107. In embodiment 82 provided herein is the composition of any one of embodiments 78 through 81 wherein the nuclease sequence is at least 85% identical to the sequence. In embodiment 83 provided herein is the composition of any one of embodiments 78 through 81 wherein the nuclease sequence is at least 90% identical to the sequence. In embodiment 84 provided herein is the composition of any one of embodiments 78 through 81 wherein the nuclease sequence is at least 95% identical to the sequence. In embodiment 85 provided herein is the composition of any one of embodiments 78 through 81 wherein the nuclease sequence is at least 97.5% identical to the sequence. In embodiment 86 provided herein is the composition of any one of embodiments 78 through 81 wherein the nuclease sequence is 100% identical to the sequence. In embodiment 87 provided herein is the composition of any one of embodiments 1 through 71 wherein the spacer sequence comprises a sequence capable of hybridizing with a target nucleotide sequence within a human ADORA2A, B2M, CD3E, CD38, CD40LG, CD52, CIITA, CSF2, CTLA4, DCK, FAS, HAVCR2 (also called TIM3), LAG3, PDCD1 (also called PD-1), PTPN6, TIGIT, TRAC, TRBC1, TRBC2, TRBC1_2 (or TRBC1+2), CARD11, CD247, IL7R, LCK, PLCG1, ALPNR, BBS1, CALR, CD3G, CD58, COL17A1, DEFB134, ERAP1, ERAP2, IFNGR1, IFNGR2, JAK1, JAK2, mir-101-2, MLANA, PSMB5, PSMB8, PSMB9, PTCD2, RFX5, RFXANK, RFXAP, RPL23, SOX10, SRP54, STAT1, Tap1, TAP2, TAPBP, TWF1, CD3D, or NLRC5 gene. In embodiment 88 provided herein is the composition of any one of embodiments 1 through 71 wherein the spacer sequence comprises a sequence capable of hybridizing with a target nucleotide sequence within a safe harbor site. In embodiment 89 provided herein is the composition of any one of embodiments 3 and 37 through 71 wherein the dual gNA when complexed with a Cas nuclease as an RNP results in at least 70% of the editing efficiency as compared to a 5′ and 3′ propanediol modified single gNA. In embodiment 90 provided herein is the composition of any one of embodiments 3 and 37 through 71 wherein the dual gNA when complexed with a Cas nuclease as an RNP results in at least 80% of the editing efficiency as compared to a 5′ and 3′ propanediol modified single gNA. In embodiment 91 provided herein is the composition of any one of embodiments 3 and 37 through 71 wherein the dual gNA when complexed with a Cas nuclease as an RNP results in at least 90% of the editing efficiency as compared to a 5′ and 3′ propanediol modified single gNA. In embodiment 92 provided herein is the composition of any one of embodiments 3 and 37 through 71 wherein the dual gNA when complexed with a Cas nuclease as an RNP results in the same editing efficiency as compared to a single 5′ and 3′ propanediol modified gNA. In embodiment 93 provided herein is the composition of any one of embodiments 3 and 37 through 71 wherein the modified gNA when complexed with a Cas nuclease as an RNP results in higher editing efficiency as compared to a single gNA. In embodiment 94 provided herein is a eukaryotic cell comprising the gRNA of any of embodiments 1 through 71. In embodiment 95 provided herein is a eukaryotic cell comprising the nucleic acid-guided nuclease complex of any of embodiments 73 through 86. In embodiment 96 provided herein is the composition of embodiment 94 or embodiment 95 wherein the eukaryotic cell is an allogeneic cell. In embodiment 97 provided herein is the composition of any one of embodiments 94 through 96 wherein the eukaryotic cell is an immune cell. In embodiment 98 provided herein is the composition of embodiment 97 wherein the immune cell is a human immune cell. In embodiment 99 provided herein is the composition of embodiment 97 wherein the immune cell comprises a neutrophil, an eosinophil, a basophil, a mast cell, a monocyte, a macrophage, a dendritic cell, a natural killer cell, or a lymphocyte. In embodiment 100 provided herein is the composition of embodiment 97 wherein the immune cell is a T cell. In embodiment 101 provided herein is the composition of embodiment 97 wherein the immune cell is a CART cell. In embodiment 102 provided herein is the composition of any one of embodiments 94 through 96 wherein the eukaryotic cell is a stem cell. In embodiment 103 provided herein is the composition of embodiment 102 wherein the stem cell is a human pluripotent stem cell. In embodiment 104 provided herein is the composition of embodiment 102 wherein the stem cell is an embryonic stem cell or an induced pluripotent stem cell. In embodiment 105 provided herein is the composition of embodiment 102 wherein the stem cell is a hematopoietic stem cell. In embodiment 106 provided herein is a method of cleaving a target DNA having a target nucleotide sequence, the method comprising contacting the target DNA with the composition of any one of embodiments 73 through 86, thereby resulting in cleavage of the target DNA. In embodiment 107 provided herein is the method of embodiment 106, wherein the contacting occurs in vitro. In embodiment 108 provided herein is the method of embodiment 106, wherein the contacting occurs in a cell ex vivo. In embodiment 109 provided herein is the method of embodiment 108, wherein the target DNA is genomic DNA of the cell. In embodiment 110 provided herein is the method of embodiment 108, wherein the system is delivered into the cell as a pre-formed RNP complex. In embodiment 111 provided herein is the method of embodiment 110, wherein the pre-formed RNP complex is delivered into the cell by electroporation, lipofection, or a viral method. In embodiment 112 provided herein is the method of embodiment 111 wherein the pre-formed RNP complex is delivered into the cell by electroporation. In embodiment 113 provided herein is a method of editing the genome of a eukaryotic cell, the method comprising delivering the engineered, non-naturally occurring system of any one of embodiments 73 through 86, or components thereof and/or one or more polynucleotides coding for one or more components thereof, into the eukaryotic cell, thereby resulting in editing of the genome of the eukaryotic cell. In embodiment 114 provided herein is the method of embodiment 113, wherein the system is delivered into the cell as a pre-formed RNP complex. In embodiment 115 provided herein is the method of embodiment 113 or 114, wherein the system is delivered into the cell by electroporation, lipofection, or a viral method. In embodiment 116 provided herein is the method of embodiment 113 or 114, wherein the system is delivered into the cell by electroporation. In embodiment 117 provided herein is the method of any one of embodiments 113 through 116, wherein the cell is an immune cell. In embodiment 118 provided herein is the method of embodiment 117, wherein the immune cell is a neutrophil, eosinophil, basophil, mast cell, monocyte, macrophage, dendritic cell, natural killer cell, or a lymphocyte. In embodiment 119 provided herein is the method of embodiment 117, wherein the immune cell is a T lymphocyte. In embodiment 120 provided herein is the method of embodiment 119, wherein an exogenous donor template is delivered in addition to the RNP wherein the donor template is used to repair the cleaved target DNA. In embodiment 121 provided herein is the method of embodiment 120 wherein the exogenous donor template is CAR cassette. In embodiment 122 provided herein is the composition of a CART cell resulting from the method of embodiment 121. In embodiment 123 provided herein is the method of embodiment 113 wherein the engineered, non-naturally occurring system is delivered to a plurality of eukaryotic cells, and wherein the system comprises a guide nucleic acid comprising one or modifications as described herein, wherein the editing efficiency of the genomes of the plurality of cells is increased by at least 5% compared to the editing efficiency when the same system but without the modification or modifications is used. In embodiment 124 provided herein is a pharmaceutical composition comprising the composition of any one of embodiments 1 through 93 and a pharmaceutically acceptable carrier. In embodiment 125 provided herein is a method of treating a disease or a disorder comprising administering to a subject in need thereof an effective amount of a composition of any one of embodiments 1 through 93, or an effective amount of cells modified by treatment with a composition of any one of embodiments 1 through 93. In embodiment 126 provided herein is the method of embodiment 125 comprising administering to a subject in need thereof of cells modified by treatment with a composition of any one of embodiment 1 to 93. In embodiment 127 provided herein is the method of embodiment 125 wherein the cells are cells that are removed from an individual and treated ex vivo with a composition of any one of embodiment 1 to 93. In embodiment 128 provided herein is the method of embodiment 127 wherein the subject in need of treatment and the individual whose cells are treated ex vivo are the same. In embodiment 129 provided herein is a composition comprising the composition of any one of embodiments 1 through 72 further comprising a Cas protein. In embodiment 130 provided herein is the composition of embodiment 128 wherein the Cas protein is a Cas nuclease. In embodiment 131 provided herein is the composition of embodiment 130 wherein the Cas nuclease is a Type I, II, III, IV, V, or VI Cas nuclease. In embodiment 132 provided herein is the composition of embodiment 131 wherein the Cas nuclease is a Type II Cas nuclease.

VII. EXAMPLES Example 1

In this Example various combinations of modified and unmodified modulator and targeter nucleic acids were used with a Cas nuclease and the editing efficiency for each combination was evaluated.

Modifications included at least one of 2′-O-methyl (M), a phosphorothioate (S), a phosphonoacetate (P), a thiophosphonoacetate (SP), a 2′-O-methyl-3′-phosphorothioate (MS), a 2′-O-methyl-3′-phosphonoacetate (MP), a 2′-O-methyl-3′-thiophosphonoacetate (MSP), a 2′-deoxy-3′-phosphonoacetate (DP), a 2′-deoxy-3′-thiophosphonoacetate (DSP), propanediol (Alt-R) or a combination thereof at either the 3′ or 5′ end. The modified/unmodified crRNA and tracrRNA (sequences shown in Table 27) were mixed in the molar ratio 1:1 (200pmol+200pmol) at room temperature and incubated for 15 min. For the formation of the RNPs 100 pmol unmodified/modified gRNA were mixed with 100 pmol Mad7 nuclease and transfected into primary Pan T cells using the Lonza nucleofector system. Combinations of modifications tested are shown in FIG. 2 .

FIG. 3 shows data for editing efficiency (as measured by # of reads modified/total # of reads) in primary T cells in an exon at a gene locus. The gRNA designs are shown and show the various combination of modifications tested at either the 3′ and/or the 5′ end of the crRNA or tracrRNA. Sequences for each tested modification are shown in Table 27. The Figure shows the editing results relative to the single gRNA design (left bar) vs. the negative control (far right bar). It is observed that the modifications made to the crRNA make a much larger difference than the tracrRNA although the combination of dual modified crRNA and tracrRNA make the greatest increase in editing efficiency.

TABLE 27 Modified Single and Dual gRNAs Descrip- SEQ Name tion ID NO Sequence¹ sgRNA - 1038 /AltR1/TAATTTCTACTCTTGTAGATGAGTCTCTCAG CTGGTACACG/AltR2/ STAR Modulator 1039 TAATTTCTACTC Targeter 1040 TTGTAGATGAGTCTCTCAGCTGGTACACG STAR Modulator 1041 /AltR1/TAATTTCTACTC MOD1 Targeter 1042 TTGTAGATGAGTCTCTCAGCTGGTACACG STAR Modulator 1043 TAATTTCTACTC MOD2 Targeter 1044 TTGTAGATGAGTCTCTCAGCTGGTACACG/AltR2/ STAR Modulator 1045 /AltR1/TAATTTCTACTC/AltR2/ MOD3 Targeter 1046 TTGTAGATGAGTCTCTCAGCTGGTACACG STAR Modulator 1047 TAATTTCTACTC MOD4 Targeter 1048 /AltR1/TTGTAGATGAGTCTCTCAGCTGGTACACG/A ItR2/ STAR Modulator 1049 /AltR1/TAATTTCTACTC MOD5 Targeter 1050 TTGTAGATGAGTCTCTCAGCTGGTACACG/AltR2/ STAR Modulator 1051 /AltR1/TAATTTCTACTC/AltR2/ MOD6 Targeter 1052 /AltR1/TTGTAGATGAGTCTCTCAGCTGGTACACG/A 1tR2/ ¹/AltR1/ indiciated a sequence modified with a 5′ Alt-R (propanediol) modification. AltR2/ indicates a sequence modified with a 3' Alt-R (propanediol) modification.

Example 2

In this Example various combinations of modified and unmodified modulator and targeter nucleic acids were used with a Cas nuclease and the editing efficiency for each combination was evaluated for three gene targets (Gene 1, Gene 2, Gene 3).

Modifications included at least one of 2′-O-methyl (M), a phosphorothioate (S), a phosphonoacetate (P), a thiophosphonoacetate (SP), a 2′-O-methyl-3′-phosphorothioate (MS), a 2′-O-methyl-3′-phosphonoacetate (MP), a 2′-O-methyl-3′-thiophosphonoacetate (MSP), a 2′-deoxy-3′-phosphonoacetate (DP), a 2′-deoxy-3′-thiophosphonoacetate (DSP), a 2′-fluoro-ribonucleotide, propanediol (Alt-R) or a combination thereof at either the 3′ or 5′ end. The modified/unmodified crRNA and tracrRNA were mixed in the molar ratio 1:1 (200pmol+200pmol) at room temperature and incubated for 15 min. For the formation of the RNPs 100 pmol unmodified/modified gRNA were mixed with 100 pmol Mad7 nuclease and transfected into primary Pan T cells using the Lonza nucleofector system. Sequences for each modulator nucleic acid and targeter nucleic acid used in the study with their respective modifications are shown in Table 28 and Table 29.

The specific sequence for each modulator and targeter complex in FIGS. 4-6 may be deduced using the naming convention (modulator description) x (targeter description) using Table 28 and Table 29. For example, an experimental test using complex Mod_A_7_x_Tar 1 for gene 3 would comprise a modulator of SEQ ID NO: 1031 and a targeter of SEQ ID NO: 1008. It is observed that some combinations made to the modulator-targeter complex demonstrate activity greater than the sgRNA. It is also observed that some combinations made to the modulator-targeter complex demonstrate lower but sufficient (greater than or equal to 70% activity) activity compared to the sgRNA.

FIGS. 4A and B show data for the editing efficiency (as measured by # of reads modified/total # of reads) in primary T cells in an exon at a gene locus for gene 1 for dual gRNAs. Each tested gNA is shown on the x-axis with the first two representing single gRNA controls. The editing efficiency for each tested dual gRNA is normalized to the activity of the single gRNA control. The dotted line represents an editing efficiency of 70% relative to the single gRNA control. The dashed line represents an editing efficiency equal to the single gRNA control. FIG. 4A shows normalized editing efficiencies for dual guide RNAs comprising modulator nucleic acids with a terminal 3′ A nucleotide. Control gRNAs for FIG. 4A are SEQ ID NO: 1056. FIG. 4B shows normalized editing efficiencies for dual guide RNAs comprising modulator nucleic acids with a terminal 3′ C nucleotide. Control RNAs for FIG. 4B are SEQ ID NO: 1055.

FIGS. 5A and B show data for the editing efficiency (as measured by # of reads modified/total # of reads) in primary T cells in an exon at a gene locus for gene 2 for dual gRNAs. Each tested gNA is shown on the x-axis with the first two representing single gRNA controls. The editing efficiency for each tested dual gRNA is normalized to the activity of the single gRNA control. The dotted line represents an editing efficiency of 70% relative to the single gRNA control. The dashed line represents an editing efficiency equal to the single gRNA control. FIG. 5A shows normalized editing efficiencies for dual guide RNAs comprising modulator nucleic acids with a terminal 3′ A nucleotide. Control RNAs for FIG. 5A are SEQ ID NO: 1058. FIG. 5B shows normalized editing efficiencies for dual guide RNAs comprising modulator nucleic acids with a terminal 3′ C nucleotide. Control RNAs for FIG. 5B are SEQ ID NO: 1057.

FIGS. 6A and B show data for the editing efficiency (as measured by # of reads modified/total # of reads) in primary T cells in an exon at a gene locus for gene 3 for dual gRNAs. Each tested gNA is shown on the x-axis with the first two representing single gRNA controls. The editing efficiency for each tested dual gRNA is normalized to the activity of the single gRNA control. The dotted line represents an editing efficiency of 70% relative to the single gRNA control. The dashed line represents an editing efficiency equal to the single gRNA control. FIG. 6A shows normalized editing efficiencies for dual guide RNAs comprising modulator nucleic acids with a terminal 3′ A nucleotide. Control RNAs for FIG. 6A are SEQ ID NO: 1054. FIG. 6B shows normalized editing efficiencies for dual guide RNAs comprising modulator nucleic acids with a terminal 3′ C nucleotide. Control RNAs for FIG. 6B are SEQ ID NO: 1053.

TABLE 28 Targeter Sequences SEQ ID NO Description Sequence¹ 1000 Tar_1_gene TTGTAGATCACAGGAGCCGACCTGCCTAC 2 1001 Tar_2_gene TTGTAGATCACAGGAGCCGACCTGCCTAC/AltR2/ 2 1002 Tar_3_gene TTGTAGATCACAGGAGCCGACCTGCCT*mA*mC 2 1003 Tar_4_gene TTGTAGATCACAGGAGCCGACCTG/12FC//12FC//12FT// 2 12FA//12FC/ 1004 Tar_1_gene TTGTAGATCAAGGACTTCAGCTGGGGGAA 1 1005 Tar_2_gene TTGTAGATCAAGGACTTCAGCTGGGGGAA/AltR2/ 1 1006 Tar_3_gene TTGTAGATCAAGGACTTCAGCTGGGGG*mA*mA 1 1007 Tar_4_gene TTGTAGATCAAGGACTTCAGCTGG/12FG//12FG//12FG// 1 12FA//12FA/ 1008 Tar_1_gene TTGTAGATGAGTCTCTCAGCTGGTACACG 3 1009 Tar_2_gene TTGTAGATGAGTCTCTCAGCTGGTACACG/AltR2/ 3 1010 Tar_3_gene TTGTAGATGAGTCTCTCAGCTGGTACA*mC*mG 3 1011 Tar_4_gene TTGTAGATGAGTCTCTCAGCTGGT/12FA//12FC//12FA// 3 12FC//12FG/ ¹m indicates a 2-O-methoxy phosphorothioate nucleotide modification. *indicates a phosphorothioate internucleotide linkage modification. /12FN/ indicates a 2'-fluoro nucleotide modification where the N may comprise any base (A, T, G, or C). /AltR2/ indicates a sequence modified with a 3' Alt-R (propanediol) modification as shown in FIG. 7B.

TABLE 29 Modulator Sequences SEQ ID NO Description Sequences¹ 1012 STAR_MOD_C_1 TAATTTCTACTC 1013 STAR_MOD_C_2 /Alt1/TAATTTCTACTC 1014 STAR_MOD_C_3 mT*A*TAATTTCTACTC 1015 STAR_MOD_C_4 mT*mA*TAATTTCTACTC 1016 STAR_MOD_C_5 AGACCTTTTTAATTTCTACTC 1017 STAR_MOD_C_6 /Alt1/AGACCTTTTTAATTTCTACTC 1018 STAR_MOD_C_7 A*G*A*C*C*T*T*T*T*TAATTTCTAC TC 1019 STAR_MOD_C_8 mA*mG*ACCTTTTTAATTTCTACTC 1020 STAR_MOD_C_9 mA*G*ACCTTTTTAATTTCTACTC 1021 STAR_MOD_C_10 GTCAAAAGACCTTTTTAATTTCTACTC 1022 STAR_MOD_C_11 /Alt1/GTCAAAAGACCTTTTTAATTTC TACTC 1023 STAR_MOD_C_12 mG*mT*CAAAAGACCTTTTTAATTTCT ACTC 1024 STAR_MOD_C_13 mG*T*CAAAAGACCTTTTTAATTTCTAC TC 1025 STAR_MOD_A_1 TAATTTCTACTA 1026 STAR_MOD_A_2 /Alt1/TAATTTCTACTA 1027 STAR_MOD_A_3 mT*A*TAATTTCTACTA 1028 STAR_MOD_A_4 mT*mA*TAATTTCTACTA 1029 STAR_MOD_A_5 AGACCTTTTTAATTTCTACTA 1030 STAR_MOD_A_6 /Alt1/AGACCTTTTTAATTTCTACTA 1031 STAR_MOD_A_7 A*G*A*C*C*T*T*T*T*TAATTTCTA CTA 1032 STAR_MOD_A_8 mA*mG*ACCTTTTTAATTTCTACTA 1033 STAR_MOD_A_9 mA*G*ACCTTTTTAATTTCTACTA 1034 STAR_MOD_A_10 GTCAAAAGACCTTTTTAATTTCTACTA 1035 STAR_MOD_A_11 /Alt1/GTCAAAAGACCTTTTTAATTT CTACTA 1036 STAR_MOD_A_12 mG*mT*CAAAAGACCTTTTTAATTTCT ACTA 1037 STAR_MOD_A_13 mG*T*CAAAAGACCTTTTTAATTTCTA CTA ¹m indicates a 2-O-methoxy phosphorothioate nucleotide modification. *indicates a phosphorothioate internucleotide linkage modification. /Alt1/ indicates a sequence modified a 5' Alt-R (propanediol) modification as shown in FIG. 7A.

TABLE 30 Control Sequences SEQ ID NO Description Sequences¹ 1053 gGENE3_plat /AltR1/TAATTTCTACTCTTGTAGATGAGTCTC e_1 and TCAGCTGGTACACG/AltR2/ gGENE3 plate 2 1054 gGENE3_plat /AltR1/TAATTTCTACTATTGTAGATGAGTCTC e_3 and TCAGCTGGTACACG/AltR2/ gGENE3 plat e_4 1055 gGENE1_plat /AltR1/TAATTTCTACTCTTGTAGATCAAGGAC e_2 TTCAGCTGGGGGAA/AltR2/ 1056 gGENE1_plat /AltR1/TAATTTCTACTATTGTAGATCAAGGAC e_3 and TTCAGCTGGGGGAA/AltR2/ gGENE1_plat e_4 1057 gGENE2_plat /AltR1/TAATTTCTACTCTTGTAGATCACAGGA e_1 and GCCGACCTGCCTAC/AltR2/ gGENE2_plat e_2 1058 gGENE2_plat /AltR1/TAATTTCTACTATTGTAGATCACAGGA e_3 and GCCGACCTGCCTAC/AltR2/ gGENE2_plat e_4

Example 3

In this example, various combinations of modified and unmodified modulator and targeter nucleic acids targeting the B2M gene were used with a Cas nuclease. For each combination, the editing efficiency and surface expression of HLA-1 was evaluated.

Modifications included at least one of 2′-O-methyl (M), a phosphorothioate (S), a phosphonoacetate (P), a thiophosphonoacetate (SP), a 2′-O-methyl-3′-phosphorothioate (MS), a 2′-O-methyl-3′-phosphonoacetate (MP), a 2′-O-methyl-3′-thiophosphonoacetate (MSP), a 2′-deoxy-3′-phosphonoacetate (DP), a 2′-deoxy-3′-thiophosphonoacetate (DSP), a 2′-fluoro-ribonucleotide, propanediol (Alt-R) or a combination thereof at either the 3′ or 5′ end. The modified/unmodified crRNA and tracrRNA were mixed in the molar ratio 1:1 (200pmol+200pmol) at room temperature and incubated for 15 min. For the formation of the RNPs 100 pmol unmodified/modified gRNA were mixed with 100 pmol Mad7 nuclease and transfected into primary Pan T cells using the Lonza nucleofector system. Sequences for each modulator nucleic acid and targeter nucleic acid used in the study with their respective modifications are shown in Table 31 and Table 29.

The specific sequence for each modulator and targeter complex in FIGS. 7-8 may be deduced using the naming convention (modulator description) (targeter description) using Table 31 and Table 29. For example, an experimental test using complex Mod C2 Tar 2 would comprise a modulator comprising SEQ ID NO: 1013 and a targeter comprising SEQ ID NO: 999. It is observed that some combinations made to the modulator-targeter complex demonstrate activity greater than the sgRNA. It is observed that some combinations made to the modulator-targeter complex demonstrate activity similar to the sgRNA. It is also observed that some combinations made to the modulator-targeter complex demonstrate lower but sufficient activity compared to the sgRNA.

FIG. 7 show data for the editing efficiency at the B2M gene (as measured by % INDELs formed) in primary T cells after treatment with various combinations of modified and unmodified modulator and targeter nucleic acids complexed with MAD7. INDEL formation was measured by amplicon sequencing of the gene post treatment. Each tested gNA is shown on the x-axis with the first two representing a no gRNA and single gRNA controls, respectively. INDEL formation as a percentage of total reads is shown on the y-axis.

FIG. 8 show data for the editing efficiency and resultant reduction in HLA-1 surface expression in primary T cells as measured by flow cytometry (proportion of cells lacking HLA-1 expression in the population) after treatment with various combinations of modified and unmodified modulator and targeter nucleic acids complexed with MAD7. Each tested gNA is shown on the x-axis with the first two representing a no gRNA (cell only control) and a single gRNA control, respectively.

TABLE 31 B2M Targeter Sequences SEQ ID NO Description Sequence 998 Tar_1_B2M TTGTAGATAGTGGGGGTGAATTCAGTGTA 999 Tar_2_B2M TTGTAGATAGTGGGGGTGAATTCAGTGTA/ AltR2/

While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby. 

What is claimed is:
 1. A composition comprising a synthetic guide nucleic acid (gNA) comprising: (i) a targeter nucleic acid comprising: (a) a spacer sequence configured to hybridize with a target nucleotide sequence, and (b) a targeter stem sequence; and (ii) a modulator nucleic acid comprising: (a) a modulator stem sequence complementary to the target stem sequence, and (b) a 5′ sequence; wherein the targeter stem sequence and the modulator stem sequence each comprise 4-10 nucleotides that base pair with each other, and the gNA is capable of binding to a CRISPR Type VA nucleic acid-guided nuclease and forming a nucleic acid-guided nuclease complex, wherein the targeter and modulator nucleic acids are separate polynucleotides, and wherein the targeter nucleic acid or the modulator nucleic acid, or both, comprise one or more modified nucleotides or one or more modified internucleotide linkages at or near its 3′ end, at or near its 5′ end, or both, and wherein the modulator nucleic acid comprises at least one modified nucleotide and at least two modified internucleotide linkages within the first 10 nucleotides from the 5′ end.
 2. The composition of claim 1 wherein the modulator nucleic acid comprises one to ten phosphorothioate modifications to internucleotide linkages.
 3. The composition of claim 1 wherein the modulator nucleic acid comprises at least one modified nucleotide and at least two modified internucleotide linkages within the first five nucleotides from the 5′ end.
 4. The composition of claim 3 wherein the modulator nucleic acid comprises one to five phosphorothioate modifications to internucleotide linkages between one or more of the first five nucleotides from the 5′ end.
 5. The composition of claim 3 wherein the modulator nucleic acid comprises one to five 2′-O-methoxy modifications to nucleotides within the first five nucleotides from the 5′ end.
 6. The composition of claim 3 wherein the modulator nucleic acid comprises one to five fluoro modifications to nucleotides within the first five nucleotides from the 5′ end.
 7. The composition of claim 1, further comprising the Type VA nucleic acid-guided nuclease complexed with the gNA.
 8. The composition of claim 7, wherein the Type VA nucleic acid-guided nuclease comprises an amino acid sequence that is is at least 80% identical to an amino acid sequence of an ABW, ART, or MAD nuclease.
 9. The composition of claim 8 wherein the Type VA nucleic acid nuclease comprises an amino acid sequence that is is at least 80% identical to an amino acid sequence of MAD1, MAD2, MAD3, MAD4, MAD5, MAD6, MAD7, MAD8, MAD9, MAD10, MAD11, MAD12, MAD13, MAD14, MAD15, MAD16, MAD17, MAD18, MAD19, or MAD20.
 10. The composition of claim 9 wherein the Type VA nucleic acid nuclease comprises an amino acid sequence at least 80% identical to SEQ ID NO:
 1. 11. The composition of claim 8 wherein the Type VA nucleic acid nuclease comprises an amino acid sequence at least 80% identical to an amino acid sequence of ART1, ART2, ART3, ART4, ART5, ART6, ART7, ART8, ART9, ART10, ART11, ART12, ART13, ART14, ART15, ART16, ART17, ART18, ART19, ART20, ART21, ART22, ART23, ART24, ART25, ART26, ART27, ART28, ART28, ART30, ART31, ART32, ART33, ART34, ART35, or ART11*.
 12. A method of editing a genome of a eukaryotic cell comprising (I) delivering to the eukaryotic cell (A) one or more synthetic guide nucleic acids (gNA), or polynucleotides encoding the one or more gNAs, comprising (i) a targeter nucleic acid comprising: (a) a spacer sequence configured to hybridize with a target nucleotide sequence, and (b) a targeter stem sequence; and (ii) a modulator nucleic acid comprising: (a) a modulator stem sequence complementary to the target stem sequence, and (b) a 5′ sequence; wherein the targeter stem sequence and the modulator stem sequence each comprise 4-10 nucleotides that base pair with each other, and the gNA is capable of binding to a CRISPR Type VA nucleic acid-guided nuclease and forming a nucleic acid-guided nuclease complex, wherein the targeter and modulator nucleic acids are separate polynucleotides, and wherein the targeter nucleic acid or the modulator nucleic acid, or both, comprise one or more modified nucleotides or one or more modified internucleotide linkages at or near its 3′ end, at or near its 5′ end, or both, and wherein the modulator nucleic acid comprises at least one modified nucleotide and at least two modified internucleotide linkages within the first 10 nucleotides from the 5′ end; (B) the Type VA nucleic acid-guided nuclease, or polynucleotides encoding the nuclease; wherein the gNA and the Type V nucleic acid-guided nuclease form a nucleic acid-guided nuclease complex; and (II) contacting the genome with the nucleic acid-guided nuclease complex to form one or more strand breaks in the genome.
 13. The method of claim 12 wherein the modulator nucleic acid comprises one to ten phosphorothioate modifications to internudleotide linkages.
 14. The method of claim 12 wherein the modulator nucleic acid comprises at least one modified nucleotide and at least two modified internucleotide linkages within the first five nucleotides from the 5′ end.
 15. The method of claim 14 wherein the modulator nucleic acid comprises one to five phosphorothioate modifications to internucleotide linkages between one or more of the first five nucleotides from the 5′ end.
 16. The method of claim 14 wherein the modulator nucleic acid comprises one to five 2′-O-methoxy modifications to nucleotides within the first five nucleotides from the 5′ end.
 17. The method of claim 14 wherein the modulator nucleic acid comprises one to five fluoro modifications to nucleotides within the first five nucleotides from the 5′ end.
 18. The method of claim 12, wherein the Type VA nucleic acid-guided nuclease comprises an amino acid sequence that is is at least 80% identical to an amino acid sequence of an ABW, ART, or MAD nuclease.
 19. The method of claim 18 wherein the Type VA nucleic acid nuclease comprises an amino acid sequence that is is at least 80% identical to an amino acid sequence of MAD1, MAD2, MAD3, MAD4, MAD5, MAD6, MAD7, MAD8, MAD9, MAD10, MAD11, MAD12, MAD13, MAD14, MAD15, MAD16, MAD17, MAD18, MAD19, or MAD20.
 20. The method of claim 19 wherein the Type VA nucleic acid nuclease comprises an amino acid sequence at least 80% identical to SEQ ID NO:
 1. 21. The method of claim 18 wherein the Type VA nucleic acid nuclease comprises an amino acid sequence at least 80% identical to an amino acid sequence of ART1, ART2, ART3, ART4, ART5, ART6, ART7, ART8, ART9, ART10, ART11, ART12, ART13, ART14, ART15, ART16, ART17, ART18, ART19, ART20, ART21, ART22, ART23, ART24, ART25, ART26, ART27, ART28, ART28, ART30, ART31, ART32, ART33, ART34, ART35, or ART11*.
 22. A composition comprising a synthetic guide nucleic acid (gNA) comprising (i) a targeter nucleic acid comprising: (a) a spacer sequence configured to hybridize with a target nucleotide sequence, and (b) a targeter stem sequence; and (ii) a modulator nucleic acid comprising: (a) a modulator stem sequence complementary to the target stem sequence, and (b) a 5′ sequence; wherein (1) the targeter nucleic acid and modulator nucleic acids are separate polynucleotides, (2) the predicted minimum free energy of hybridization of the targeter stem sequence and the modulator stem sequence, as determined by the RNAcofold Web Server, is between −10 and −4 kcal/mol, and (3) the gNA is capable of binding to a CRISPR Type V nucleic acid-guided nuclease and forming a nucleic acid-guided nuclease complex.
 23. The composition of claim 22, wherein the predicted minimum free energy of hybridization of the targeter stem sequence and the modulator stem sequence, as determined by the RNAcofold WebServer, is between −7 and −4 kcal/mol.
 24. The composition of claim 22, wherein the targeter and modulator nucleic acids comprise a single polynucleotide.
 25. The composition of claim 22, wherein the targeter and modulator nucleic acids are separate polynucleotides.
 26. The composition of claim 22, wherein the targeter nucleic acid or the modulator nucleic acid, or both, comprise one or more modified nucleotides at or near its 3′ end, if present, at or near its 5′ end, if present, or both.
 27. The composition of claim 26, wherein the modulator nucleic acid comprises at least one modified nucleotide and at least two modified internucleotide linkages within the first five nucleotides from the 5′ end.
 28. The composition of claim 22, further comprising the Type VA nucleic acid-guided nuclease.
 29. The composition of claim 28, wherein the amino acid sequence of the Type VA nucleic acid-guided nuclease is at least 80% identical to an amino acid sequence of an ABW, ART, or MAD nuclease.
 30. A method of editing a genome of a eukaryotic cell comprising (I) delivering to the eukaryotic cell (A) one or more synthetic guide nucleic acids (gNA), or polynucleotides encoding the one or more gNAs, comprising (i) a targeter nucleic acid comprising: (a) a spacer sequence configured to hybridize with a target nucleotide sequence, and (b) a targeter stem sequence; and (ii) a modulator nucleic acid comprising: (a) a modulator stem sequence complementary to the target stem sequence, and (b) a 5′ sequence; wherein (1) the targeter nucleic acid and modulator nucleic acids are separate polynucleotides, (2) the predicted minimum free energy of the targeter stem sequence and the modulator stem sequence as determined by the RNAcofold Web Server is between −10 and −4 kcal/mol, and (3) the gNA is capable of binding to a CRISPR Type VA nucleic acid-guided nuclease and forming a nucleic acid-guided nuclease complex; (B) one or more Type VA nucleic acid-guided nucleases, or polynucleotides encoding the one or more nucleases; wherein the gNA and the Type V nucleic acid-guided nuclease form a nucleic acid-guided nuclease complex; and (II) contacting the genome with the nucleic acid-guided nuclease complex to form one or more strand breaks in the genome. 